<!DOCTYPE html>
<html lang="" xml:lang="">
<head>

  <meta charset="utf-8" />
  <meta http-equiv="X-UA-Compatible" content="IE=edge" />
  <title>2 Common Chemotherapy Regimens | 　　　　</title>
  <meta name="description" content="2 Common Chemotherapy Regimens | 　　　　" />
  <meta name="generator" content="bookdown 0.22 and GitBook 2.6.7" />

  <meta property="og:title" content="2 Common Chemotherapy Regimens | 　　　　" />
  <meta property="og:type" content="book" />
  
  
  
  

  <meta name="twitter:card" content="summary" />
  <meta name="twitter:title" content="2 Common Chemotherapy Regimens | 　　　　" />
  
  
  




  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <meta name="apple-mobile-web-app-capable" content="yes" />
  <meta name="apple-mobile-web-app-status-bar-style" content="black" />
  
  
<link rel="prev" href="chemotherapeutic-and-biologic-drugs.html"/>
<link rel="next" href="chemotherapy-dosage-based-on-hepatic-function.html"/>
<script src="libs/header-attrs-2.10/header-attrs.js"></script>
<script src="libs/jquery-3.5.1/jquery.min.js"></script>
<link href="libs/gitbook-2.6.7/css/style.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-table.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-bookdown.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-highlight.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-search.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-fontsettings.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-clipboard.css" rel="stylesheet" />









<link href="libs/anchor-sections-1.0.1/anchor-sections.css" rel="stylesheet" />
<script src="libs/anchor-sections-1.0.1/anchor-sections.js"></script>
<script src="libs/htmlwidgets-1.5.3/htmlwidgets.js"></script>
<link href="libs/datatables-css-0.0.0/datatables-crosstalk.css" rel="stylesheet" />
<script src="libs/datatables-binding-0.18/datatables.js"></script>
<link href="libs/dt-core-1.10.20/css/jquery.dataTables.min.css" rel="stylesheet" />
<link href="libs/dt-core-1.10.20/css/jquery.dataTables.extra.css" rel="stylesheet" />
<script src="libs/dt-core-1.10.20/js/jquery.dataTables.min.js"></script>
<link href="libs/nouislider-7.0.10/jquery.nouislider.min.css" rel="stylesheet" />
<script src="libs/nouislider-7.0.10/jquery.nouislider.min.js"></script>
<link href="libs/selectize-0.12.0/selectize.bootstrap3.css" rel="stylesheet" />
<script src="libs/selectize-0.12.0/selectize.min.js"></script>
<link href="libs/dt-plugin-searchhighlight-1.10.20/source.css" rel="stylesheet" />
<script src="libs/dt-plugin-searchhighlight-1.10.20/jquery.highlight.js"></script>
<script src="libs/dt-plugin-searchhighlight-1.10.20/source.min.js"></script>
<link href="libs/crosstalk-1.1.1/css/crosstalk.css" rel="stylesheet" />
<script src="libs/crosstalk-1.1.1/js/crosstalk.min.js"></script>
<link href="libs/tabwid-1.0.0/tabwid.css" rel="stylesheet" />




<link rel="stylesheet" href="css/JhengHei.css" type="text/css" />
</head>

<body>



  <div class="book without-animation with-summary font-size-2 font-family-1" data-basepath=".">

    <div class="book-summary">
      <nav role="navigation">

<ul class="summary">
<li><a href="index.html#pharmed"><strong>《pharmed》</strong></a></li>
<li><a href="part-chemotherapy.html#part---chemotherapy"><em>Part - Chemotherapy</em></a></li>
<li class="chapter" data-level="1" data-path="chemotherapeutic-and-biologic-drugs.html"><a href="chemotherapeutic-and-biologic-drugs.html"><i class="fa fa-check"></i><b>1</b> Chemotherapeutic and Biologic Drugs</a>
<ul>
<li class="chapter" data-level="1.1" data-path="chemotherapeutic-and-biologic-drugs.html"><a href="chemotherapeutic-and-biologic-drugs.html#abemaciclib"><i class="fa fa-check"></i><b>1.1</b> Abemaciclib</a></li>
<li class="chapter" data-level="1.2" data-path="chemotherapeutic-and-biologic-drugs.html"><a href="chemotherapeutic-and-biologic-drugs.html#bevacizumab"><i class="fa fa-check"></i><b>1.2</b> Bevacizumab</a></li>
<li class="chapter" data-level="1.3" data-path="chemotherapeutic-and-biologic-drugs.html"><a href="chemotherapeutic-and-biologic-drugs.html#capecitabine"><i class="fa fa-check"></i><b>1.3</b> Capecitabine</a></li>
<li class="chapter" data-level="1.4" data-path="chemotherapeutic-and-biologic-drugs.html"><a href="chemotherapeutic-and-biologic-drugs.html#carboplatin"><i class="fa fa-check"></i><b>1.4</b> Carboplatin</a></li>
<li class="chapter" data-level="1.5" data-path="chemotherapeutic-and-biologic-drugs.html"><a href="chemotherapeutic-and-biologic-drugs.html#cetuximab"><i class="fa fa-check"></i><b>1.5</b> Cetuximab</a></li>
<li class="chapter" data-level="1.6" data-path="chemotherapeutic-and-biologic-drugs.html"><a href="chemotherapeutic-and-biologic-drugs.html#cobimetinib"><i class="fa fa-check"></i><b>1.6</b> Cobimetinib</a></li>
<li class="chapter" data-level="1.7" data-path="chemotherapeutic-and-biologic-drugs.html"><a href="chemotherapeutic-and-biologic-drugs.html#dabrafenib"><i class="fa fa-check"></i><b>1.7</b> Dabrafenib</a></li>
<li class="chapter" data-level="1.8" data-path="chemotherapeutic-and-biologic-drugs.html"><a href="chemotherapeutic-and-biologic-drugs.html#fluorouracil"><i class="fa fa-check"></i><b>1.8</b> 5-Fluorouracil</a></li>
<li class="chapter" data-level="1.9" data-path="chemotherapeutic-and-biologic-drugs.html"><a href="chemotherapeutic-and-biologic-drugs.html#ipilimumab"><i class="fa fa-check"></i><b>1.9</b> Ipilimumab</a></li>
<li class="chapter" data-level="1.10" data-path="chemotherapeutic-and-biologic-drugs.html"><a href="chemotherapeutic-and-biologic-drugs.html#irinotecan"><i class="fa fa-check"></i><b>1.10</b> Irinotecan</a></li>
<li class="chapter" data-level="1.11" data-path="chemotherapeutic-and-biologic-drugs.html"><a href="chemotherapeutic-and-biologic-drugs.html#nivolumab"><i class="fa fa-check"></i><b>1.11</b> Nivolumab</a></li>
<li class="chapter" data-level="1.12" data-path="chemotherapeutic-and-biologic-drugs.html"><a href="chemotherapeutic-and-biologic-drugs.html#oxaliplatin"><i class="fa fa-check"></i><b>1.12</b> Oxaliplatin</a></li>
<li class="chapter" data-level="1.13" data-path="chemotherapeutic-and-biologic-drugs.html"><a href="chemotherapeutic-and-biologic-drugs.html#paclitaxel"><i class="fa fa-check"></i><b>1.13</b> Paclitaxel</a></li>
<li class="chapter" data-level="1.14" data-path="chemotherapeutic-and-biologic-drugs.html"><a href="chemotherapeutic-and-biologic-drugs.html#panitumumab"><i class="fa fa-check"></i><b>1.14</b> Panitumumab</a></li>
<li class="chapter" data-level="1.15" data-path="chemotherapeutic-and-biologic-drugs.html"><a href="chemotherapeutic-and-biologic-drugs.html#pembrolizumab"><i class="fa fa-check"></i><b>1.15</b> Pembrolizumab</a></li>
<li class="chapter" data-level="1.16" data-path="chemotherapeutic-and-biologic-drugs.html"><a href="chemotherapeutic-and-biologic-drugs.html#ramucirumab"><i class="fa fa-check"></i><b>1.16</b> Ramucirumab</a></li>
<li class="chapter" data-level="1.17" data-path="chemotherapeutic-and-biologic-drugs.html"><a href="chemotherapeutic-and-biologic-drugs.html#regorafenib"><i class="fa fa-check"></i><b>1.17</b> Regorafenib</a></li>
<li class="chapter" data-level="1.18" data-path="chemotherapeutic-and-biologic-drugs.html"><a href="chemotherapeutic-and-biologic-drugs.html#trametinib"><i class="fa fa-check"></i><b>1.18</b> Trametinib</a></li>
<li class="chapter" data-level="1.19" data-path="chemotherapeutic-and-biologic-drugs.html"><a href="chemotherapeutic-and-biologic-drugs.html#vemurafenib"><i class="fa fa-check"></i><b>1.19</b> Vemurafenib</a></li>
<li class="chapter" data-level="1.20" data-path="chemotherapeutic-and-biologic-drugs.html"><a href="chemotherapeutic-and-biologic-drugs.html#ziv-aflibercept"><i class="fa fa-check"></i><b>1.20</b> Ziv-aflibercept</a></li>
</ul></li>
<li class="chapter" data-level="2" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html"><i class="fa fa-check"></i><b>2</b> Common Chemotherapy Regimens</a>
<ul>
<li class="chapter" data-level="2.1" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#adrenocortical-cancer"><i class="fa fa-check"></i><b>2.1</b> ADRENOCORTICAL CANCER</a></li>
<li class="chapter" data-level="2.2" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#anal-cancer"><i class="fa fa-check"></i><b>2.2</b> ANAL CANCER</a></li>
<li class="chapter" data-level="2.3" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#basal-cell-cancer"><i class="fa fa-check"></i><b>2.3</b> BASAL CELL CANCER</a></li>
<li class="chapter" data-level="2.4" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#biliary-tract-cancer"><i class="fa fa-check"></i><b>2.4</b> BILIARY TRACT CANCER</a></li>
<li class="chapter" data-level="2.5" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#bladder-cancer"><i class="fa fa-check"></i><b>2.5</b> BLADDER CANCER</a></li>
<li class="chapter" data-level="2.6" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#brain-cancer"><i class="fa fa-check"></i><b>2.6</b> BRAIN CANCER</a></li>
<li class="chapter" data-level="2.7" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#breast-cancer"><i class="fa fa-check"></i><b>2.7</b> BREAST CANCER</a></li>
<li class="chapter" data-level="2.8" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#cancer-of-unknown-primary"><i class="fa fa-check"></i><b>2.8</b> CANCER OF UNKNOWN PRIMARY</a></li>
<li class="chapter" data-level="2.9" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#carcinoid-tumors-and-neuroendocrine-tumors"><i class="fa fa-check"></i><b>2.9</b> CARCINOID TUMORS AND NEUROENDOCRINE TUMORS</a></li>
<li class="chapter" data-level="2.10" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#cervical-cancer"><i class="fa fa-check"></i><b>2.10</b> CERVICAL CANCER</a></li>
<li class="chapter" data-level="2.11" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#colorectal-cancer"><i class="fa fa-check"></i><b>2.11</b> COLORECTAL CANCER</a></li>
<li class="chapter" data-level="2.12" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#endometrial-cancer"><i class="fa fa-check"></i><b>2.12</b> ENDOMETRIAL CANCER</a></li>
<li class="chapter" data-level="2.13" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#esophageal-cancer"><i class="fa fa-check"></i><b>2.13</b> ESOPHAGEAL CANCER</a></li>
<li class="chapter" data-level="2.14" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#gastric-cancer"><i class="fa fa-check"></i><b>2.14</b> GASTRIC CANCER</a></li>
<li class="chapter" data-level="2.15" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#gastrointestinal-stromal-tumor-gist"><i class="fa fa-check"></i><b>2.15</b> GASTROINTESTINAL STROMAL TUMOR (GIST)</a></li>
<li class="chapter" data-level="2.16" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#head-and-neck-cancer"><i class="fa fa-check"></i><b>2.16</b> HEAD AND NECK CANCER</a></li>
<li class="chapter" data-level="2.17" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#hepatocellular-cancer"><i class="fa fa-check"></i><b>2.17</b> HEPATOCELLULAR CANCER</a></li>
<li class="chapter" data-level="2.18" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#kaposis-sarcoma"><i class="fa fa-check"></i><b>2.18</b> KAPOSI’S SARCOMA</a></li>
<li class="chapter" data-level="2.19" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#leukemia"><i class="fa fa-check"></i><b>2.19</b> LEUKEMIA</a></li>
<li class="chapter" data-level="2.20" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#lung-cancer"><i class="fa fa-check"></i><b>2.20</b> LUNG CANCER</a></li>
<li class="chapter" data-level="2.21" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#lymphoma"><i class="fa fa-check"></i><b>2.21</b> LYMPHOMA</a></li>
<li class="chapter" data-level="2.22" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#malignant-melanoma"><i class="fa fa-check"></i><b>2.22</b> MALIGNANT MELANOMA</a></li>
<li class="chapter" data-level="2.23" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#malignant-mesothelioma"><i class="fa fa-check"></i><b>2.23</b> MALIGNANT MESOTHELIOMA</a></li>
<li class="chapter" data-level="2.24" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#merkel-cell-cancer"><i class="fa fa-check"></i><b>2.24</b> MERKEL CELL CANCER</a></li>
<li class="chapter" data-level="2.25" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#multiple-myeloma"><i class="fa fa-check"></i><b>2.25</b> MULTIPLE MYELOMA</a></li>
<li class="chapter" data-level="2.26" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#myelodysplastic-syndrome"><i class="fa fa-check"></i><b>2.26</b> MYELODYSPLASTIC SYNDROME</a></li>
<li class="chapter" data-level="2.27" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#osteogenic-sarcoma"><i class="fa fa-check"></i><b>2.27</b> OSTEOGENIC SARCOMA</a></li>
<li class="chapter" data-level="2.28" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#ovarian-cancer-epithelial"><i class="fa fa-check"></i><b>2.28</b> OVARIAN CANCER (EPITHELIAL)</a></li>
<li class="chapter" data-level="2.29" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#ovarian-cancer-germ-cell"><i class="fa fa-check"></i><b>2.29</b> OVARIAN CANCER (GERM CELL)</a></li>
<li class="chapter" data-level="2.30" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#pancreatic-cancer"><i class="fa fa-check"></i><b>2.30</b> PANCREATIC CANCER</a></li>
<li class="chapter" data-level="2.31" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#prostate-cancer"><i class="fa fa-check"></i><b>2.31</b> PROSTATE CANCER</a></li>
<li class="chapter" data-level="2.32" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#renal-cell-cancer"><i class="fa fa-check"></i><b>2.32</b> RENAL CELL CANCER</a></li>
<li class="chapter" data-level="2.33" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#soft-tissue-sarcomas"><i class="fa fa-check"></i><b>2.33</b> SOFT TISSUE SARCOMAS</a></li>
<li class="chapter" data-level="2.34" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#testicular-cancer"><i class="fa fa-check"></i><b>2.34</b> TESTICULAR CANCER</a></li>
<li class="chapter" data-level="2.35" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#thymoma"><i class="fa fa-check"></i><b>2.35</b> THYMOMA</a></li>
<li class="chapter" data-level="2.36" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#thyroid-cancer"><i class="fa fa-check"></i><b>2.36</b> THYROID CANCER</a></li>
<li class="chapter" data-level="2.37" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#waldenströms-macroglobulinemia"><i class="fa fa-check"></i><b>2.37</b> WALDENSTRÖM’S MACROGLOBULINEMIA</a></li>
</ul></li>
<li class="chapter" data-level="3" data-path="chemotherapy-dosage-based-on-hepatic-function.html"><a href="chemotherapy-dosage-based-on-hepatic-function.html"><i class="fa fa-check"></i><b>3</b> Chemotherapy Dosage Based on Hepatic Function</a>
<ul>
<li class="chapter" data-level="3.1" data-path="chemotherapy-dosage-based-on-hepatic-function.html"><a href="chemotherapy-dosage-based-on-hepatic-function.html#recommended-dose-reduction-for-hepatic-dysfunction"><i class="fa fa-check"></i><b>3.1</b> Recommended Dose Reduction for Hepatic Dysfunction</a></li>
</ul></li>
<li class="chapter" data-level="4" data-path="chemotherapy-dosage-based-on-renal-function.html"><a href="chemotherapy-dosage-based-on-renal-function.html"><i class="fa fa-check"></i><b>4</b> Chemotherapy Dosage Based on Renal Function</a>
<ul>
<li class="chapter" data-level="4.1" data-path="chemotherapy-dosage-based-on-renal-function.html"><a href="chemotherapy-dosage-based-on-renal-function.html#recommended-dose-reduction-for-renal-dysfunction"><i class="fa fa-check"></i><b>4.1</b> Recommended Dose Reduction for Renal Dysfunction</a></li>
</ul></li>
<li class="chapter" data-level="5" data-path="dialysis-of-chemotherapy-drugs.html"><a href="dialysis-of-chemotherapy-drugs.html"><i class="fa fa-check"></i><b>5</b> Dialysis of Chemotherapy Drugs</a>
<ul>
<li class="chapter" data-level="5.1" data-path="dialysis-of-chemotherapy-drugs.html"><a href="dialysis-of-chemotherapy-drugs.html#guidelines-for-dialysis-of-chemotherapy-drugs"><i class="fa fa-check"></i><b>5.1</b> Guidelines for Dialysis of Chemotherapy Drugs</a></li>
</ul></li>
<li class="chapter" data-level="6" data-path="oncology-performance-status.html"><a href="oncology-performance-status.html"><i class="fa fa-check"></i><b>6</b> Oncology Performance Status</a>
<ul>
<li class="chapter" data-level="6.1" data-path="oncology-performance-status.html"><a href="oncology-performance-status.html#karnofsky-performance"><i class="fa fa-check"></i><b>6.1</b> Karnofsky Performance</a></li>
<li class="chapter" data-level="6.2" data-path="oncology-performance-status.html"><a href="oncology-performance-status.html#lansky-performance"><i class="fa fa-check"></i><b>6.2</b> Lansky Performance</a></li>
<li class="chapter" data-level="6.3" data-path="oncology-performance-status.html"><a href="oncology-performance-status.html#ecog-performance"><i class="fa fa-check"></i><b>6.3</b> ECOG Performance</a></li>
</ul></li>
<li class="chapter" data-level="7" data-path="common-terminology-criteria-for-adverse-events.html"><a href="common-terminology-criteria-for-adverse-events.html"><i class="fa fa-check"></i><b>7</b> Common Terminology Criteria for Adverse Events</a>
<ul>
<li class="chapter" data-level="7.1" data-path="common-terminology-criteria-for-adverse-events.html"><a href="common-terminology-criteria-for-adverse-events.html#ctcae-v5.0"><i class="fa fa-check"></i><b>7.1</b> CTCAE v5.0</a></li>
</ul></li>
<li><a href="part-oncology.html#part---oncology"><em>Part - Oncology</em></a></li>
<li class="chapter" data-level="8" data-path="colon-cancer.html"><a href="colon-cancer.html"><i class="fa fa-check"></i><b>8</b> Colon Cancer</a>
<ul>
<li class="chapter" data-level="8.1" data-path="colon-cancer.html"><a href="colon-cancer.html#regimens-for-advanced-or-metastatic-disease"><i class="fa fa-check"></i><b>8.1</b> Regimens for Advanced or Metastatic Disease</a></li>
<li class="chapter" data-level="8.2" data-path="colon-cancer.html"><a href="colon-cancer.html#systemic-therapy-for-advanced-or-metastatic-disease---chemotherapy-regimens"><i class="fa fa-check"></i><b>8.2</b> Systemic Therapy for Advanced or Metastatic Disease - Chemotherapy Regimens</a></li>
</ul></li>
<li><a href="part-others.html#part---others"><em>Part - Others</em></a></li>
<li class="chapter" data-level="9" data-path="icd-10-cm.html"><a href="icd-10-cm.html"><i class="fa fa-check"></i><b>9</b> ICD 10 CM</a>
<ul>
<li class="chapter" data-level="9.1" data-path="icd-10-cm.html"><a href="icd-10-cm.html#國際疾病分類第十版中英對照檢索"><i class="fa fa-check"></i><b>9.1</b> 國際疾病分類第十版中英對照檢索</a></li>
</ul></li>
<li class="chapter" data-level="10" data-path="pnce-drp-classification.html"><a href="pnce-drp-classification.html"><i class="fa fa-check"></i><b>10</b> PNCE-DRP Classification</a>
<ul>
<li class="chapter" data-level="10.1" data-path="pnce-drp-classification.html"><a href="pnce-drp-classification.html#pharmaceutical-care-network-europe---classification-for-drug-related-problems-v9.1"><i class="fa fa-check"></i><b>10.1</b> Pharmaceutical Care Network Europe - Classification for Drug related problems V9.1</a></li>
</ul></li>
<li class="chapter" data-level="11" data-path="frequently-used-abbreviations.html"><a href="frequently-used-abbreviations.html"><i class="fa fa-check"></i><b>11</b> Frequently Used Abbreviations</a>
<ul>
<li class="chapter" data-level="11.1" data-path="frequently-used-abbreviations.html"><a href="frequently-used-abbreviations.html#medical-abbreviations"><i class="fa fa-check"></i><b>11.1</b> Medical Abbreviations</a></li>
</ul></li>
<li class="chapter" data-level="12" data-path="frequently-used-links.html"><a href="frequently-used-links.html"><i class="fa fa-check"></i><b>12</b> Frequently Used Links</a>
<ul>
<li class="chapter" data-level="12.1" data-path="frequently-used-links.html"><a href="frequently-used-links.html#醫藥參考"><i class="fa fa-check"></i><b>12.1</b> 醫藥參考</a></li>
<li class="chapter" data-level="12.2" data-path="frequently-used-links.html"><a href="frequently-used-links.html#醫藥文獻"><i class="fa fa-check"></i><b>12.2</b> 醫藥文獻</a></li>
<li class="chapter" data-level="12.3" data-path="frequently-used-links.html"><a href="frequently-used-links.html#交互作用"><i class="fa fa-check"></i><b>12.3</b> 交互作用</a></li>
<li class="chapter" data-level="12.4" data-path="frequently-used-links.html"><a href="frequently-used-links.html#藥物辨識"><i class="fa fa-check"></i><b>12.4</b> 藥物辨識</a></li>
<li class="chapter" data-level="12.5" data-path="frequently-used-links.html"><a href="frequently-used-links.html#藥品給付"><i class="fa fa-check"></i><b>12.5</b> 藥品給付</a></li>
<li class="chapter" data-level="12.6" data-path="frequently-used-links.html"><a href="frequently-used-links.html#醫藥計算"><i class="fa fa-check"></i><b>12.6</b> 醫藥計算</a></li>
</ul></li>
<li class="chapter" data-level="13" data-path="memo.html"><a href="memo.html"><i class="fa fa-check"></i><b>13</b> Memo</a>
<ul>
<li class="chapter" data-level="13.1" data-path="memo.html"><a href="memo.html#daily-tasks"><i class="fa fa-check"></i><b>13.1</b> Daily Tasks</a></li>
<li class="chapter" data-level="13.2" data-path="memo.html"><a href="memo.html#print-medical-orders"><i class="fa fa-check"></i><b>13.2</b> Print Medical Orders</a></li>
</ul></li>
</ul>

      </nav>
    </div>

    <div class="book-body">
      <div class="body-inner">
        <div class="book-header" role="navigation">
          <h1>
            <i class="fa fa-circle-o-notch fa-spin"></i><a href="./">　　　　</a>
          </h1>
        </div>

        <div class="page-wrapper" tabindex="-1" role="main">
          <div class="page-inner">

            <section class="normal" id="section-">
<div id="common-chemotherapy-regimens" class="section level1" number="2">
<h1><span class="header-section-number">2</span> Common Chemotherapy Regimens</h1>
<div id="adrenocortical-cancer" class="section level2" number="2.1">
<h2><span class="header-section-number">2.1</span> ADRENOCORTICAL CANCER</h2>
<div id="combination-regimens" class="section level3" number="2.1.1">
<h3><span class="header-section-number">2.1.1</span> Combination Regimens</h3>
<div id="etoposide-doxorubicin-cisplatin-mitotane" class="section level4" number="2.1.1.1">
<h4><span class="header-section-number">2.1.1.1</span> Etoposide + Doxorubicin + Cisplatin + Mitotane</h4>
<ul>
<li>Etoposide: 100 mg/m2 IV on days 5–7</li>
<li>Doxorubicin: 20 mg/m2 on days 1 and 8</li>
<li>Cisplatin: 40 mg/m2 IV on days 1 and 9</li>
<li>Mitotane: 4 g PO daily</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Fassnacht M, et al. N Engl J Med 2012;366:2189–2197.</p>
</blockquote>
</div>
<div id="streptozocin-mitotane" class="section level4" number="2.1.1.2">
<h4><span class="header-section-number">2.1.1.2</span> Streptozocin + Mitotane</h4>
<ul>
<li>Streptozocin: 1,000 mg IV on days 1–5 for cycle 1 and 2,000 mg IV on days 1–5 on subsequent cycles</li>
<li>Mitotane: 4 g PO daily</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Fassnacht M, et al. N Engl J Med 2012;366:2189–2197.</p>
</blockquote>
</div>
</div>
</div>
<div id="anal-cancer" class="section level2" number="2.2">
<h2><span class="header-section-number">2.2</span> ANAL CANCER</h2>
<div id="combined-modality-therapy" class="section level3" number="2.2.1">
<h3><span class="header-section-number">2.2.1</span> Combined Modality Therapy</h3>
<div id="fluorouracil-mitomycin-c-radiation-therapy-rtogecog-regimen" class="section level4" number="2.2.1.1">
<h4><span class="header-section-number">2.2.1.1</span> 5-Fluorouracil + Mitomycin-C + Radiation Therapy (RTOG/ECOG regimen)</h4>
<ul>
<li>5-Fluorouracil: 1,000 mg/m2/day IV continuous infusion on days 1–4 and 29–32</li>
<li>Mitomycin-C: 10 mg/m2 IV (maximum of 20 mg) on days 1 and 29</li>
<li>Radiation therapy: 180 cGy/day, 5 days/week for a total of 5 weeks (total dose, 4500 cGy)</li>
<li>Chemotherapy is given concurrently with radiation therapy.</li>
</ul>
<blockquote>
<p>Flam M, et al. J Clin Oncol 1996;14:2527–2539.</p>
</blockquote>
</div>
<div id="fluorouracil-mitomycin-c-radiation-therapy-eortc-regimen" class="section level4" number="2.2.1.2">
<h4><span class="header-section-number">2.2.1.2</span> 5-Fluorouracil + Mitomycin-C + Radiation Therapy (EORTC regimen)</h4>
<ul>
<li>5-Fluorouracil: 200 mg/m2/day IV continuous infusion on days 1–26</li>
<li>Mitomycin-C: 10 mg/m2 IV on day 1</li>
<li>Radiation therapy: 180 cGy/day, 5 days/week for a total of 4 weeks (total dose, 3600 cGy)</li>
<li>Chemotherapy is given concurrently with radiation therapy. There is a 2-week break following the completion of this first treatment, after which the second treatment is initiated with concurrent chemotherapy and radiation therapy.</li>
<li>5-Fluorouracil: 200 mg/m2/day IV continuous infusion on days 1–17</li>
<li>Mitomycin-C: 10 mg/m2 IV on day 1</li>
<li>Radiation therapy: Total dose, 2340 cGy over 17 days</li>
</ul>
<blockquote>
<p>Bosset JF, et al. Eur J Cancer 2003;39:45–51.</p>
</blockquote>
</div>
<div id="capecitabine-mitomycin-c-radiation-therapy" class="section level4" number="2.2.1.3">
<h4><span class="header-section-number">2.2.1.3</span> Capecitabine + Mitomycin-C + Radiation Therapy</h4>
<ul>
<li>Capecitabine 825 mg/m2 PO bid on Monday–Friday</li>
<li>Mitomycin-C 10 mg/m2 IV on days 1 and 29</li>
<li>Radiation therapy Total dose, 5500 cGy over 6 weeks</li>
<li>Chemotherapy is given concurrently with radiation therapy.</li>
</ul>
<blockquote>
<p>Goodman KA et al. Int J Radiat Oncol Biol Phys 2017; 98:1087–1095.</p>
</blockquote>
</div>
<div id="fluorouracil-cisplatin-radiation-therapy" class="section level4" number="2.2.1.4">
<h4><span class="header-section-number">2.2.1.4</span> 5-Fluorouracil + Cisplatin + Radiation Therapy</h4>
<ul>
<li>5-Fluorouracil: 250 mg/m2/day IV continuous infusion on days 1–5 of each week of radiation therapy</li>
<li>Cisplatin: 4 mg/m2/day IV continuous infusion on days 1–5 of each week of radiation therapy</li>
<li>Radiation therapy: Total dose, 5500 cGy over 6 weeks</li>
<li>Chemotherapy is given concurrently with radiation therapy.</li>
</ul>
<blockquote>
<p>Hung A, et al. Cancer 2003;97:1195–1202.</p>
</blockquote>
<p>or</p>
<ul>
<li>Phase I (days 1–56)
<ul>
<li>5-Fluorouracil: 1,000 mg/m2/day IV continuous infusion on days 1–5 and 29–33</li>
<li>Cisplatin: 100 mg/m2 on days 1 and 29</li>
</ul></li>
<li>Phase II (days 57–112)
<ul>
<li>5-Fluorouracil: 1,000 mg/m2/day IV continuous infusion on days 57–60 and 99–102</li>
<li>Mitomycin-C: 10 mg/m2 IV on days 57 and 99</li>
<li>Radiation therapy: 180 cGy/day, 5 days/week on days 57–59 and days 99–108 for a total dose of 3060 cGy</li>
</ul></li>
<li>Phase III (days 127–131)</li>
<li>5-Fluorouracil: 800 mg/m2/day IV continuous infusion on days 127–131</li>
<li>Cisplatin: 100 mg/m2 on day 127</li>
<li>Radiation therapy: 180 cGy/day, 5 days/week on days 127–131</li>
<li>Combined modality therapy for poor prognosis anal cancer.</li>
</ul>
<blockquote>
<p>Meropol NJ, et al. J Clin Oncol 2008;26:3229–3214.</p>
</blockquote>
</div>
<div id="xelox-radiation-therapy" class="section level4" number="2.2.1.5">
<h4><span class="header-section-number">2.2.1.5</span> XELOX + Radiation Therapy</h4>
<ul>
<li>Capecitabine: 825 mg/m2 PO bid on Monday–Friday for 6 weeks</li>
<li>Oxaliplatin: 50 mg/m2 IV on days 1, 8, 22, 29</li>
<li>Radiation therapy: 180 cGy/day, 5 days/week for a total of 6 weeks</li>
<li>Chemotherapy is given concurrently with radiation therapy.</li>
</ul>
<blockquote>
<p>Eng C, et al. J Clin Oncol 2009;27:15S (abstract 4116).</p>
</blockquote>
</div>
</div>
<div id="metastatic-disease---combination-regimens" class="section level3" number="2.2.2">
<h3><span class="header-section-number">2.2.2</span> Metastatic Disease - Combination Regimens</h3>
<div id="fluorouracil-cisplatin" class="section level4" number="2.2.2.1">
<h4><span class="header-section-number">2.2.2.1</span> 5-Fluorouracil + Cisplatin</h4>
<ul>
<li>5-Fluorouracil: 1,000 mg/m2/day IV continuous infusion on days 1–5</li>
<li>Cisplatin: 100 mg/m2 IV on day 2</li>
<li>Repeat cycles every 4 weeks.</li>
</ul>
<blockquote>
<p>Faivre C, et al. Bull Cancer 1999;86:861–865.</p>
</blockquote>
</div>
</div>
<div id="metastatic-disease---single-agent-regimens" class="section level3" number="2.2.3">
<h3><span class="header-section-number">2.2.3</span> Metastatic Disease - Single-Agent Regimens</h3>
<div id="pembrolizumab-1" class="section level4" number="2.2.3.1">
<h4><span class="header-section-number">2.2.3.1</span> Pembrolizumab</h4>
<ul>
<li>Pembrolizumab: 10 mg/kg IV on day 1</li>
<li>Repeat cycles every 2 weeks.</li>
</ul>
<blockquote>
<p>Ott PA, et al. Ann Oncol 2017;28:1036–1041.</p>
</blockquote>
</div>
</div>
</div>
<div id="basal-cell-cancer" class="section level2" number="2.3">
<h2><span class="header-section-number">2.3</span> BASAL CELL CANCER</h2>
<div id="single-agent-regimens" class="section level3" number="2.3.1">
<h3><span class="header-section-number">2.3.1</span> Single-Agent Regimens</h3>
<div id="vismodegib" class="section level4" number="2.3.1.1">
<h4><span class="header-section-number">2.3.1.1</span> Vismodegib</h4>
<ul>
<li>Vismodegib: 150 mg PO daily</li>
<li>Continue treatment until disease progression.</li>
</ul>
<blockquote>
<p>Seklulic A, et al. N Engl J Med 2012;366:2171–2179.</p>
</blockquote>
</div>
<div id="sonidegib" class="section level4" number="2.3.1.2">
<h4><span class="header-section-number">2.3.1.2</span> Sonidegib</h4>
<ul>
<li>Sonidegib: 200 mg PO daily</li>
<li>Continue treatment until disease progression.</li>
</ul>
<blockquote>
<p>Migden MR, et al. Lancet Oncol 2015;16:716–728.</p>
</blockquote>
</div>
</div>
</div>
<div id="biliary-tract-cancer" class="section level2" number="2.4">
<h2><span class="header-section-number">2.4</span> BILIARY TRACT CANCER</h2>
<div id="combination-regimens-1" class="section level3" number="2.4.1">
<h3><span class="header-section-number">2.4.1</span> Combination Regimens</h3>
<div id="gemcitabine-cisplatin" class="section level4" number="2.4.1.1">
<h4><span class="header-section-number">2.4.1.1</span> Gemcitabine + Cisplatin</h4>
<ul>
<li>Gemcitabine: 1,250 mg/m2 IV on days 1 and 8</li>
<li>Cisplatin: 75 mg/m2 on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Thongprasert S, et al. Ann Oncol 2005;16:279–281.</p>
</blockquote>
<p>or</p>
<ul>
<li>Gemcitabine: 1,000 mg/m2 IV on days 1 and 8</li>
<li>Cisplatin: 25 mg/m2 on days 1 and 8</li>
<li>Repeat cycle every 21 days for 8 cycles.</li>
</ul>
<blockquote>
<p>Valle JW, et al. N Engl J Med 2010;362:1273–1281.</p>
</blockquote>
</div>
<div id="gemcitabine-capecitabine" class="section level4" number="2.4.1.2">
<h4><span class="header-section-number">2.4.1.2</span> Gemcitabine + Capecitabine</h4>
<ul>
<li>Gemcitabine: 1,000 mg/m2 IV on days 1 and 8</li>
<li>Capecitabine: 650 mg/m2 PO bid on days 1–14</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Knox JJ, et al. J Clin Oncol 2005;23:2332–2338.</p>
</blockquote>
</div>
<div id="gemcitabine-oxaliplatin" class="section level4" number="2.4.1.3">
<h4><span class="header-section-number">2.4.1.3</span> Gemcitabine + Oxaliplatin</h4>
<ul>
<li>Gemcitabine: 1,000 mg/m2 IV on day 1</li>
<li>Oxaliplatin: 100 mg/m2 on day 2</li>
<li>Repeat cycle every 14 days.</li>
</ul>
<blockquote>
<p>Andre T, et al. Ann Oncol 2004;15:1339–1343.</p>
</blockquote>
</div>
<div id="fluorouracil-cisplatin-1" class="section level4" number="2.4.1.4">
<h4><span class="header-section-number">2.4.1.4</span> 5-Fluorouracil + Cisplatin</h4>
<ul>
<li>5-Fluorouracil: 400 mg/m2 IV on day 1, followed by 600 mg/m2 IV infusion over 22 hours on days 1 and 2</li>
<li>Cisplatin: 50 mg/m2 IV on day 2</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Taieb J, et al. Ann Oncol 2002;13:1192–1196.</p>
</blockquote>
</div>
<div id="capecitabine-cisplatin" class="section level4" number="2.4.1.5">
<h4><span class="header-section-number">2.4.1.5</span> Capecitabine + Cisplatin</h4>
<ul>
<li>Capecitabine: 1,250 mg/m2 PO bid on days 1–14</li>
<li>Cisplatin: 60 mg/m2 IV on day 2</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Hong YS, et al. Cancer Chemother Pharmacol 2007;60:321–328.</p>
</blockquote>
</div>
<div id="capecitabine-oxaliplatin" class="section level4" number="2.4.1.6">
<h4><span class="header-section-number">2.4.1.6</span> Capecitabine + Oxaliplatin</h4>
<ul>
<li>Capecitabine: 1,000 mg/m2 PO bid on days 1–14</li>
<li>Oxaliplatin: 130 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Nehls O, et al. Br J Cancer 2008;98:309–315.</p>
</blockquote>
</div>
</div>
<div id="single-agent-regimens-1" class="section level3" number="2.4.2">
<h3><span class="header-section-number">2.4.2</span> Single-Agent Regimens</h3>
<div id="capecitabine-1" class="section level4" number="2.4.2.1">
<h4><span class="header-section-number">2.4.2.1</span> Capecitabine</h4>
<ul>
<li>Capecitabine: 1,000 mg/m2 PO bid on days 1–14</li>
<li>Repeat cycle every 21 days. Dose may be reduced to 825–900 mg/m2 PO bid on days 1–14.</li>
</ul>
<blockquote>
<p>Patt YZ, et al. Cancer 2004;101:578–586.</p>
</blockquote>
</div>
<div id="docetaxel" class="section level4" number="2.4.2.2">
<h4><span class="header-section-number">2.4.2.2</span> Docetaxel</h4>
<ul>
<li>Docetaxel: 100 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Papakostas P, et al. Eur J Cancer 2001;37:1833–1838.</p>
</blockquote>
</div>
<div id="gemcitabine" class="section level4" number="2.4.2.3">
<h4><span class="header-section-number">2.4.2.3</span> Gemcitabine</h4>
<ul>
<li>Gemcitabine: 1,000 mg/m2 IV on days 1 and 8</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Park JS, et al. Jpn J Clin Oncol 2005;35:68–73.</p>
</blockquote>
</div>
</div>
</div>
<div id="bladder-cancer" class="section level2" number="2.5">
<h2><span class="header-section-number">2.5</span> BLADDER CANCER</h2>
<div id="combination-regimens-2" class="section level3" number="2.5.1">
<h3><span class="header-section-number">2.5.1</span> Combination Regimens</h3>
<div id="itp" class="section level4" number="2.5.1.1">
<h4><span class="header-section-number">2.5.1.1</span> ITP</h4>
<ul>
<li>Ifosfamide: 1,500 mg/m2 IV on days 1–3</li>
<li>Paclitaxel: 200 mg/m2 IV over 3 hours on day 1</li>
<li>Cisplatin: 70 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days. G-CSF support is recommended. Regimen can also be administered every 28 days.</li>
</ul>
<blockquote>
<p>Bajorin DF, et al. Cancer 2000;88:1671–1678.</p>
</blockquote>
</div>
<div id="dose-dense-gemcitabine-cisplatin" class="section level4" number="2.5.1.2">
<h4><span class="header-section-number">2.5.1.2</span> Dose-Dense Gemcitabine + Cisplatin</h4>
<ul>
<li>Gemcitabine: 2,500 mg/m2 IV on day 1</li>
<li>Cisplatin: 35 mg/m2 IV on days 1 and 2</li>
<li>Repeat cycle every 14 days for up to 6 cycles.</li>
</ul>
<blockquote>
<p>Iyer G, et al. J Clin Oncol 2018. doi: 10.1200/JCO.2017.75.0158.</p>
</blockquote>
</div>
<div id="gemcitabine-cisplatin-1" class="section level4" number="2.5.1.3">
<h4><span class="header-section-number">2.5.1.3</span> Gemcitabine + Cisplatin</h4>
<ul>
<li>Gemcitabine: 1,000 mg/m2 IV on days 1, 8, and 15</li>
<li>Cisplatin: 75 mg/m2 IV on day 1</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Kaufman D, et al. J Clin Oncol 2000;18:1921–1927.</p>
</blockquote>
</div>
<div id="gemcitabine-carboplatin" class="section level4" number="2.5.1.4">
<h4><span class="header-section-number">2.5.1.4</span> Gemcitabine + Carboplatin</h4>
<ul>
<li>Gemcitabine: 1,000 mg/m2 IV on days 1 and 8</li>
<li>Carboplatin: AUC of 4, IV on day 1</li>
<li>Repeat cycle every 21 days up to 6 cycles.</li>
</ul>
<blockquote>
<p>Linardou H, et al. Urology 2004;64:479–484.</p>
</blockquote>
</div>
<div id="gemcitabine-paclitaxel" class="section level4" number="2.5.1.5">
<h4><span class="header-section-number">2.5.1.5</span> Gemcitabine + Paclitaxel</h4>
<ul>
<li>Gemcitabine: 1,000 mg/m2 IV on days 1, 8, and 15</li>
<li>Paclitaxel: 200 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Meluch AA, et al. J Clin Oncol 2001;19:3018–3024.</p>
</blockquote>
<p>or</p>
<ul>
<li>Gemcitabine: 2,500 mg/m2 IV on day 1</li>
<li>Paclitaxel: 150 mg/m2 IV on day 1</li>
<li>Repeat cycle every 14 days.</li>
</ul>
<blockquote>
<p>Sternberg CN, et al. Cancer 2001;92:2993–2998.</p>
</blockquote>
</div>
<div id="gemcitabine-docetaxel" class="section level4" number="2.5.1.6">
<h4><span class="header-section-number">2.5.1.6</span> Gemcitabine + Docetaxel</h4>
<ul>
<li>Gemcitabine: 1,000 mg/m2 IV on days 1, 8, and 15</li>
<li>Docetaxel: 60 mg/m2 IV on day 1</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Gitlitz BJ, et al. Cancer 2003;98:1863–1869.</p>
</blockquote>
</div>
<div id="dose-dense-mvac" class="section level4" number="2.5.1.7">
<h4><span class="header-section-number">2.5.1.7</span> Dose-Dense MVAC</h4>
<ul>
<li>Methotrexate: 30 mg/m2 IV on days 1, 15, and 22</li>
<li>Vinblastine: 3 mg/m2 IV on days 2, 15, and 22</li>
<li>Doxorubicin: 30 mg/m2 IV on day 2</li>
<li>Cisplatin: 70 mg/m2 IV on day 2</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Sternberg CN, et al. Cancer 1989;64:2448–2458.</p>
</blockquote>
</div>
<div id="cmv" class="section level4" number="2.5.1.8">
<h4><span class="header-section-number">2.5.1.8</span> CMV</h4>
<ul>
<li>Cisplatin: 100 mg/m2 IV on day 2 (give 12 hours after methotrexate)</li>
<li>Methotrexate: 30 mg/m2 IV on days 1 and 8</li>
<li>Vinblastine: 4 mg/m2 IV on days 1 and 8</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Harker WG, et al. J Clin Oncol 1985;3:1463–1470.</p>
</blockquote>
</div>
<div id="mcv" class="section level4" number="2.5.1.9">
<h4><span class="header-section-number">2.5.1.9</span> MCV</h4>
<ul>
<li>Methotrexate: 30 mg/m2 IV on days 1, 15, and 22</li>
<li>Carboplatin: AUC of 4.5, IV on day 1</li>
<li>Vinblastine: 3 mg/m2 IV on days 1, 15, and 22</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Santis MD, et al. J Clin Oncol 2009;27:5634–5638.</p>
</blockquote>
</div>
<div id="docetaxel-cisplatin" class="section level4" number="2.5.1.10">
<h4><span class="header-section-number">2.5.1.10</span> Docetaxel + Cisplatin</h4>
<ul>
<li>Docetaxel: 75 mg/m2 IV on day 1</li>
<li>Cisplatin: 75 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days up to 6 cycles.</li>
</ul>
<blockquote>
<p>Garcia del Muro X, et al. Br J Cancer 2002;86:326–330.</p>
</blockquote>
</div>
<div id="paclitaxel-carboplatin" class="section level4" number="2.5.1.11">
<h4><span class="header-section-number">2.5.1.11</span> Paclitaxel + Carboplatin</h4>
<ul>
<li>Paclitaxel: 225 mg/m2 IV over 3 hours on day 1</li>
<li>Carboplatin: AUC of 6, IV on day 1, given 15 minutes after paclitaxel</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Vaughn D, et al. Cancer 2002;95:1022–1027.</p>
</blockquote>
</div>
<div id="cap" class="section level4" number="2.5.1.12">
<h4><span class="header-section-number">2.5.1.12</span> CAP</h4>
<ul>
<li>Cyclophosphamide: 400 mg/m2 IV on day 1</li>
<li>Doxorubicin: 40 mg/m2 IV on day 1</li>
<li>Cisplatin: 75 mg/m2 IV on day 2</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Dreicer R, et al. J Clin Oncol 2000;18:1058–1061.</p>
</blockquote>
</div>
<div id="fluorouracil-mitomycin-c-radiation-therapy" class="section level4" number="2.5.1.13">
<h4><span class="header-section-number">2.5.1.13</span> 5-Fluorouracil + Mitomycin-C + Radiation Therapy</h4>
<ul>
<li>5-Fluorouracil: 500 mg/m2/day IV continuous infusion on days 1–5 and 16–20 of radiotherapy</li>
<li>Mitomycin-C: 12 mg/m2 IV on day 1</li>
<li>Radiation therapy 275 cGy/day, 5 days/week for a total of 4 weeks (total dose, 5,500 cGy) or 200 cGy/day for 6.5 weeks (total dose, 6,400 cGy)</li>
<li>Chemotherapy is given concurrently with radiation therapy.</li>
</ul>
<blockquote>
<p>James ND, et al. N Engl J Med 2012;366:1477–1488.</p>
</blockquote>
</div>
</div>
<div id="single-agent-regimens-2" class="section level3" number="2.5.2">
<h3><span class="header-section-number">2.5.2</span> Single-Agent Regimens</h3>
<div id="gemcitabine-1" class="section level4" number="2.5.2.1">
<h4><span class="header-section-number">2.5.2.1</span> Gemcitabine</h4>
<ul>
<li>Gemcitabine: 1,200 mg/m2 IV on days 1, 8, and 15</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Moore MJ, et al. J Clin Oncol 1997;15:3441–3445.</p>
</blockquote>
</div>
<div id="paclitaxel-1" class="section level4" number="2.5.2.2">
<h4><span class="header-section-number">2.5.2.2</span> Paclitaxel</h4>
<ul>
<li>Paclitaxel: 250 mg/m2 IV over 24 hours on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Roth BJ, et al. J Clin Oncol 1994;12:2264–2270.</p>
</blockquote>
<p>or</p>
<ul>
<li>Paclitaxel: 80 mg/m2 IV weekly for 3 weeks</li>
<li>Repeat cycle every 4 weeks.</li>
</ul>
<blockquote>
<p>Vaughn D, et al. J Clin Oncol 2002;20:937–940.</p>
</blockquote>
</div>
<div id="pemetrexed" class="section level4" number="2.5.2.3">
<h4><span class="header-section-number">2.5.2.3</span> Pemetrexed</h4>
<ul>
<li>Pemetrexed: 500 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days.</li>
<li>Folic acid at 350–1,000 µg PO daily beginning 1–2 weeks prior to therapy and vitamin B12 at 1,000 µg IM to start 1–2 weeks prior to first dose of therapy and repeated every 3 cycles.</li>
</ul>
<blockquote>
<p>Sweeney CJ, et al. J Clin Oncol 2006;24:3451–3457.</p>
</blockquote>
</div>
<div id="atezolizumab" class="section level4" number="2.5.2.4">
<h4><span class="header-section-number">2.5.2.4</span> Atezolizumab</h4>
<ul>
<li>Atezolizumab: 1,200 mg IV on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Rosenberg JE, et al. Lancet 2016;387:1909–1920.</p>
</blockquote>
</div>
<div id="avelumab" class="section level4" number="2.5.2.5">
<h4><span class="header-section-number">2.5.2.5</span> Avelumab</h4>
<ul>
<li>Avelumab: 10 mg/kg IV on day 1</li>
<li>Repeat cycle every 14 days.</li>
</ul>
<blockquote>
<p>Powles T, et al. Ann Oncol 2016;27 (suppl 6):842.</p>
</blockquote>
</div>
<div id="darvalumab" class="section level4" number="2.5.2.6">
<h4><span class="header-section-number">2.5.2.6</span> Darvalumab</h4>
<ul>
<li>Darvalumab: 10 mg/kg IV on day 1</li>
<li>Repeat cycle every 14 days.</li>
</ul>
<blockquote>
<p>Massard C, et al. J Clin Oncol 2016;34:3199–3125.</p>
</blockquote>
</div>
<div id="nivolumab-1" class="section level4" number="2.5.2.7">
<h4><span class="header-section-number">2.5.2.7</span> Nivolumab</h4>
<ul>
<li>Nivolumab: 240 mg IV on day 1</li>
<li>Repeat cycle every 14 days.</li>
<li>May also administer at 480 mg IV on day 1 with cycles repeated every 28 days.</li>
</ul>
<blockquote>
<p>Sharma P, et al. Lancet Oncol 2017;18:312–322.</p>
</blockquote>
</div>
<div id="pembrolizumab-2" class="section level4" number="2.5.2.8">
<h4><span class="header-section-number">2.5.2.8</span> Pembrolizumab</h4>
<ul>
<li>Pembrolizumab: 200 mg IV on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Farina MS, et al. Drugs 2017;77:1077–1089.</p>
</blockquote>
</div>
</div>
</div>
<div id="brain-cancer" class="section level2" number="2.6">
<h2><span class="header-section-number">2.6</span> BRAIN CANCER</h2>
<div id="adjuvant-therapy---combination-regimens" class="section level3" number="2.6.1">
<h3><span class="header-section-number">2.6.1</span> Adjuvant Therapy - Combination Regimens</h3>
<div id="temozolomide-radiation-therapy" class="section level4" number="2.6.1.1">
<h4><span class="header-section-number">2.6.1.1</span> Temozolomide Radiation Therapy</h4>
<ul>
<li>Radiation therapy: 200 cGy/day for 5 days per week for total of 6 weeks</li>
<li>Temozolomide: 75 mg/m2 PO daily for 6 weeks with radiation therapy. After a 4-week break, 150 mg/m2 PO on days 1–5</li>
<li>Repeat temozolomide monotherapy every 28 days for up to 6 cycles. If well tolerated, can increase dose to 200 mg/m2 on subsequent cycles. Patients should be placed on either inhaled pentamidine or trimethoprim/sulfamethoxazole for PCP prophylaxis during the combined-modality regimen.</li>
</ul>
<blockquote>
<p>Stupp R, et al. N Engl J Med 2005;352:987–995.</p>
</blockquote>
</div>
<div id="pcv" class="section level4" number="2.6.1.2">
<h4><span class="header-section-number">2.6.1.2</span> PCV</h4>
<ul>
<li>Procarbazine: 60 mg/m2 PO on days 8–21</li>
<li>Lomustine: 130 mg/m2 PO on day 1</li>
<li>Vincristine: 1.4 mg/m2 IV on days 8 and 29</li>
<li>Repeat cycle every 8 weeks for 6 cycles.</li>
</ul>
<blockquote>
<p>Levin VA, et al. Int J Radiat Oncol Biol Phys 1990;18:321–324.</p>
</blockquote>
</div>
</div>
<div id="adjuvant-therapy---single-agent-regimens" class="section level3" number="2.6.2">
<h3><span class="header-section-number">2.6.2</span> Adjuvant Therapy - Single-Agent Regimens</h3>
<div id="carmustine" class="section level4" number="2.6.2.1">
<h4><span class="header-section-number">2.6.2.1</span> Carmustine</h4>
<ul>
<li>Carmustine: 220 mg/m2 IV on day 1</li>
<li>Repeat cycle every 6–8 weeks for 1 year.</li>
</ul>
<blockquote>
<p>DeAngelis LM, et al. Ann Neurol 1998;44:691–695.</p>
</blockquote>
<p>or</p>
<ul>
<li>Carmustine: 75–100 mg/m2 IV on days 1 and 2</li>
<li>Repeat cycle every 6–8 weeks [47].</li>
</ul>
<blockquote>
<p>DeAngelis LM, et al. Ann Neurol 1998;44:691–695.</p>
</blockquote>
</div>
</div>
<div id="advanced-disease---combination-regimens" class="section level3" number="2.6.3">
<h3><span class="header-section-number">2.6.3</span> Advanced Disease - Combination Regimens</h3>
<div id="pcv-1" class="section level4" number="2.6.3.1">
<h4><span class="header-section-number">2.6.3.1</span> PCV</h4>
<ul>
<li>Procarbazine: 75 mg/m2 PO on days 8–21</li>
<li>Lomustine: 130 mg/m2 PO on day 1</li>
<li>Vincristine: 1.4 mg/m2 IV on days 8 and 29</li>
<li>Repeat cycle every 8 weeks.</li>
</ul>
<blockquote>
<p>Buckner JC, et al. J Clin Oncol 2003;21:251–255.</p>
</blockquote>
</div>
<div id="irinotecan-bevacizumab" class="section level4" number="2.6.3.2">
<h4><span class="header-section-number">2.6.3.2</span> Irinotecan + Bevacizumab</h4>
<ul>
<li>Irinotecan: 125 mg/m2 IV on day 1</li>
<li>Bevacizumab: 10 mg/kg IV on day 1</li>
<li>Repeat cycle every 2 weeks for 6 cycles.</li>
</ul>
<blockquote>
<p>Vredenburgh JJ, et al. J Clin Oncol 2007;25:4722–4729.</p>
</blockquote>
</div>
<div id="temozolomide-bevacizumab" class="section level4" number="2.6.3.3">
<h4><span class="header-section-number">2.6.3.3</span> Temozolomide + Bevacizumab</h4>
<ul>
<li>Temozolomide: 150 mg/m2 PO on days 1–5</li>
<li>Bevacizumab: 10 mg/kg IV on days 1 and 14</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Nicholas MK, et al. J Clin Oncol 2009;27:15S (abstract 2016).</p>
</blockquote>
</div>
<div id="carboplatin-irinotecan-bevacizumab" class="section level4" number="2.6.3.4">
<h4><span class="header-section-number">2.6.3.4</span> Carboplatin + Irinotecan + Bevacizumab</h4>
<ul>
<li>Carboplatin: AUC of 4, IV on day 1</li>
<li>Irinotecan: 340 mg/m2 IV on days 1 and 14</li>
<li>Bevacizumab: 10 mg/kg IV on days 1 and 14</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Reardon DA, et al. Cancer 2011;26:188–193.</p>
</blockquote>
</div>
<div id="temozolomide-lomustine" class="section level4" number="2.6.3.5">
<h4><span class="header-section-number">2.6.3.5</span> Temozolomide + Lomustine</h4>
<ul>
<li>Temozolomide: 100 mg/m2 PO on days 2–6</li>
<li>Lomustine: 100 mg/m2 PO on day 1</li>
<li>Repeat cycle every 28 days up to 6 cycles.</li>
</ul>
<blockquote>
<p>Glas M, et al. J Clin Oncol, 2009;27:1257–1261.</p>
</blockquote>
</div>
</div>
<div id="advanced-disease---single-agent-regimens" class="section level3" number="2.6.4">
<h3><span class="header-section-number">2.6.4</span> Advanced Disease - Single-Agent Regimens</h3>
<div id="carmustine-1" class="section level4" number="2.6.4.1">
<h4><span class="header-section-number">2.6.4.1</span> Carmustine</h4>
<ul>
<li>Carmustine: 200 mg/m2 IV on day 1</li>
<li>Repeat cycle every 6–8 weeks.</li>
</ul>
<blockquote>
<p>Yung A, et al. Proc Am Soc Clin Oncol 1999;18:139a.</p>
</blockquote>
</div>
<div id="procarbazine" class="section level4" number="2.6.4.2">
<h4><span class="header-section-number">2.6.4.2</span> Procarbazine</h4>
<ul>
<li>Procarbazine: 150 mg/m2 PO daily divided into 3 doses</li>
<li>Repeat daily.</li>
</ul>
<blockquote>
<p>Yung A, et al. Proc Am Soc Clin Oncol 1999;18:139a.</p>
</blockquote>
</div>
<div id="temozolomide" class="section level4" number="2.6.4.3">
<h4><span class="header-section-number">2.6.4.3</span> Temozolomide</h4>
<ul>
<li>Temozolomide: 150 mg/m2 PO on days 1–5</li>
<li>Repeat cycle every 28 days.</li>
<li>If tolerated, can increase dose to 200 mg/m2.</li>
</ul>
<blockquote>
<p>Yung A, et al. J Clin Oncol 1999;17:2762–2771.</p>
</blockquote>
</div>
<div id="irinotecan-1" class="section level4" number="2.6.4.4">
<h4><span class="header-section-number">2.6.4.4</span> Irinotecan</h4>
<ul>
<li>Irinotecan: 350 mg/m2 IV over 90 min on day 1</li>
<li>Repeat cycle every 3 weeks.</li>
</ul>
<blockquote>
<p>Raymond E, et al. Ann Oncol 2003;14:603–614.</p>
</blockquote>
<p>or</p>
<ul>
<li>Irinotecan: 125 mg/m2 IV weekly for 4 weeks</li>
<li>Repeat cycle every 6 weeks.</li>
</ul>
<blockquote>
<p>Friedman H, et al. J Clin Oncol 1999;17:1516–1525.</p>
</blockquote>
</div>
<div id="bevacizumab-1" class="section level4" number="2.6.4.5">
<h4><span class="header-section-number">2.6.4.5</span> Bevacizumab</h4>
<ul>
<li>Bevacizumab: 15 mg/kg IV on day 1</li>
<li>Repeat cycle every 3 weeks.</li>
</ul>
<blockquote>
<p>Beal K, et al. Radiat Oncol 2011;6:2–15.</p>
</blockquote>
</div>
</div>
</div>
<div id="breast-cancer" class="section level2" number="2.7">
<h2><span class="header-section-number">2.7</span> BREAST CANCER</h2>
<div id="neoadjuvant-therapy---combination-regimens" class="section level3" number="2.7.1">
<h3><span class="header-section-number">2.7.1</span> Neoadjuvant Therapy - Combination Regimens</h3>
<div id="act" class="section level4" number="2.7.1.1">
<h4><span class="header-section-number">2.7.1.1</span> ACT</h4>
<ul>
<li>Doxorubicin: 60 mg/m2 IV on day 1</li>
<li>Cyclophosphamide: 600 mg/m2 IV on day 1</li>
<li>Docetaxel: 100 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days for a total of 4 cycles, followed by surgery.</li>
</ul>
<blockquote>
<p>Bear H, et al. J Clin Oncol 2003;21:4165–4174.</p>
</blockquote>
</div>
<div id="docetaxel-carboplatin-pertuzumab-trastuzumab" class="section level4" number="2.7.1.2">
<h4><span class="header-section-number">2.7.1.2</span> Docetaxel + Carboplatin + Pertuzumab + Trastuzumab</h4>
<ul>
<li>Docetaxel: 75 mg/m2 IV on day 1</li>
<li>Carboplatin: AUC 6, IV on day 1</li>
<li>Pertuzumab: 840 mg IV loading dose on day 1 and then 420 mg IV every 3 weeks</li>
<li>Trastuzumab: 8 mg/kg IV loading dose on day 1 and then 6mg/kg IV every 3 weeks</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Schneeweiss A, et al. Ann Oncol 2013;24:2278–2284.</p>
</blockquote>
</div>
</div>
<div id="adjuvant-therapy---combination-regimens-her2-negative-disease" class="section level3" number="2.7.2">
<h3><span class="header-section-number">2.7.2</span> Adjuvant Therapy - Combination Regimens: HER2-negative disease</h3>
<div id="ac" class="section level4" number="2.7.2.1">
<h4><span class="header-section-number">2.7.2.1</span> AC</h4>
<ul>
<li>Doxorubicin: 60 mg/m2 IV on day 1</li>
<li>Cyclophosphamide: 600 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days for a total of 4 cycles.</li>
</ul>
<blockquote>
<p>Fisher B, et al. J Clin Oncol 2000;8:1483–1496.</p>
</blockquote>
</div>
<div id="act-1" class="section level4" number="2.7.2.2">
<h4><span class="header-section-number">2.7.2.2</span> AC→T</h4>
<ul>
<li>Doxorubicin: 60 mg/m2 IV on day 1</li>
<li>Cyclophosphamide: 600 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days for a total of 4 cycles, followed by</li>
<li>Paclitaxel: 175 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days for a total of 4 cycles.</li>
</ul>
<blockquote>
<p>Hudis C, et al. J Clin Oncol 1999;17:93–100.</p>
</blockquote>
</div>
<div id="act-weekly" class="section level4" number="2.7.2.3">
<h4><span class="header-section-number">2.7.2.3</span> AC→T (weekly)</h4>
<ul>
<li>Doxorubicin: 60 mg/m2 IV on day 1</li>
<li>Cyclophosphamide: 600 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days for a total of 4 cycles, followed by</li>
<li>Paclitaxel: 80 mg/m2 IV on day 1</li>
<li>Repeat on a weekly schedule for 12 weeks.</li>
</ul>
<blockquote>
<p>Sparano JA, et al. N Engl J Med 2008;358:1663–1671.</p>
</blockquote>
</div>
<div id="acdocetaxel" class="section level4" number="2.7.2.4">
<h4><span class="header-section-number">2.7.2.4</span> AC→Docetaxel</h4>
<ul>
<li>Doxorubicin: 60 mg/m2 IV on day 1</li>
<li>Cyclophosphamide: 600 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days for a total of 4 cycles, followed by</li>
<li>Docetaxel: 100 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days for a total of 4 cycles.</li>
</ul>
<blockquote>
<p>Sparano J, et al. San Antonio Breast Cancer Symposium 2005 (abstract 48).</p>
</blockquote>
</div>
<div id="acdocetaxel-weekly" class="section level4" number="2.7.2.5">
<h4><span class="header-section-number">2.7.2.5</span> AC→Docetaxel (weekly)</h4>
<ul>
<li>Doxorubicin: 60 mg/m2 IV on day 1</li>
<li>Cyclophosphamide: 600 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days for a total of 4 cycles, followed by</li>
<li>Docetaxel: 35 mg/m2 IV on day 1</li>
<li>Repeat weekly for a total of 12 weeks.</li>
</ul>
<blockquote>
<p>Jones S, et al. J Clin Oncol 2006;24:5381–5387.</p>
</blockquote>
</div>
<div id="tc" class="section level4" number="2.7.2.6">
<h4><span class="header-section-number">2.7.2.6</span> TC</h4>
<ul>
<li>Docetaxel: 75 mg/m2 IV on day 1</li>
<li>Cyclophosphamide: 600 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days for a total of 4 cycles.</li>
</ul>
<blockquote>
<p>Martin M, et al. N Engl J Med 2005;352:2302–2313.</p>
</blockquote>
</div>
<div id="tac" class="section level4" number="2.7.2.7">
<h4><span class="header-section-number">2.7.2.7</span> TAC</h4>
<ul>
<li>Docetaxel: 75 mg/m2 IV on day 1</li>
<li>Doxorubicin: 50 mg/m2 IV on day 1</li>
<li>Cyclophosphamide: 500 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days for a total of 6 cycles.</li>
</ul>
<blockquote>
<p>Budman DR, et al. J Natl Cancer Inst 1998;90:1205–1211.</p>
</blockquote>
</div>
<div id="caf" class="section level4" number="2.7.2.8">
<h4><span class="header-section-number">2.7.2.8</span> CAF</h4>
<ul>
<li>Cyclophosphamide: 600 mg/m2 IV on day 1</li>
<li>Doxorubicin: 60 mg/m2 IV on day 1</li>
<li>5-Fluorouracil: 600 mg/m2 IV on day 1</li>
<li>Repeat cycle every 28 days for a total of 4 cycles.</li>
</ul>
<blockquote>
<p>Weiss RB, et al. Am J Med 1987;83:455–463.</p>
</blockquote>
</div>
<div id="epirubicin-cmf" class="section level4" number="2.7.2.9">
<h4><span class="header-section-number">2.7.2.9</span> Epirubicin + CMF</h4>
<ul>
<li>Epirubicin: 100 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days for 4 cycles, followed by</li>
<li>Cyclophosphamide: 600 mg/m2 IV on day 1</li>
<li>Methotrexate: 40 mg/m2 IV on day 1</li>
<li>5-Fluorouracil: 600 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days for a total of 4 cycles.</li>
</ul>
<blockquote>
<p>Poole CJ, et al. N Engl J Med 2006;355:1851–1862.</p>
</blockquote>
</div>
<div id="fec" class="section level4" number="2.7.2.10">
<h4><span class="header-section-number">2.7.2.10</span> FEC</h4>
<ul>
<li>5-Fluorouracil: 500 mg/m2 IV on day 1</li>
<li>Epirubicin: 100 mg/m2 IV on day 1</li>
<li>Cyclophosphamide: 500 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days for a total of 6 cycles.</li>
</ul>
<blockquote>
<p>Coombes RC, et al. J Clin Oncol 1996;14:35–45.</p>
</blockquote>
</div>
<div id="fecdocetaxel" class="section level4" number="2.7.2.11">
<h4><span class="header-section-number">2.7.2.11</span> FEC→Docetaxel</h4>
<ul>
<li>5-Fluorouracil: 500 mg/m2 IV on day 1</li>
<li>Epirubicin: 100 mg/m2 IV on day 1</li>
<li>Cyclophosphamide: 500 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days for a total of 6 cycles, followed by</li>
<li>Docetaxel: 100 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days for 3 cycles.</li>
</ul>
<blockquote>
<p>Roche H, et al. J Clin Oncol 2006;24:5664–5671.</p>
</blockquote>
</div>
</div>
<div id="adjuvant-therapy---dose-dense-combination-regimens-her2-negative-disease" class="section level3" number="2.7.3">
<h3><span class="header-section-number">2.7.3</span> Adjuvant Therapy - Dose-Dense Combination Regimens: HER2-negative disease</h3>
<div id="act-2" class="section level4" number="2.7.3.1">
<h4><span class="header-section-number">2.7.3.1</span> AC→T</h4>
<ul>
<li>Doxorubicin: 60 mg/m2 IV on day 1</li>
<li>Cyclophosphamide: 600 mg/m2 IV on day 1</li>
<li>Repeat cycle every 14 days for a total of 4 cycles, followed by</li>
<li>Paclitaxel: 175 mg/m2 IV on day 1</li>
<li>Repeat cycle every 14 days for a total of 4 cycles.</li>
<li>Administer pegfilgrastim 6 mg SC on day 2 of each treatment cycle.</li>
</ul>
<blockquote>
<p>Burstein HJ, et al. J Clin Oncol 2005;23:8340–8347.</p>
</blockquote>
</div>
<div id="atc" class="section level4" number="2.7.3.2">
<h4><span class="header-section-number">2.7.3.2</span> A→T→C</h4>
<ul>
<li>Doxorubicin: 60 mg/m2 IV on day 1</li>
<li>Repeat cycle every 2 weeks for 4 cycles, followed by</li>
<li>Paclitaxel: 175 mg/m2 IV on day 1</li>
<li>Repeat cycle every 2 weeks for 4 cycles, followed by</li>
<li>Cyclophosphamide: 600 mg/m2 IV on day 1</li>
<li>Repeat cycle every 2 weeks for 4 cycles.</li>
<li>Administer filgrastim 5 µg/kg SC on days 3–10 of each treament cycle.</li>
</ul>
<blockquote>
<p>Citron M, et al. J Clin Oncol 2003;21:1431–1439.</p>
</blockquote>
</div>
<div id="acdocetaxel-1" class="section level4" number="2.7.3.3">
<h4><span class="header-section-number">2.7.3.3</span> AC→Docetaxel</h4>
<ul>
<li>Doxorubicin: 60 mg/m2 IV on day 1</li>
<li>Cyclophosphamide: 600 mg/m2 IV on day 1</li>
<li>Repeat cycle every 14 days for a total of 4 cycles, followed by</li>
<li>Docetaxel: 75 mg/m2 IV on day 1</li>
<li>Repeat cycle every 14 days for a total of 4 cycles.</li>
<li>Administer pegfilgrastim 6 mg SC on day 2 of each treatment cycle.</li>
</ul>
<blockquote>
<p>Puhalla S, et al. J Clin Oncol 2008;26:1691–1697.</p>
</blockquote>
</div>
<div id="docetaxelac" class="section level4" number="2.7.3.4">
<h4><span class="header-section-number">2.7.3.4</span> Docetaxel→AC</h4>
<ul>
<li>Docetaxel: 75 mg/m2 IV on day 1</li>
<li>Repeat cycle every 14 days for a total of 4 cycles, followed by</li>
<li>Doxorubicin: 60 mg/m2 IV on day 1</li>
<li>Cyclophosphamide: 600 mg/m2 IV on day 1</li>
<li>Repeat cycle every 14 days for a total of 4 cycles.</li>
<li>Administer pegfilgrastim 6 mg SC on day 2 of each treatment cycle.</li>
</ul>
<blockquote>
<p>Puhalla S, et al. J Clin Oncol 2008;26:1691–1697.</p>
</blockquote>
</div>
</div>
<div id="adjuvant-therapy---combination-regimens-her2-positive-disease" class="section level3" number="2.7.4">
<h3><span class="header-section-number">2.7.4</span> Adjuvant Therapy - Combination Regimens: HER2-positive disease</h3>
<div id="act-trastuzumab" class="section level4" number="2.7.4.1">
<h4><span class="header-section-number">2.7.4.1</span> AC→T + Trastuzumab</h4>
<ul>
<li>Doxorubicin: 60 mg/m2 IV on day 1</li>
<li>Cyclophosphamide: 600 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days for a total of 4 cycles, followed by</li>
<li>Paclitaxel: 80 mg/m2 IV over 1 hour on day 1</li>
<li>Trastuzumab: 4 mg/kg IV loading dose, then 2 mg/kg IV weekly</li>
<li>Repeat weekly for 12 weeks, followed by</li>
<li>Trastuzumab: 2 mg/kg IV weekly</li>
<li>Repeat weekly for 40 weeks.</li>
</ul>
<blockquote>
<p>Romond EH, et al. N Engl J Med. 2005;353:1673–1684.</p>
</blockquote>
</div>
<div id="act-trastuzumab-dose-dense" class="section level4" number="2.7.4.2">
<h4><span class="header-section-number">2.7.4.2</span> AC→T + Trastuzumab (dose dense)</h4>
<ul>
<li>Doxorubicin: 60 mg/m2 IV on day 1</li>
<li>Cyclophosphamide: 600 mg/m2 IV on day 1</li>
<li>Repeat cycle every 14 days for a total of 4 cycles, followed by</li>
<li>Paclitaxel: 175 mg/m2 IV on day 1</li>
<li>Repeat cycle every 14 days for a total of 4 cycles.</li>
<li>Trastuzumab: 4 mg/kg IV loading dose along with paclitaxel and then 2 mg/kg IV weekly</li>
<li>Trastuzumab is administered for a total of 1 year.</li>
</ul>
<blockquote>
<p>Dang C, et al. J Clin Oncol 2006;24:17S (abstract 582).</p>
</blockquote>
</div>
<div id="tch" class="section level4" number="2.7.4.3">
<h4><span class="header-section-number">2.7.4.3</span> TCH</h4>
<ul>
<li>Docetaxel: 75 mg/m2 IV on day 1</li>
<li>Carboplatin: AUC of 6, IV on day 1</li>
<li>Trastuzumab: 4 mg/kg IV loading dose and then 2 mg/kg IV weekly</li>
<li>Repeat chemotherapy every 21 days for a total of 6 cycles. At the completion of chemotherapy, trastuzumab is administered at 6 mg/kg IV every 3 weeks for a total of 1 year.</li>
</ul>
<blockquote>
<p>Slamon D, et al. San Antonio Breast Cancer Symposium 2006 (abstract 52).</p>
</blockquote>
</div>
<div id="dhfec" class="section level4" number="2.7.4.4">
<h4><span class="header-section-number">2.7.4.4</span> DH→FEC</h4>
<ul>
<li>Docetaxel: 100 mg/m2 IV on day 1</li>
<li>Trastuzumab 4 mg/kg IV loading dose on day 1 and then 2 mg/kg IV weekly</li>
<li>Repeat cycle every 21 days for 3 cycles, followed by</li>
<li>5-Fluorouracil: 600 mg/m2 IV on day 1</li>
<li>Epirubicin: 60 mg/m2 IV on day 1</li>
<li>Cyclophosphamide: 600 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days for 3 cycles.</li>
</ul>
<blockquote>
<p>Joensuu H, et al. N Engl J Med 2006;354:809–820.</p>
</blockquote>
</div>
<div id="pertuzumab-trastuzumab-docetaxel" class="section level4" number="2.7.4.5">
<h4><span class="header-section-number">2.7.4.5</span> Pertuzumab + Trastuzumab + Docetaxel</h4>
<ul>
<li>Docetaxel: 75 mg/m2 IV on day 1</li>
<li>Trastuzumab: 8 mg/kg IV loading dose on day 1 and then 6 mg/kg IV every 3 weeks</li>
<li>Pertuzumab: 840 mg IV loading dose on day 1 and then 420 mg IV every 3 weeks</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Baselga J, et al. N Engl J Med 2012;366:109–119.</p>
</blockquote>
</div>
</div>
<div id="adjuvant-therapy---single-agent-regimens-1" class="section level3" number="2.7.5">
<h3><span class="header-section-number">2.7.5</span> Adjuvant Therapy - Single-Agent Regimens</h3>
<div id="neratinib" class="section level4" number="2.7.5.1">
<h4><span class="header-section-number">2.7.5.1</span> Neratinib</h4>
<ul>
<li>Neratinib: 240 mg PO daily</li>
<li>Repeat daily for 1 year in patients following trastuzumab-based adjuvant therapy.</li>
</ul>
<blockquote>
<p>Chan A, et al. Lancet Oncol 2016;17:367–377.</p>
</blockquote>
</div>
</div>
<div id="adjuvant-therapy---hormonal-regimens" class="section level3" number="2.7.6">
<h3><span class="header-section-number">2.7.6</span> Adjuvant Therapy - Hormonal Regimens</h3>
<div id="tamoxifen" class="section level4" number="2.7.6.1">
<h4><span class="header-section-number">2.7.6.1</span> Tamoxifen</h4>
<ul>
<li>Tamoxifen: 20 mg PO daily</li>
<li>Repeat daily for 5 years in patients with ER+ tumors or ER status unknown.</li>
</ul>
<blockquote>
<p>Fisher B, et al. J Natl Cancer Inst 1997;89:1673–1682.</p>
</blockquote>
</div>
<div id="anastrozole" class="section level4" number="2.7.6.2">
<h4><span class="header-section-number">2.7.6.2</span> Anastrozole</h4>
<ul>
<li>Anastrozole: 1 mg PO daily</li>
<li>Repeat daily for 5 years in patients with ER+ tumors or ER status unknown.</li>
</ul>
<blockquote>
<p>Howell A, et al. Lancet 2005;365:60–62.</p>
</blockquote>
</div>
<div id="letrozole" class="section level4" number="2.7.6.3">
<h4><span class="header-section-number">2.7.6.3</span> Letrozole</h4>
<ul>
<li>Letrozole: 2.5 mg PO daily</li>
<li>Repeat daily for 5 years in patients with ER+ or PR+ tumors.</li>
</ul>
<blockquote>
<p>BIG I-98 Collaborative Group, et al. N Engl J Med 2009;361:766–776.</p>
</blockquote>
</div>
<div id="tamoxifen-letrozole" class="section level4" number="2.7.6.4">
<h4><span class="header-section-number">2.7.6.4</span> Tamoxifen + Letrozole</h4>
<ul>
<li>Tamoxifen: 20 mg PO daily for 5 years, followed by</li>
<li>Letrozole: 2.5 mg PO daily for 5 years</li>
</ul>
<blockquote>
<p>Goss PE, et al. J Natl Cancer Inst 2005;97:1262–1271.</p>
</blockquote>
</div>
<div id="tamoxifen-exemestane" class="section level4" number="2.7.6.5">
<h4><span class="header-section-number">2.7.6.5</span> Tamoxifen + Exemestane</h4>
<ul>
<li>Tamoxifen: 20 mg PO daily for 2–3 years, followed by</li>
<li>Exemestane: 25 mg PO daily for the remainder of 5 years</li>
</ul>
<blockquote>
<p>Coombes RC, et al. N Engl J Med 2004;350:1081–1092.</p>
</blockquote>
</div>
<div id="tamoxifen-goserelin-zoledronic-acid" class="section level4" number="2.7.6.6">
<h4><span class="header-section-number">2.7.6.6</span> Tamoxifen + Goserelin + Zoledronic acid</h4>
<ul>
<li>Tamoxifen: 20 mg PO daily</li>
<li>Goserelin: 3.6 mg SC every 28 days</li>
<li>Zoledronic acid: 4 mg IV every 6 months</li>
<li>Continue treatment for a total of 3 years.</li>
</ul>
<blockquote>
<p>Gnant M, et al. N Engl J Med 2009;360:679–691.</p>
</blockquote>
</div>
<div id="anastrozole-goserelin-zoledronic-acid" class="section level4" number="2.7.6.7">
<h4><span class="header-section-number">2.7.6.7</span> Anastrozole + Goserelin + Zoledronic acid</h4>
<ul>
<li>Anastrozole: 1 mg PO daily</li>
<li>Goserelin: 3.6 mg SC every 28 days</li>
<li>Zoledronic acid: 4 mg IV every 6 months</li>
<li>Continue treatment for a total of 3 years.</li>
</ul>
<blockquote>
<p>Gnant M, et al. N Engl J Med 2009;360:679–691.</p>
</blockquote>
</div>
<div id="everolimus-exemestane" class="section level4" number="2.7.6.8">
<h4><span class="header-section-number">2.7.6.8</span> Everolimus + Exemestane</h4>
<ul>
<li>Everolimus: 10 mg PO daily</li>
<li>Exemestane: 25 mg PO daily</li>
</ul>
<blockquote>
<p>Baselga J, et al. N Engl J Med 2012;366:520–529.</p>
</blockquote>
</div>
</div>
<div id="metastatic-disease---combination-regimens-her2-negative-disease" class="section level3" number="2.7.7">
<h3><span class="header-section-number">2.7.7</span> Metastatic Disease - Combination Regimens: HER2-negative disease</h3>
<div id="ac-1" class="section level4" number="2.7.7.1">
<h4><span class="header-section-number">2.7.7.1</span> AC</h4>
<ul>
<li>Doxorubicin: 60 mg/m2 IV on day 1</li>
<li>Cyclophosphamide: 600 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Fisher B, et al. J Clin Oncol 2000;8:1483–1496.</p>
</blockquote>
</div>
<div id="at" class="section level4" number="2.7.7.2">
<h4><span class="header-section-number">2.7.7.2</span> AT</h4>
<ul>
<li>Doxorubicin: 50 mg/m2 IV on day 1</li>
<li>Paclitaxel: 150 mg/m2 IV over 24 hours on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Sledge GE, et al. J Clin Oncol 2003;21:588–592.</p>
</blockquote>
<p>or</p>
<ul>
<li>Doxorubicin: 60 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days up to a maximum of 8 cycles, followed by</li>
<li>Paclitaxel: 175 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days until disease progression.</li>
</ul>
<blockquote>
<p>Sledge GE, et al. J Clin Oncol 2003;21:588–592.</p>
</blockquote>
<p>or</p>
<ul>
<li>Paclitaxel: 175 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days until disease progression, followed by</li>
<li>Doxorubicin: 60 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days up to a maximum of 8 cycles.</li>
</ul>
<blockquote>
<p>Sledge GE, et al. J Clin Oncol 2003;21:588–592.</p>
</blockquote>
</div>
<div id="caf-1" class="section level4" number="2.7.7.3">
<h4><span class="header-section-number">2.7.7.3</span> CAF</h4>
<ul>
<li>Cyclophosphamide: 600 mg/m2 IV on day 1</li>
<li>Doxorubicin: 60 mg/m2 IV on day 1</li>
<li>5-Fluorouracil: 600 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Weiss RB, et al. Am J Med 1987;83:455–463.</p>
</blockquote>
</div>
<div id="cef" class="section level4" number="2.7.7.4">
<h4><span class="header-section-number">2.7.7.4</span> CEF</h4>
<ul>
<li>Cyclophosphamide: 75 mg/m2 PO on days 1–14</li>
<li>Epirubicin: 60 mg/m2 IV on days 1 and 8</li>
<li>5-Fluorouracil: 500 mg/m2 IV on days 1 and 8</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Levine MN, et al. J Clin Oncol 1998;16:2651–2658.</p>
</blockquote>
</div>
<div id="cmf" class="section level4" number="2.7.7.5">
<h4><span class="header-section-number">2.7.7.5</span> CMF</h4>
<ul>
<li>Cyclophosphamide: 600 mg/m2 IV on day 1</li>
<li>Methotrexate: 40 mg/m2 IV on day 1</li>
<li>5-Fluorouracil: 600 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Poole CJ, et al. N Engl J Med 2006;355:1851–1862.</p>
</blockquote>
</div>
<div id="capecitabine-docetaxel-xt" class="section level4" number="2.7.7.6">
<h4><span class="header-section-number">2.7.7.6</span> Capecitabine + Docetaxel (XT)</h4>
<ul>
<li>Capecitabine: 1,250 mg/m2 PO bid on days 1–14</li>
<li>Docetaxel: 75 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days.</li>
<li>May decrease dose of capecitabine to 825–1,000 mg/m2 PO bid on days 1–14 to reduce the risk of toxicity without compromising clinical efficacy.</li>
</ul>
<blockquote>
<p>O’Shaughnessy J, et al. J Clin Oncol 2002;20:2812–2823.</p>
</blockquote>
</div>
<div id="capecitabine-paclitaxel-xp" class="section level4" number="2.7.7.7">
<h4><span class="header-section-number">2.7.7.7</span> Capecitabine + Paclitaxel (XP)</h4>
<ul>
<li>Capecitabine: 825 mg/m2 PO bid on days 1–14</li>
<li>Paclitaxel: 175 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Biganzoli L, et al. Oncologist 2002;7 (Suppl):29–35.</p>
</blockquote>
</div>
<div id="capecitabine-navelbine-xn" class="section level4" number="2.7.7.8">
<h4><span class="header-section-number">2.7.7.8</span> Capecitabine + Navelbine (XN)</h4>
<ul>
<li>Capecitabine: 1,000 mg/m2 PO bid on days 1–14</li>
<li>Navelbine: 25 mg/m2 IV on days 1 and 8</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Biganzoli L, et al. Oncologist 2002;7 (Suppl):29–35.</p>
</blockquote>
</div>
<div id="capecitabine-ixabepilone-xi" class="section level4" number="2.7.7.9">
<h4><span class="header-section-number">2.7.7.9</span> Capecitabine + Ixabepilone (XI)</h4>
<ul>
<li>Capecitabine: 1,000 mg/m2 PO bid on days 1–14</li>
<li>Ixabepilone: 40 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Thomas ES, et al. J Clin Oncol 2007;25:5210–5217.</p>
</blockquote>
</div>
<div id="docetaxel-doxorubicin" class="section level4" number="2.7.7.10">
<h4><span class="header-section-number">2.7.7.10</span> Docetaxel + Doxorubicin</h4>
<ul>
<li>Docetaxel: 75 mg/m2 IV on day 1</li>
<li>Doxorubicin: 50 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Dieras V. Oncology 1997;11:31–33.</p>
</blockquote>
</div>
<div id="doxorubicin-liposome-docetaxel" class="section level4" number="2.7.7.11">
<h4><span class="header-section-number">2.7.7.11</span> Doxorubicin liposome + Docetaxel</h4>
<ul>
<li>Doxorubicin liposome: 30 mg/m2 on day 1</li>
<li>Docetaxel: 60 mg/m2 on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Brufman G, et al. Ann Oncol 1997;8:155–162.</p>
</blockquote>
</div>
<div id="fec-100" class="section level4" number="2.7.7.12">
<h4><span class="header-section-number">2.7.7.12</span> FEC-100</h4>
<ul>
<li>5-Fluorouracil: 500 mg/m2 IV on day 1</li>
<li>Epirubicin: 100 mg/m2 IV on day 1</li>
<li>Cyclophosphamide: 500 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Sparano JA, et al. J Clin Oncol 2001;19:3117–3125.</p>
</blockquote>
</div>
<div id="fec-75" class="section level4" number="2.7.7.13">
<h4><span class="header-section-number">2.7.7.13</span> FEC-75</h4>
<ul>
<li>5-Fluorouracil: 500 mg/m2 IV on day 1</li>
<li>Epirubicin: 75 mg/m2 IV on day 1</li>
<li>Cyclophosphamide: 500 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>The French Epirubicin Study Group. J Clin Oncol 1991;9:305–312.</p>
</blockquote>
</div>
<div id="fec-50" class="section level4" number="2.7.7.14">
<h4><span class="header-section-number">2.7.7.14</span> FEC-50</h4>
<ul>
<li>5-Fluorouracil: 500 mg/m2 IV on day 1</li>
<li>Epirubicin: 50 mg/m2 IV on day 1</li>
<li>Cyclophosphamide: 500 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>The French Epirubicin Study Group. J Clin Oncol 1991;9:305–312.</p>
</blockquote>
</div>
<div id="gemcitabine-paclitaxel-1" class="section level4" number="2.7.7.15">
<h4><span class="header-section-number">2.7.7.15</span> Gemcitabine + Paclitaxel</h4>
<ul>
<li>Gemcitabine: 1,250 mg/m2 IV on days 1 and 8</li>
<li>Paclitaxel: 175 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>O’Shaughnessy J, et al. Proc Am Soc Clin Oncol 2003;22:7 (abstract 25).</p>
</blockquote>
</div>
<div id="carboplatin-paclitaxel" class="section level4" number="2.7.7.16">
<h4><span class="header-section-number">2.7.7.16</span> Carboplatin + Paclitaxel</h4>
<ul>
<li>Carboplatin: AUC of 6, IV on day 1</li>
<li>Paclitaxel: 200 mg/m2 IV over 3 hours on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Perez EA, et al. Cancer 2000;88:124–131.</p>
</blockquote>
</div>
<div id="carboplatin-docetaxel" class="section level4" number="2.7.7.17">
<h4><span class="header-section-number">2.7.7.17</span> Carboplatin + Docetaxel</h4>
<ul>
<li>Carboplatin: AUC of 6, IV on day 1</li>
<li>Docetaxel: 75 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Fitch V, et al. Proc Am Soc Clin Oncol 2003;22:23 (abstract 90).</p>
</blockquote>
</div>
<div id="paclitaxel-bevacizumab" class="section level4" number="2.7.7.18">
<h4><span class="header-section-number">2.7.7.18</span> Paclitaxel + Bevacizumab</h4>
<ul>
<li>Paclitaxel: 90 mg/m2 IV on days 1, 8, and 15</li>
<li>Bevacizumab: 10 mg/kg on days 1 and 15</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Miller K, et al. N Engl J Med 2007;35:2666–2676.</p>
</blockquote>
</div>
</div>
<div id="metastatic-disease---combination-regimens-her2-positive-disease" class="section level3" number="2.7.8">
<h3><span class="header-section-number">2.7.8</span> Metastatic Disease - Combination Regimens: HER2-positive disease</h3>
<div id="pertuzumab-trastuzumab-docetaxel-1" class="section level4" number="2.7.8.1">
<h4><span class="header-section-number">2.7.8.1</span> Pertuzumab + Trastuzumab + Docetaxel</h4>
<ul>
<li>Docetaxel: 75 mg/m2 IV on day 1</li>
<li>Trastuzumab: 8 mg/kg IV loading dose on day 1 and then 6 mg/kg IV every 3 weeks</li>
<li>Pertuzumab: 840 mg IV loading dose on day 1 and then 420 mg IV every 3 weeks</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Baselga J, et al. N Engl J Med 2012;366:109–119.</p>
</blockquote>
</div>
<div id="trastuzumab-paclitaxel" class="section level4" number="2.7.8.2">
<h4><span class="header-section-number">2.7.8.2</span> Trastuzumab + Paclitaxel</h4>
<ul>
<li>Trastuzumab: 4 mg/kg IV loading dose and then 2 mg/kg weekly</li>
<li>Paclitaxel: 175 mg/m2 IV over 3 hours on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Slamon DJ, et al. N Engl J Med 2001;344:783–792.</p>
</blockquote>
<p>or</p>
<ul>
<li>Trastuzumab: 4 mg/kg IV loading dose and then 2 mg/kg weekly</li>
<li>Paclitaxel: 80 mg/m2 IV weekly</li>
<li>Repeat cycle every 4 weeks.</li>
</ul>
<blockquote>
<p>Goldenberg MM, et al. Clin Ther 1999;21:309–318.</p>
</blockquote>
</div>
<div id="trastuzumab-docetaxel" class="section level4" number="2.7.8.3">
<h4><span class="header-section-number">2.7.8.3</span> Trastuzumab + Docetaxel</h4>
<ul>
<li>Trastuzumab: 4 mg/kg IV loading dose and then 2 mg/kg IV on days 8 and 15 Docetaxel: 35 mg/m2 IV on days 1, 8, and 15</li>
<li>First cycle is administered weekly for 3 weeks, with 1-week rest. For subsequent cycles,</li>
<li>Trastuzumab: 2 mg/kg IV weekly
Docetaxel: 35 mg/m2 IV weekly</li>
<li>Repeat cycle every 4 weeks.</li>
</ul>
<blockquote>
<p>Francisco E, et al. J Clin Oncol 2002;20:1800–1808.</p>
</blockquote>
</div>
<div id="tch-1" class="section level4" number="2.7.8.4">
<h4><span class="header-section-number">2.7.8.4</span> TCH</h4>
<ul>
<li>Carboplatin: AUC of 6, IV on day 1</li>
<li>Docetaxel: 75 mg/m2 IV on day 1</li>
<li>Trastuzumab: 4 mg/kg IV loading dose on day 1 and then 2 mg/kg IV on days 8 and 15, 2 mg/kg IV weekly thereafter</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Pegram M, et al. Proc Am Soc Clin Oncol 2007;25 (LBA1008).</p>
</blockquote>
</div>
<div id="gemcitabine-carboplatin-trastuzumab" class="section level4" number="2.7.8.5">
<h4><span class="header-section-number">2.7.8.5</span> Gemcitabine + Carboplatin + Trastuzumab</h4>
<ul>
<li>Gemcitabine: 1,500 mg/m2 IV on day 1</li>
<li>Carboplatin: AUC of 2.5, IV on day 1</li>
<li>Trastuzumab: 8 mg/kg IV loading dose on day 1 and then 4 mg/kg IV every 2 weeks</li>
<li>Repeat cycle every 2 weeks.</li>
</ul>
<blockquote>
<p>Loesch D, et al. Clin Breast Cancer 2008;8:178–186.</p>
</blockquote>
</div>
<div id="trastuzumab-navelbine" class="section level4" number="2.7.8.6">
<h4><span class="header-section-number">2.7.8.6</span> Trastuzumab + Navelbine</h4>
<ul>
<li>Trastuzumab: 4 mg/kg IV loading dose and then 2 mg/kg IV weekly</li>
<li>Navelbine: 25 mg/m2 IV weekly</li>
<li>Repeat on a weekly basis until disease progression.</li>
</ul>
<blockquote>
<p>Burstein HJ, et al. J Clin Oncol 2001;19:2722–2730.</p>
</blockquote>
</div>
<div id="trastuzumab-gemcitabine" class="section level4" number="2.7.8.7">
<h4><span class="header-section-number">2.7.8.7</span> Trastuzumab + Gemcitabine</h4>
<ul>
<li>Trastuzumab: 4 mg/kg IV loading dose and then 2 mg/kg IV weekly</li>
<li>Gemcitabine: 1,200 mg/m2 IV weekly for 2 weeks</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>O’Shaughnessy J, et al. Clin Breast Cancer 2004;5:142–147.</p>
</blockquote>
</div>
<div id="trastuzumab-capecitabine" class="section level4" number="2.7.8.8">
<h4><span class="header-section-number">2.7.8.8</span> Trastuzumab + Capecitabine</h4>
<ul>
<li>Trastuzumab: 4 mg/kg IV loading dose and then 2 mg/kg IV weekly</li>
<li>Capecitabine: 1,250 mg/m2 PO bid on days 1–14</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Schaller G, et al. J Clin Oncol 2007;25:3246–3250.</p>
</blockquote>
<p>or</p>
<ul>
<li>Trastuzumab: 8 mg/kg IV loading dose and then 6 mg/kg IV on day 1 of all subsequent cycles</li>
<li>Capecitabine: 1,250 mg/m2 PO bid on days 1–14</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Bartsch R, et al. J Clin Oncol 2007;25:3853–3858.</p>
</blockquote>
</div>
<div id="trastuzumab-lapatinib" class="section level4" number="2.7.8.9">
<h4><span class="header-section-number">2.7.8.9</span> Trastuzumab + Lapatinib</h4>
<ul>
<li>Trastuzumab: 4 mg/kg IV loading dose and then 2 mg/kg IV weekly</li>
<li>Lapatinib: 1,000 mg PO daily</li>
<li>Continue until disease progression.</li>
</ul>
<blockquote>
<p>Blackwell KL, et al. J Clin Oncol 2010;28:1124–1130.</p>
</blockquote>
</div>
<div id="capecitabine-lapatinib" class="section level4" number="2.7.8.10">
<h4><span class="header-section-number">2.7.8.10</span> Capecitabine + Lapatinib</h4>
<ul>
<li>Capecitabine: 1,000 mg/m2 PO bid on days 1–14</li>
<li>Lapatinib: 1,250 mg PO daily</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Geyer CE, et al. N Engl J Med 2006;355:2733–2743.</p>
</blockquote>
</div>
<div id="everolimus-exemestane-1" class="section level4" number="2.7.8.11">
<h4><span class="header-section-number">2.7.8.11</span> Everolimus + Exemestane</h4>
<ul>
<li>Everolimus: 10 mg PO daily</li>
<li>Exemestane: 25 mg PO daily</li>
</ul>
<blockquote>
<p>Baselga J, et al. N Engl J Med 2012;366:520–529.</p>
</blockquote>
</div>
<div id="palbociclib-letrozole" class="section level4" number="2.7.8.12">
<h4><span class="header-section-number">2.7.8.12</span> Palbociclib + Letrozole</h4>
<ul>
<li>Palbociclib: 125 mg PO daily for 21 days</li>
<li>Letrozole: 2.5 mg PO daily</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Finn RS, et al. Lancet Oncol 2015;16;25–35.</p>
</blockquote>
</div>
<div id="ribociclib-letrozole" class="section level4" number="2.7.8.13">
<h4><span class="header-section-number">2.7.8.13</span> Ribociclib + Letrozole</h4>
<ul>
<li>Ribociclib: 600 mg PO daily for 21 days</li>
<li>Letrozole: 2.5 mg PO daily</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Hortobagyi GN, et al. N Engl J Med 2016;375:1738–1748.</p>
</blockquote>
</div>
<div id="palbociclib-fulvestrant" class="section level4" number="2.7.8.14">
<h4><span class="header-section-number">2.7.8.14</span> Palbociclib + Fulvestrant</h4>
<ul>
<li>Palbociclib: 125 mg PO daily for 21 days</li>
<li>Fulvestrant: 500 mg IM on days 1 and 15 of first cycle and then 500 mg IM on day 1 for all subsequent cycles</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Turner NC, et al. N Engl J Med 2015;373:209–219.</p>
</blockquote>
</div>
<div id="abemaciclib-fulvestrant" class="section level4" number="2.7.8.15">
<h4><span class="header-section-number">2.7.8.15</span> Abemaciclib + Fulvestrant</h4>
<ul>
<li>Abemaciclib: 150 mg PO bid</li>
<li>Fulvestrant: 500 mg IM on days 1 and 15 of first cycle and then 500 mg IM on day 1 for all subsequent cycles</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Sledge GW, et al. J Clin Oncol 2017;35:2875–2884.</p>
</blockquote>
</div>
<div id="abemaciclib-anastrozole" class="section level4" number="2.7.8.16">
<h4><span class="header-section-number">2.7.8.16</span> Abemaciclib + Anastrozole</h4>
<ul>
<li>Abemaciclib: 150 mg PO bid</li>
<li>Anastrozole: 1 mg PO daily</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Goetz MP, et al. J Clin Oncol 2017;35:3638–3646.</p>
</blockquote>
</div>
<div id="abemaciclib-letrozole" class="section level4" number="2.7.8.17">
<h4><span class="header-section-number">2.7.8.17</span> Abemaciclib + Letrozole</h4>
<ul>
<li>Abemaciclib: 150 mg PO bid</li>
<li>Letrozole: 2.5 mg PO daily</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Goetz MP, et al. J Clin Oncol 2017;35:3638–3646.</p>
</blockquote>
</div>
</div>
<div id="metastatic-disease---single-agent-regimens-1" class="section level3" number="2.7.9">
<h3><span class="header-section-number">2.7.9</span> Metastatic Disease - Single-Agent Regimens</h3>
<div id="tamoxifen-1" class="section level4" number="2.7.9.1">
<h4><span class="header-section-number">2.7.9.1</span> Tamoxifen</h4>
<ul>
<li>Tamoxifen: 20 mg PO daily</li>
</ul>
<blockquote>
<p>Jaiyesimi IA, et al. J Clin Oncol 1995;13:513–529.</p>
</blockquote>
</div>
<div id="toremifene" class="section level4" number="2.7.9.2">
<h4><span class="header-section-number">2.7.9.2</span> Toremifene</h4>
<ul>
<li>Toremifene: 60 mg PO daily</li>
</ul>
<blockquote>
<p>Hayes DF, et al. J Clin Oncol 1995;13:2556–2566.</p>
</blockquote>
</div>
<div id="exemestane" class="section level4" number="2.7.9.3">
<h4><span class="header-section-number">2.7.9.3</span> Exemestane</h4>
<ul>
<li>Exemestane: 25 mg PO daily</li>
</ul>
<blockquote>
<p>Lonning PE, et al. J Clin Oncol 2000;18:2234–2244.</p>
</blockquote>
</div>
<div id="anastrozole-1" class="section level4" number="2.7.9.4">
<h4><span class="header-section-number">2.7.9.4</span> Anastrozole</h4>
<ul>
<li>Anastrozole: 1 mg PO daily</li>
</ul>
<blockquote>
<p>Buzdar A, et al. J Clin Oncol 1996;14:2000–2011.</p>
</blockquote>
</div>
<div id="letrozole-1" class="section level4" number="2.7.9.5">
<h4><span class="header-section-number">2.7.9.5</span> Letrozole</h4>
<ul>
<li>Letrozole: 2.5 mg PO daily</li>
</ul>
<blockquote>
<p>Dombernowsky P, et al. J Clin Oncol 1998;16:453–461.</p>
</blockquote>
</div>
<div id="fulvestrant" class="section level4" number="2.7.9.6">
<h4><span class="header-section-number">2.7.9.6</span> Fulvestrant</h4>
<ul>
<li>Fulvestrant: 250 mg IM on day 1</li>
<li>Repeat injection every month.</li>
</ul>
<blockquote>
<p>Howell A. Clin Cancer Res 2001;7 (Suppl 12):4402s–4410s.</p>
</blockquote>
<p>or</p>
<ul>
<li>Fulvestrant: 500 mg IM loading dose on day 1, then 500 mg IM on days 15 and 29</li>
<li>Continue treatment on a monthly basis until disease progression.</li>
</ul>
<blockquote>
<p>Di Leo A, et al. J Clin Oncol 2010;28:4594–4600.</p>
</blockquote>
</div>
<div id="megestrol" class="section level4" number="2.7.9.7">
<h4><span class="header-section-number">2.7.9.7</span> Megestrol</h4>
<ul>
<li>Megestrol: 40 mg PO qid</li>
</ul>
<blockquote>
<p>Kimmick GG, et al. Cancer Treat Res 1998;94:231–254.</p>
</blockquote>
</div>
<div id="trastuzumab" class="section level4" number="2.7.9.8">
<h4><span class="header-section-number">2.7.9.8</span> Trastuzumab</h4>
<ul>
<li>Trastuzumab: 4 mg/kg IV loading dose and then 2 mg/kg IV weekly</li>
<li>Repeat cycle weekly for a total of 10 weeks. In the absence of disease progression, continue weekly maintenance dose of 2 mg/kg.</li>
</ul>
<blockquote>
<p>Baselga J, et al. Semin Oncol 1999;26 (Suppl 12):78–83.</p>
</blockquote>
<p>or</p>
<ul>
<li>Trastuzumab: 8 mg/kg IV loading dose, then 6 mg/kg IV every 3 weeks</li>
<li>Continue treatment until disease progression.</li>
</ul>
<blockquote>
<p>Baselga J, et al. J Clin Oncol 2005;23:2162–2171.</p>
</blockquote>
</div>
<div id="ado-trastuzumab-emtansine" class="section level4" number="2.7.9.9">
<h4><span class="header-section-number">2.7.9.9</span> Ado-trastuzumab emtansine</h4>
<ul>
<li>Ado-trastuzumab: 3.6 mg/kg IV on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Verma S, et al. N Engl J Med 2012;367:1783–1791.</p>
</blockquote>
</div>
<div id="capecitabine-2" class="section level4" number="2.7.9.10">
<h4><span class="header-section-number">2.7.9.10</span> Capecitabine</h4>
<ul>
<li>Capecitabine: 1,250 mg/m2 PO bid for 2 weeks followed by 1-week rest period</li>
<li>Repeat cycle every 21 days. May decrease dose to 850–1,000 mg/m2 PO bid on days 1–14 to reduce risk of toxicity without compromising clinical efficacy.</li>
</ul>
<blockquote>
<p>Blum JL, et al. J Clin Oncol 1999;17:485–493.</p>
</blockquote>
</div>
<div id="docetaxel-1" class="section level4" number="2.7.9.11">
<h4><span class="header-section-number">2.7.9.11</span> Docetaxel</h4>
<ul>
<li>Docetaxel: 100 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Chan S. Oncology 1997;11 (Suppl 8):19–24.</p>
</blockquote>
<p>or</p>
<ul>
<li>Docetaxel: 35–40 mg/m2 IV weekly for 6 weeks</li>
<li>Repeat cycle every 8 weeks.</li>
</ul>
<blockquote>
<p>Baselga J and Tabernero JM. Oncologist 2001;6 (Suppl 3):26–29.</p>
</blockquote>
</div>
<div id="paclitaxel-2" class="section level4" number="2.7.9.12">
<h4><span class="header-section-number">2.7.9.12</span> Paclitaxel</h4>
<ul>
<li>Paclitaxel: 175 mg/m2 IV over 3 hours on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Holmes FA, et al. J Natl Cancer Inst 1991;83:1797–1805.</p>
</blockquote>
<p>or</p>
<ul>
<li>Paclitaxel: 80–100 mg/m2 IV weekly for 3 weeks</li>
<li>Repeat cycle every 4 weeks.</li>
</ul>
<blockquote>
<p>Perez EA. Oncologist 1998;3:373–389.</p>
</blockquote>
</div>
<div id="ixabepilone" class="section level4" number="2.7.9.13">
<h4><span class="header-section-number">2.7.9.13</span> Ixabepilone</h4>
<ul>
<li>Ixabepilone: 40 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Perez EA, et al. J Clin Oncol 2007;25:3407–3414.</p>
</blockquote>
</div>
<div id="vinorelbine" class="section level4" number="2.7.9.14">
<h4><span class="header-section-number">2.7.9.14</span> Vinorelbine</h4>
<ul>
<li>Vinorelbine: 30 mg/m2 IV on day 1</li>
<li>Repeat cycle every 7 days.</li>
</ul>
<blockquote>
<p>Fumoleau P, et al. Semin Oncol 1995;22 (Suppl 5):22–28.</p>
</blockquote>
</div>
<div id="doxorubicin" class="section level4" number="2.7.9.15">
<h4><span class="header-section-number">2.7.9.15</span> Doxorubicin</h4>
<ul>
<li>Doxorubicin: 20 mg/m2 IV on day 1</li>
<li>Repeat cycle every 7 days.</li>
</ul>
<blockquote>
<p>Torti FM, et al. Ann Intern Med 1983;99:745–749.</p>
</blockquote>
</div>
<div id="gemcitabine-2" class="section level4" number="2.7.9.16">
<h4><span class="header-section-number">2.7.9.16</span> Gemcitabine</h4>
<ul>
<li>Gemcitabine: 725 mg/m2 IV weekly for 3 weeks</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Carmichael J, et al. Semin Oncol 1996;23 (Suppl 10):77–81.</p>
</blockquote>
</div>
<div id="doxorubicin-liposome" class="section level4" number="2.7.9.17">
<h4><span class="header-section-number">2.7.9.17</span> Doxorubicin liposome</h4>
<ul>
<li>Doxorubicin liposome: 40 mg/m2 IV on day 1</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Al-Batran SE, et al. Oncol 2006;70:141–146.</p>
</blockquote>
</div>
<div id="abraxane" class="section level4" number="2.7.9.18">
<h4><span class="header-section-number">2.7.9.18</span> Abraxane</h4>
<ul>
<li>Abraxane: 260 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>O’Shaughnessy JA, et al. Breast Cancer Res Treat 2003;82:Suppl 1 (abstract 43).</p>
</blockquote>
<p>or</p>
<ul>
<li>Abraxane: 125 mg/m2 IV on days 1, 8, and 15</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>O’Shaughnessy JA, et al. Breast Cancer Res Treat 2004;88:Suppl 1 (abstract 1070).</p>
</blockquote>
</div>
<div id="eribulin" class="section level4" number="2.7.9.19">
<h4><span class="header-section-number">2.7.9.19</span> Eribulin</h4>
<ul>
<li>Eribulin: 1.4 mg/m2 IV on days 1 and 8</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Cortes J, et al. Lancet 2011;377:914–923.</p>
</blockquote>
</div>
<div id="abemaciclib-1" class="section level4" number="2.7.9.20">
<h4><span class="header-section-number">2.7.9.20</span> Abemaciclib</h4>
<ul>
<li>Abemaciclib: 150 mg PO bid</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Dickler MN, et al. Clin Cancer Res 2017. <a href="doi:10.1158/1078-0432" class="uri">doi:10.1158/1078-0432</a>.</p>
</blockquote>
</div>
<div id="olaparib" class="section level4" number="2.7.9.21">
<h4><span class="header-section-number">2.7.9.21</span> Olaparib</h4>
<ul>
<li>Olaparib: 300 mg PO bid</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Robson M, et al. N Engl J Med 2017;377:523–533.</p>
</blockquote>
</div>
</div>
</div>
<div id="cancer-of-unknown-primary" class="section level2" number="2.8">
<h2><span class="header-section-number">2.8</span> CANCER OF UNKNOWN PRIMARY</h2>
<div id="combination-regimens-3" class="section level3" number="2.8.1">
<h3><span class="header-section-number">2.8.1</span> Combination Regimens</h3>
<div id="pce" class="section level4" number="2.8.1.1">
<h4><span class="header-section-number">2.8.1.1</span> PCE</h4>
<ul>
<li>Paclitaxel: 200 mg/m2 IV over 1 hour on day 1</li>
<li>Carboplatin: AUC of 6, IV on day 1</li>
<li>Etoposide: 50 mg alternating with 100 mg PO on days 1–10</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Hainsworth JD, et al. J Clin Oncol 1997;15:2385–2393.</p>
</blockquote>
</div>
<div id="ep" class="section level4" number="2.8.1.2">
<h4><span class="header-section-number">2.8.1.2</span> EP</h4>
<ul>
<li>Etoposide: 100 mg/m2 IV on days 1–5</li>
<li>Cisplatin: 100 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Longeval E, et al. Cancer 1982;50:2751–2756.</p>
</blockquote>
</div>
<div id="peb" class="section level4" number="2.8.1.3">
<h4><span class="header-section-number">2.8.1.3</span> PEB</h4>
<ul>
<li>Cisplatin: 20 mg/m2 IV on days 1–5</li>
<li>Etoposide: 100 mg/m2 IV on days 1–5</li>
<li>Bleomycin: 30 units IV on days 1, 8, and 15</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Hainsworth JD, et al. J Clin Oncol 1992;10:912–922.</p>
</blockquote>
</div>
<div id="gcp" class="section level4" number="2.8.1.4">
<h4><span class="header-section-number">2.8.1.4</span> GCP</h4>
<ul>
<li>Gemcitabine: 1,000 mg/m2 IV on days 1 and 8</li>
<li>Carboplatin: AUC of 5, IV on day 1</li>
<li>Paclitaxel: 200 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days for 4 cycles. This is to be followed by paclitaxel at 70 mg/m2 IV every week for 6 weeks with a 2-week rest. Repeat for a total of 3 cycles.</li>
</ul>
<blockquote>
<p>Greco FA, et al. J Clin Oncol 2002;20:1651–1656.</p>
</blockquote>
</div>
<div id="gemcitabine-cisplatin-paclitaxel" class="section level4" number="2.8.1.5">
<h4><span class="header-section-number">2.8.1.5</span> Gemcitabine + Cisplatin + Paclitaxel</h4>
<ul>
<li>Gemcitabine: 1,000 mg/m2 IV on days 1 and 8</li>
<li>Cisplatin: 75 mg/m2 IV on day 1</li>
<li>Paclitaxel: 175 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Moller AK, et al. Acta Oncol 2010;49:423–430.</p>
</blockquote>
</div>
<div id="gemcitabine-irinotecan" class="section level4" number="2.8.1.6">
<h4><span class="header-section-number">2.8.1.6</span> Gemcitabine + Irinotecan</h4>
<ul>
<li>Gemcitabine: 1,000 mg/m2 IV on days 1 and 8</li>
<li>Irinotecan: 100 mg/m2 IV on days 1 and 8</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Hainsworth JD, et al. Cancer J 2010;16:70–75.</p>
</blockquote>
</div>
<div id="capecitabine-oxaliplatin-1" class="section level4" number="2.8.1.7">
<h4><span class="header-section-number">2.8.1.7</span> Capecitabine + Oxaliplatin</h4>
<ul>
<li>Capecitabine: 1,000 mg/m2 PO on days 1–14</li>
<li>Oxaliplatin: 130 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Hainsworth JD, et al. Cancer 2010;116:2448–2454.</p>
</blockquote>
</div>
<div id="bevacizumab-erlotinib" class="section level4" number="2.8.1.8">
<h4><span class="header-section-number">2.8.1.8</span> Bevacizumab + Erlotinib</h4>
<ul>
<li>Bevacizumab: 10 mg/kg IV on day 1</li>
<li>Erlotinib: 150 mg PO daily</li>
<li>Continue until disease progression.</li>
</ul>
<blockquote>
<p>Hainsworth JD, et al. J Clin Oncol 2007;25:1747–1752.</p>
</blockquote>
</div>
</div>
</div>
<div id="carcinoid-tumors-and-neuroendocrine-tumors" class="section level2" number="2.9">
<h2><span class="header-section-number">2.9</span> CARCINOID TUMORS AND NEUROENDOCRINE TUMORS</h2>
<div id="combination-regimens-4" class="section level3" number="2.9.1">
<h3><span class="header-section-number">2.9.1</span> Combination Regimens</h3>
<div id="fluorouracil-streptozocin" class="section level4" number="2.9.1.1">
<h4><span class="header-section-number">2.9.1.1</span> 5-Fluorouracil + Streptozocin</h4>
<ul>
<li>5-Fluorouracil: 400 mg/m2/day IV on days 1–5</li>
<li>Streptozocin: 500 mg/m2/day IV on days 1–5</li>
<li>Repeat cycle every 6 weeks.</li>
</ul>
<blockquote>
<p>Moertel CG, et al. N Engl J Med 1992;326:519–526.</p>
</blockquote>
</div>
<div id="doxorubicin-streptozocin" class="section level4" number="2.9.1.2">
<h4><span class="header-section-number">2.9.1.2</span> Doxorubicin + Streptozocin</h4>
<ul>
<li>Doxorubicin: 50 mg/m2 IV on days 1 and 22</li>
<li>Streptozocin: 500 mg/m2/day IV on days 1–5</li>
<li>Repeat cycle every 6 weeks.</li>
</ul>
<blockquote>
<p>Moertel CG, et al. N Engl J Med 1992;326:519–526.</p>
</blockquote>
</div>
<div id="cisplatin-etoposide" class="section level4" number="2.9.1.3">
<h4><span class="header-section-number">2.9.1.3</span> Cisplatin + Etoposide</h4>
<ul>
<li>Cisplatin: 45 mg/m2/day IV continuous infusion on days 2 and 3</li>
<li>Etoposide: 130 mg/m2/day IV continuous infusion on days 1–3</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Moertel CG, et al. Cancer 1991;68:227–232.</p>
</blockquote>
</div>
<div id="everolimus-octreotide-lar" class="section level4" number="2.9.1.4">
<h4><span class="header-section-number">2.9.1.4</span> Everolimus + Octreotide LAR</h4>
<ul>
<li>Everolimus: 10 mg PO daily</li>
<li>Octreotide LAR: 30 mg IM on day 1</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Pavel ME, et al. Lancet 2011;378:2005–2012.</p>
</blockquote>
</div>
<div id="capecitabine-temozolomide" class="section level4" number="2.9.1.5">
<h4><span class="header-section-number">2.9.1.5</span> Capecitabine + Temozolomide</h4>
<ul>
<li>Capecitabine: 750 mg/day PO on days 1–14</li>
<li>Temozolomide: 200 mg/m2/day PO on days 10–14</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Strosberg JR, et al. Cancer 2011;117:268–275.</p>
</blockquote>
</div>
</div>
<div id="single-agent-regimens-3" class="section level3" number="2.9.2">
<h3><span class="header-section-number">2.9.2</span> Single-Agent Regimens</h3>
<div id="octreotide" class="section level4" number="2.9.2.1">
<h4><span class="header-section-number">2.9.2.1</span> Octreotide</h4>
<ul>
<li>Octreotide: 150–250 µg SC tid</li>
<li>Continue until disease progression.</li>
</ul>
<blockquote>
<p>Saltz L, et al. Cancer 1993;72:244.</p>
</blockquote>
</div>
<div id="lanreotide" class="section level4" number="2.9.2.2">
<h4><span class="header-section-number">2.9.2.2</span> Lanreotide</h4>
<ul>
<li>Lanreotide: 120 mg SC on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Coplin ME, et al. N Engl J Med 2014;371:224–233.</p>
</blockquote>
</div>
<div id="sunitinib" class="section level4" number="2.9.2.3">
<h4><span class="header-section-number">2.9.2.3</span> Sunitinib</h4>
<ul>
<li>Sunitinib: 50 mg PO daily for 4 weeks</li>
<li>Repeat cycle every 6 weeks.</li>
</ul>
<blockquote>
<p>Kulke MH, et al. J Clin Oncol 2008;26:3403–3410.</p>
</blockquote>
</div>
<div id="everolimus" class="section level4" number="2.9.2.4">
<h4><span class="header-section-number">2.9.2.4</span> Everolimus</h4>
<ul>
<li>Everolimus: 10 mg PO daily</li>
<li>Continue treatment until disease progression.</li>
</ul>
<blockquote>
<p>Yao JC, et al. N Engl J Med 2011;364:514–523.</p>
</blockquote>
</div>
<div id="lutetium-lu-177-dotatate" class="section level4" number="2.9.2.5">
<h4><span class="header-section-number">2.9.2.5</span> Lutetium Lu 177 dotatate</h4>
<ul>
<li>Lutetium Lu 177 dotatate: 120 mg SC on day 1</li>
<li>Repeat every 8 weeks for a total of 4 doses.</li>
<li>Long-acting octreotide 30 mg IM should be administered at 4 to 24 hours after each dose of lutetium Lu 177 dotatate.</li>
</ul>
<blockquote>
<p>Strosberg J, et al. N Engl J Med 2017;376:125–135.</p>
</blockquote>
</div>
</div>
</div>
<div id="cervical-cancer" class="section level2" number="2.10">
<h2><span class="header-section-number">2.10</span> CERVICAL CANCER</h2>
<div id="combination-regimens-5" class="section level3" number="2.10.1">
<h3><span class="header-section-number">2.10.1</span> Combination Regimens</h3>
<div id="cisplatin-radiation-therapy" class="section level4" number="2.10.1.1">
<h4><span class="header-section-number">2.10.1.1</span> Cisplatin + Radiation Therapy</h4>
<ul>
<li>Radiation therapy: 1.8 to 2 Gy per fraction (total dose, 45 Gy)</li>
<li>Cisplatin: 40 mg/m2 IV weekly (maximal dose, 70 mg per week)</li>
<li>Cisplatin is given 4 hours before radiation therapy on weeks 1–6.</li>
</ul>
<blockquote>
<p>Rose PG, et al. N Engl J Med 1995;15:1144.</p>
</blockquote>
</div>
<div id="paclitaxel-cisplatin" class="section level4" number="2.10.1.2">
<h4><span class="header-section-number">2.10.1.2</span> Paclitaxel + Cisplatin</h4>
<ul>
<li>Paclitaxel: 135 mg/m2 IV over 24 hours on day 1</li>
<li>Cisplatin: 75 mg/m2 IV on day 2</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Morris M, et al. N Engl J Med 1999;340:1137–1143.</p>
</blockquote>
</div>
<div id="cisplatin-topotecan" class="section level4" number="2.10.1.3">
<h4><span class="header-section-number">2.10.1.3</span> Cisplatin + Topotecan</h4>
<ul>
<li>Cisplatin: 50 mg/m2 IV on day 1</li>
<li>Topotecan: 0.75 mg/m2/day IV on days 1–3</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Fiorica J, et al. Gynecol Oncol 2002;85:89–94.</p>
</blockquote>
</div>
<div id="paclitaxel-topotecan" class="section level4" number="2.10.1.4">
<h4><span class="header-section-number">2.10.1.4</span> Paclitaxel + Topotecan</h4>
<ul>
<li>Paclitaxel: 175 mg/m2 IV on day 1</li>
<li>Topotecan: 0.75 mg/m2 IV on days 1-3</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Tewari KS, et al. J Clin Oncol 2013;31:Suppl (abstract 3).</p>
</blockquote>
</div>
<div id="paclitaxel-topotecan-bevacizumab" class="section level4" number="2.10.1.5">
<h4><span class="header-section-number">2.10.1.5</span> Paclitaxel + Topotecan + Bevacizumab</h4>
<ul>
<li>Paclitaxel: 175 mg/m2 IV on day 1</li>
<li>Topotecan: 0.75 mg/m2/day IV on days 1–3</li>
<li>Bevacizumab: 15 mg/kg IV on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Tewari KS, et al. J Clin Oncol 2013;31:Suppl (abstract 3).</p>
</blockquote>
</div>
<div id="cisplatin-paclitaxel-bevacizumab" class="section level4" number="2.10.1.6">
<h4><span class="header-section-number">2.10.1.6</span> Cisplatin + Paclitaxel + Bevacizumab</h4>
<ul>
<li>Cisplatin: 50 mg/m2 IV on day 1</li>
<li>Paclitaxel: 135–175 mg/m2 IV on day 1</li>
<li>Bevacizumab: 15 mg/kg IV on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Tewari KS, et al. J Clin Oncol 2013;31:Suppl (abstract 3).</p>
</blockquote>
</div>
<div id="bip" class="section level4" number="2.10.1.7">
<h4><span class="header-section-number">2.10.1.7</span> BIP</h4>
<ul>
<li>Bleomycin: 30 U IV over 24 hours on day 1</li>
<li>Ifosfamide: 5,000 mg/m2 IV over 24 hours on day 2</li>
<li>Mesna: 6,000 mg/m2 IV over 36 hours on day 2</li>
<li>Cisplatin: 50 mg/m2 IV on day 2</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Buxton EJ, et al. J Natl Cancer Inst 1989;81:359–361.</p>
</blockquote>
</div>
<div id="bic" class="section level4" number="2.10.1.8">
<h4><span class="header-section-number">2.10.1.8</span> BIC</h4>
<ul>
<li>Bleomycin: 30 U IV on day 1</li>
<li>Ifosfamide: 2,000 mg/m2 IV on days 1–3</li>
<li>Mesna: 400 mg/m2 IV, 15 minutes before ifosfamide dose, then 400 mg/m2 IV at 4 and 8 hours following ifosfamide</li>
<li>Carboplatin: 200 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Murad AM, et al. J Clin Oncol 1994;12:55–59.</p>
</blockquote>
</div>
<div id="cisplatin-5-fluorouracil" class="section level4" number="2.10.1.9">
<h4><span class="header-section-number">2.10.1.9</span> Cisplatin + 5-Fluorouracil</h4>
<ul>
<li>Cisplatin: 75 mg/m2 IV on day 1</li>
<li>5-Fluorouracil: 1,000 mg/m2/day IV continuous infusion on days 2–5</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Whitney CW, et al. J Clin Oncol 1999;17:1339–1348.</p>
</blockquote>
</div>
<div id="cisplatin-vinorelbine" class="section level4" number="2.10.1.10">
<h4><span class="header-section-number">2.10.1.10</span> Cisplatin + Vinorelbine</h4>
<ul>
<li>Cisplatin: 80 mg/m2 IV on day 1</li>
<li>Vinorelbine: 25 mg/m2 IV on days 1 and 8</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Pignata S, et al. J Clin Oncol 1999;17:756–760.</p>
</blockquote>
</div>
<div id="cisplatin-irinotecan" class="section level4" number="2.10.1.11">
<h4><span class="header-section-number">2.10.1.11</span> Cisplatin + Irinotecan</h4>
<ul>
<li>Cisplatin: 60 mg/m2 IV on day 1</li>
<li>Irinotecan: 60 mg/m2 IV on days 1, 8, and 15</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Chitapanarux I, et al. Gynecol Oncol 2003;89:402–407.</p>
</blockquote>
</div>
<div id="cisplatin-gemcitabine" class="section level4" number="2.10.1.12">
<h4><span class="header-section-number">2.10.1.12</span> Cisplatin + Gemcitabine</h4>
<ul>
<li>Cisplatin: 50 mg/m2 IV on day 1</li>
<li>Gemcitabine: 1,000 mg/m2 IV on days 1 and 8</li>
<li>Repeat cycle every 21 days for up to 6 cycles.</li>
</ul>
<blockquote>
<p>Monk BJ, et al. Proc Am Soc Clin Oncol 2008;26:(LBA5504).</p>
</blockquote>
<p>or</p>
<ul>
<li>Cisplatin: 30 mg/m2 IV on day 1</li>
<li>Gemcitabine: 800 mg/m2 IV on days 1 and 8</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Brewer CA, et al. Gynecol Oncol 2006;100:385–388.</p>
</blockquote>
</div>
<div id="carboplatin-docetaxel-1" class="section level4" number="2.10.1.13">
<h4><span class="header-section-number">2.10.1.13</span> Carboplatin + Docetaxel</h4>
<ul>
<li>Carboplatin: AUC of 6, IV on day 1</li>
<li>Docetaxel: 60 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Nagao S, et al. Gynecol Oncol 2005;96:805–809.</p>
</blockquote>
</div>
<div id="cisplatin-pemetrexed" class="section level4" number="2.10.1.14">
<h4><span class="header-section-number">2.10.1.14</span> Cisplatin + Pemetrexed</h4>
<ul>
<li>Cisplatin: 50 mg/m2 IV on day 1</li>
<li>Pemetrexed: 500 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days. Folic acid at 350–1,000 µg PO q day and vitamin B12 at 1,000 µg IM to sart 1 week prior to first dose of pemetrexed and repeated every 3 cycles.</li>
</ul>
<blockquote>
<p>Miller DS, et al. J Clin Oncol 2014;32:2744–2749.</p>
</blockquote>
</div>
</div>
<div id="single-agent-regimens-4" class="section level3" number="2.10.2">
<h3><span class="header-section-number">2.10.2</span> Single-Agent Regimens</h3>
<div id="docetaxel-2" class="section level4" number="2.10.2.1">
<h4><span class="header-section-number">2.10.2.1</span> Docetaxel</h4>
<ul>
<li>Docetaxel: 100 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Levy T, et al. Proc Am Soc Clin Oncol 1996;15:292a.</p>
</blockquote>
</div>
<div id="paclitaxel-3" class="section level4" number="2.10.2.2">
<h4><span class="header-section-number">2.10.2.2</span> Paclitaxel</h4>
<ul>
<li>Paclitaxel: 175 mg/m2 IV over 3 hours on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Thigpen T, et al. Semin Oncol 1997;24 (Suppl 2):41–46.</p>
</blockquote>
</div>
<div id="irinotecan-2" class="section level4" number="2.10.2.3">
<h4><span class="header-section-number">2.10.2.3</span> Irinotecan</h4>
<ul>
<li>Irinotecan: 125 mg/m2 IV weekly for 4 weeks</li>
<li>Repeat cycle every 6 weeks.</li>
</ul>
<blockquote>
<p>Verschraegen CF, et al. J Clin Oncol 1997;15:625–631.</p>
</blockquote>
</div>
<div id="topotecan" class="section level4" number="2.10.2.4">
<h4><span class="header-section-number">2.10.2.4</span> Topotecan</h4>
<ul>
<li>Topotecan: 1.5 mg/m2/day on days 1–5</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Muderspach LI, et al. Gynecol Oncol 2001;81:213–215.</p>
</blockquote>
</div>
<div id="pemetrexed-1" class="section level4" number="2.10.2.5">
<h4><span class="header-section-number">2.10.2.5</span> Pemetrexed</h4>
<ul>
<li>Pemetrexed: 500 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days. Folic acid at 350–1,000 µg PO q day and vitamin B12 at 1,000 µg IM to start 1 week prior to first dose of therapy and repeated every 3 cycles.</li>
</ul>
<blockquote>
<p>Lorusso D, et al. Ann Oncol 2010;21:61–66.</p>
</blockquote>
</div>
<div id="gemcitabine-3" class="section level4" number="2.10.2.6">
<h4><span class="header-section-number">2.10.2.6</span> Gemcitabine</h4>
<ul>
<li>Gemcitabine: 800 mg/m2 IV on days 1, 8, and 15</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Schilder RJ, et al. Gynecol Oncol 2005;95:103–107.</p>
</blockquote>
</div>
<div id="pembrolizumab-3" class="section level4" number="2.10.2.7">
<h4><span class="header-section-number">2.10.2.7</span> Pembrolizumab</h4>
<ul>
<li>Pembrolizumab: 200 mg IV on day 1</li>
<li>Repeat cycle every 3 weeks.</li>
</ul>
<blockquote>
<p>Schellens JHM, et al. J Clin Oncol 2017;35 (Suppl: abstr 5514).</p>
</blockquote>
</div>
</div>
</div>
<div id="colorectal-cancer" class="section level2" number="2.11">
<h2><span class="header-section-number">2.11</span> COLORECTAL CANCER</h2>
<div id="neoadjuvant-combined-modality-therapy-for-rectal-cancer---combination-regimens" class="section level3" number="2.11.1">
<h3><span class="header-section-number">2.11.1</span> Neoadjuvant Combined Modality Therapy for Rectal Cancer - Combination Regimens</h3>
<div id="fluorouracil-radiation-therapy-german-aio-regimen" class="section level4" number="2.11.1.1">
<h4><span class="header-section-number">2.11.1.1</span> 5-Fluorouracil + Radiation Therapy (German AIO regimen)</h4>
<ul>
<li>5-Fluorouracil: 1,000 mg/m2/day IV continuous infusion on days 1–5</li>
<li>Repeat infusional 5-FU on weeks 1 and 5.</li>
<li>Radiation therapy: 180 cGy/day for 5 days per week (total dose, 5040 cGy)</li>
<li>Followed by surgical resection and then adjuvant chemotherapy with 5-FU at 500 mg/m2 IV for 5 days every 28 days for a total of 4 cycles.</li>
</ul>
<blockquote>
<p>Sauer R, et al. N Engl J Med 2004;351:1731–1740.</p>
</blockquote>
</div>
<div id="infusion-5-fu-radiation-therapy" class="section level4" number="2.11.1.2">
<h4><span class="header-section-number">2.11.1.2</span> Infusion 5-FU + Radiation Therapy</h4>
<ul>
<li>5-Fluorouracil: 225 mg/m2/day IV continuous infusion throughout entire course of radiation therapy</li>
<li>Radiation therapy: 180 cGy/day for 5 days per week (total dose, 5040 cGy)</li>
<li>Followed by surgical resection and then adjuvant chemotherapy with capecitabine, 5-FU/LV, or FOLFOX4 for a total of 4 months.</li>
</ul>
<blockquote>
<p>Minsky BD. Oncology 1994;6:53–58.</p>
</blockquote>
</div>
<div id="capecitabine-radiation-therapy" class="section level4" number="2.11.1.3">
<h4><span class="header-section-number">2.11.1.3</span> Capecitabine + Radiation Therapy</h4>
<ul>
<li>Capecitabine: 825 mg/m2 PO bid throughout the entire course of radiation therapy or 900–1,000 mg/m2 PO bid on days 1–5 of each week of radiation therapy</li>
<li>Radiation therapy: 180 cGy/day for 5 days per week (total dose, 5040 cGy)</li>
<li>Followed by surgical resection and then adjuvant chemotherapy with capecitabine, 5-FU, or 5-FU/LV for a total of 4 cycles.</li>
</ul>
<blockquote>
<p>Minsky BD. Clin Colorectal Cancer 2004;4 (Suppl 1):S29–36.</p>
</blockquote>
</div>
<div id="fulv-oxaliplatin-radiation-therapy" class="section level4" number="2.11.1.4">
<h4><span class="header-section-number">2.11.1.4</span> 5-FU/LV Oxaliplatin + Radiation Therapy</h4>
<ul>
<li>5-Fluorouracil: 200 mg/m2/day IV continuous infusion throughout entire course of radiation therapy</li>
<li>Oxaliplatin: 60 mg/m2 IV on days 1, 8, 15, 22, 29, and 36</li>
<li>Radiation therapy: 180 cGy/day for 5 days each week (total dose, 5040 cGy)</li>
<li>Followed by surgical resection 4–6 weeks after completion of chemoradiotherapy and then adjuvant chemotherapy.</li>
</ul>
<blockquote>
<p>Ryan DP, et al. J Clin Oncol 2006;24:2557–2562.</p>
</blockquote>
</div>
<div id="xelox-radiation-therapy-1" class="section level4" number="2.11.1.5">
<h4><span class="header-section-number">2.11.1.5</span> XELOX + Radiation Therapy</h4>
<ul>
<li>Capecitabine: 825 mg/m2 PO bid on days 1–14 and 22–35</li>
<li>Oxaliplatin: 50 mg/m2 IV on days 1, 8, 22, and 29</li>
<li>Radiation therapy: 180 cGy/day for 5 days per week (total dose, 5040 cGy)</li>
<li>Followed by surgical resection and then adjuvant chemotherapy with</li>
<li>Capecitabine: 1,000 mg/m2 PO bid on days 1–14</li>
<li>Oxaliplatin: 130 mg/m2 IV on day 1</li>
<li>Repeat cycle every 3 weeks for 4 cycles.</li>
</ul>
<blockquote>
<p>Rodel C, et al. J Clin Oncol 2007;25:110–117.</p>
</blockquote>
</div>
</div>
<div id="adjuvant-therapy---combination-regimens-1" class="section level3" number="2.11.2">
<h3><span class="header-section-number">2.11.2</span> Adjuvant Therapy - Combination Regimens</h3>
<div id="fluorouracil-leucovorin-mayo-clinic-schedule" class="section level4" number="2.11.2.1">
<h4><span class="header-section-number">2.11.2.1</span> 5-Fluorouracil + Leucovorin (Mayo Clinic schedule)</h4>
<ul>
<li>5-Fluorouracil: 425 mg/m2 IV on days 1–5</li>
<li>Leucovorin: 20 mg/m2 IV on days 1–5, administered before 5-fluorouracil</li>
<li>Repeat cycle every 4–5 weeks for a total of 6 cycles.</li>
</ul>
<blockquote>
<p>O’Connell MJ, et al. J Clin Oncol 1997;15:246–250.</p>
</blockquote>
</div>
<div id="fluorouracil-leucovorin-weekly-schedule-high-dose" class="section level4" number="2.11.2.2">
<h4><span class="header-section-number">2.11.2.2</span> 5-Fluorouracil + Leucovorin (weekly schedule, high dose)</h4>
<ul>
<li>5-Fluorouracil: 500 mg/m2 IV weekly for 6 weeks</li>
<li>Leucovorin: 500 mg/m2 IV over 2 hours weekly for 6 weeks, administered before 5-fluorouracil</li>
<li>Repeat cycle every 8 weeks for a total of 4 cycles (32 weeks total).</li>
</ul>
<blockquote>
<p>Wolmark N, et al. J Clin Oncol 1993;11:1879–1887.</p>
</blockquote>
</div>
<div id="fluorouracil-leucovorin-weekly-schedule-low-dose" class="section level4" number="2.11.2.3">
<h4><span class="header-section-number">2.11.2.3</span> 5-Fluorouracil + Leucovorin (weekly schedule, low dose)</h4>
<ul>
<li>5-Fluorouracil: 500 mg/m2 IV weekly for 6 weeks</li>
<li>Leucovorin: 20 mg/m2 IV weekly for 6 weeks, administered before 5-fluorouracil</li>
<li>Repeat cycle every 8 weeks for a total of 4 or 6 cycles (32 or 48 weeks total).</li>
</ul>
<blockquote>
<p>Benson AB, et al. Oncology 2000;14:203–212.</p>
</blockquote>
</div>
<div id="oxaliplatin-1-5-fluorouracil-1-leucovorin-folfox4" class="section level4" number="2.11.2.4">
<h4><span class="header-section-number">2.11.2.4</span> Oxaliplatin 1 5-Fluorouracil 1 Leucovorin (FOLFOX4)</h4>
<ul>
<li>Oxaliplatin: 85 mg/m2 IV on day 1</li>
<li>5-Fluorouracil: 400 mg/m2 IV bolus, followed by 600 mg/m2 IV continuous infusion for 22 hours on days 1 and 2</li>
<li>Leucovorin: 200 mg/m2 IV on days 1 and 2 as a 2-hour infusion before 5-fluorouracil</li>
<li>Repeat cycle every 2 weeks for a total of 12 cycles (6 months total).</li>
</ul>
<blockquote>
<p>Andre, T et al. N Engl J Med 2004;350:2343–2351.</p>
</blockquote>
</div>
<div id="oxaliplatin-5-fluorouracil-leucovorin-mfolfox7" class="section level4" number="2.11.2.5">
<h4><span class="header-section-number">2.11.2.5</span> Oxaliplatin + 5-Fluorouracil + Leucovorin (mFOLFOX7)</h4>
<ul>
<li>Oxaliplatin: 100 mg/m2 IV on day 1</li>
<li>5-Fluorouracil: 3,000 mg/m2 IV continuous infusion on days 1 and 2 for 46 hours</li>
<li>Leucovorin: 200 mg/m2 IV on day 1 as a 2-hour infusion before 5-fluorouracil</li>
<li>Repeat cycle every 2 weeks for a total of 12 cycles (6 months total).</li>
</ul>
<blockquote>
<p>Chung KY and Saltz LB. Cancer J 2007;13:192–197.</p>
</blockquote>
</div>
<div id="flox" class="section level4" number="2.11.2.6">
<h4><span class="header-section-number">2.11.2.6</span> FLOX</h4>
<ul>
<li>5-Fluorouracil: 500 mg/m2 IV weekly for 6 weeks, administered 1 hour after LV infusion begun</li>
<li>Leucovorin: 500 mg/m2 IV over 2 hours weekly for 6 weeks, administered before 5-fluorouracil</li>
<li>Oxaliplatin: 85 mg/m2 IV administered before 5-fluorouracil and LV and on days 1, 15, and 29</li>
<li>Repeat cycle every 8 weeks for a total of 3 cycles (6 months total).</li>
</ul>
<blockquote>
<p>Kuebler JP, et al. J Clin Oncol 2007;25:2198–2204.</p>
</blockquote>
</div>
<div id="oxaliplatin-capecitabine-xelox" class="section level4" number="2.11.2.7">
<h4><span class="header-section-number">2.11.2.7</span> Oxaliplatin + Capecitabine (XELOX)</h4>
<ul>
<li>Oxaliplatin: 130 mg/m2 IV on day 1</li>
<li>Capecitabine: 1,000 mg/m2 PO bid on days 1–14</li>
<li>Repeat cycle every 3 weeks for a total of 8 cycles (6 months total). Dose may be decreased to 850 mg/m2 PO bid days 1–14 to reduce risk of toxicity without compromising efficacy.</li>
</ul>
<blockquote>
<p>Schmoll HJ, et al. J Clin Oncol 2007;25:102–109.</p>
</blockquote>
</div>
<div id="lv5fu2-degramont-regimen" class="section level4" number="2.11.2.8">
<h4><span class="header-section-number">2.11.2.8</span> LV5FU2 (deGramont regimen)</h4>
<ul>
<li>5-Fluorouracil: 400 mg/m2 IV bolus, followed by 600 mg/m2 IV continuous infusion for 22 hours on days 1 and 2</li>
<li>Leucovorin: 200 mg/m2 IV on days 1 and 2 as a 2-hour infusion before 5-fluorouracil
or</li>
<li>L-Leucovorin: 100 mg/m2 IV on days 1 and 2 as a 2-hour infusion before 5-fluorouracil</li>
<li>Repeat cycle every 2 weeks for a total of 12 cycles.</li>
</ul>
<blockquote>
<p>Andre, T et al. N Engl J Med 2004;350:2343–2351.</p>
</blockquote>
</div>
<div id="capecitabine-3" class="section level4" number="2.11.2.9">
<h4><span class="header-section-number">2.11.2.9</span> Capecitabine</h4>
<ul>
<li>Capecitabine: 1,250 mg/m2 PO bid on days 1–14</li>
<li>Repeat cycle every 21 days for a total of 8 cycles. Dose may be decreased to 850–1,000 mg/m2 PO bid on days 1–14 to reduce risk of toxicity without compromising clinical efficacy.</li>
</ul>
<blockquote>
<p>Twelves C, et al. N Engl J Med 2005;352:2696–2704.</p>
</blockquote>
</div>
</div>
<div id="metastatic-disease---combination-regimens-1" class="section level3" number="2.11.3">
<h3><span class="header-section-number">2.11.3</span> Metastatic Disease - Combination Regimens</h3>
<div id="irinotecan-5-fluorouracil-leucovorin-modified-ifl-saltz-regimen" class="section level4" number="2.11.3.1">
<h4><span class="header-section-number">2.11.3.1</span> Irinotecan + 5-Fluorouracil + Leucovorin (Modified IFL Saltz regimen)</h4>
<ul>
<li>Irinotecan: 125 mg/m2 IV over 90 minutes weekly for 2 weeks</li>
<li>5-Fluorouracil: 500 mg/m2 IV weekly for 2 weeks</li>
<li>Leucovorin: 20 mg/m2 IV weekly for 2 weeks</li>
<li>Repeat cycle every 3 weeks.</li>
</ul>
<blockquote>
<p>Hwang JJ, et al. Am J Oncol Rev 2003;2 (Suppl 5):15–25.</p>
</blockquote>
</div>
<div id="irinotecan-5-fluorouracil-leucovorin-douillard-regimen" class="section level4" number="2.11.3.2">
<h4><span class="header-section-number">2.11.3.2</span> Irinotecan + 5-Fluorouracil + Leucovorin (Douillard regimen)</h4>
<ul>
<li>Irinotecan: 180 mg/m2 IV on day 1</li>
<li>5-Fluorouracil: 400 mg/m2 IV bolus, followed by 600 g/m2 IV continuous infusion for 22 hours on days 1 and 2</li>
<li>Leucovorin: 200 mg/m2 IV on days 1 and 2 as a 2-hour infusion prior to 5-fluorouracil</li>
<li>Repeat cycle every 2 weeks.</li>
</ul>
<blockquote>
<p>Douillard JY, et al. Lancet 2000;355:1041–1047.</p>
</blockquote>
</div>
<div id="irinotecan-5-fluorouracil-leucovorin-folfiri-regimen" class="section level4" number="2.11.3.3">
<h4><span class="header-section-number">2.11.3.3</span> Irinotecan + 5-Fluorouracil + Leucovorin (FOLFIRI regimen)</h4>
<ul>
<li>Irinotecan: 180 mg/m2 IV on day 1</li>
<li>5-Fluorouracil: 400 mg/m2 IV bolus on day 1, followed by 2,400 mg/m2 IV continuous infusion for 46 hours</li>
<li>Leucovorin: 200 mg/m2 IV on day 1 as a 2-hour infusion prior to 5-fluorouracil</li>
<li>Repeat cycle every 2 weeks.</li>
</ul>
<blockquote>
<p>Andre T, et al. Eur J Cancer 1999;35:1343–1347.</p>
</blockquote>
</div>
<div id="oxaliplatin-5-fluorouracil-leucovorin-folfox4" class="section level4" number="2.11.3.4">
<h4><span class="header-section-number">2.11.3.4</span> Oxaliplatin + 5-Fluorouracil + Leucovorin (FOLFOX4)</h4>
<ul>
<li>Oxaliplatin: 85 mg/m2 IV on day 1</li>
<li>5-Fluorouracil: 400 mg/m2 IV bolus, followed by 600 mg/m2 IV continuous infusion for 22 hours on days 1 and 2</li>
<li>Leucovorin: 200 mg/m2 IV on days 1 and 2 as a 2-hour infusion before 5-fluorouracil
or</li>
<li>L-Leucovorin: 100 mg/m2 IV on days 1 and 2 as a 2-hour infusion before 5-fluorouracil</li>
<li>Repeat cycle every 2 weeks.</li>
</ul>
<blockquote>
<p>de Gramont A, et al. J Clin Oncol 2000;18:2938–2947.</p>
</blockquote>
</div>
<div id="oxaliplatin-5-fluorouracil-leucovorin-folfox6" class="section level4" number="2.11.3.5">
<h4><span class="header-section-number">2.11.3.5</span> Oxaliplatin + 5-Fluorouracil + Leucovorin (FOLFOX6)</h4>
<ul>
<li>Oxaliplatin: 100 mg/m2 IV on day 1</li>
<li>5-Fluorouracil: 400 mg/m2 IV bolus on day 1, followed by 2,400 mg/m2 IV continuous infusion for 46 hours</li>
<li>Leucovorin: 400 mg/m2 IV on day 1 as a 2-hour infusion before 5-fluorouracil</li>
<li>Repeat cycle every 2 weeks.</li>
</ul>
<blockquote>
<p>Tournigand C, et al. J Clin Oncol 2004;22:229–237.</p>
</blockquote>
</div>
<div id="oxaliplatin-5-fluorouracil-leucovorin-folfox7" class="section level4" number="2.11.3.6">
<h4><span class="header-section-number">2.11.3.6</span> Oxaliplatin + 5-Fluorouracil + Leucovorin (FOLFOX7)</h4>
<ul>
<li>Oxaliplatin: 130 mg/m2 IV on day 1</li>
<li>5-Fluorouracil: 2,400 mg/m2 IV continuous infusion on days 1 and 2 for 46 hours</li>
<li>Leucovorin: 400 mg/m2 IV on day 1 as a 2-hour infusion before 5-fluorouracil
or</li>
<li>L-Leucovorin: 200 mg/m2 IV on days 1 and 2 as a 2-hour infusion before 5-fluorouracil</li>
<li>Repeat cycle every 2 weeks.</li>
</ul>
<blockquote>
<p>Andre T, et al. Proc Am Soc Clin Oncol 2003;22:253 (abstract 1016).</p>
</blockquote>
</div>
<div id="oxaliplatin-5-fluorouracil-leucovorin-mfolfox7-1" class="section level4" number="2.11.3.7">
<h4><span class="header-section-number">2.11.3.7</span> Oxaliplatin + 5-Fluorouracil + Leucovorin (mFOLFOX7)</h4>
<ul>
<li>Oxaliplatin: 100 mg/m2 IV on day 1</li>
<li>5-Fluorouracil: 3,000 mg/m2 IV continuous infusion on days 1 and 2 for 46 hours</li>
<li>Leucovorin: 200 mg/m2 IV on day 1 as a 2-hour infusion before 5-fluorouracil</li>
<li>Repeat cycle every 2 weeks.</li>
</ul>
<blockquote>
<p>Maindrault-Goebel F, et al. J Clin Oncol 2006;24 (June 20 Supplement):3504.</p>
</blockquote>
</div>
<div id="folfoxiri" class="section level4" number="2.11.3.8">
<h4><span class="header-section-number">2.11.3.8</span> FOLFOXIRI</h4>
<ul>
<li>Irinotecan: 165 mg/m2 IV on day 1</li>
<li>Oxaliplatin: 85 mg/m2 IV on day 1</li>
<li>5-Fluorouracil: 3,200 mg/m2 IV continuous infusion for 46 hours on days 1 and 2</li>
<li>Leucovorin: 200 mg/m2 IV on day 1 as a 2-hour infusion prior to 5-fluorouracil</li>
<li>Repeat cycle every 2 weeks for a total of 12 cycles.</li>
</ul>
<blockquote>
<p>Falcone A, et al. J Clin Oncol 2007;25:1670–1676.</p>
</blockquote>
</div>
<div id="folfoxiri-bevacizumab" class="section level4" number="2.11.3.9">
<h4><span class="header-section-number">2.11.3.9</span> FOLFOXIRI + Bevacizumab</h4>
<ul>
<li>Irinotecan: 165 mg/m2 IV on day 1</li>
<li>Oxaliplatin: 85 mg/m2 IV on day 1</li>
<li>5-Fluorouracil: 3,200 mg/m2 IV continuous infusion for 46 hours on days 1 and 2</li>
<li>Leucovorin: 200 mg/m2 IV on day 1 as a 2-hour infusion prior to 5-fluorouracil</li>
<li>Bevacizumab: 5 mg/kg IV on day 1</li>
<li>Repeat cycle every 2 weeks.</li>
</ul>
<blockquote>
<p>Loupakis F, et al. N Engl J Med 2014;371:1609–1618.</p>
</blockquote>
</div>
<div id="folfoxiri-panitumumab" class="section level4" number="2.11.3.10">
<h4><span class="header-section-number">2.11.3.10</span> FOLFOXIRI + Panitumumab</h4>
<ul>
<li>Irinotecan: 150 mg/m2 IV on day 1</li>
<li>Oxaliplatin: 85 mg/m2 IV on day 1</li>
<li>5-Fluorouracil: 3,000 mg/m2 IV continuous infusion for 46 hours on days 1 and 2</li>
<li>Leucovorin: 200 mg/m2 IV on day 1 as a 2-hour infusion prior to 5-fluorouracil</li>
<li>Panitumumab: 6 mg/kg IV on day 1</li>
<li>Repeat cycle every 2 weeks.</li>
</ul>
<blockquote>
<p>Fornaro L, et al. Ann Oncol 2013;24:2062–2067.</p>
</blockquote>
</div>
<div id="cetuximab-irinotecan" class="section level4" number="2.11.3.11">
<h4><span class="header-section-number">2.11.3.11</span> Cetuximab + Irinotecan</h4>
<ul>
<li>Cetuximab: 400 mg/m2 IV loading dose, then 250 mg/m2 IV weekly</li>
<li>Irinotecan: 350 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Cunningham D, et al. N Engl J Med 2004;351:337–345.</p>
</blockquote>
<p>or</p>
<ul>
<li>Cetuximab: 400 mg/m2 IV loading dose, then 250 mg/m2 IV weekly</li>
<li>Irinotecan: 180 mg/m2 IV on day 1</li>
<li>Repeat cycle every 14 days.</li>
</ul>
<blockquote>
<p>Cunningham D, et al. N Engl J Med 2004;351:337–345.</p>
</blockquote>
</div>
<div id="capecitabine-oxaliplatin-xelox" class="section level4" number="2.11.3.12">
<h4><span class="header-section-number">2.11.3.12</span> Capecitabine + Oxaliplatin (XELOX)</h4>
<ul>
<li>Capecitabine: 1,000 mg/m2 PO bid on days 1–14</li>
<li>Oxaliplatin: 130 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days. May decrease dose of capecitabine to 850 mg/m2 PO bid and dose of oxaliplatin to 100 mg/m2 IV to reduce risk of toxicity without compromising clinical efficacy.</li>
</ul>
<blockquote>
<p>Scheithauer W, et al. J Clin Oncol 2003;21:1307–1312.</p>
</blockquote>
<p>or</p>
<ul>
<li>Capecitabine: 1,750 mg/m2 PO bid on days 1–7</li>
<li>Oxaliplatin: 85 mg/m2 IV on day 1</li>
<li>Repeat cycle every 14 days. May decrease dose of capecitabine to 1,000–1,250 mg/m2 PO bid to reduce risk of toxicity without compromising clinical efficacy.</li>
</ul>
<blockquote>
<p>Scheithauer W, et al. J Clin Oncol 2003;21:1307–1312.</p>
</blockquote>
</div>
<div id="capecitabine-irinotecan-xeliri" class="section level4" number="2.11.3.13">
<h4><span class="header-section-number">2.11.3.13</span> Capecitabine + Irinotecan (XELIRI)</h4>
<ul>
<li>Capecitabine: 1,000 mg/m2 PO bid on days 1–14</li>
<li>Irinotecan: 250 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days. May decrease dose of capecitabine to 850 mg/m2 PO bid and dose of irinotecan to 200 mg/m2 IV to reduce risk of toxicity without compromising clinical efficacy.</li>
</ul>
<blockquote>
<p>Kerr D. Oncology 2002;16 (Suppl 14):12–15.</p>
</blockquote>
<p>or</p>
<ul>
<li>Capecitabine: 1,500 mg/m2 PO bid on days 2–8</li>
<li>Irinotecan: 150 mg/m2 IV on day 1</li>
<li>Repeat cycle every 14 days.</li>
</ul>
<blockquote>
<p>Borner MM, et al. Ann Oncol 2005;16:282–288.</p>
</blockquote>
</div>
<div id="capecitabine-mitomycin-c" class="section level4" number="2.11.3.14">
<h4><span class="header-section-number">2.11.3.14</span> Capecitabine + Mitomycin-C</h4>
<ul>
<li>Capecitabine: 1,000 mg/m2 PO bid on days 1–14</li>
<li>Mitomycin-C: 7 mg/m2 IV on day 1</li>
<li>Repeat capecitabine every 3 weeks and mitomycin-C every 6 weeks.</li>
</ul>
<blockquote>
<p>Lim DH, et al. Cancer Chemother Pharmacol 2005;56:10–14.</p>
</blockquote>
</div>
<div id="oxaliplatin-irinotecan-irox-regimen" class="section level4" number="2.11.3.15">
<h4><span class="header-section-number">2.11.3.15</span> Oxaliplatin + Irinotecan (IROX regimen)</h4>
<ul>
<li>Oxaliplatin: 85 mg/m2 IV on day 1</li>
<li>Irinotecan: 200 mg/m2 IV on day 1</li>
<li>Repeat cycle every 3 weeks.</li>
</ul>
<blockquote>
<p>Goldberg RM, et al. J Clin Oncol 2004;22:23–30.</p>
</blockquote>
</div>
<div id="fluorouracil-leucovorin-roswell-park-schedule-high-dose" class="section level4" number="2.11.3.16">
<h4><span class="header-section-number">2.11.3.16</span> 5-Fluorouracil + Leucovorin (Roswell Park schedule, high dose)</h4>
<ul>
<li>5-Fluorouracil: 500 mg/m2 IV weekly for 6 weeks</li>
<li>Leucovorin: 500 mg/m2 IV weekly for 6 weeks,</li>
<li>administered before 5-fluorouracil</li>
<li>Repeat cycle every 8 weeks.</li>
</ul>
<blockquote>
<p>Petrelli N, et al. J Clin Oncol 1989;7:1419–1426.</p>
</blockquote>
</div>
<div id="fluorouracil-leucovorin-bevacizumab" class="section level4" number="2.11.3.17">
<h4><span class="header-section-number">2.11.3.17</span> 5-Fluorouracil + Leucovorin + Bevacizumab</h4>
<ul>
<li>5-Fluorouracil: 500 mg/m2 IV weekly for 6 weeks</li>
<li>Leucovorin: 500 mg/m2 IV weekly for 6 weeks, administered before 5-fluorouracil</li>
<li>Bevacizumab: 5 mg/kg IV every 2 weeks</li>
<li>Repeat cycle every 8 weeks.</li>
</ul>
<blockquote>
<p>Kabbinavar F, et al. J Clin Oncol 2005;23:3697–3705.</p>
</blockquote>
</div>
<div id="fluorouracil-leucovorin-german-schedule-low-dose" class="section level4" number="2.11.3.18">
<h4><span class="header-section-number">2.11.3.18</span> 5-Fluorouracil + Leucovorin (German schedule, low dose)</h4>
<ul>
<li>5-Fluorouracil: 600 mg/m2 IV weekly for 6 weeks</li>
<li>Leucovorin: 20 mg/m2 IV weekly for 6 weeks, administered before 5-fluorouracil</li>
<li>Repeat cycle every 8 weeks.</li>
</ul>
<blockquote>
<p>Jager E, et al. J Clin Oncol 1996;14:2274–2279.</p>
</blockquote>
</div>
<div id="fluorouracil-leucovorin-de-gramont-regimen" class="section level4" number="2.11.3.19">
<h4><span class="header-section-number">2.11.3.19</span> 5-Fluorouracil + Leucovorin (de Gramont regimen)</h4>
<ul>
<li>5-Fluorouracil: 400 mg/m2 IV and then 600 mg/m2 IV for 22 hours on days 1 and 2</li>
<li>Leucovorin: 200 mg/m2 IV on days 1 and 2 as a 2-hour infusion before 5-fluorouracil</li>
<li>Repeat cycle every 2 weeks.</li>
</ul>
<blockquote>
<p>de Gramont A, et al. J Clin Oncol 1997;15:808–815.</p>
</blockquote>
</div>
<div id="folfox4-bevacizumab" class="section level4" number="2.11.3.20">
<h4><span class="header-section-number">2.11.3.20</span> FOLFOX4 + Bevacizumab</h4>
<ul>
<li>Oxaliplatin: 85 mg/m2 IV on day 1</li>
<li>5-Fluorouracil: 400 mg/m2 IV bolus, followed by 600 mg/m2 IV continuous infusion on days 1 and 2</li>
<li>Leucovorin: 200 mg/m2 IV on days 1 and 2 as a 2-hour infusion before 5-fluorouracil</li>
<li>Bevacizumab: 10 mg/kg IV every 2 weeks</li>
<li>Repeat cycle every 2 weeks.</li>
</ul>
<blockquote>
<p>Giantonio BJ, et al. J Clin Oncol 2007;25:1539–1544.</p>
</blockquote>
</div>
<div id="lv5fu2-mitomycin-c" class="section level4" number="2.11.3.21">
<h4><span class="header-section-number">2.11.3.21</span> LV5FU2 + Mitomycin-C</h4>
<ul>
<li>5-Fluorouracil: 400 mg/m2 IV bolus, followed by 600 mg/m2 IV continuous infusion on days 1 and 2</li>
<li>Leucovorin: 200 mg/m2 IV on days 1 and 2 as a 2-hour infusion before 5-fluorouracil</li>
<li>Mitomycin-C: 7 mg/m2 IV on day 1</li>
<li>Repeat 5-FU/LV every 2 weeks and mitomycin-C every 4 weeks.</li>
</ul>
<blockquote>
<p>Dimou A, et al. Expert Opin Investing Drugs 2010;19:723–735.</p>
</blockquote>
</div>
<div id="capecitabine-oxaliplatin-xelox-bevacizumab" class="section level4" number="2.11.3.22">
<h4><span class="header-section-number">2.11.3.22</span> Capecitabine + Oxaliplatin (XELOX) + Bevacizumab</h4>
<ul>
<li>Capecitabine: 850 mg/m2 PO bid on days 1–14</li>
<li>Oxaliplatin: 130 mg/m2 IV on day 1</li>
<li>Bevacizumab: 7.5 mg/kg every 3 weeks</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Hochster HS, et al. J Clin Oncol 2008;26:3523–3529.</p>
</blockquote>
</div>
<div id="cetuximab-bevacizumab-irinotecan" class="section level4" number="2.11.3.23">
<h4><span class="header-section-number">2.11.3.23</span> Cetuximab + Bevacizumab + Irinotecan</h4>
<ul>
<li>Cetuximab: 400 mg/m2 IV loading dose, then 250 mg/m2 IV weekly</li>
<li>Bevacizumab: 5 mg/kg IV every 2 weeks</li>
<li>Irinotecan: 180 mg/m2 IV on day 1</li>
<li>Repeat cycle every 2 weeks.</li>
</ul>
<blockquote>
<p>Saltz L, et al. J Clin Oncol 2007;22:4557–4561.</p>
</blockquote>
</div>
<div id="cetuximab-bevacizumab" class="section level4" number="2.11.3.24">
<h4><span class="header-section-number">2.11.3.24</span> Cetuximab + Bevacizumab</h4>
<ul>
<li>Cetuximab: 400 mg/m2 IV loading dose, then 250 mg/m2 IV weekly</li>
<li>Bevacizumab: 5 mg/kg IV every 2 weeks</li>
<li>Repeat cycle every 2 weeks.</li>
</ul>
<blockquote>
<p>Saltz L, et al. J Clin Oncol 2007;22:4557–4561.</p>
</blockquote>
</div>
<div id="irinotecan-cetuximab" class="section level4" number="2.11.3.25">
<h4><span class="header-section-number">2.11.3.25</span> Irinotecan + Cetuximab</h4>
<ul>
<li>Irinotecan: 125 mg/m2 IV weekly for 4 weeks</li>
<li>Cetuximab: 400 mg/m2 IV loading dose, then 250 mg/m2 IV weekly</li>
<li>Repeat cycle every 6 weeks.</li>
</ul>
<blockquote>
<p>Buziad AC, et al. Clin Colorectal Cancer 2010;9:282–289.
Cunningham D, et al. N Engl J Med 2004;351:537–545.</p>
</blockquote>
<p>or</p>
<ul>
<li>Irinotecan: 350 mg/m2 IV on day 1</li>
<li>Cetuximab: 400 mg/m2 IV loading dose, then 250 mg/m2 IV weekly</li>
<li>Repeat cycle every 3 weeks.</li>
</ul>
<blockquote>
<p>Sobrero AF, et al. J Clin Oncol 2008;26:2311–2319.</p>
</blockquote>
</div>
<div id="folfiri-cetuximab" class="section level4" number="2.11.3.26">
<h4><span class="header-section-number">2.11.3.26</span> FOLFIRI + Cetuximab</h4>
<ul>
<li>Irinotecan: 180 mg/m2 IV on day 1</li>
<li>5-Fluorouracil: 400 mg/m2 IV bolus followed by 2,400 mg/m2 IV continuous infusion for 46 hours on days 1 and 2</li>
<li>Leucovorin: 400 mg/m2 IV on day 1 as a 2-hour infusion prior to 5-fluorouracil</li>
<li>Cetuximab: 400 mg/m2 IV loading dose, then 250 mg/m2 IV weekly</li>
<li>Repeat cycle every 2 weeks.</li>
</ul>
<blockquote>
<p>van Cutsem EV, et al. N Engl J Med 2009;360:1408–1417.</p>
</blockquote>
</div>
<div id="folfox4-cetuximab" class="section level4" number="2.11.3.27">
<h4><span class="header-section-number">2.11.3.27</span> FOLFOX4 + Cetuximab</h4>
<ul>
<li>Oxaliplatin: 85 mg/m2 IV on day 1</li>
<li>5-Fluorouracil: 400 mg/m2 IV bolus followed by 600 mg/m2 IV continuous infusion for 22 hours on days 1 and 2</li>
<li>Leucovorin: 200 mg/m2 IV on days 1 and 2 as a 2-hour infusion prior to 5-fluorouracil</li>
<li>Cetuximab: 400 mg/m2 IV loading dose, then 250 mg/m2 IV weekly</li>
<li>Repeat cycle every 2 weeks.</li>
</ul>
<blockquote>
<p>Bokemeyer C, et al. J Clin Oncol 2009;27:663–671.</p>
</blockquote>
</div>
<div id="folfox6-cetuximab" class="section level4" number="2.11.3.28">
<h4><span class="header-section-number">2.11.3.28</span> FOLFOX6 + Cetuximab</h4>
<ul>
<li>Oxaliplatin: 85 mg/m2 IV on day 1</li>
<li>5-Fluorouracil: 400 mg/m2 IV bolus on day 1, followed by 2,400 mg/m2 IV continuous infusion over 46 hours on days 1 and 2</li>
<li>Leucovorin: 400 mg/m2 IV on day 1 as a 2-hour infusion before 5-fluorouracil</li>
<li>Cetuximab: 400 mg/m2 IV loading dose and then 250 mg/m2 IV weekly</li>
<li>Repeat cycle every 2 weeks.</li>
</ul>
<blockquote>
<p>Scott J, et al. J Clin Oncol 2005;23:16S (abstract 3705).</p>
</blockquote>
</div>
<div id="folfox4-panitumumab" class="section level4" number="2.11.3.29">
<h4><span class="header-section-number">2.11.3.29</span> FOLFOX4 + Panitumumab</h4>
<ul>
<li>Oxaliplatin: 85 mg/m2 IV on day 1</li>
<li>5-Fluorouracil: 400 mg/m2 IV bolus followed by 600 mg/m2 IV continuous infusion for 22 hours on days 1 and 2</li>
<li>Leucovorin: 200 mg/m2 IV on days 1 and 2 as a 2-hour infusion before 5-fluorouracil</li>
<li>Panitumumab: 6 mg/kg IV on day 1</li>
<li>Repeat cycle every 2 weeks.</li>
</ul>
<blockquote>
<p>Doullard JY, et al. J Clin Oncol 2010;28:4697–4705.</p>
</blockquote>
</div>
<div id="folfiri-panitumumab" class="section level4" number="2.11.3.30">
<h4><span class="header-section-number">2.11.3.30</span> FOLFIRI + Panitumumab</h4>
<ul>
<li>Irinotecan: 180 mg/m2 IV on day 1</li>
<li>5-Fluorouracil: 400 mg/m2 IV bolus on day 1, followed by 2,400 mg/m2 IV continuous infusion for 46 hours on days 1 and 2</li>
<li>Leucovorin: 400 mg/m2 IV on day 1 as a 2-hour infusion before 5-fluorouracil</li>
<li>Panitumumab: 6 mg/kg IV on day 1</li>
<li>Repeat cycle every 2 weeks.</li>
</ul>
<blockquote>
<p>Peeters M, et al. J Clin Oncol 2010;28:4706–4713.</p>
</blockquote>
</div>
<div id="folfiri-bevacizumab" class="section level4" number="2.11.3.31">
<h4><span class="header-section-number">2.11.3.31</span> FOLFIRI + Bevacizumab</h4>
<ul>
<li>Irinotecan: 180 mg/m2 IV on day 1</li>
<li>5-Fluorouracil: 400 mg/m2 IV bolus on day 1, followed by 2,400 mg/m2 IV continuous infusion for 46 hours on days 1 and 2</li>
<li>Leucovorin: 400 mg/m2 IV on day 1 as a 2-hour infusion prior to 5-fluorouracil</li>
<li>Bevacizumab: 5 mg/kg IV every 2 weeks</li>
<li>Repeat cycle every 2 weeks.</li>
</ul>
<blockquote>
<p>Kopetz S, et al. J Clin Oncol 2007;25:18S (abstract 4027).</p>
</blockquote>
</div>
<div id="xeliri-bevacizumab" class="section level4" number="2.11.3.32">
<h4><span class="header-section-number">2.11.3.32</span> XELIRI + Bevacizumab</h4>
<ul>
<li>Irinotecan: 200 mg/m2 IV on day 1</li>
<li>Capecitabine: 800 mg/m2 PO on days 1-14</li>
<li>Bevacizumab: 7.5 mg/kg IV on day 1</li>
<li>Repeat cycle every 3 weeks.</li>
</ul>
<blockquote>
<p>Xu RH, et al. Lancet Oncol 2019;25:660–671.</p>
</blockquote>
</div>
<div id="folfiri-ziv-aflibercept" class="section level4" number="2.11.3.33">
<h4><span class="header-section-number">2.11.3.33</span> FOLFIRI + Ziv-aflibercept</h4>
<ul>
<li>Irinotecan: 180 mg/m2 IV on day 1</li>
<li>5-Fluorouracil: 400 mg/m2 IV bolus on day 1, followed by 2,400 mg/m2 IV continuous infusion for 46 hours on days 1 and 2</li>
<li>Leucovorin: 400 mg/m2 IV on day 1 as a 2-hour infusion prior to 5-fluorouracil</li>
<li>Ziv-aflibercept: 4 mg/kg IV on day 1</li>
<li>Repeat cycle every 2 weeks.</li>
</ul>
<blockquote>
<p>van Cutsem EE, et al. J Clin Oncol 2012;30:3499–3506.</p>
</blockquote>
</div>
<div id="folfiri-ramucirumab" class="section level4" number="2.11.3.34">
<h4><span class="header-section-number">2.11.3.34</span> FOLFIRI + Ramucirumab</h4>
<ul>
<li>Irinotecan: 180 mg/m2 IV on day 1</li>
<li>5-Fluorouracil: 400 mg/m2 IV bolus on day 1, followed by 2,400 mg/m2 IV continuous infusion for 46 hours on days 1 and 2</li>
<li>Leucovorin: 400 mg/m2 IV on day 1 as a 2-hour infusion prior to 5-fluorouracil</li>
<li>Ramucirumab: 8 mg/kg IV on day 1</li>
<li>Repeat cycle every 2 weeks.</li>
</ul>
<blockquote>
<p>Tabernero J, et al. Lancet Oncol 2015;16:499–508.</p>
</blockquote>
</div>
<div id="nivolumab-ipilimumab" class="section level4" number="2.11.3.35">
<h4><span class="header-section-number">2.11.3.35</span> Nivolumab + Ipilimumab</h4>
<ul>
<li>Nivolumab: 3 mg/kg IV on day 1</li>
<li>Ipilimumab: 1 mg/kg IV on day1</li>
<li>Repeat cycle every 21 days for 4 cycles and then treat with nivolumab at 3 mg/kg or 240 mg IV every 14 days until disease progression or toxicity.</li>
</ul>
<blockquote>
<p>Overman MJ, et al. J Clin Oncol 2018;36:773–779.</p>
</blockquote>
</div>
</div>
<div id="metastatic-disease---hepatic-artery-infusion" class="section level3" number="2.11.4">
<h3><span class="header-section-number">2.11.4</span> Metastatic Disease - Hepatic Artery Infusion</h3>
<div id="floxuridine" class="section level4" number="2.11.4.1">
<h4><span class="header-section-number">2.11.4.1</span> Floxuridine</h4>
<ul>
<li>Floxuridine (FUDR): 0.3 mg/kg/day HAI on days 1–14</li>
<li>Dexamethasone: 20 mg HAI on days 1–14</li>
<li>Heparin: 50,000 U HAI on days 1–14</li>
<li>Repeat cycle every 14 days.</li>
</ul>
<blockquote>
<p>Kemeny N, et al. J Clin Oncol 1994;12:2288–2295.</p>
</blockquote>
</div>
</div>
<div id="metastatic-disease---single-agent-regimens-2" class="section level3" number="2.11.5">
<h3><span class="header-section-number">2.11.5</span> Metastatic Disease - Single-Agent Regimens</h3>
<div id="capecitabine-4" class="section level4" number="2.11.5.1">
<h4><span class="header-section-number">2.11.5.1</span> Capecitabine</h4>
<ul>
<li>Capecitabine: 1,250 mg/m2 PO bid on days 1–14</li>
<li>Repeat cycle every 21 days. Dose may be decreased to 850–1,000 mg/m2 PO bid on days 1–14 to reduce risk of toxicity without compromising clinical efficacy.</li>
</ul>
<blockquote>
<p>Hoff P, et al. J Clin Oncol 2001;15:2282–2292.</p>
</blockquote>
</div>
<div id="cpt-11-weekly-schedule" class="section level4" number="2.11.5.2">
<h4><span class="header-section-number">2.11.5.2</span> CPT-11 (weekly schedule)</h4>
<ul>
<li>CPT-11: 125 mg/m2 IV over 90 minutes weekly for 4 weeks</li>
<li>Repeat cycle every 6 weeks.</li>
</ul>
<blockquote>
<p>Pitot HC, et al. J Clin Oncol 1997;15:2910–2919.</p>
</blockquote>
<p>or</p>
<ul>
<li>CPT-11: 125 mg/m2 IV over 90 minutes weekly for 2 weeks</li>
<li>Repeat cycle every 3 weeks.</li>
</ul>
<p>or</p>
<ul>
<li>CPT-11: 175 mg/m2 IV on days 1 and 10</li>
<li>Repeat cycle every 3 weeks.</li>
</ul>
<blockquote>
<p>Ulrich-Pur H, et al. Ann Oncol 2001;12:1269–1272.</p>
</blockquote>
</div>
<div id="cpt-11-monthly-schedule" class="section level4" number="2.11.5.3">
<h4><span class="header-section-number">2.11.5.3</span> CPT-11 (monthly schedule)</h4>
<ul>
<li>CPT-11: 350 mg/m2 IV on day 1</li>
<li>Repeat cycle every 3 weeks.</li>
</ul>
<blockquote>
<p>Rougier P, et al. J Clin Oncol 1997;15:251–260.</p>
</blockquote>
</div>
<div id="cetuximab-1" class="section level4" number="2.11.5.4">
<h4><span class="header-section-number">2.11.5.4</span> Cetuximab</h4>
<ul>
<li>Cetuximab: 400 mg/m2 IV loading dose, then 250 mg/m2 IV weekly</li>
<li>Repeat cycle on a weekly basis.</li>
</ul>
<blockquote>
<p>Saltz LB, et al. J Clin Oncol 2004;22:1201–1208.</p>
</blockquote>
<p>or</p>
<ul>
<li>Cetuximab: 500 mg/m2 IV every 2 weeks (no loading dose is necessary)</li>
<li>Repeat cycle every 2 weeks.</li>
</ul>
<blockquote>
<p>Tabernero J, et al. J Clin Oncol 2006;24:18S (abstract 3085).</p>
</blockquote>
</div>
<div id="panitumumab-1" class="section level4" number="2.11.5.5">
<h4><span class="header-section-number">2.11.5.5</span> Panitumumab</h4>
<ul>
<li>Panitumumab: 6 mg/kg IV every 2 weeks</li>
<li>Repeat cycle every 2 weeks.</li>
</ul>
<blockquote>
<p>van Cutsem EV, et al. J Clin Oncol 2007;25:1658–1664.</p>
</blockquote>
</div>
<div id="fluorouracil-continuous-infusion" class="section level4" number="2.11.5.6">
<h4><span class="header-section-number">2.11.5.6</span> 5-Fluorouracil (continuous infusion)</h4>
<ul>
<li>5-Fluorouracil: 2,600 mg/m2 IV over 24 hours weekly</li>
<li>Repeat cycle weekly for 4 weeks.</li>
</ul>
<blockquote>
<p>Leichman CG, et al. J Clin Oncol 1995;13:1303–1311.</p>
</blockquote>
<p>or</p>
<ul>
<li>5-Fluorouracil: 1,000 mg/m2/day IV continuous infusion on days 1–4</li>
<li>Repeat cycle every 21–28 days.</li>
</ul>
<blockquote>
<p>Leichman CG. Oncology 1999;13 (Suppl 3):26–32.</p>
</blockquote>
<p>or</p>
<ul>
<li>5-Fluorouracil: 200 mg/m2/day IV continuous infusion on days 1–4</li>
<li>L-Leucovorin: 5 mg/m2/day IV on days 1–14</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Falcone A, et al. Cancer Chemother Pharmacol 1999;44:159–163.</p>
</blockquote>
</div>
<div id="regorafenib-1" class="section level4" number="2.11.5.7">
<h4><span class="header-section-number">2.11.5.7</span> Regorafenib</h4>
<ul>
<li>Regorafenib: 160 mg PO daily on days 1–21</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Grothey A, et al. J Clin Oncol 2012; Suppl 4 (abstract LBA385).</p>
</blockquote>
</div>
<div id="tas-102" class="section level4" number="2.11.5.8">
<h4><span class="header-section-number">2.11.5.8</span> TAS-102</h4>
<ul>
<li>TAS-102: 35 mg/m2 PO bid on days 1–5 and 8–12</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Mayer RJ, et al. N Engl J Med 2015;20:1909–1919.</p>
</blockquote>
</div>
<div id="pembrolizumab-4" class="section level4" number="2.11.5.9">
<h4><span class="header-section-number">2.11.5.9</span> Pembrolizumab</h4>
<ul>
<li>Pembrolizumab: 200 mg IV on day 1</li>
<li>Repeat cycle every 3 weeks.</li>
</ul>
<blockquote>
<p>Le D, et al. N Engl J Med 2015;372:2509–2520.</p>
</blockquote>
</div>
<div id="nivolumab-2" class="section level4" number="2.11.5.10">
<h4><span class="header-section-number">2.11.5.10</span> Nivolumab</h4>
<ul>
<li>Nivolumab: 3 mg/kg IV on day 1</li>
<li>Repeat cycle every 2 weeks. May also administer using a fixed dose of 240 mg IV on day 1 every 2 weeks or 480 mg IV on day 1 every 4 weeks.</li>
</ul>
<blockquote>
<p>Overman MJ, et al. Lancet Oncol 2017;18:1182–1191.</p>
</blockquote>
</div>
</div>
</div>
<div id="endometrial-cancer" class="section level2" number="2.12">
<h2><span class="header-section-number">2.12</span> ENDOMETRIAL CANCER</h2>
<div id="combination-regimens-6" class="section level3" number="2.12.1">
<h3><span class="header-section-number">2.12.1</span> Combination Regimens</h3>
<div id="paclitaxel-carboplatin-1" class="section level4" number="2.12.1.1">
<h4><span class="header-section-number">2.12.1.1</span> Paclitaxel + Carboplatin</h4>
<ul>
<li>Paclitaxel: 175 mg/m2 IV over 3 hours on day 1</li>
<li>Carboplatin: AUC of 5–7, IV on day 1</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Hoskins PJ, et al. J Clin Oncol 2001;19:4048–4053.</p>
</blockquote>
</div>
<div id="ac-2" class="section level4" number="2.12.1.2">
<h4><span class="header-section-number">2.12.1.2</span> AC</h4>
<ul>
<li>Doxorubicin: 60 mg/m2 IV on day 1</li>
<li>Cyclophosphamide: 500 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Thigpen JT, et al. J Clin Oncol 1994;12:1408–1414.</p>
</blockquote>
</div>
<div id="ap" class="section level4" number="2.12.1.3">
<h4><span class="header-section-number">2.12.1.3</span> AP</h4>
<ul>
<li>Doxorubicin: 50 mg/m2 IV on day 1</li>
<li>Cisplatin: 50 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Deppe G, et al. Eur J Gynecol Oncol 1994;15:263–266.</p>
</blockquote>
</div>
<div id="doxorubicin-paclitaxel" class="section level4" number="2.12.1.4">
<h4><span class="header-section-number">2.12.1.4</span> Doxorubicin + Paclitaxel</h4>
<ul>
<li>Doxorubicin: 50 mg/m2 IV on day 1</li>
<li>Paclitaxel: 150 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Fiorica JV. Oncologist 2002;7 (Suppl 5):36–45.</p>
</blockquote>
</div>
<div id="cisplatin-doxorubicin-paclitaxel" class="section level4" number="2.12.1.5">
<h4><span class="header-section-number">2.12.1.5</span> Cisplatin + Doxorubicin + Paclitaxel</h4>
<ul>
<li>Cisplatin: 50 mg/m2 IV on day 1</li>
<li>Doxorubicin: 45 mg/m2 IV on day 1</li>
<li>Paclitaxel: 160 mg/m2 IV over 3 hours on day 2</li>
<li>Filgrastim: 5 µg/kg SC on days 3–12</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Fleming GF, et al. J Clin Oncol 2004;22:2159–2165.</p>
</blockquote>
</div>
<div id="cap-1" class="section level4" number="2.12.1.6">
<h4><span class="header-section-number">2.12.1.6</span> CAP</h4>
<ul>
<li>Cyclophosphamide: 500 mg/m2 IV on day 1</li>
<li>Doxorubicin: 50 mg/m2 IV on day 1</li>
<li>Cisplatin: 50 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Burke TW, et al. Gynecol Oncol 1994;55:47–50.</p>
</blockquote>
</div>
<div id="carboplatin-doxorubicin-liposome" class="section level4" number="2.12.1.7">
<h4><span class="header-section-number">2.12.1.7</span> Carboplatin + Doxorubicin liposome</h4>
<ul>
<li>Carboplatin: AUC of 5, IV on day 1</li>
<li>Doxorubicin liposome: 40 mg/m2 IV on day 1</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Pignata S, et al. Br J Cancer 2007;96:1639–1643.</p>
</blockquote>
</div>
<div id="paclitaxel-ifosfamide-carcinosarcoma" class="section level4" number="2.12.1.8">
<h4><span class="header-section-number">2.12.1.8</span> Paclitaxel + Ifosfamide (carcinosarcoma)</h4>
<ul>
<li>Paclitaxel: 135 mg/m2 IV over 3 hours on day 1</li>
<li>Ifosfamide: 1,600 mg/m2/day IV on days 1–3</li>
<li>Repeat cycle every 21 days for up to 8 cycles. Mesna to be given as either IV or PO. G-CSF support at 5 µg/kg/day SC to be started on day 4.</li>
</ul>
<blockquote>
<p>Homesley HD, et al. J Clin Oncol 2007;25:526–531.</p>
</blockquote>
</div>
<div id="cisplatin-ifosfamide-carcinosarcoma" class="section level4" number="2.12.1.9">
<h4><span class="header-section-number">2.12.1.9</span> Cisplatin + Ifosfamide (carcinosarcoma)</h4>
<ul>
<li>Cisplatin: 20 mg/m2/day IV on days 1-4</li>
<li>Ifosfamide: 1,500 mg/m2/day IV on day 1</li>
<li>Mesna: 120 mg/m2 IV (loading dose) followed by 1,500 mg/m2/day for 24 hours</li>
<li>Repeat cycle every 21 days for 3 cycles.</li>
</ul>
<blockquote>
<p>Wolfson AH, et al. J Clin Oncol 2006;24(18S):5001.</p>
</blockquote>
</div>
<div id="gemcitabine-docetaxel-1" class="section level4" number="2.12.1.10">
<h4><span class="header-section-number">2.12.1.10</span> Gemcitabine + Docetaxel</h4>
<ul>
<li>Gemcitabine: 900 mg/m2 IV on days 1 and 8</li>
<li>Docetaxel: 100 mg/m2 IV on day 8</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Hensley ML, et al. Gynecol Oncol 2008;109:329–334.</p>
</blockquote>
</div>
</div>
<div id="single-agent-regimens-5" class="section level3" number="2.12.2">
<h3><span class="header-section-number">2.12.2</span> Single-Agent Regimens</h3>
<div id="doxorubicin-1" class="section level4" number="2.12.2.1">
<h4><span class="header-section-number">2.12.2.1</span> Doxorubicin</h4>
<ul>
<li>Doxorubicin: 60 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Muss HB. Semin Oncol 1994;21:107–113.</p>
</blockquote>
</div>
<div id="megestrol-1" class="section level4" number="2.12.2.2">
<h4><span class="header-section-number">2.12.2.2</span> Megestrol</h4>
<ul>
<li>Megestrol: 160 mg PO daily</li>
<li>Repeat on a daily basis.</li>
</ul>
<blockquote>
<p>Thigpen JT, et al. J Clin Oncol 1999;17:1736–1744.</p>
</blockquote>
</div>
<div id="paclitaxel-4" class="section level4" number="2.12.2.3">
<h4><span class="header-section-number">2.12.2.3</span> Paclitaxel</h4>
<ul>
<li>Paclitaxel: 200 mg/m2 IV over 3 hours on day 1</li>
<li>Repeat cycle every 21 days. Reduce dose to 175 mg/m2 IV for patients with prior pelvic radiation therapy.</li>
</ul>
<blockquote>
<p>Ball H, et al. Gynecol Oncol 1996;62:278–282.</p>
</blockquote>
</div>
<div id="topotecan-1" class="section level4" number="2.12.2.4">
<h4><span class="header-section-number">2.12.2.4</span> Topotecan</h4>
<ul>
<li>Topotecan: 1.0 mg/m2/day IV on days 1–5</li>
<li>Repeat cycle every 21 days. Reduce dose to 0.8 mg/m2/day IV on days 1–3 in patients with prior radiation therapy.</li>
</ul>
<blockquote>
<p>Wadler S, et al. J Clin Oncol 2003;21:2110–2114.</p>
</blockquote>
</div>
<div id="temsirolimus" class="section level4" number="2.12.2.5">
<h4><span class="header-section-number">2.12.2.5</span> Temsirolimus</h4>
<ul>
<li>Temsirolimus: 25 mg IV on day 1</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Oza AM, et al. J Clin Oncol 2011;29:3278–3285.</p>
</blockquote>
</div>
</div>
</div>
<div id="esophageal-cancer" class="section level2" number="2.13">
<h2><span class="header-section-number">2.13</span> ESOPHAGEAL CANCER</h2>
<div id="neoadjuvant-combined-modality-therapy" class="section level3" number="2.13.1">
<h3><span class="header-section-number">2.13.1</span> Neoadjuvant Combined Modality Therapy</h3>
<div id="fluorouracil-cisplatin-radiation-therapy-prodige5accord17" class="section level4" number="2.13.1.1">
<h4><span class="header-section-number">2.13.1.1</span> 5-Fluorouracil + Cisplatin + Radiation Therapy (PRODIGE5/ACCORD17)</h4>
<ul>
<li>5-Fluorouracil: 1,000 mg/m2/day IV continuous infusion on days 1–4</li>
<li>Cisplatin: 75 mg/m2 IV on day 1</li>
<li>Repeat cycle every 28 days for a total of 2 cycles given concurrently with radiation therapy. Two additional cycles are given every 21 days after completion of the combined modality therapy.</li>
<li>Radiation therapy: 200 cGy/day for 5 days per week to a total dose of 5,000 cGy over 5 weeks</li>
</ul>
<blockquote>
<p>Conroy T, et al. Lancet Oncol 2014;15:305–314.</p>
</blockquote>
</div>
<div id="folfox-radiation-therapy-prodige5accord17" class="section level4" number="2.13.1.2">
<h4><span class="header-section-number">2.13.1.2</span> FOLFOX + Radiation Therapy (PRODIGE5/ACCORD17)</h4>
<ul>
<li>Oxaliplatin: 85 mg/m2 IV on day 1</li>
<li>5-Fluorouracil: 400 mg/m2 IV bolus on day 1, followed by 1,600 mg/m2 IV continuous infusion for 46 hours</li>
<li>Leucovorin: 200 mg/m2 IV on day 1 as a 2-hour infusion before the bolus 5-fluorouracil dose</li>
<li>Radiation therapy: 200 cGy/day for 5 days per week to a total dose of 5,000 cGy over 5 weeks</li>
<li>Repeat cycle every 2 weeks for a total of 6 cycles with the first 3 cycles given concurrently with radiation therapy.</li>
</ul>
<blockquote>
<p>Conroy T, et al. Lancet Oncol 2014;15:305–314.</p>
</blockquote>
</div>
<div id="capox-radiation-therapy" class="section level4" number="2.13.1.3">
<h4><span class="header-section-number">2.13.1.3</span> CAPOX + Radiation Therapy</h4>
<ul>
<li>Oxaliplatin: 85 mg/m2 IV on days 1, 15, and 29</li>
<li>Capecitabine: 625 mg/m2 PO bid on days 1–5 for 5 weeks</li>
<li>Radiation therapy: 180 cGy/day for 5 days per week to a total dose of 5400 cGy</li>
<li>Chemotherapy is given concurrently with radiation therapy, followed by surgical resection.</li>
</ul>
<blockquote>
<p>Javle MM, et al. Cancer Invest 2009;27:193–200.</p>
</blockquote>
</div>
<div id="fluorouracil-cisplatin-radiation-therapy-ffd-french-regimen" class="section level4" number="2.13.1.4">
<h4><span class="header-section-number">2.13.1.4</span> 5-Fluorouracil + Cisplatin + Radiation Therapy (FFD French regimen)</h4>
<ul>
<li>5-Fluorouracil: 800 mg/m2/day IV continuous infusion on days 1–5</li>
<li>Cisplatin: 15 mg/m2 IV on days 1–5. Administer on days 1, 22, 43, 64, and 92</li>
<li>Radiation therapy: 200 cGy/day for 5 days per week to a total dose of 6600 cGy over 6.5 weeks</li>
<li>Chemotherapy is given concurrently with radiation therapy, followed by surgical resection.</li>
</ul>
<blockquote>
<p>Bedenne L, et al. J Clin Oncol 2007;25:1160–1168.</p>
</blockquote>
</div>
<div id="fluorouracil-cisplatin-radiation-therapy-hopkinsyale-regimen" class="section level4" number="2.13.1.5">
<h4><span class="header-section-number">2.13.1.5</span> 5-Fluorouracil + Cisplatin + Radiation Therapy (Hopkins/Yale regimen)</h4>
<ul>
<li>5-Fluorouracil: 225 mg/m2/day IV continuous infusion on days 1–30</li>
<li>Cisplatin: 20 mg/m2/day IV on days 1–5 and 26–30</li>
<li>Radiation therapy: 200 cGy/day to a total dose of 4400 cGy</li>
<li>Chemotherapy is given concurrently with radiation therapy. Followed by esophagectomy and then adjuvant chemotherapy in patients who had total gross removal of disease with negative margins.</li>
</ul>
</div>
</div>
<div id="adjuvant-chemotherapy" class="section level3" number="2.13.2">
<h3><span class="header-section-number">2.13.2</span> Adjuvant Chemotherapy</h3>
<ul>
<li>Paclitaxel: 135 mg/m2 IV for 24 hours on day 1</li>
<li>Cisplatin: 75 mg/m2 IV on day 2</li>
<li>Adjuvant chemotherapy is given 8–12 weeks after esophagectomy, and each cycle is given every 21 days for a total of 3 cycles.</li>
</ul>
<blockquote>
<p>Heath El, et al. J Clin Oncol 2000;18:868–876.</p>
</blockquote>
</div>
<div id="magic-trial" class="section level3" number="2.13.3">
<h3><span class="header-section-number">2.13.3</span> MAGIC Trial</h3>
<div id="preoperative-ecf-chemotherapy" class="section level4" number="2.13.3.1">
<h4><span class="header-section-number">2.13.3.1</span> Preoperative ECF Chemotherapy</h4>
<ul>
<li>Epirubicin: 50 mg/m2 IV on day 1</li>
<li>Cisplatin: 60 mg/m2 IV on day 1</li>
<li>5-Fluorouracil: 200 mg/m2/day IV continuous infusion on days 1–21</li>
<li>Repeat cycle every 21 days for 3 cycles.</li>
<li>Followed by esophagectomy and then adjuvant chemotherapy in patients who had total gross removal of disease with negative margins.</li>
</ul>
<blockquote>
<p>Cunningham D, et al. N Engl J Med 2006;355:11–20.</p>
</blockquote>
</div>
</div>
<div id="adjuvant-chemotherapy-1" class="section level3" number="2.13.4">
<h3><span class="header-section-number">2.13.4</span> Adjuvant Chemotherapy</h3>
<ul>
<li>Epirubicin: 50 mg/m2 IV on day 1</li>
<li>Cisplatin: 60 mg/m2 IV on day 1</li>
<li>5-Fluorouracil: 200 mg/m2/day IV continuous infusion on days 1–21</li>
<li>Repeat cycle every 21 days for 3 cycles.</li>
</ul>
<blockquote>
<p>Cunningham D, et al. N Engl J Med 2006;355:11–20.</p>
</blockquote>
</div>
<div id="metastatic-disease---combination-regimens-2" class="section level3" number="2.13.5">
<h3><span class="header-section-number">2.13.5</span> Metastatic Disease - Combination Regimens</h3>
<div id="fluorouracil-cisplatin-2" class="section level4" number="2.13.5.1">
<h4><span class="header-section-number">2.13.5.1</span> 5-Fluorouracil + Cisplatin</h4>
<ul>
<li>5-Fluorouracil: 1,000 mg/m2/day IV continuous infusion on days 1–5</li>
<li>Cisplatin: 100 mg/m2 IV on day 1</li>
<li>Repeat cycle on weeks 1, 5, 8, and 11.</li>
</ul>
<blockquote>
<p>Kies MS, et al. Cancer 1987;60:2156–2160.</p>
</blockquote>
</div>
<div id="irinotecan-cisplatin" class="section level4" number="2.13.5.2">
<h4><span class="header-section-number">2.13.5.2</span> Irinotecan + Cisplatin</h4>
<ul>
<li>Irinotecan: 65 mg/m2 IV weekly for 4 weeks</li>
<li>Cisplatin: 30 mg/m2 IV weekly for 4 weeks</li>
<li>Repeat cycle every 6 weeks.</li>
</ul>
<blockquote>
<p>Ilson DH, et al. J Clin Oncol 1999;17:3270–3275.</p>
</blockquote>
</div>
<div id="paclitaxel-cisplatin-1" class="section level4" number="2.13.5.3">
<h4><span class="header-section-number">2.13.5.3</span> Paclitaxel + Cisplatin</h4>
<ul>
<li>Paclitaxel: 200 mg/m2 IV over 24 hours on day 1</li>
<li>Cisplatin: 75 mg/m2 IV on day 2</li>
<li>Repeat cycle every 21 days. G-CSF support is recommended.</li>
</ul>
<blockquote>
<p>Ilson DH, et al. J Clin Oncol 1998;16:1826–1834.</p>
</blockquote>
</div>
<div id="capecitabine-oxaliplatin-2" class="section level4" number="2.13.5.4">
<h4><span class="header-section-number">2.13.5.4</span> Capecitabine + Oxaliplatin</h4>
<ul>
<li>Capecitabine: 1,000 mg/m2 PO bid on days 1–14</li>
<li>Oxaliplatin: 130 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>van Meerten E, et al. Br J Cancer 2007;96:1348–1352.</p>
</blockquote>
</div>
<div id="ecf" class="section level4" number="2.13.5.5">
<h4><span class="header-section-number">2.13.5.5</span> ECF</h4>
<ul>
<li>Epirubicin: 50 mg/m2 IV on day 1</li>
<li>Cisplatin: 60 mg/m2 IV on day 1</li>
<li>5-Fluorouracil: 200 mg/m2/day IV continuous infusion</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Cunningham D, et al. N Engl J Med 2008;358:36–46.</p>
</blockquote>
</div>
<div id="eof" class="section level4" number="2.13.5.6">
<h4><span class="header-section-number">2.13.5.6</span> EOF</h4>
<ul>
<li>Epirubicin: 50 mg/m2 IV on day 1</li>
<li>Oxaliplatin: 130 mg/m2 IV on day 1</li>
<li>5-Fluorouracil: 200 mg/m2/day IV continuous infusion</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Cunningham D, et al. N Engl J Med 2008;358:36–46.</p>
</blockquote>
</div>
<div id="ecx" class="section level4" number="2.13.5.7">
<h4><span class="header-section-number">2.13.5.7</span> ECX</h4>
<ul>
<li>Epirubicin: 50 mg/m2 IV on day 1</li>
<li>Cisplatin: 60 mg/m2 IV on day 1</li>
<li>Capecitabine: 625 mg/m2 PO bid continuously</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Cunningham D, et al. N Engl J Med 2008;358:36–46.</p>
</blockquote>
</div>
<div id="eox" class="section level4" number="2.13.5.8">
<h4><span class="header-section-number">2.13.5.8</span> EOX</h4>
<ul>
<li>Epirubicin: 50 mg/m2 IV on day 1</li>
<li>Oxaliplatin: 130 mg/m2 IV on day 1</li>
<li>Capecitabine: 625 mg/m2 PO bid continuously</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Cunningham D, et al. N Engl J Med 2008;358:36–46.</p>
</blockquote>
</div>
</div>
<div id="metastatic-disease---single-agent-regimens-3" class="section level3" number="2.13.6">
<h3><span class="header-section-number">2.13.6</span> Metastatic Disease - Single-Agent Regimens</h3>
<div id="paclitaxel-5" class="section level4" number="2.13.6.1">
<h4><span class="header-section-number">2.13.6.1</span> Paclitaxel</h4>
<ul>
<li>Paclitaxel: 250 mg/m2 IV over 24 hours on day 1</li>
<li>Repeat cycle every 21 days. G-CSF support is recommended.</li>
</ul>
<blockquote>
<p>Ajani JA, et al. Semin Oncol 1995;22 (Suppl 6):35–40.</p>
</blockquote>
</div>
<div id="pembrolizumab-5" class="section level4" number="2.13.6.2">
<h4><span class="header-section-number">2.13.6.2</span> Pembrolizumab</h4>
<ul>
<li>Pembrolizumab: 200 mg IV on day 1</li>
<li>Repeat cycle every 3 weeks.</li>
</ul>
<blockquote>
<p>Fuchs CS, et al. JAMA Oncol 2018;4:e180013.</p>
</blockquote>
</div>
</div>
</div>
<div id="gastric-cancer" class="section level2" number="2.14">
<h2><span class="header-section-number">2.14</span> GASTRIC CANCER</h2>
<div id="adjuvant-therapy" class="section level3" number="2.14.1">
<h3><span class="header-section-number">2.14.1</span> Adjuvant Therapy</h3>
<p>One cycle of chemotherapy is administered as follows:
- 5-Fluorouracil: 425 mg/m2 IV on days 1–5
- Leucovorin: 20 mg/m2 IV on days 1–5
- Chemoradiotherapy is then started 28 days after the start of the initial cycle of chemotherapy as follows:
- Radiation therapy: 180 cGy/day to a total dose of 4,500 cGy, starting on day 28
- 5-Fluorouracil: 400 mg/m2 IV on days 1–4 and days 23–25 of radiation therapy
- Leucovorin: 20 mg/m2 IV on days 1–4 and days 23–25 of radiation therapy
- Chemoradiotherapy is followed by 2 cycles of chemotherapy that are given 1 month apart and include:
- 5-Fluorouracil: 425 mg/m2 IV on days 1–5
- Leucovorin: 20 mg/m2 IV on days 1–5</p>
<blockquote>
<p>MacDonald JS, et al. N Engl J Med 2001;345:725–730.</p>
</blockquote>
<div id="capecitabine-oxaliplatin-3" class="section level4" number="2.14.1.1">
<h4><span class="header-section-number">2.14.1.1</span> Capecitabine + Oxaliplatin</h4>
<ul>
<li>Capecitabine: 1,000 mg/m2 PO bid on days 1–14</li>
<li>Oxaliplatin: 130 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days for 6 months.</li>
</ul>
<blockquote>
<p>Bang Y, et al. J Clin Oncol 2011;29:185 (LBA4002).</p>
</blockquote>
</div>
</div>
<div id="metastatic-disease---combination-regimens-3" class="section level3" number="2.14.2">
<h3><span class="header-section-number">2.14.2</span> Metastatic Disease - Combination Regimens</h3>
<div id="dcf" class="section level4" number="2.14.2.1">
<h4><span class="header-section-number">2.14.2.1</span> DCF</h4>
<ul>
<li>Docetaxel: 75 mg/m2 IV on day 1</li>
<li>Cisplatin: 75 mg/m2 IV on day 1</li>
<li>5-Fluorouracil: 750 mg/m2/day IV continuous infusion on days 1–5</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Ajani JA, et al. J Clin Oncol 2007;25:3205–3209.</p>
</blockquote>
</div>
<div id="cf" class="section level4" number="2.14.2.2">
<h4><span class="header-section-number">2.14.2.2</span> CF</h4>
<ul>
<li>Cisplatin: 100 mg/m2 IV on day 1</li>
<li>5-Fluorouracil: 1,000 mg/m2/day IV continuous infusion on days 1–5</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Wilke M, et al. J Clin Oncol 1989;7:1318–1326.</p>
</blockquote>
</div>
<div id="ecf-1" class="section level4" number="2.14.2.3">
<h4><span class="header-section-number">2.14.2.3</span> ECF</h4>
<ul>
<li>Epirubicin: 50 mg/m2 IV on day 1</li>
<li>Cisplatin: 60 mg/m2 IV on day 1</li>
<li>5-Fluorouracil: 200 mg/m2/day IV continuous infusion</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Cunningham D, et al. N Engl J Med 2008;358:36–46.</p>
</blockquote>
</div>
<div id="eof-1" class="section level4" number="2.14.2.4">
<h4><span class="header-section-number">2.14.2.4</span> EOF</h4>
<ul>
<li>Epirubicin: 50 mg/m2 IV on day 1</li>
<li>Oxaliplatin: 130 mg/m2 IV on day 1</li>
<li>5-Fluorouracil: 200 mg/m2/day IV continuous infusion</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Cunningham D, et al. N Engl J Med 2008;358:36–46.</p>
</blockquote>
</div>
<div id="ecx-1" class="section level4" number="2.14.2.5">
<h4><span class="header-section-number">2.14.2.5</span> ECX</h4>
<ul>
<li>Epirubicin: 50 mg/m2 IV on day 1</li>
<li>Cisplatin: 60 mg/m2 IV on day 1</li>
<li>Capecitabine: 625 mg/m2 PO bid continuously</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Cunningham D, et al. N Engl J Med 2008;358:36–46.</p>
</blockquote>
</div>
<div id="eox-1" class="section level4" number="2.14.2.6">
<h4><span class="header-section-number">2.14.2.6</span> EOX</h4>
<ul>
<li>Epirubicin: 50 mg/m2 IV on day 1</li>
<li>Oxaliplatin: 130 mg/m2 IV on day 1</li>
<li>Capecitabine: 625 mg/m2 PO bid continuously</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Cunningham D, et al. N Engl J Med 2008;358:36–46.</p>
</blockquote>
</div>
<div id="ip" class="section level4" number="2.14.2.7">
<h4><span class="header-section-number">2.14.2.7</span> IP</h4>
<ul>
<li>Irinotecan: 70 mg/m2 IV on days 1 and 15</li>
<li>Cisplatin: 80 mg/m2 IV on day 1</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Shirao K, et al. J Clin Oncol 1997;15:921–927.</p>
</blockquote>
</div>
<div id="ipb" class="section level4" number="2.14.2.8">
<h4><span class="header-section-number">2.14.2.8</span> IPB</h4>
<ul>
<li>Irinotecan: 65 mg/m2 IV on days 1 and 8</li>
<li>Cisplatin: 30 mg/m2 IV on days 1 and 8</li>
<li>Bevacizumab: 15 mg/kg IV on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Shah MA, et al. J Clin Oncol 2006;24:5201–5206.</p>
</blockquote>
</div>
<div id="docetaxel-cisplatin-1" class="section level4" number="2.14.2.9">
<h4><span class="header-section-number">2.14.2.9</span> Docetaxel + Cisplatin</h4>
<ul>
<li>Docetaxel: 85 mg/m2 IV on day 1</li>
<li>Cisplatin: 75 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Ajani JA, et al. Proc Am Soc Clin Oncol 2000;20:165a (abstract 657).</p>
</blockquote>
</div>
<div id="ido" class="section level4" number="2.14.2.10">
<h4><span class="header-section-number">2.14.2.10</span> IDO</h4>
<ul>
<li>Irinotecan: 150 mg/m2 IV on day 1</li>
<li>Docetaxel: 60 mg/m2 IV on day 1</li>
<li>Oxaliplatin: 85 mg/m2 IV on day 2</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Di Lauro L, et al. Br J Cancer 2007;97:593–599.</p>
</blockquote>
</div>
<div id="capecitabine-cisplatin-1" class="section level4" number="2.14.2.11">
<h4><span class="header-section-number">2.14.2.11</span> Capecitabine + Cisplatin</h4>
<ul>
<li>Capecitabine: 1,000 mg/m2 PO bid on days 1–14</li>
<li>Cisplatin: 80 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Kang Y, et al. J Clin Oncol 2006;24:18S (LBA4018).</p>
</blockquote>
</div>
<div id="xp-trastuzumab" class="section level4" number="2.14.2.12">
<h4><span class="header-section-number">2.14.2.12</span> XP + Trastuzumab</h4>
<ul>
<li>Capecitabine: 1,000 mg/m2 PO bid on days 1–14</li>
<li>Cisplatin: 80 mg/m2 IV on day 1</li>
<li>Trastuzumab: 8 mg/kg IV loading dose, then 6 mg/kg IV every 3 weeks</li>
<li>Repeat cycle every 21 days [280].</li>
</ul>
</div>
<div id="fp-trastuzumab" class="section level4" number="2.14.2.13">
<h4><span class="header-section-number">2.14.2.13</span> FP + Trastuzumab</h4>
<ul>
<li>5-Fluorouracil: 800 mg/m2 IV continuous infusion on days 1–5</li>
<li>Cisplatin: 80 mg/m2 IV on day 1</li>
<li>Trastuzumab: 8 mg/kg IV loading dose, then 6 mg/kg IV every 3 weeks</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>van Cutsem EV, et al. J Clin Oncol 2009;27:18s (LBA4509).</p>
</blockquote>
</div>
<div id="flo" class="section level4" number="2.14.2.14">
<h4><span class="header-section-number">2.14.2.14</span> FLO</h4>
<ul>
<li>5-Fluorouracil: 2,600 mg/m2 IV on day 1 as a continuous infusion over 24 hours</li>
<li>Leucovorin: 200 mg/m2 IV on day 1 as a 2-hour infusion</li>
<li>Oxaliplatin: 85 mg/m2 IV on day 1</li>
<li>Repeat cycle every 14 days.</li>
</ul>
<blockquote>
<p>Al-Batran SE, et al. J Clin Oncol 2008;26:1435–1442.</p>
</blockquote>
</div>
<div id="mfolfox6" class="section level4" number="2.14.2.15">
<h4><span class="header-section-number">2.14.2.15</span> mFOLFOX6</h4>
<ul>
<li>Oxaliplatin: 100 mg/m2 IV on day 1</li>
<li>5-Fluorouracil: 2,400 mg/m2 IV infusion for 46 hours starting on day 1</li>
<li>Leucovorin: 100 mg/m2 IV on day 1 as a 2-hour infusion prior to 5-FU</li>
<li>Repeat cycle every 2 weeks.</li>
</ul>
<blockquote>
<p>Keam B, et al. BMC Cancer 2008;8:148.</p>
</blockquote>
</div>
<div id="paclitaxel-ramucirumab" class="section level4" number="2.14.2.16">
<h4><span class="header-section-number">2.14.2.16</span> Paclitaxel + Ramucirumab</h4>
<ul>
<li>Paclitaxel: 80 mg/m2 IV on days 1, 8, and 15</li>
<li>Ramucirumab: 8 mg/kg IV on days 1 and 15</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Wilke H, et al. Lancet Oncol 2014;11;1224–1235.</p>
</blockquote>
</div>
</div>
<div id="metastatic-disease---single-agent-regimens-4" class="section level3" number="2.14.3">
<h3><span class="header-section-number">2.14.3</span> Metastatic Disease - Single-Agent Regimens</h3>
<div id="fluorouracil-1" class="section level4" number="2.14.3.1">
<h4><span class="header-section-number">2.14.3.1</span> 5-Fluorouracil</h4>
<ul>
<li>5-Fluorouracil: 500 mg/m2 IV on days 1–5</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Cullinan SA, et al. J Clin Oncol 1994;12:412–416.</p>
</blockquote>
</div>
<div id="fluorouracil-leucovorin" class="section level4" number="2.14.3.2">
<h4><span class="header-section-number">2.14.3.2</span> 5-Fluorouracil + Leucovorin</h4>
<ul>
<li>5-Fluorouracil: 370 mg/m2 IV on days 1–5</li>
<li>Leucovorin: 200 mg/m2 IV on days 1–5</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Cascinu S, et al. J Chemother 1992;4:185–188.</p>
</blockquote>
</div>
<div id="docetaxel-3" class="section level4" number="2.14.3.3">
<h4><span class="header-section-number">2.14.3.3</span> Docetaxel</h4>
<ul>
<li>Docetaxel: 100 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>O’Connell MJ. J Clin Oncol 1985;3:1032–1039.</p>
</blockquote>
<p>or
- Docetaxel: 36 mg/m2 IV weekly for 6 weeks
- Repeat cycle every 8 weeks.</p>
<blockquote>
<p>Ajani JA. Oncology 2002;16 (suppl 6):89–96.</p>
</blockquote>
</div>
<div id="ramucirumab-1" class="section level4" number="2.14.3.4">
<h4><span class="header-section-number">2.14.3.4</span> Ramucirumab</h4>
<ul>
<li>Ramucirumab: 8 mg/kg IV on day 1</li>
<li>Repeat cycle every 14 days.</li>
</ul>
<blockquote>
<p>Fuchs CS, et al. Lancet 2014;383:31–39.</p>
</blockquote>
</div>
<div id="pembrolizumab-6" class="section level4" number="2.14.3.5">
<h4><span class="header-section-number">2.14.3.5</span> Pembrolizumab</h4>
<ul>
<li>Pembrolizumab: 200 mg IV on day 1</li>
<li>Repeat cycle every 3 weeks.</li>
</ul>
<blockquote>
<p>Fuchs CS, et al. JAMA Oncol 2018;4:e180013.</p>
</blockquote>
</div>
</div>
</div>
<div id="gastrointestinal-stromal-tumor-gist" class="section level2" number="2.15">
<h2><span class="header-section-number">2.15</span> GASTROINTESTINAL STROMAL TUMOR (GIST)</h2>
<div id="adjuvant-therapy-1" class="section level3" number="2.15.1">
<h3><span class="header-section-number">2.15.1</span> Adjuvant Therapy</h3>
<div id="imatinib" class="section level4" number="2.15.1.1">
<h4><span class="header-section-number">2.15.1.1</span> Imatinib</h4>
<ul>
<li>Imatinib: 400 mg/day PO</li>
<li>Continue treatment for a total of 3 years.</li>
</ul>
<blockquote>
<p>Joensu H, et al. J Clin Oncol 2011;29:18S (LBA1).</p>
</blockquote>
</div>
</div>
<div id="metastatic-disease---single-agent-regimens-5" class="section level3" number="2.15.2">
<h3><span class="header-section-number">2.15.2</span> Metastatic Disease - Single-Agent Regimens</h3>
<div id="imatinib-1" class="section level4" number="2.15.2.1">
<h4><span class="header-section-number">2.15.2.1</span> Imatinib</h4>
<ul>
<li>Imatinib: 400 mg/day PO</li>
<li>Continue treatment until disease progression. May increase dose to 600 mg/day if no response is seen. In patients with KIT exon 9 (or exon 11) mutation, use dose of 800 mg/day (400 mg bid).</li>
</ul>
<blockquote>
<p>Demetri GD, et al. N Engl J Med 2002;347:472–480.</p>
</blockquote>
</div>
<div id="nilotinib" class="section level4" number="2.15.2.2">
<h4><span class="header-section-number">2.15.2.2</span> Nilotinib</h4>
<ul>
<li>Nilotinib: 400 mg PO bid</li>
<li>Continue treatment until disease progression.</li>
</ul>
<blockquote>
<p>Montemurro M, et al. Eur J Cancer 2009;45:2293–2297.</p>
</blockquote>
</div>
<div id="sunitinib-1" class="section level4" number="2.15.2.3">
<h4><span class="header-section-number">2.15.2.3</span> Sunitinib</h4>
<ul>
<li>Sunitinib: 50 mg/day PO for 4 weeks</li>
<li>Repeat cycle every 6 weeks.</li>
</ul>
<blockquote>
<p>Demetri GD, et al. Proc GI ASCO 2006 (abstract 8).</p>
</blockquote>
</div>
<div id="sorafenib" class="section level4" number="2.15.2.4">
<h4><span class="header-section-number">2.15.2.4</span> Sorafenib</h4>
<ul>
<li>Sorafenib: 400 mg/day PO bid</li>
<li>Continue treatment until disease progression.</li>
</ul>
<blockquote>
<p>Italiano A, et al. Ann Surg Oncol 2012;19:1551–1559.</p>
</blockquote>
</div>
<div id="regorafenib-2" class="section level4" number="2.15.2.5">
<h4><span class="header-section-number">2.15.2.5</span> Regorafenib</h4>
<ul>
<li>Regorafenib: 160 mg/day PO for 21 days</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Demetri GD, et al. Lancet 2013;381:295–302.</p>
</blockquote>
</div>
</div>
</div>
<div id="head-and-neck-cancer" class="section level2" number="2.16">
<h2><span class="header-section-number">2.16</span> HEAD AND NECK CANCER</h2>
<div id="combined-modality-therapy-1" class="section level3" number="2.16.1">
<h3><span class="header-section-number">2.16.1</span> Combined Modality Therapy</h3>
<div id="cetuximab-radiation-therapy" class="section level4" number="2.16.1.1">
<h4><span class="header-section-number">2.16.1.1</span> Cetuximab + Radiation Therapy</h4>
<ul>
<li>Cetuximab: 400 mg/m2 IV loading dose, 1 week before radiation therapy, then 250 mg/m2 IV weekly</li>
<li>Radiation therapy: 200 cGy/day for 5 days per week (total dose, 7,000 cGy)</li>
<li>Cetuximab is given concurrently with radiation therapy.</li>
</ul>
<blockquote>
<p>Bonner JA, et al. N Engl J Med 2006;354:567–578.</p>
</blockquote>
</div>
<div id="tpf-induction-chemotherapy-followed-by-carboplatin-radiation-therapy" class="section level4" number="2.16.1.2">
<h4><span class="header-section-number">2.16.1.2</span> TPF Induction Chemotherapy Followed by Carboplatin + Radiation Therapy</h4>
<ul>
<li>Docetaxel: 75 mg/m2 IV on day 1</li>
<li>Cisplatin: 75–100 mg/m2 IV on day 1</li>
<li>5-Fluorouracil: 1,000 mg/m2/day IV continuous infusion on days 1–4</li>
<li>Repeat cycle every 3 weeks for 3 cycles followed by:</li>
<li>Carboplatin: AUC of 1.5, IV weekly for 7 weeks during radiation therapy</li>
<li>Radiation therapy: 200 cGy/day to a total dose of 7,400 cGy</li>
<li>At the completion of chemoradiotherapy, surgical resection as indicated.</li>
</ul>
<blockquote>
<p>Posner MR, et al. N Engl J Med 2007;357:1705–1715.</p>
</blockquote>
</div>
</div>
<div id="combination-regimens-7" class="section level3" number="2.16.2">
<h3><span class="header-section-number">2.16.2</span> Combination Regimens</h3>
<div id="tip" class="section level4" number="2.16.2.1">
<h4><span class="header-section-number">2.16.2.1</span> TIP</h4>
<ul>
<li>Paclitaxel: 175 mg/m2 IV over 3 hours on day 1</li>
<li>Mesna: 400 mg/m2 IV before ifosfamide and 200 mg/m2 IV, 4 hours after ifosfamide</li>
<li>Cisplatin: 60 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21–28 days.</li>
</ul>
<blockquote>
<p>Shin DS, et al. J Clin Oncol 1998;16:1325–1330.</p>
</blockquote>
</div>
<div id="tpf" class="section level4" number="2.16.2.2">
<h4><span class="header-section-number">2.16.2.2</span> TPF</h4>
<ul>
<li>Docetaxel: 75 mg/m2 IV on day 1</li>
<li>Cisplatin: 75–100 mg/m2 IV over 24 hours on day 1</li>
<li>5-Fluorouracil: 1,000 mg/m2 over 24 hours on days 1–4</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Posner M, et al. J Clin Oncol 2001;19:1096–1104.</p>
</blockquote>
</div>
<div id="tic" class="section level4" number="2.16.2.3">
<h4><span class="header-section-number">2.16.2.3</span> TIC</h4>
<ul>
<li>Paclitaxel: 175 mg/m2 IV over 3 hours on day 1</li>
<li>Ifosfamide: 1,000 mg/m2 IV over 2 hours on days 1–3</li>
<li>Mesna: 400 mg/m2 IV before ifosfamide and 200 mg/m2 IV, 4 hours after ifosfamide</li>
<li>Carboplatin: AUC of 6, IV on day 1</li>
<li>Repeat cycle every 21–28 days.</li>
</ul>
<blockquote>
<p>Shin DM, et al. Cancer 1999;91:1316–1323.</p>
</blockquote>
</div>
<div id="paclitaxel-carboplatin-2" class="section level4" number="2.16.2.4">
<h4><span class="header-section-number">2.16.2.4</span> Paclitaxel + Carboplatin</h4>
<ul>
<li>Paclitaxel: 175 mg/m2 IV over 3 hours on day 1</li>
<li>Carboplatin: AUC of 6, IV on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Fountzilas G, et al. Semin Oncol 1997;24 (Suppl 2):65–67.</p>
</blockquote>
</div>
<div id="paclitaxel-cisplatin-2" class="section level4" number="2.16.2.5">
<h4><span class="header-section-number">2.16.2.5</span> Paclitaxel + Cisplatin</h4>
<ul>
<li>Paclitaxel: 175 mg/m2 IV over 3 hours on day 1</li>
<li>Cisplatin: 75 mg/m2 IV on day 2</li>
<li>G-CSF: 5 µg/kg/day SC on days 4–10</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Hitt R, et al. Semin Oncol 1995;22 (Suppl 15):50–54.</p>
</blockquote>
</div>
<div id="pf" class="section level4" number="2.16.2.6">
<h4><span class="header-section-number">2.16.2.6</span> PF</h4>
<ul>
<li>Cisplatin: 100 mg/m2 IV on day 1</li>
<li>5-Fluorouracil: 1,000 mg/m2/day IV continuous infusion on days 1–5</li>
<li>Repeat cycle every 21–28 days.</li>
</ul>
<blockquote>
<p>Kish JA, et al. Cancer 1984;53:1819–1824.</p>
</blockquote>
</div>
<div id="carboplatin-5-fu" class="section level4" number="2.16.2.7">
<h4><span class="header-section-number">2.16.2.7</span> Carboplatin + 5-FU</h4>
<ul>
<li>Carboplatin: AUC of 5, IV on day 1</li>
<li>5-Fluorouracil: 1,000 mg/m2/day IV continuous infusion on days 1–4</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Vokes EE, et al. Cancer 1989;63 (Suppl 6):1048–1053.</p>
</blockquote>
</div>
<div id="pf-cetuximab" class="section level4" number="2.16.2.8">
<h4><span class="header-section-number">2.16.2.8</span> PF + Cetuximab</h4>
<ul>
<li>Cisplatin: 100 mg/m2 IV on day 1</li>
<li>5-Fluorouracil: 1,000 mg/m2/day IV continuous infusion on days 1–4</li>
<li>Cetuximab: 400 mg/m2 IV loading dose, then 250 mg/m2 IV weekly</li>
<li>Repeat cycle every 21 days for up to 6 cycles. If no evidence of disease progression at the end of 6 cycles, can continue with weekly cetuximab.</li>
</ul>
<blockquote>
<p>Vermorken JB, et al. N Engl J Med 2008;359:1116–1127.</p>
</blockquote>
</div>
<div id="carboplatin-5-fu-1-cetuximab" class="section level4" number="2.16.2.9">
<h4><span class="header-section-number">2.16.2.9</span> Carboplatin + 5-FU 1 Cetuximab</h4>
<ul>
<li>Carboplatin: AUC of 5, IV on day 1</li>
<li>5-Fluorouracil: 1,000 mg/m2/day IV continuous infusion on days 1–4</li>
<li>Cetuximab: 400 mg/m2 IV loading dose, then 250 mg/m2 IV weekly</li>
<li>Repeat cycle every 21 days for up to 6 cycles. If no evidence of disease progression at the end of 6 cycles, can continue with weekly cetuximab.</li>
</ul>
<blockquote>
<p>Vermorken JB, et al. N Engl J Med 2008;359:1116–1127.</p>
</blockquote>
</div>
<div id="cisplatin-cetuximab" class="section level4" number="2.16.2.10">
<h4><span class="header-section-number">2.16.2.10</span> Cisplatin + Cetuximab</h4>
<ul>
<li>Cisplatin: 100 mg/m2 IV on day 1</li>
<li>Cetuximab: 400 mg/m2 IV loading dose, then 250 mg/m2 IV weekly</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Burtness B, et al. J Clin Oncol 2005;23:8646–8654.</p>
</blockquote>
</div>
<div id="pf-larynx-preservation" class="section level4" number="2.16.2.11">
<h4><span class="header-section-number">2.16.2.11</span> PF-Larynx Preservation</h4>
<ul>
<li>Cisplatin: 100 mg/m2 IV on day 1</li>
<li>5-Fluorouracil: 1,000 mg/m2/day IV continuous infusion on days 1–5</li>
<li>Radiation therapy: 6,600–7,600 cGy in 180–200 cGy fractions</li>
<li>Repeat cycle every 21–28 days for 3 cycles.</li>
</ul>
<blockquote>
<p>Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med 1991;324:1685–1690.</p>
</blockquote>
</div>
<div id="concurrent-chemoradiation-therapy-for-laryngeal-preservation" class="section level4" number="2.16.2.12">
<h4><span class="header-section-number">2.16.2.12</span> Concurrent Chemoradiation Therapy for Laryngeal Preservation</h4>
<ul>
<li>Cisplatin: 100 mg/m2 IV on days 1, 22, and 43</li>
<li>Radiation therapy: 7,000 cGy in 200 cGy fractions</li>
<li>Administer cisplatin concurrently with radiation therapy.</li>
</ul>
<blockquote>
<p>Forastiere AA, et al. N Engl J Med 2003;349:2091–2098.</p>
</blockquote>
</div>
<div id="chemoradiotherapy-for-nasopharyngeal-cancer" class="section level4" number="2.16.2.13">
<h4><span class="header-section-number">2.16.2.13</span> Chemoradiotherapy for Nasopharyngeal Cancer</h4>
<ul>
<li>Cisplatin: 100 mg/m2 IV on days 1, 22, and 43 during radiotherapy</li>
<li>Radiation therapy: Total dose of 7,000 cGy in 180–200 cGy fractions</li>
<li>At the completion of chemoradiotherapy, chemotherapy is administered as follows:</li>
<li>Cisplatin: 80 mg/m2 IV on day 1</li>
<li>5-Fluorouracil: 1,000 mg/m2/day IV continuous infusion on days 1–4</li>
<li>Repeat cycle every 28 days for a total of 3 cycles.</li>
</ul>
<blockquote>
<p>Al-Sarraf M, et al. J Clin Oncol 1998;16:1310–1317.</p>
</blockquote>
</div>
<div id="vp" class="section level4" number="2.16.2.14">
<h4><span class="header-section-number">2.16.2.14</span> VP</h4>
<ul>
<li>Vinorelbine: 25 mg/m2 IV on days 1 and 8</li>
<li>Cisplatin: 80 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Gebbia V, et al. Am J Clin Oncol 1995;18:293–296.</p>
</blockquote>
</div>
</div>
<div id="single-agent-regimens-6" class="section level3" number="2.16.3">
<h3><span class="header-section-number">2.16.3</span> Single-Agent Regimens</h3>
<div id="docetaxel-4" class="section level4" number="2.16.3.1">
<h4><span class="header-section-number">2.16.3.1</span> Docetaxel</h4>
<ul>
<li>Docetaxel: 100 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Dreyfuss A, et al. Proc Am Soc Clin Oncol 1995;14:875a.</p>
</blockquote>
</div>
<div id="paclitaxel-6" class="section level4" number="2.16.3.2">
<h4><span class="header-section-number">2.16.3.2</span> Paclitaxel</h4>
<ul>
<li>Paclitaxel: 250 mg/m2 IV over 24 hours on day 1</li>
<li>Repeat cycle every 21 days.
or</li>
<li>Paclitaxel: 137–175 mg/m2 IV over 3 hours on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Forastiere AA, et al. Ann Oncol 1994;5 (Suppl 6):51–54.</p>
</blockquote>
</div>
<div id="methotrexate" class="section level4" number="2.16.3.3">
<h4><span class="header-section-number">2.16.3.3</span> Methotrexate</h4>
<ul>
<li>Methotrexate: 40 mg/m2 IV or IM weekly</li>
<li>Repeat cycle every week.</li>
</ul>
<blockquote>
<p>Hong WK, et al. N Engl J Med 1983;308:75–79.</p>
</blockquote>
</div>
<div id="vinorelbine-1" class="section level4" number="2.16.3.4">
<h4><span class="header-section-number">2.16.3.4</span> Vinorelbine</h4>
<ul>
<li>Vinorelbine: 30 mg/m2 IV weekly</li>
<li>Repeat cycle every week.</li>
</ul>
<blockquote>
<p>Degardin M, et al. Ann Oncol 1998;9:1103–1107.</p>
</blockquote>
</div>
<div id="cetuximab-2" class="section level4" number="2.16.3.5">
<h4><span class="header-section-number">2.16.3.5</span> Cetuximab</h4>
<ul>
<li>Cetuximab: 400 mg/m2 IV loading dose, then 250 mg/m2 IV weekly</li>
<li>Repeat cycle every week.</li>
</ul>
<blockquote>
<p>Vermorken JB, et al. J Clin Oncol 2007;25:2171–2177.</p>
</blockquote>
</div>
<div id="pembrolizumab-7" class="section level4" number="2.16.3.6">
<h4><span class="header-section-number">2.16.3.6</span> Pembrolizumab</h4>
<ul>
<li>Pembrolizumab: 200 mg IV on day 1</li>
<li>Repeat cycle every 3 weeks.</li>
</ul>
<blockquote>
<p>Bauml J, et al. J Clin Oncol 2016;34:abstract 6011.</p>
</blockquote>
</div>
<div id="nivolumab-3" class="section level4" number="2.16.3.7">
<h4><span class="header-section-number">2.16.3.7</span> Nivolumab</h4>
<ul>
<li>Nivolumab: 240 mg IV on day 1</li>
<li>Repeat cycle every 14 days.</li>
</ul>
<blockquote>
<p>Ferris RL, et al. N Engl J Med 2016;375:1856–1867.</p>
</blockquote>
</div>
</div>
</div>
<div id="hepatocellular-cancer" class="section level2" number="2.17">
<h2><span class="header-section-number">2.17</span> HEPATOCELLULAR CANCER</h2>
<div id="combination-regimens-8" class="section level3" number="2.17.1">
<h3><span class="header-section-number">2.17.1</span> Combination Regimens</h3>
<div id="gemox" class="section level4" number="2.17.1.1">
<h4><span class="header-section-number">2.17.1.1</span> GEMOX</h4>
<ul>
<li>Gemcitabine: 1,000 mg/m2 IV on day 1</li>
<li>Oxaliplatin: 100 mg/m2 IV on day 2</li>
<li>Repeat cycle every 2 weeks.</li>
</ul>
<blockquote>
<p>Taieb J, et al. Cancer 2003;98:2664–2670.</p>
</blockquote>
</div>
<div id="folfox4" class="section level4" number="2.17.1.2">
<h4><span class="header-section-number">2.17.1.2</span> FOLFOX4</h4>
<ul>
<li>Oxaliplatin: 85 mg/m2 IV on day 1</li>
<li>5-Fluorouracil: 400 mg/m2 IV bolus, followed by 600 mg/m2 IV continuous infusion for 22 hours on days 1 and 2</li>
<li>Leucovorin: 200 mg/m2 IV on days 1 and 2 as a 2-hour infusion before 5-fluorouracil</li>
<li>Repeat cycle every 2 weeks.</li>
</ul>
<blockquote>
<p>Qin S, et al. J Clin Oncol 2010:28; 303S (abstract 408).</p>
</blockquote>
</div>
<div id="bevacizumab-erlotinib-1" class="section level4" number="2.17.1.3">
<h4><span class="header-section-number">2.17.1.3</span> Bevacizumab + Erlotinib</h4>
<ul>
<li>Bevacizumab: 10 mg/kg IV on days 1 and 14</li>
<li>Erlotinib: 150 mg PO daily</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Thomas MB, et al. J Clin Oncol 2009;27:843–850.</p>
</blockquote>
</div>
</div>
<div id="single-agent-regimens-7" class="section level3" number="2.17.2">
<h3><span class="header-section-number">2.17.2</span> Single-Agent Regimens</h3>
<div id="sorafenib-1" class="section level4" number="2.17.2.1">
<h4><span class="header-section-number">2.17.2.1</span> Sorafenib</h4>
<ul>
<li>Sorafenib: 400 mg PO bid</li>
<li>Continue until disease progression. Dose may be reduced to 400 mg once daily or 400 mg every 2 days.</li>
</ul>
<blockquote>
<p>Llovet J, et al. N Engl J Med 2008;359:378–390.</p>
</blockquote>
</div>
<div id="regorafenib-3" class="section level4" number="2.17.2.2">
<h4><span class="header-section-number">2.17.2.2</span> Regorafenib</h4>
<ul>
<li>Regorafenib: 160 mg PO daily for 21 days</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Bruix J, et al. Lancet 2017;389:56–66.</p>
</blockquote>
</div>
<div id="doxorubicin-2" class="section level4" number="2.17.2.3">
<h4><span class="header-section-number">2.17.2.3</span> Doxorubicin</h4>
<ul>
<li>Doxorubicin: 20–30 mg/m2 IV weekly</li>
<li>Repeat cycle every week.</li>
</ul>
<blockquote>
<p>Venook AP, et al. J Clin Oncol 1994;12:1323–1334.</p>
</blockquote>
</div>
<div id="cisplatin" class="section level4" number="2.17.2.4">
<h4><span class="header-section-number">2.17.2.4</span> Cisplatin</h4>
<ul>
<li>Cisplatin: 80 mg/m2 IV on day 1</li>
<li>Repeat cycle every week.</li>
</ul>
<blockquote>
<p>Okada S, et al. Oncology 1993;50:22–26.</p>
</blockquote>
</div>
<div id="capecitabine-5" class="section level4" number="2.17.2.5">
<h4><span class="header-section-number">2.17.2.5</span> Capecitabine</h4>
<ul>
<li>Capecitabine: 1,000 mg/m2 PO bid on days 1–14</li>
<li>Repeat cycle every 21 days. Dose may be reduced to 825–900 mg/m2 PO bid on days 1–14. This dose reduction may decrease risk of toxicity without compromising clinical efficacy.</li>
</ul>
<blockquote>
<p>Patt YZ, et al. Cancer 2004;101:578–586.</p>
</blockquote>
</div>
<div id="bevacizumab-2" class="section level4" number="2.17.2.6">
<h4><span class="header-section-number">2.17.2.6</span> Bevacizumab</h4>
<ul>
<li>Bevacizumab: 10 mg/kg IV on day 1</li>
<li>Repeat cycle every 14 days.</li>
</ul>
<blockquote>
<p>Siegel AB, et al. J Clin Oncol 2008;26:2992–2998.</p>
</blockquote>
</div>
<div id="pembrolizumab-8" class="section level4" number="2.17.2.7">
<h4><span class="header-section-number">2.17.2.7</span> Pembrolizumab</h4>
<ul>
<li>Pembrolizumab: 10 mg/kg IV on day 1</li>
<li>Repeat cycle every 14 days.</li>
</ul>
<blockquote>
<p>Zhu AX, et al. Lancet Oncol 2018. doi: 10.1016/S1470-2045(18)30351-6.</p>
</blockquote>
</div>
</div>
</div>
<div id="kaposis-sarcoma" class="section level2" number="2.18">
<h2><span class="header-section-number">2.18</span> KAPOSI’S SARCOMA</h2>
<div id="combination-regimens-9" class="section level3" number="2.18.1">
<h3><span class="header-section-number">2.18.1</span> Combination Regimens</h3>
<div id="bv" class="section level4" number="2.18.1.1">
<h4><span class="header-section-number">2.18.1.1</span> BV</h4>
<ul>
<li>Bleomycin: 10 U/m2 IV on days 1 and 15</li>
<li>Vincristine: 1.4 mg/m2 IV on days 1 and 15 (maximum, 2 mg)</li>
<li>Repeat cycle every 2 weeks.</li>
</ul>
<blockquote>
<p>Ireland-Gill A, et al. Semin Oncol 1992;19 (Suppl 5):32–37.</p>
</blockquote>
</div>
<div id="abv" class="section level4" number="2.18.1.2">
<h4><span class="header-section-number">2.18.1.2</span> ABV</h4>
<ul>
<li>Doxorubicin: 40 mg/m2 IV on day 1</li>
<li>Bleomycin: 15 U/m2 IV on days 1 and 15</li>
<li>Vinblastine: 6 mg/m2 IV on day 1</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Laubenstein LL, et al. J Clin Oncol 1984;2:1115–1120.</p>
</blockquote>
</div>
</div>
<div id="single-agent-regimens-8" class="section level3" number="2.18.2">
<h3><span class="header-section-number">2.18.2</span> Single-Agent Regimens</h3>
<div id="daunorubicin-liposome" class="section level4" number="2.18.2.1">
<h4><span class="header-section-number">2.18.2.1</span> Daunorubicin liposome</h4>
<ul>
<li>Daunorubicin liposome: 40 mg/m2 IV on day 1</li>
<li>Repeat cycle every 14 days.</li>
</ul>
<blockquote>
<p>Gill PS, et al. J Clin Oncol 1996;14:2353–2364.</p>
</blockquote>
</div>
<div id="doxorubicin-liposome-1" class="section level4" number="2.18.2.2">
<h4><span class="header-section-number">2.18.2.2</span> Doxorubicin liposome</h4>
<ul>
<li>Doxorubicin liposome: 20 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Northfelt DW, et al. J Clin Oncol 1997;15:653–659.</p>
</blockquote>
</div>
<div id="paclitaxel-7" class="section level4" number="2.18.2.3">
<h4><span class="header-section-number">2.18.2.3</span> Paclitaxel</h4>
<ul>
<li>Paclitaxel: 135 mg/m2 IV over 3 hours on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Gill PS, et al. J Clin Oncol 1999;17:1876–1880.</p>
</blockquote>
<p>or
- Paclitaxel: 100 mg/m2 IV over 3 hours on day 1
- Repeat cycle every 2 weeks.</p>
<blockquote>
<p>Gill PS, et al. Cancer 2002;95:147–154.</p>
</blockquote>
</div>
<div id="docetaxel-5" class="section level4" number="2.18.2.4">
<h4><span class="header-section-number">2.18.2.4</span> Docetaxel</h4>
<ul>
<li>Docetaxel: 25 mg/m2 IV weekly for 8 weeks, then every other week</li>
<li>Continue until disease progression.</li>
</ul>
<blockquote>
<p>Lim ST, et al. Cancer 2005;103:417–421.</p>
</blockquote>
</div>
<div id="etoposide" class="section level4" number="2.18.2.5">
<h4><span class="header-section-number">2.18.2.5</span> Etoposide</h4>
<ul>
<li>Etoposide: 50 mg PO daily on days 1–7</li>
<li>Repeat cycle every 2 weeks.</li>
</ul>
<blockquote>
<p>Evans SR, et al. J Clin Oncol 2002;20:3236–3241.</p>
</blockquote>
</div>
<div id="vinorelbine-2" class="section level4" number="2.18.2.6">
<h4><span class="header-section-number">2.18.2.6</span> Vinorelbine</h4>
<ul>
<li>Vinorelbine: 30 mg/m2 IV on day 1</li>
<li>Repeat cycle every 2 weeks.</li>
</ul>
<blockquote>
<p>Nasti G, et al. J Clin Oncol 2000;18:1550–1557.</p>
</blockquote>
</div>
<div id="interferon-alpha" class="section level4" number="2.18.2.7">
<h4><span class="header-section-number">2.18.2.7</span> Interferon-alpha</h4>
<ul>
<li>Interferon alpha-2a: 36 million IU/m2 SC or IM, daily for 8–12 weeks.</li>
</ul>
<blockquote>
<p>Real FX, et al. J Clin Oncol 1986;4:544–551.</p>
</blockquote>
<ul>
<li>Interferon alpha-2b: 30 million IU/m2 SC or IM, 3 times weekly.</li>
</ul>
<blockquote>
<p>Groopman JE, et al. Ann Intern Med 1984;100:671–676.</p>
</blockquote>
</div>
</div>
</div>
<div id="leukemia" class="section level2" number="2.19">
<h2><span class="header-section-number">2.19</span> LEUKEMIA</h2>
<div id="acute-lymphocytic-leukemia---induction-therapy" class="section level3" number="2.19.1">
<h3><span class="header-section-number">2.19.1</span> Acute Lymphocytic Leukemia - Induction Therapy</h3>
<div id="linker-regimen" class="section level4" number="2.19.1.1">
<h4><span class="header-section-number">2.19.1.1</span> Linker Regimen</h4>
<ul>
<li>Daunorubicin: 50 mg/m2 IV every 24 hours on days 1–3</li>
<li>Vincristine: 2 mg IV on days 1, 8, 15, and 22</li>
<li>Prednisone: 60 mg/m2 PO divided into 3 doses on days 1–28</li>
<li>L-Asparaginase: 6,000 U/m2 IM on days 17–28</li>
<li>If bone marrow on day 14 is positive for residual leukemia,</li>
<li>Daunorubicin: 50 mg/m2 IV on day 15</li>
<li>If bone marrow on day 28 is positive for residual leukemia,</li>
<li>Daunorubicin: 50 mg/m2 IV on days 29 and 30</li>
<li>Vincristine: 2 mg IV on days 29 and 36</li>
<li>Prednisone: 60 mg/m2 PO on days 29–42</li>
<li>L-Asparaginase: 6,000 U/m2 IM on days 29–35</li>
</ul>
<blockquote>
<p>Linker CA, et al. Blood 1987;69:1242–1248.
Linker CA, et al. Blood 1991;78:2814–2822.</p>
</blockquote>
</div>
</div>
<div id="acute-lymphocytic-leukemia---consolidation-therapy" class="section level3" number="2.19.2">
<h3><span class="header-section-number">2.19.2</span> Acute Lymphocytic Leukemia - Consolidation Therapy</h3>
<div id="linker-regimen-1" class="section level4" number="2.19.2.1">
<h4><span class="header-section-number">2.19.2.1</span> Linker Regimen</h4>
<ul>
<li>Treatment A (cycles 1, 3, 5, and 7)</li>
<li>Daunorubicin: 50 mg/m2 IV on days 1 and 2</li>
<li>Vincristine: 2 mg IV on days 1 and 8</li>
<li>Prednisone: 60 mg/m2 PO on days 1–14</li>
<li>L-Asparaginase: 12,000 U/m2 on days 2, 4, 7, 9, 11, and 14</li>
<li>Treatment B (cycles 2, 4, 6, and 8)</li>
<li>Teniposide: 165 mg/m2 IV on days 1, 4, 8, and 11</li>
<li>Cytarabine: 300 mg/m2 IV on days 1, 4, 8, and 11</li>
<li>Treatment C (cycle 9)</li>
<li>Methotrexate: 690 mg/m2 IV over 42 hours</li>
<li>Leucovorin: 15 mg/m2 IV every 6 hours for 12 doses beginning at 42 hours</li>
</ul>
<blockquote>
<p>Linker CA, et al. Blood 1987;69:1242–1248.
Linker CA, et al. Blood 1991;78:2814–2822.</p>
</blockquote>
</div>
</div>
<div id="acute-lymphocytic-leukemia---maintenance-therapy" class="section level3" number="2.19.3">
<h3><span class="header-section-number">2.19.3</span> Acute Lymphocytic Leukemia - Maintenance Therapy</h3>
<div id="linker-regimen-2" class="section level4" number="2.19.3.1">
<h4><span class="header-section-number">2.19.3.1</span> Linker Regimen</h4>
<ul>
<li>Methotrexate: 20 mg/m2 PO weekly</li>
<li>6-Mercaptopurine: 75 mg/m2 PO daily</li>
<li>Continue for a total of 30 months of complete response.</li>
</ul>
<blockquote>
<p>Linker CA, et al. Blood 1987;69:1242–1248.
Linker CA, et al. Blood 1991;78:2814–2822.</p>
</blockquote>
</div>
<div id="cns-prophylaxis" class="section level4" number="2.19.3.2">
<h4><span class="header-section-number">2.19.3.2</span> CNS Prophylaxis</h4>
<ul>
<li>Cranial irradiation: 1,800 cGy in 10 fractions over 12–14 days</li>
<li>Methotrexate: 12 mg IT weekly for 6 weeks</li>
<li>Begin within 1 week of complete response.</li>
<li>In patients with documented CNS involvement at time of diagnosis, intrathecal chemotherapy should begin during induction chemotherapy.</li>
<li>Methotrexate: 12 mg IT weekly for 10 doses</li>
<li>Cranial irradiation: 2,800 cGy</li>
</ul>
</div>
</div>
<div id="acute-lymphocytic-leukemia---induction-therapy-1" class="section level3" number="2.19.4">
<h3><span class="header-section-number">2.19.4</span> Acute Lymphocytic Leukemia - Induction Therapy</h3>
<div id="larson-regimen" class="section level4" number="2.19.4.1">
<h4><span class="header-section-number">2.19.4.1</span> Larson Regimen</h4>
<ul>
<li>Induction (weeks 1–4)
<ul>
<li>Cyclophosphamide: 1,200 mg/m2 IV on day 1</li>
<li>Daunorubicin: 45 mg/m2 IV on days 1–3</li>
<li>Vincristine: 2 mg IV on days 1, 8, 15, and 22</li>
<li>Prednisone: 60 mg/m2/day PO on days 1–21</li>
<li>L-Asparaginase: 6,000 U/m2 SC on days 5, 8, 11, 15, 18, 22</li>
</ul></li>
<li>Early Intensification (weeks 5–12)
<ul>
<li>Methotrexate: 15 mg IT on day 1</li>
<li>Cyclophosphamide: 1,000 mg/m2 IV on day 1</li>
<li>6-Mercaptopurine: 60 mg/m2/day PO on days 1–14</li>
<li>Cytarabine: 75 mg/m2 IV on days 1–4 and 8–11</li>
<li>Vincristine: 2 mg IV on days 15 and 22</li>
<li>L-Asparaginase: 6,000 U/m2 SC on days 15, 18, 22, and 25</li>
<li>Repeat the early intensification cycle once.</li>
</ul></li>
<li>CNS Prophylaxis and Interim Maintenance (weeks 13–25)
<ul>
<li>Cranial irradiation: 2,400 cGy on days 1–12</li>
<li>Methotrexate: 15 mg IT on days 1, 8, 15, 22, and 29</li>
<li>6-Mercaptopurine: 60 mg/m2/day PO on days 1–70</li>
<li>Methotrexate: 20 mg/m2 PO on days 36, 43, 50, 57, and 64</li>
</ul></li>
<li>Late Intensification (weeks 26–33)
<ul>
<li>Doxorubicin: 30 mg/m2 IV on days 1, 8, and 15</li>
<li>Vincristine: 2 mg IV on days 1, 8, and 15</li>
<li>Dexamethasone: 10 mg/m2/day PO on days 1–14</li>
<li>Cyclophosphamide: 1,000 mg/m2 IV on day 29</li>
<li>6-Thioguanine: 60 mg/m2/day PO on days 29–42</li>
<li>Cytarabine: 75 mg/m2 on days 29, 32, 36–39</li>
</ul></li>
<li>Prolonged Maintenance (continue until 24 months after diagnosis)
<ul>
<li>Vincristine: 2 mg IV on day 1</li>
<li>Prednisone: 60 mg/m2/day PO on days 1–5</li>
<li>Methotrexate: 20 mg/m2 PO on days 1, 8, 15, and 22</li>
<li>6-Mercaptopurine: 80 mg/m2/day PO on days 1–28</li>
<li>Repeat maintenance cycle every 28 days.</li>
</ul></li>
</ul>
<blockquote>
<p>Larson R, et al. Blood 1995;85:2025–2037.</p>
</blockquote>
</div>
<div id="hyper-cvad-regimen" class="section level4" number="2.19.4.2">
<h4><span class="header-section-number">2.19.4.2</span> Hyper-CVAD Regimen</h4>
<ul>
<li>Cyclophosphamide: 300 mg/m2 IV every 12 hours for 6 doses on days 1–3</li>
<li>Mesna: 600 mg/m2 IV over 24 hours on days 1–3 ending 6 hours after the last dose of cyclophosphamide</li>
<li>Vincristine: 2 mg IV on days 4 and 11</li>
<li>Doxorubicin: 50 mg/m2 IV on day 4</li>
<li>Dexamethasone: 40 mg PO or IV on days 1–4 and 11–14</li>
<li>Alternate cycles every 21 days with the following:</li>
<li>Methotrexate: 200 mg/m2 IV over 2 hours, followed by 800 mg/m2 IV over 24 hours on day 1</li>
<li>Leucovorin: 15 mg IV every 6 hours for 8 doses, starting 24 hours after the completion of methotrexate infusion</li>
<li>Cytarabine: 3,000 mg/m2 IV every 12 hours for 4 doses on days 2–3</li>
<li>Methylprednisolone: 50 mg IV bid on days 1–3</li>
<li>Alternate 4 cycles of hyper-CVAD with 4 cycles of high-dose methotrexate and cytarabine therapy.</li>
</ul>
<blockquote>
<p>Kantarjian HM, et al. J Clin Oncol 2000;18:547–561.</p>
</blockquote>
</div>
<div id="cns-prophylaxis-1" class="section level4" number="2.19.4.3">
<h4><span class="header-section-number">2.19.4.3</span> CNS Prophylaxis</h4>
<ul>
<li>Methotrexate: 12 mg IT on day 2</li>
<li>Cytarabine: 100 mg IT on day 8</li>
<li>Repeat with each cycle of chemotherapy, depending on the risk of CNS disease.</li>
</ul>
</div>
<div id="supportive-care" class="section level4" number="2.19.4.4">
<h4><span class="header-section-number">2.19.4.4</span> Supportive Care</h4>
<ul>
<li>Ciprofloxacin: 500 mg PO bid</li>
<li>Fluconazole: 200 mg/day PO</li>
<li>Acyclovir: 200 mg PO bid</li>
<li>G-CSF: 10 µg/kg/day starting 24 hours after the end of chemotherapy (i.e., on day 5 of hyper-CVAD therapy and on day 4 of high-dose methotrexate and cytarabine therapy)</li>
</ul>
</div>
</div>
<div id="acute-lymphocytic-leukemia---single-agent-regimens" class="section level3" number="2.19.5">
<h3><span class="header-section-number">2.19.5</span> Acute Lymphocytic Leukemia - Single-Agent Regimens</h3>
<div id="clofarabine" class="section level4" number="2.19.5.1">
<h4><span class="header-section-number">2.19.5.1</span> Clofarabine</h4>
<ul>
<li>Clofarabine: 52 mg/m2 IV for 5 days</li>
<li>Repeat cycle every 2–6 weeks.</li>
</ul>
<blockquote>
<p>Faderl S, et al. Cancer 2005;103:1985–1995.</p>
</blockquote>
</div>
<div id="nelarabine" class="section level4" number="2.19.5.2">
<h4><span class="header-section-number">2.19.5.2</span> Nelarabine</h4>
<ul>
<li>Nelarabine: 1.5 g/m2/day IV on days 1, 3, and 5</li>
<li>Repeat cycle every 28 days up to a total of 4 cycles.</li>
</ul>
<blockquote>
<p>DeAngelo DJ, et al. Blood 2007;109:5136–5142.</p>
</blockquote>
</div>
<div id="imatinib-2" class="section level4" number="2.19.5.3">
<h4><span class="header-section-number">2.19.5.3</span> Imatinib</h4>
<ul>
<li>Imatinib: 600 mg PO daily</li>
<li>Continue until disease progression.</li>
</ul>
<blockquote>
<p>Ottman OG, et al. Blood 2002;100:1965–1971.</p>
</blockquote>
</div>
<div id="dasatinib" class="section level4" number="2.19.5.4">
<h4><span class="header-section-number">2.19.5.4</span> Dasatinib</h4>
<ul>
<li>Dasatinib: 70 mg PO bid</li>
<li>Continue until disease progression.</li>
</ul>
<blockquote>
<p>Talpaz M, et al. N Engl J Med 2006;354:2531–2541.</p>
</blockquote>
</div>
<div id="nilotinib-1" class="section level4" number="2.19.5.5">
<h4><span class="header-section-number">2.19.5.5</span> Nilotinib</h4>
<ul>
<li>Nilotinib: 400–600 mg PO bid</li>
<li>Continue until disease progression.</li>
</ul>
<blockquote>
<p>Kantarjian HM, et al. N Engl J Med 2006;354:2542–2551.</p>
</blockquote>
</div>
<div id="blinatumomab" class="section level4" number="2.19.5.6">
<h4><span class="header-section-number">2.19.5.6</span> Blinatumomab</h4>
<ul>
<li>Blinatumomab: 9 µg IV on days 1–7 and 28 µg IV on days 8–28 on cycle 1; 28 µg on days 1–28 on all subsequent cycles</li>
<li>Repeat cycle every 42 days.</li>
</ul>
<blockquote>
<p>Topp MS, et al. Lancet Oncol 2015;16:57–66.</p>
</blockquote>
</div>
<div id="inotuzumab" class="section level4" number="2.19.5.7">
<h4><span class="header-section-number">2.19.5.7</span> Inotuzumab</h4>
<ul>
<li>Inotuzumab: 0.8 mg/m2 IV on days 1, 8, and 15</li>
<li>Repeat cycle every 21 days.</li>
<li>For patients who achieve CR or CRi:
<ul>
<li>Inotuzumab: 0.5 mg/m2 IV on days 1, 8, and 15</li>
<li>Repeat cycle every 28 days.</li>
</ul></li>
<li>For patients who do not achieve CR or CRi:
<ul>
<li>Inotuzumab: 0.8 mg/m2 IV on day 1 0.5 mg/m2 IV on days 8 and 15</li>
<li>Repeat cycle every 28 days.</li>
</ul></li>
</ul>
<blockquote>
<p>Kantarjian H, et al. N Engl J Med 2016;375:740–753.</p>
</blockquote>
</div>
</div>
<div id="acute-myelogenous-leukemia---induction-regimens" class="section level3" number="2.19.6">
<h3><span class="header-section-number">2.19.6</span> Acute Myelogenous Leukemia - Induction Regimens</h3>
<div id="ara-c-daunorubicin-7-3" class="section level4" number="2.19.6.1">
<h4><span class="header-section-number">2.19.6.1</span> Ara-C + Daunorubicin (7 + 3)</h4>
<ul>
<li>Cytarabine: 100 mg/m2/day IV continuous infusion on days 1–7</li>
<li>Daunorubicin: 45 mg/m2 IV on days 1–3</li>
</ul>
<blockquote>
<p>Yates JW, et al. Cancer Chemother Rep 1973;57:485–488.</p>
</blockquote>
</div>
<div id="liposomal-daunorubicin-and-cytarabine" class="section level4" number="2.19.6.2">
<h4><span class="header-section-number">2.19.6.2</span> Liposomal Daunorubicin and Cytarabine</h4>
<ul>
<li>Liposomal daunorubicin and cytarabine: 100 U/m2 (44 mg/m2 daunorubicin and 100 mg/m2 cytarabine) IV on days 1, 3, and 5</li>
<li>A second induction course and up to 2 cycles of consolidation therapy can be given.</li>
</ul>
<blockquote>
<p>Lancet JE, et al. Blood 2014;123:3239–3246.</p>
</blockquote>
</div>
<div id="ara-c-daunorubicin-gemtuzumab" class="section level4" number="2.19.6.3">
<h4><span class="header-section-number">2.19.6.3</span> Ara-C + Daunorubicin + Gemtuzumab</h4>
<ul>
<li>Cytarabine: 200 mg/m2 IV on days 1–7</li>
<li>Daunorubicin: 60 mg/m2 IV on days 1–3</li>
<li>Gemtuzumab: 3 mg/m2 IV on days 1, 4, and 7</li>
</ul>
<blockquote>
<p>Goodwin CD, et al. Leukemia 2017;31:1855–1868.</p>
</blockquote>
</div>
<div id="ara-c-idarubicin" class="section level4" number="2.19.6.4">
<h4><span class="header-section-number">2.19.6.4</span> Ara-C + Idarubicin</h4>
<ul>
<li>Cytarabine: 100 mg/m2/day IV continuous infusion on days 1–7</li>
<li>Idarubicin: 12 mg/m2 IV on days 1–3</li>
</ul>
<blockquote>
<p>Preisler H, et al. Blood 1987;69:1441–1449.</p>
</blockquote>
</div>
<div id="ara-c-doxorubicin" class="section level4" number="2.19.6.5">
<h4><span class="header-section-number">2.19.6.5</span> Ara-C + Doxorubicin</h4>
<ul>
<li>Cytarabine: 100 mg/m2/day IV continuous infusion on days 1–7</li>
<li>Doxorubicin: 30 mg/m2 IV on days 1–3</li>
</ul>
<blockquote>
<p>Preisler H, et al. Cancer Treat Rep 1977;61:89–92.</p>
</blockquote>
</div>
<div id="ara-c-clofarabine" class="section level4" number="2.19.6.6">
<h4><span class="header-section-number">2.19.6.6</span> Ara-C + Clofarabine</h4>
<ul>
<li>Clofarabine: 40 mg/m2 IV over 1 hour on days 2–6</li>
<li>Cytarabine: 1,000 mg/m2 IV over 2 hours on days 1–5</li>
<li>Repeat cycles every 4–6 weeks for up to a total of 3 cycles.</li>
</ul>
<blockquote>
<p>Faderi S, et al. Blood 2006;108:45–51.</p>
</blockquote>
</div>
<div id="ara-c-daunorubicin-midostaurin" class="section level4" number="2.19.6.7">
<h4><span class="header-section-number">2.19.6.7</span> Ara-C + Daunorubicin + Midostaurin</h4>
<ul>
<li>Cytarabine: 200 mg/m2 IV on days 1–7</li>
<li>Daunorubicin: 60 mg/m2 IV on days 1–3</li>
<li>Midostaurin: 50 mg/m2 PO bid on days 8–21</li>
<li>In patients who achieve a complete remission after induction therapy, they should then receive consolidation therapy</li>
</ul>
</div>
</div>
<div id="acute-myelogenous-leukemia---consolidation" class="section level3" number="2.19.7">
<h3><span class="header-section-number">2.19.7</span> Acute Myelogenous Leukemia - Consolidation</h3>
<ul>
<li>Cytarabine: 3,000 mg/m2 IV every 12 hours on days 1, 3, and 5</li>
<li>Midostaurin: 50 mg/m2 PO bid on days 8–21</li>
<li>Repeat cycle every 28 days for a total of 4 cycles of consolidation therapy.</li>
<li>In patients who remain in complete remission after completion of consolidation therapy, they then receive maintenance therapy</li>
</ul>
</div>
<div id="acute-myelogenous-leukemia---maintenance" class="section level3" number="2.19.8">
<h3><span class="header-section-number">2.19.8</span> Acute Myelogenous Leukemia - Maintenance</h3>
<ul>
<li>Midostaurin: 50 mg/m2 PO bid</li>
<li>Repeat cycle every 28 days for a total of 12 cycles.</li>
</ul>
<blockquote>
<p>Stone RM, et al. N Engl J Med 2017; doi: 10.1056/NEJMoa1614359.</p>
</blockquote>
<div id="aida-acute-promyelocytic-leukemia-only" class="section level4" number="2.19.8.1">
<h4><span class="header-section-number">2.19.8.1</span> AIDA (acute promyelocytic leukemia only)</h4>
<ul>
<li>ATRA: 45 mg/m2 PO daily</li>
<li>Idarubicin: 12 mg/m2 IV on days 2, 4, 6, and 8</li>
</ul>
<blockquote>
<p>Amadori S, et al. J Clin Oncol;34:972–979.</p>
</blockquote>
</div>
<div id="tretinoin-daunorubicin-cytarabine-acute-promyelocytic-leukemia" class="section level4" number="2.19.8.2">
<h4><span class="header-section-number">2.19.8.2</span> Tretinoin + Daunorubicin + Cytarabine (acute promyelocytic leukemia)</h4>
<ul>
<li>ATRA: 45 mg/m2 PO daily</li>
<li>Daunorubicin: 60 mg/m2 IV on days 1–3</li>
<li>Cytarabine: 200 mg/m2 IV on days 1–7</li>
</ul>
<blockquote>
<p>Sanz MA, et al. Blood 2010;115:5137–5146.</p>
</blockquote>
</div>
<div id="tretinoin-arsenic-trioxide-acute-promyelocytic-leukemia" class="section level4" number="2.19.8.3">
<h4><span class="header-section-number">2.19.8.3</span> Tretinoin + Arsenic trioxide (acute promyelocytic leukemia)</h4>
<ul>
<li>ATRA: 45 mg/m2 PO daily</li>
<li>Arsenic trioxide: 0.15 mg/kg/day IV starting on day 10</li>
<li>Continue treatment until CR. Once in CR, patients receive the following:</li>
<li>ATRA: 45 mg/m2 PO daily on weeks 1–2, 5–6, 9–10, 13–14, 17–18, 21–22, and 25–26</li>
<li>Arsenic trioxide: 0.15 mg/kg/day IV on Monday–Friday on weeks 1–4, 9–12, 17–20, and 25–28</li>
<li>Therapy should be terminated 28 weeks after the CR date.</li>
</ul>
<blockquote>
<p>Estey E, et al. Blood 2006;107:3469–3473.</p>
</blockquote>
</div>
<div id="mitoxantrone-etoposide-salvage-regimen" class="section level4" number="2.19.8.4">
<h4><span class="header-section-number">2.19.8.4</span> Mitoxantrone + Etoposide (salvage regimen)</h4>
<ul>
<li>Mitoxantrone: 10 mg/m2/day IV on days 1–5</li>
<li>Etoposide: 100 mg/m2/day IV on days 1–5</li>
</ul>
<blockquote>
<p>Ho AD, et al. J Clin Oncol 1988;6:213–217.</p>
</blockquote>
</div>
<div id="flag" class="section level4" number="2.19.8.5">
<h4><span class="header-section-number">2.19.8.5</span> FLAG</h4>
<ul>
<li>Fludarabine: 30 mg/m2 IV on days 1–5</li>
<li>Cytarabine: 2,000 mg/m2/day IV over 4 hours on days 1–5 starting 3.5 hours after fludarabine</li>
<li>G-CSF: 5 µg/kg/day SC starting 24 hours before chemotherapy</li>
<li>An additional cycle may be given in the setting of a partial response.</li>
</ul>
<blockquote>
<p>Montillo M, et al. Am J Hematol 1998;58:105–109.</p>
</blockquote>
</div>
</div>
<div id="acute-myelogenous-leukemia---consolidation-regimens" class="section level3" number="2.19.9">
<h3><span class="header-section-number">2.19.9</span> Acute Myelogenous Leukemia - Consolidation Regimens</h3>
<div id="ara-c-daunorubicin-5-2" class="section level4" number="2.19.9.1">
<h4><span class="header-section-number">2.19.9.1</span> Ara-C + Daunorubicin (5 + 2)</h4>
<ul>
<li>Cytarabine: 100 mg/m2/day IV continuous infusion on days 1–5</li>
<li>Daunorubicin: 45 mg/m2 IV on days 1 and 2</li>
</ul>
<blockquote>
<p>Wiernik PH, et al. Blood 1992;79:313–319.</p>
</blockquote>
</div>
<div id="liposomal-daunorubicin-and-cytarabine-1" class="section level4" number="2.19.9.2">
<h4><span class="header-section-number">2.19.9.2</span> Liposomal Daunorubicin and Cytarabine</h4>
<ul>
<li>Liposomal daunorubicin and cytarabine: 29 mg/m2 daunorubicin and 65 mg/m2 cytarabine on days 1 and 3</li>
</ul>
<blockquote>
<p>Lancet JE, et al. Blood 2014;123:3239–3246.</p>
</blockquote>
</div>
<div id="ara-c-idarubicin-1" class="section level4" number="2.19.9.3">
<h4><span class="header-section-number">2.19.9.3</span> Ara-C + Idarubicin</h4>
<ul>
<li>Cytarabine: 100 mg/m2 IV continuous infusion on days 1–5</li>
<li>Idarubicin: 13 mg/m2 IV on days 1 and 2</li>
<li>Repeat cycle every 21–28 days.</li>
</ul>
<blockquote>
<p>Tallman MS, et al. Blood 2005;106:1154–1163.</p>
</blockquote>
</div>
</div>
<div id="acute-myelogenous-leukemia---single-agent-regimens" class="section level3" number="2.19.10">
<h3><span class="header-section-number">2.19.10</span> Acute Myelogenous Leukemia - Single-Agent Regimens</h3>
<div id="cladribine" class="section level4" number="2.19.10.1">
<h4><span class="header-section-number">2.19.10.1</span> Cladribine</h4>
<ul>
<li>Cladribine: 0.1 mg/kg/day IV continuous infusion on days 1–7</li>
</ul>
<blockquote>
<p>Santana VM, et al. J Clin Oncol 1992;10:364–369.</p>
</blockquote>
</div>
<div id="high-dose-cytarabine" class="section level4" number="2.19.10.2">
<h4><span class="header-section-number">2.19.10.2</span> High-Dose Cytarabine</h4>
<ul>
<li>Cytarabine: 1,500–3,000 mg/m2 IV over 3 hours, every 12 hours on days 1, 3, and 5</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Gardin C, et al. Blood 2007;109:5129–5132.</p>
</blockquote>
</div>
<div id="clofarabine-1" class="section level4" number="2.19.10.3">
<h4><span class="header-section-number">2.19.10.3</span> Clofarabine</h4>
<ul>
<li>Clofarabine: 40 mg/m2 IV on days 1–5</li>
<li>Repeat cycle every 3–6 weeks.</li>
</ul>
<blockquote>
<p>Kantarjian HM, et al. Blood 2003;102:2379–2386.</p>
</blockquote>
</div>
<div id="tretinoin-acute-promyelocytic-leukemia-only" class="section level4" number="2.19.10.4">
<h4><span class="header-section-number">2.19.10.4</span> Tretinoin (acute promyelocytic leukemia only)</h4>
<p>Tretinoin: 45 mg/m2 PO daily in 1–2 divided doses</p>
<blockquote>
<p>Degos L, et al. Blood 1995;85:2643–2653.</p>
</blockquote>
</div>
<div id="arsenic-trioxide-acute-promyelocytic-leukemia-only" class="section level4" number="2.19.10.5">
<h4><span class="header-section-number">2.19.10.5</span> Arsenic trioxide (acute promyelocytic leukemia only)</h4>
<ul>
<li>Arsenic trioxide: 0.15 mg/kg IV daily</li>
</ul>
<blockquote>
<p>Soignet SL, et al. J Clin Oncol 2001;19:3852–3860.</p>
</blockquote>
<ul>
<li>Continue until bone marrow remission up to a maximum of 60 doses. Patients who meet the criteria for clinical CR can receive an additional course of arsenic trioxide as consolidation beginning 3–4 weeks after completion of induction therapy up to a cumulative total of 25 doses.</li>
</ul>
<blockquote>
<p>Sievers EL, et al. Blood 1999;11:3678–3684.</p>
</blockquote>
</div>
<div id="sorafenib-2" class="section level4" number="2.19.10.6">
<h4><span class="header-section-number">2.19.10.6</span> Sorafenib</h4>
<ul>
<li>Sorafenib: 200-400 mg PO bid</li>
<li>Continue until disease progression or stem cell transplant.</li>
</ul>
<blockquote>
<p>Man CH, et al. Blood 2012;119:5133–5143.</p>
</blockquote>
</div>
<div id="azacitidine" class="section level4" number="2.19.10.7">
<h4><span class="header-section-number">2.19.10.7</span> Azacitidine</h4>
<ul>
<li>Azacitidine: 75 mg/m2 SC daily for 7 days</li>
<li>Repeat cycle every 28 days for at least 6 cycles.</li>
</ul>
<blockquote>
<p>Fenaux P, et al. J Clin Oncol 2010;28:562–569.</p>
</blockquote>
</div>
<div id="decitabine" class="section level4" number="2.19.10.8">
<h4><span class="header-section-number">2.19.10.8</span> Decitabine</h4>
<ul>
<li>Decitabine: 20 mg/m2 IV on days 1–5</li>
<li>Repeat cycle every 4 weeks.</li>
</ul>
<blockquote>
<p>Kantarjian HM, et al. J Clin Oncol 2012;30:2670–2677.</p>
</blockquote>
</div>
<div id="enasidenib" class="section level4" number="2.19.10.9">
<h4><span class="header-section-number">2.19.10.9</span> Enasidenib</h4>
<ul>
<li>Enasidenib: 100 mg PO daily</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Stein EM, et al. Blood 2017;130:722–731.</p>
</blockquote>
</div>
</div>
<div id="chronic-lymphocytic-leukemia---combination-regimens" class="section level3" number="2.19.11">
<h3><span class="header-section-number">2.19.11</span> Chronic Lymphocytic Leukemia - Combination Regimens</h3>
<div id="cvp" class="section level4" number="2.19.11.1">
<h4><span class="header-section-number">2.19.11.1</span> CVP</h4>
<ul>
<li>Cyclophosphamide: 400 mg/m2 PO on days 1–5 (or 800 mg/m2 IV on day 1)</li>
<li>Vincristine: 1.4 mg/m2 IV on day 1 (maximum dose, 2 mg)</li>
<li>Prednisone: 100 mg/m2 PO on days 1–5</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Raphael B, et al. J Clin Oncol 1991;9:770–776.</p>
</blockquote>
</div>
<div id="cf-1" class="section level4" number="2.19.11.2">
<h4><span class="header-section-number">2.19.11.2</span> CF</h4>
<ul>
<li>Cyclophosphamide: 1,000 mg/m2 IV on day 1</li>
<li>Fludarabine: 20 mg/m2 IV on days 1–5</li>
<li>Trimethoprim/sulfamethoxazole (Bactrim DS) 1 tablet PO bid</li>
<li>Repeat cycle every 21–28 days.</li>
</ul>
<blockquote>
<p>Keating MJ, et al. Blood 1998;92:1165–1171.</p>
</blockquote>
</div>
<div id="fp" class="section level4" number="2.19.11.3">
<h4><span class="header-section-number">2.19.11.3</span> FP</h4>
<ul>
<li>Fludarabine: 30 mg/m2 IV on days 1–5</li>
<li>Prednisone: 30 mg/m2 IV on days 1–5</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>O’Brien S, et al. Blood 1993;82:1695–1700.</p>
</blockquote>
</div>
<div id="cp" class="section level4" number="2.19.11.4">
<h4><span class="header-section-number">2.19.11.4</span> CP</h4>
<ul>
<li>Chlorambucil: 30 mg/m2 PO on day 1</li>
<li>Prednisone: 80 mg PO on days 1–5</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Raphael B, et al. J Clin Oncol 1991;9:770–776.</p>
</blockquote>
</div>
<div id="fr" class="section level4" number="2.19.11.5">
<h4><span class="header-section-number">2.19.11.5</span> FR</h4>
<ul>
<li>Fludarabine: 25 mg/m2 IV on days 1–5</li>
<li>Rituximab: 375 mg/m2 IV on days 1 and 4 of cycle 1 and then on day 1 thereafter</li>
<li>Repeat cycle every 28 days for 6 cycles.</li>
</ul>
<blockquote>
<p>Byrd JC, et al. Blood 2003;101:6–14.
Byrd JC, et al. J Clin Oncol 2011;29:1349–1355.</p>
</blockquote>
</div>
<div id="fcr" class="section level4" number="2.19.11.6">
<h4><span class="header-section-number">2.19.11.6</span> FCR</h4>
<ul>
<li>Fludarabine: 25 mg/m2 IV on days 1–3</li>
<li>Cyclophosphamide: 250 mg/m2 IV on days 1–3</li>
<li>Rituximab: 375 mg/m2 IV on day 1</li>
<li>Repeat cycle every 28 days for 6 cycles. On cycles 2–6, rituximab is given at 500 mg/m2.</li>
</ul>
<blockquote>
<p>Keating M, et al. J Clin Oncol 2005;22:4079–4088.</p>
</blockquote>
</div>
<div id="pcr" class="section level4" number="2.19.11.7">
<h4><span class="header-section-number">2.19.11.7</span> PCR</h4>
<ul>
<li>Pentostatin: 2 mg/m2 IV on day 1</li>
<li>Cyclophosphamide: 600 mg/m2 IV on day 1</li>
<li>Rituximab: 375 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Kay NE, et al. Blood 2004;104 (abstract 339).</p>
</blockquote>
</div>
<div id="bendamustine-rituximab" class="section level4" number="2.19.11.8">
<h4><span class="header-section-number">2.19.11.8</span> Bendamustine + Rituximab</h4>
<ul>
<li>Bendamustine: 90 mg/m2 IV on days 1 and 2</li>
<li>Rituximab: 375 mg/m2 IV on day 0 of cycle 1, then 500 mg/m2 IV on day 1 of cycles 2–6</li>
<li>Repeat cycle every 28 days for up to 6 cycles.</li>
</ul>
<blockquote>
<p>Byrd JC, et al. J Clin Oncol 2014;32:3039–3047.</p>
</blockquote>
</div>
<div id="venetoclax-rituximab" class="section level4" number="2.19.11.9">
<h4><span class="header-section-number">2.19.11.9</span> Venetoclax + Rituximab</h4>
<ul>
<li>Venetoclax: 20 mg/day PO on days 1–7, 50 mg/day PO on days 8–14, 100 mg/day PO on days 15–21, 200 mg/day PO on days 22–28, and then 400 mg/day PO daily</li>
<li>Venetoclax: 400 mg PO daily</li>
<li>Rituximab: 375 mg/m2 IV on day 1 of cycle 1, then 500 mg/m2 IV on day 1 of cycles 2–6</li>
<li>Repeat cycle every 28 days for up to 6 cycles. After cycle 6, venetoclax is continued at 400 mg PO daily for up to 2 years.</li>
</ul>
<blockquote>
<p>Seymour JF, et al. N Engl J Med 2018;378:1107–1120.</p>
</blockquote>
</div>
<div id="idelasib-rituximab" class="section level4" number="2.19.11.10">
<h4><span class="header-section-number">2.19.11.10</span> Idelasib + Rituximab</h4>
<ul>
<li>Idelasib: 150 mg PO bid</li>
<li>Rituximab: 375 mg/m2 IV on day 1, then 500 mg/m2 IV every 2 weeks for 4 doses and then every 4 weeks for 3 doses for a total of 8 doses</li>
</ul>
<blockquote>
<p>Furman RR, et al. N Engl J Med 2014;370:997–1007.</p>
</blockquote>
</div>
<div id="obinutuzumab-chlorambucil" class="section level4" number="2.19.11.11">
<h4><span class="header-section-number">2.19.11.11</span> Obinutuzumab + Chlorambucil</h4>
<ul>
<li>Obinutuzumab: 100 mg IV on day 1, cycle 1; 900 mg IV on day 2, cycle 1; 1,000 mg IV on days 8 and 15 of cycle 1; 1,000 mg IV on day 1 of cycles 2–6</li>
<li>Chlorambucil: 0.5 mg/kg PO on days 1 and 15</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Goede V, et al. N Engl J Med 2014;370:1101–1110.</p>
</blockquote>
</div>
</div>
<div id="chronic-lymphocytic-leukemia---single-agent-regimens" class="section level3" number="2.19.12">
<h3><span class="header-section-number">2.19.12</span> Chronic Lymphocytic Leukemia - Single-Agent Regimens</h3>
<div id="alemtuzumab" class="section level4" number="2.19.12.1">
<h4><span class="header-section-number">2.19.12.1</span> Alemtuzumab</h4>
<ul>
<li>Alemtuzumab: 30 mg/day IV, 3 times per week</li>
<li>Repeat weekly for up to a maximum of 23 weeks. Premedicate with diphenhydramine 50 mg PO and acetaminophen 625 mg PO 30 minutes before drug infusion. Patients should be placed on trimethoprim/sulfamethoxazole (Bactrim DS) PO bid and famciclovir 250 mg PO bid from day 8 through 2 months following completion of therapy.</li>
</ul>
<blockquote>
<p>Osterborg A, et al. J Clin Oncol 1997;15:1567–1574.</p>
</blockquote>
</div>
<div id="chlorambucil" class="section level4" number="2.19.12.2">
<h4><span class="header-section-number">2.19.12.2</span> Chlorambucil</h4>
<ul>
<li>Chlorambucil: 6–14 mg/day PO as induction therapy and then 0.7 mg/kg PO for 2–4 days</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Dighiero G, et al. N Engl J Med 1998;338:1506–1514.</p>
</blockquote>
</div>
<div id="cladribine-1" class="section level4" number="2.19.12.3">
<h4><span class="header-section-number">2.19.12.3</span> Cladribine</h4>
<ul>
<li>Cladribine: 0.09 mg/kg/day IV continuous infusion on days 1–7</li>
<li>Repeat cycle every 28–35 days.</li>
</ul>
<blockquote>
<p>Saven A, et al. J Clin Oncol 1995;13:570–574.</p>
</blockquote>
</div>
<div id="fludarabine" class="section level4" number="2.19.12.4">
<h4><span class="header-section-number">2.19.12.4</span> Fludarabine</h4>
<ul>
<li>Fludarabine: 20–30 mg/m2 IV on days 1–5</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Keating MJ, et al. Blood 1988;92:1165–1171.</p>
</blockquote>
</div>
<div id="prednisone" class="section level4" number="2.19.12.5">
<h4><span class="header-section-number">2.19.12.5</span> Prednisone</h4>
<ul>
<li>Prednisone: 20–30 mg/m2/day PO for 1–3 weeks.</li>
</ul>
<blockquote>
<p>Sawitsky A, et al. Blood 1977;50:1049.</p>
</blockquote>
</div>
<div id="rituximab" class="section level4" number="2.19.12.6">
<h4><span class="header-section-number">2.19.12.6</span> Rituximab</h4>
<ul>
<li>Rituximab: 375 mg/m2 IV weekly for 4 weeks</li>
<li>Repeat cycle every 6 months for a total of 4 courses.</li>
</ul>
<blockquote>
<p>Hainsworth JD, et al. J Clin Oncol 2003;21:1746–1751.</p>
</blockquote>
</div>
<div id="ofatumumab" class="section level4" number="2.19.12.7">
<h4><span class="header-section-number">2.19.12.7</span> Ofatumumab</h4>
<ul>
<li>Ofatumumab: 300 mg IV initial dose followed 1 week later by 2,000 mg IV weekly dose for 7 doses, followed 4 weeks later by 2,000 mg IV every 4 weeks for 4 doses.</li>
<li>A total of 12 doses is recommended.</li>
</ul>
<blockquote>
<p>Wierda WG, et al. J Clin Oncol 2010;28:1749–1755.</p>
</blockquote>
</div>
<div id="pentostatin" class="section level4" number="2.19.12.8">
<h4><span class="header-section-number">2.19.12.8</span> Pentostatin</h4>
<ul>
<li>Pentostatin: 4 mg/m2 IV on day 1</li>
<li>Repeat cycle every 14 days.</li>
</ul>
<blockquote>
<p>Grever MR, et al. J Clin Oncol 1985;3:1196–1201.</p>
</blockquote>
</div>
<div id="bendamustine" class="section level4" number="2.19.12.9">
<h4><span class="header-section-number">2.19.12.9</span> Bendamustine</h4>
<ul>
<li>Bendamustine: 100 mg/m2 IV on days 1 and 2</li>
<li>Repeat cycle every 28 days for up to 6 cycles.</li>
</ul>
<blockquote>
<p>Alvado M, et al. Semin Oncol 2002;29(4 Suppl 13):19–22.</p>
</blockquote>
<p>or
- Bendamustine: 60 mg/m2 IV on days 1–5
- Repeat cycle every 28 days. In patients &gt;70 years, use dose of 50 mg/m2.</p>
<blockquote>
<p>Kath R, et al. J Cancer Res Clin Oncol 2001;127:48–54.</p>
</blockquote>
</div>
<div id="lenalidomide" class="section level4" number="2.19.12.10">
<h4><span class="header-section-number">2.19.12.10</span> Lenalidomide</h4>
<ul>
<li>Lenalidomide: 10 mg PO daily on days 1–28</li>
<li>Increase dose by 5 mg every 28 days up to a maximum of 25 mg daily until disease progression or toxicity.</li>
</ul>
<blockquote>
<p>Ferrajoli A, et al. Blood 2008;111:5291–5297.</p>
</blockquote>
</div>
<div id="ibrutinib" class="section level4" number="2.19.12.11">
<h4><span class="header-section-number">2.19.12.11</span> Ibrutinib</h4>
<ul>
<li>Ibrutinib: 560 mg PO daily</li>
<li>Continue treatment until disease progression.</li>
</ul>
<blockquote>
<p>Byrd JC, et al. N Engl J Med 2014;369:32–42.</p>
</blockquote>
</div>
<div id="venetoclax" class="section level4" number="2.19.12.12">
<h4><span class="header-section-number">2.19.12.12</span> Venetoclax</h4>
<ul>
<li>Venetoclax: 20 mg/day PO on days 1–7, 50 mg/day PO on days 8–14, 100 mg/day PO on days 15–21, 200 mg/day PO on days 22–28, and then 400 mg/day PO daily</li>
<li>Continue treatment until disease progression.</li>
</ul>
<blockquote>
<p>Stilgenbauer S, et al. Lancet Oncol 2016;17:768–778.</p>
</blockquote>
</div>
</div>
<div id="chronic-myelogenous-leukemia---combination-regimens" class="section level3" number="2.19.13">
<h3><span class="header-section-number">2.19.13</span> Chronic Myelogenous Leukemia - Combination Regimens</h3>
<div id="interferon-cytarabine" class="section level4" number="2.19.13.1">
<h4><span class="header-section-number">2.19.13.1</span> Interferon + Cytarabine</h4>
<ul>
<li>Interferon a-2b: 5 million U/m2 SC daily</li>
<li>Cytarabine: 20 mg/m2 SC daily for 10 days</li>
<li>Repeat cytarabine on a monthly basis. The dose of interferon should be reduced by 50% when the neutrophil count drops below 1,500/mm3, the platelet count drops below 100,000/m3, or both. Interferon and cytarabine should both be discontinued when the neutrophil count drops below 1,000/mm3, platelet count drops below 50,000/mm3, or both.</li>
</ul>
<blockquote>
<p>Guilhot F, et al. N Engl J Med 1997;337:223–229.</p>
</blockquote>
</div>
</div>
<div id="chronic-myelogenous-leukemia---single-agent-regimens" class="section level3" number="2.19.14">
<h3><span class="header-section-number">2.19.14</span> Chronic Myelogenous Leukemia - Single-Agent Regimens</h3>
<div id="imatinib-3" class="section level4" number="2.19.14.1">
<h4><span class="header-section-number">2.19.14.1</span> Imatinib</h4>
<ul>
<li>Imatinib: 400 mg/day PO (chronic phase); 600 mg/day PO (accelerated phase blast crisis)</li>
</ul>
<blockquote>
<p>Druker BJ, et al. N Engl J Med 2001;344:1031–1037.</p>
</blockquote>
</div>
<div id="dasatinib-1" class="section level4" number="2.19.14.2">
<h4><span class="header-section-number">2.19.14.2</span> Dasatinib</h4>
<ul>
<li>Dasatinib: 70 mg PO bid</li>
</ul>
<blockquote>
<p>Kantarjian HM, et al. Blood 2007;110:3540–3546.</p>
</blockquote>
<p>or
- Dasatinib: 100 mg PO daily</p>
<blockquote>
<p>Kantarjian HM, et al. N Engl J Med 2010;362:2260–2270.</p>
</blockquote>
</div>
<div id="nilotinib-2" class="section level4" number="2.19.14.3">
<h4><span class="header-section-number">2.19.14.3</span> Nilotinib</h4>
<ul>
<li>Nilotinib: 400 mg PO bid</li>
</ul>
<blockquote>
<p>Kantarjian HM, et al. Blood 2007;109:5143–5150.</p>
</blockquote>
<p>or
- Nilotinib: 300 mg PO bid</p>
<blockquote>
<p>Saglio G, et al. N Engl J Med 2010;362:2251–2259.</p>
</blockquote>
</div>
<div id="bosutinib" class="section level4" number="2.19.14.4">
<h4><span class="header-section-number">2.19.14.4</span> Bosutinib</h4>
<ul>
<li>Bosutinib: 500 mg PO daily</li>
</ul>
<blockquote>
<p>Khoury HJ, et al. Blood 2012;119:3403–3412.</p>
</blockquote>
</div>
<div id="ponatinib" class="section level4" number="2.19.14.5">
<h4><span class="header-section-number">2.19.14.5</span> Ponatinib</h4>
<ul>
<li>Ponatinib: 45 mg PO bid</li>
</ul>
<blockquote>
<p>Kantarjian HM, et al. Blood 2012;120 (abstract 915).</p>
</blockquote>
</div>
<div id="busulfan" class="section level4" number="2.19.14.6">
<h4><span class="header-section-number">2.19.14.6</span> Busulfan</h4>
<ul>
<li>Busulfan: 1.8 mg/m2/day PO</li>
</ul>
<blockquote>
<p>Hehlmann R, et al. Blood 1993;82:398–407.</p>
</blockquote>
</div>
<div id="hydroxyurea" class="section level4" number="2.19.14.7">
<h4><span class="header-section-number">2.19.14.7</span> Hydroxyurea</h4>
<ul>
<li>Hydroxyurea: 1–5 g/day PO</li>
</ul>
<blockquote>
<p>Hehlmann R, et al. Blood 1994;84:4064–4077.</p>
</blockquote>
</div>
<div id="interferon-alpha-2a" class="section level4" number="2.19.14.8">
<h4><span class="header-section-number">2.19.14.8</span> Interferon alpha-2a</h4>
<ul>
<li>Interferon alpha-2a: 9 million U/day SC</li>
</ul>
<blockquote>
<p>The Italian Cooperative Study Group on Chronic Myelogenous Leukemia. N Engl J Med 1994;330:820–825.</p>
</blockquote>
</div>
<div id="omacetaxine" class="section level4" number="2.19.14.9">
<h4><span class="header-section-number">2.19.14.9</span> Omacetaxine</h4>
<ul>
<li>Omacetaxine: 1.25 mg/m2 SC bid on days 1–14 for first cycle and induction phase followed by 1.25 mg/m2 SC bid on days 1–7 as maintenance phase</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Cortes J, et al. Blood 2012;120:2573–2581.</p>
</blockquote>
</div>
</div>
<div id="hairy-cell-leukemia---single-agent-regimens" class="section level3" number="2.19.15">
<h3><span class="header-section-number">2.19.15</span> Hairy Cell Leukemia - Single-Agent Regimens</h3>
<div id="cladribine-2" class="section level4" number="2.19.15.1">
<h4><span class="header-section-number">2.19.15.1</span> Cladribine</h4>
<ul>
<li>Cladribine: 0.09 mg/kg/day IV continuous infusion on days 1–7</li>
<li>Administer one cycle.</li>
</ul>
<blockquote>
<p>Saven A, et al. Blood 1992;79:111–1120.</p>
</blockquote>
</div>
<div id="pentostatin-1" class="section level4" number="2.19.15.2">
<h4><span class="header-section-number">2.19.15.2</span> Pentostatin</h4>
<ul>
<li>Pentostatin: 4 mg/m2 IV on day 1</li>
<li>Repeat cycle every 14 days for 6 cycles.</li>
</ul>
<blockquote>
<p>Cassileth PA, et al. J Clin Oncol 1991;9:243–246.</p>
</blockquote>
</div>
<div id="interferon-alpha-2a-1" class="section level4" number="2.19.15.3">
<h4><span class="header-section-number">2.19.15.3</span> Interferon alpha-2a</h4>
<ul>
<li>Interferon alpha-2a: 3 million U SC or IM, 3 times per week</li>
<li>Continue treatment for up to 1 to 1.5 years.</li>
</ul>
<blockquote>
<p>Ratain MJ, et al. Blood 1985;65:644–648.</p>
</blockquote>
</div>
</div>
</div>
<div id="lung-cancer" class="section level2" number="2.20">
<h2><span class="header-section-number">2.20</span> LUNG CANCER</h2>
<div id="nonsmall-cell-lung-cancer---combined-modality-therapy" class="section level3" number="2.20.1">
<h3><span class="header-section-number">2.20.1</span> Non–Small Cell Lung Cancer - Combined Modality Therapy</h3>
<div id="cisplatin-etoposide-radiation-therapy" class="section level4" number="2.20.1.1">
<h4><span class="header-section-number">2.20.1.1</span> Cisplatin + Etoposide + Radiation Therapy</h4>
<ul>
<li>Cisplatin: 50 mg/m2 IV on days 1, 8, 29, and 36</li>
<li>Etoposide: 50 mg/m2 IV on days 1–5 and 29–33</li>
<li>Radiation therapy: 180 cGy/day for a total dose of 4500 cGy</li>
<li>Chemotherapy is given concurrently with radiation therapy.</li>
</ul>
<blockquote>
<p>Gandara DR, et al. J Clin Oncol 2003;21:2004–2010.</p>
</blockquote>
</div>
<div id="weekly-carboplatin-paclitaxel-radiation-therapy" class="section level4" number="2.20.1.2">
<h4><span class="header-section-number">2.20.1.2</span> Weekly Carboplatin + Paclitaxel + Radiation Therapy</h4>
<ul>
<li>Paclitaxel: 45 mg/m2 IV weekly for 7 weeks</li>
<li>Carboplatin: AUC of 2, IV weekly for 7 weeks</li>
<li>Radiation therapy: 200 cGy/day for a total dose of 6300 cGy over 7 weeks</li>
<li>Chemotherapy is given concurrently with radiation therapy. Three to 4 weeks after the completion of chemoradiotherapy, two additional cycles of the following chemotherapy are given:</li>
<li>Paclitaxel: 200 mg/m2 IV on day 1</li>
<li>Carboplatin: AUC of 6, IV on day 1</li>
<li>Repeat cycle every 21 days for 2 cycles.</li>
</ul>
<blockquote>
<p>Belani CP, et al. J Clin Oncol 2005;23:5883–5891.</p>
</blockquote>
</div>
</div>
<div id="nonsmall-cell-lung-cancer---adjuvant-therapy---combination-regimens" class="section level3" number="2.20.2">
<h3><span class="header-section-number">2.20.2</span> Non–Small Cell Lung Cancer - Adjuvant Therapy - Combination Regimens</h3>
<div id="paclitaxel-carboplatin-3" class="section level4" number="2.20.2.1">
<h4><span class="header-section-number">2.20.2.1</span> Paclitaxel + Carboplatin</h4>
<ul>
<li>Paclitaxel: 175 mg/m2 IV over 3 hours on day 1</li>
<li>Carboplatin: AUC of 6, IV on day 1</li>
<li>Repeat cycle every 21 days for 4 cycles.</li>
</ul>
<blockquote>
<p>Strauss GM, et al. J Clin Oncol 2004; 621S (abstract 7019).</p>
</blockquote>
</div>
<div id="vinorelbine-cisplatin" class="section level4" number="2.20.2.2">
<h4><span class="header-section-number">2.20.2.2</span> Vinorelbine + Cisplatin</h4>
<ul>
<li>Vinorelbine: 25 mg/m2 IV weekly for 16 weeks</li>
<li>Cisplatin: 50 mg/m2 IV on days 1 and 8</li>
<li>Repeat cycle every 28 days for 4 cycles.</li>
</ul>
<blockquote>
<p>Winton T, et al. N Engl J Med 2005;352:2589–2597.</p>
</blockquote>
</div>
<div id="cisplatin-vinblastine" class="section level4" number="2.20.2.3">
<h4><span class="header-section-number">2.20.2.3</span> Cisplatin + Vinblastine</h4>
<ul>
<li>Cisplatin: 100 mg/m2 IV on day 1</li>
<li>Vinblastine: 4 mg/m2 IV on days 1, 8, 15, 22, and 29, then every 2 weeks after day 43</li>
<li>Repeat cycle every 28 days for 4 cycles.</li>
</ul>
<blockquote>
<p>Arriagada R, et al. N Engl J Med 2004:350:351–360.</p>
</blockquote>
</div>
<div id="etoposide-cisplatin" class="section level4" number="2.20.2.4">
<h4><span class="header-section-number">2.20.2.4</span> Etoposide + Cisplatin</h4>
<ul>
<li>Etoposide: 100 mg/m2 IV on days 1–3</li>
<li>Cisplatin: 100 mg/m2 IV on day 1</li>
<li>Repeat cycle every 28 days for 4 cycles.</li>
</ul>
<blockquote>
<p>Arriagada R, et al. N Engl J Med 2004:350:351–360.</p>
</blockquote>
</div>
<div id="pemetrexed-cisplatin" class="section level4" number="2.20.2.5">
<h4><span class="header-section-number">2.20.2.5</span> Pemetrexed + Cisplatin</h4>
<ul>
<li>Pemetrexed: 500 mg/m2 IV on day 1</li>
<li>Cisplatin: 80 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days for 6 cycles. Folic acid at 350–1,000 µg PO q day beginning 1 week prior to therapy and vitamin B12 at 1,000 µg IM beginning 1–2 weeks prior to first dose of therapy and repeated every 9 weeks. Dexamethasone at 4 mg PO bid on the day before, the day of, and the day after pemetrexed.</li>
</ul>
<blockquote>
<p>Kreuter M, et al. Ann Oncol 2012;24:986–992.</p>
</blockquote>
</div>
</div>
<div id="nonsmall-cell-lung-cancer---metastatic-disease---combination-regimens" class="section level3" number="2.20.3">
<h3><span class="header-section-number">2.20.3</span> Non–Small Cell Lung Cancer - Metastatic Disease - Combination Regimens</h3>
<div id="carboplatin-paclitaxel-pc" class="section level4" number="2.20.3.1">
<h4><span class="header-section-number">2.20.3.1</span> Carboplatin + Paclitaxel (PC)</h4>
<ul>
<li>Carboplatin: AUC of 6, IV on day 1</li>
<li>Paclitaxel: 200 mg/m2 IV over 3 hours on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Sandler AB, et al. N Engl J Med 2006;355:2542–2560.</p>
</blockquote>
</div>
<div id="carboplatin-nab-paclitaxel" class="section level4" number="2.20.3.2">
<h4><span class="header-section-number">2.20.3.2</span> Carboplatin + Nab-Paclitaxel</h4>
<ul>
<li>Carboplatin: AUC of 6, IV on day 1</li>
<li>Nab-Paclitaxel: 100 mg/m2 IV weekly on days 1, 8, and 15</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Socinski ME, et al. J Clin Oncol 2012; 30:2055–2062.</p>
</blockquote>
</div>
<div id="carboplatin-paclitaxel-weekly-regimen" class="section level4" number="2.20.3.3">
<h4><span class="header-section-number">2.20.3.3</span> Carboplatin + Paclitaxel (weekly regimen)</h4>
<ul>
<li>Carboplatin: AUC of 6, IV on day 1</li>
<li>Paclitaxel: 100 mg/m2 IV weekly for 3 weeks</li>
<li>Repeat cycle every 4 weeks up to 4 cycles. If response or stable disease, may then treat with maintenance chemotherapy of:</li>
<li>Paclitaxel: 70 mg/m2 IV weekly for 3 weeks</li>
<li>Continue until disease progression.</li>
</ul>
<blockquote>
<p>Belani CP, et al. J Clin Oncol 2008;26:468–473.</p>
</blockquote>
</div>
<div id="carboplatin-paclitaxel-bevacizumab-pcb" class="section level4" number="2.20.3.4">
<h4><span class="header-section-number">2.20.3.4</span> Carboplatin + Paclitaxel + Bevacizumab (PCB)</h4>
<ul>
<li>Carboplatin: AUC of 6, IV on day 1</li>
<li>Paclitaxel: 200 mg/m2 IV on day 1</li>
<li>Bevacizumab: 15 mg/kg IV on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Sandler AB, et al. N Engl J Med 2006;355:2542–2560.</p>
</blockquote>
</div>
<div id="gemcitabine-cisplatin-bevacizumab-gcb" class="section level4" number="2.20.3.5">
<h4><span class="header-section-number">2.20.3.5</span> Gemcitabine + Cisplatin + Bevacizumab (GCB)</h4>
<ul>
<li>Gemcitabine: 1,250 mg/m2 IV on days 1 and 8</li>
<li>Cisplatin: 80 mg/m2 IV on day 1</li>
<li>Bevacizumab: 7.5 or 15 mg/kg IV on day 1</li>
<li>Repeat cycle every 21 days for a total of 6 cycles.</li>
</ul>
<blockquote>
<p>Reck M, et al. J Clin Oncol 2009;27:1227–1234.</p>
</blockquote>
</div>
<div id="cisplatin-paclitaxel" class="section level4" number="2.20.3.6">
<h4><span class="header-section-number">2.20.3.6</span> Cisplatin + Paclitaxel</h4>
<ul>
<li>Cisplatin: 80 mg/m2 IV on day 1</li>
<li>Paclitaxel: 175 mg/m2 IV over 3 hours on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Giaccone G, et al. J Clin Oncol 1998;16:2133–2141.</p>
</blockquote>
</div>
<div id="docetaxel-carboplatin" class="section level4" number="2.20.3.7">
<h4><span class="header-section-number">2.20.3.7</span> Docetaxel + Carboplatin</h4>
<ul>
<li>Docetaxel: 75 mg/m2 IV on day 1</li>
<li>Carboplatin: AUC of 6, IV on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Fossella F, et al. J Clin Oncol 2003;21:3016–3024.</p>
</blockquote>
</div>
<div id="docetaxel-cisplatin-2" class="section level4" number="2.20.3.8">
<h4><span class="header-section-number">2.20.3.8</span> Docetaxel + Cisplatin</h4>
<ul>
<li>Docetaxel: 75 mg/m2 IV on day 1</li>
<li>Cisplatin: 75 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Belani CP, et al. Clin Lung Cancer 1999;1:144–150.</p>
</blockquote>
</div>
<div id="docetaxel-gemcitabine" class="section level4" number="2.20.3.9">
<h4><span class="header-section-number">2.20.3.9</span> Docetaxel + Gemcitabine</h4>
<ul>
<li>Docetaxel: 100 mg/m2 IV on day 8</li>
<li>Gemcitabine: 1,100 mg/m2 IV on days 1 and 8</li>
<li>Repeat cycle every 21 days. G-CSF support is required from day 9 to day 15.</li>
</ul>
<blockquote>
<p>Georgoulias V, et al. Lancet 2001;357:1478–1484.</p>
</blockquote>
</div>
<div id="gemcitabine-cisplatin-2" class="section level4" number="2.20.3.10">
<h4><span class="header-section-number">2.20.3.10</span> Gemcitabine + Cisplatin</h4>
<ul>
<li>Gemcitabine: 1,000 mg/m2 IV on days 1, 8, and 15</li>
<li>Cisplatin: 100 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Abratt RP, et al. J Clin Oncol 1997;15:744–749.</p>
</blockquote>
</div>
<div id="gemcitabine-carboplatin-1" class="section level4" number="2.20.3.11">
<h4><span class="header-section-number">2.20.3.11</span> Gemcitabine + Carboplatin</h4>
<ul>
<li>Gemcitabine: 1,000 mg/m2 IV on days 1 and 8</li>
<li>Carboplatin: AUC of 5, IV on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Langer CJ, et al. Semin Oncol 1999;26 (Suppl 4):12–18.</p>
</blockquote>
</div>
<div id="gemcitabine-vinorelbine" class="section level4" number="2.20.3.12">
<h4><span class="header-section-number">2.20.3.12</span> Gemcitabine + Vinorelbine</h4>
<ul>
<li>Gemcitabine: 1,200 mg/m2 IV on days 1 and 8</li>
<li>Vinorelbine: 30 mg/m2 IV on days 1 and 8</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Frasci G, et al. J Clin Oncol 2000;18:2529–2536.</p>
</blockquote>
</div>
<div id="vinorelbine-cisplatin-1" class="section level4" number="2.20.3.13">
<h4><span class="header-section-number">2.20.3.13</span> Vinorelbine + Cisplatin</h4>
<ul>
<li>Vinorelbine: 30 mg/m2 IV on days 1, 8, and 15</li>
<li>Cisplatin: 120 mg/m2 IV on day 1</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Smith TJ, et al. J Clin Oncol 1995;13:2166–2173.</p>
</blockquote>
</div>
<div id="vinorelbine-cisplatin-cetuximab" class="section level4" number="2.20.3.14">
<h4><span class="header-section-number">2.20.3.14</span> Vinorelbine + Cisplatin + Cetuximab</h4>
<ul>
<li>Vinorelbine: 25 mg/m2 IV on days 1 and 8</li>
<li>Cisplatin: 80 mg/m2 IV on day 1</li>
<li>Cetuximab: 400 mg/m2 IV loading dose, then 250 mg/m2 IV weekly</li>
<li>Repeat cycle every 3 weeks up to 6 cycles.</li>
</ul>
<blockquote>
<p>Pirker R, et al. Proc Am Soc Clin Oncol 2008;26 (abstract 3).</p>
</blockquote>
</div>
<div id="vinorelbine-carboplatin" class="section level4" number="2.20.3.15">
<h4><span class="header-section-number">2.20.3.15</span> Vinorelbine + Carboplatin</h4>
<ul>
<li>Vinorelbine: 25 mg/m2 IV on days 1 and 8</li>
<li>Carboplatin: AUC of 6, IV on day 1</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Cremonesi M, et al. Oncology 2003;64:97–101.</p>
</blockquote>
</div>
<div id="pemetrexed-cisplatin-1" class="section level4" number="2.20.3.16">
<h4><span class="header-section-number">2.20.3.16</span> Pemetrexed + Cisplatin</h4>
<ul>
<li>Pemetrexed: 500 mg/m2 IV on day 1</li>
<li>Cisplatin: 75 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days up to 6 cycles. Folic acid at 350–1,000 µg PO q day
beginning 1 week prior to therapy and vitamin B12 at 1,000 µg IM beginning 1–2 weeks prior to first dose of therapy and repeated every 9 weeks. Dexamethasone at 4 mg PO bid on the day before, the day of, and the day after pemetrexed.</li>
</ul>
<blockquote>
<p>Scagliotti GV, et al. J Clin Oncol 2008;21:3543–3551.</p>
</blockquote>
</div>
<div id="pemetrexed-carboplatin" class="section level4" number="2.20.3.17">
<h4><span class="header-section-number">2.20.3.17</span> Pemetrexed + Carboplatin</h4>
<ul>
<li>Pemetrexed: 500 mg/m2 IV on day 1</li>
<li>Carboplatin: AUC of 5, IV on day 1</li>
<li>Repeat cycle every 21 days up to 4 cycles. Folic acid at 350–1,000 µg PO q day beginning 1 week prior to therapy and vitamin B12 at 1,000 µg IM beginning 1–2 weeks prior to first dose of therapy and repeated every 9 weeks. Dexamethasone at 4 mg PO bid on the day before, the day of, and the day after pemetrexed.</li>
</ul>
<blockquote>
<p>Scagliotti GV. Semin Oncol 2005;32 (2 Suppl 2):S5–S8.</p>
</blockquote>
</div>
<div id="ep-1" class="section level4" number="2.20.3.18">
<h4><span class="header-section-number">2.20.3.18</span> EP</h4>
<ul>
<li>Etoposide: 120 mg/m2 IV on days 1–3</li>
<li>Cisplatin: 60 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21–28 days.</li>
</ul>
<blockquote>
<p>Longeval E, et al. Cancer 1982;50:2751–2756.</p>
</blockquote>
</div>
<div id="ep-docetaxel" class="section level4" number="2.20.3.19">
<h4><span class="header-section-number">2.20.3.19</span> EP + Docetaxel</h4>
<ul>
<li>Cisplatin: 50 mg/m2 IV on days 1, 8, 29, and 36</li>
<li>Etoposide: 50 mg/m2 IV on days 1–5 and 29–33</li>
<li>Administer concurrent thoracic radiotherapy, followed 4–6 weeks after the completion of combined modality therapy by</li>
<li>Docetaxel: 75 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days for 3 cycles. Dose of docetaxel can be escalated to 100 mg/m2 IV on subsequent cycles in the absence of toxicity.</li>
</ul>
<blockquote>
<p>Gandara D, et al. J Clin Oncol 2003;21:2004–2010.</p>
</blockquote>
</div>
<div id="docetaxel-bevacizumab" class="section level4" number="2.20.3.20">
<h4><span class="header-section-number">2.20.3.20</span> Docetaxel + Bevacizumab</h4>
<ul>
<li>Docetaxel: 75 mg/m2 IV on day 1</li>
<li>Bevacizumab: 15 mg/kg IV on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Herbst RS, et al. J Clin Oncol 2007;25:4734–4750.</p>
</blockquote>
</div>
<div id="pemetrexed-carboplatin-bevacizumab" class="section level4" number="2.20.3.21">
<h4><span class="header-section-number">2.20.3.21</span> Pemetrexed + Carboplatin + Bevacizumab</h4>
<ul>
<li>Pemetrexed: 500 mg/m2 IV on day 1</li>
<li>Carboplatin: AUC of 6, IV on day 1</li>
<li>Bevacizumab: 15 mg/kg IV on day 1</li>
<li>Repeat cycle every 21 days up to 6 cycles. Folic acid at 350–1,000 µg PO q day beginning 1 week prior to therapy and vitamin B12 at 1,000 µg IM beginning 1–2 weeks prior to first dose of therapy and repeated every 9 weeks. Dexamethasone at 4 mg PO bid on the day before, the day of, and the day after pemetrexed.</li>
</ul>
<blockquote>
<p>Patel JD, et al. J Clin Oncol 2009;27:3284–3289.</p>
</blockquote>
</div>
<div id="pemetrexed-carboplatin-pembrolizumab" class="section level4" number="2.20.3.22">
<h4><span class="header-section-number">2.20.3.22</span> Pemetrexed + Carboplatin + Pembrolizumab</h4>
<ul>
<li>Pemetrexed: 500 mg/m2 IV on day 1</li>
<li>Carboplatin: AUC of 5, IV on day 1</li>
<li>Pembrolizumab: 200 mg IV on day 1</li>
<li>Repeat cycle every 21 days up to 4 cycles. Followed by pembrolizumab maintenance therapy up to a total of 35 cycles and pemetrexed maintenance.</li>
<li>Folic acid at 350–1,000 µg PO q day beginning 1 week prior to therapy and vitamin B12 at 1,000 µg IM beginning 1–2 weeks prior to first dose of therapy and repeated every 9 weeks. Dexamethasone at 4 mg PO bid on the day before, the day of, and the day after pemetrexed.</li>
</ul>
<blockquote>
<p>Gandhi L, et al. N Engl J Med 2018;378:2078–2092.</p>
</blockquote>
</div>
<div id="pemetrexed-cisplatin-pembrolizumab" class="section level4" number="2.20.3.23">
<h4><span class="header-section-number">2.20.3.23</span> Pemetrexed + Cisplatin + Pembrolizumab</h4>
<ul>
<li>Pemetrexed: 500 mg/m2 IV on day 1</li>
<li>Cisplatin: 75 mg/m2 IV on day 1</li>
<li>Pembrolizumab: 200 mg IV on day 1</li>
<li>Repeat cycle every 21 days up to 4 cycles. Followed by pembrolizumab maintenance therapy up to a total of 35 cycles and pemetrexed maintenance.</li>
<li>Folic acid at 350–1,000 µg PO q day beginning 1 week prior to therapy and vitamin B12 at 1,000 µg IM beginning 1–2 weeks prior to first dose of therapy and repeated every 9 weeks. Dexamethasone at 4 mg PO bid on the day before, the day of, and
the day after pemetrexed.</li>
</ul>
<blockquote>
<p>Gandhi L, et al. N Engl J Med 2018;378:2078–2092.</p>
</blockquote>
</div>
<div id="cisplatin-vinorelbine-cetuximab" class="section level4" number="2.20.3.24">
<h4><span class="header-section-number">2.20.3.24</span> Cisplatin + Vinorelbine + Cetuximab</h4>
<ul>
<li>Cisplatin: 80 mg/m2 IV on day 1</li>
<li>Vinorelbine: 25 mg/m2 IV continuous on days 1 and 8</li>
<li>Cetuximab: 400 mg/m2 IV loading dose, then 250 mg/m2 IV weekly</li>
<li>Repeat cycle every 21 days up to 6 cycles.</li>
</ul>
<blockquote>
<p>Pirker R, et al. Lancet 2009;373:1525–1531.</p>
</blockquote>
</div>
<div id="platinum-based-chemotherapy-maintenance-pemetrexed-non-squamous-histology" class="section level4" number="2.20.3.25">
<h4><span class="header-section-number">2.20.3.25</span> Platinum-Based Chemotherapy + Maintenance Pemetrexed (non-squamous histology)</h4>
<ul>
<li>Platinum-based chemotherapy × 4 cycles, followed by:</li>
<li>Pemetrexed: 500 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days up to 6 cycles. Folic acid at 350–1,000 µg PO q day beginning 1 week prior to therapy and vitamin B12 at 1,000 µg IM beginning 1–2 weeks prior to first dose of therapy and repeated every 9 weeks. Dexamethasone at 4 mg PO bid on the day before, the day of, and the day after pemetrexed.</li>
</ul>
<blockquote>
<p>Belani CP, et al. J Clin Oncol 2009;27:18S (abstract CRA8000).</p>
</blockquote>
</div>
<div id="nab-paclitaxel-carboplatin" class="section level4" number="2.20.3.26">
<h4><span class="header-section-number">2.20.3.26</span> Nab-Paclitaxel + Carboplatin</h4>
<ul>
<li>Nab-Paclitaxel: 100 mg/m2 IV on days 1, 8, and 15</li>
<li>Carboplatin: AUC of 6, IV on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Socinski MA, et al. J Clin Oncol 2012;30:2055–2062.</p>
</blockquote>
</div>
<div id="docetaxel-ramucirumab" class="section level4" number="2.20.3.27">
<h4><span class="header-section-number">2.20.3.27</span> Docetaxel + Ramucirumab</h4>
<ul>
<li>Docetaxel: 75 mg/m2 IV on day 1</li>
<li>Ramucirumab: 10 mg/kg IV on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Garon EB, et al. Lancet 2014;384:665–673.</p>
</blockquote>
</div>
<div id="gemcitabine-cisplatin-necitumumab" class="section level4" number="2.20.3.28">
<h4><span class="header-section-number">2.20.3.28</span> Gemcitabine + Cisplatin + Necitumumab</h4>
<ul>
<li>Gemcitabine: 1,250 mg/m2 IV on days 1 and 8</li>
<li>Cisplatin: 75 mg/m2 IV on day 1</li>
<li>Necitumumab: 800 mg IV on days 1 and 8</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Thatcher N, et al. Lancet Oncol 2015;16:763–774.</p>
</blockquote>
</div>
<div id="dabrafenib-trametinib" class="section level4" number="2.20.3.29">
<h4><span class="header-section-number">2.20.3.29</span> Dabrafenib + Trametinib</h4>
<ul>
<li>Dabrafenib: 150 mg PO bid</li>
<li>Trametinib: 2 mg PO daily</li>
<li>Continue treatment until disease progression.</li>
</ul>
<blockquote>
<p>Planchard D, et al. Lancet Oncol 2016;17:642–650.</p>
</blockquote>
</div>
<div id="carboplatin-paclitaxel-pembrolizumab" class="section level4" number="2.20.3.30">
<h4><span class="header-section-number">2.20.3.30</span> Carboplatin + Paclitaxel + Pembrolizumab</h4>
<ul>
<li>Carboplatin: AUC of 6, IV on day 1</li>
<li>Paclitaxel: 200 mg/m2 IV on day 1</li>
<li>Pembrolizumab: 200 mg IV on day 1</li>
<li>Repeat cycle every 21 days for 4 cycles followed by pembrolizumab for up to a total of 35 treatments.</li>
</ul>
<blockquote>
<p>Paz-Ares LG, et al. J Clin Oncol 2018;36 (Suppl; abstr 105).</p>
</blockquote>
</div>
<div id="carboplatin-nab-paclitaxel-pembrolizumab" class="section level4" number="2.20.3.31">
<h4><span class="header-section-number">2.20.3.31</span> Carboplatin + Nab-Paclitaxel + Pembrolizumab</h4>
<ul>
<li>Carboplatin: AUC of 6, IV on day 1</li>
<li>Nab-Paclitaxel: 100 mg/m2 IV weekly on days 1, 8, and 15</li>
<li>Pembrolizumab: 200 mg IV on day 1</li>
<li>Repeat cycle every 21 days for 4 cycles followed by pembrolizumab for up to a total of 35 treatments.</li>
</ul>
<blockquote>
<p>Paz-Ares LG, et al. J Clin Oncol 2018;36 (Suppl; abstr 105).</p>
</blockquote>
</div>
</div>
<div id="nonsmall-cell-lung-cancer---metastatic-disease---single-agent-regimens" class="section level3" number="2.20.4">
<h3><span class="header-section-number">2.20.4</span> Non–Small Cell Lung Cancer - Metastatic Disease - Single-Agent Regimens</h3>
<div id="paclitaxel-8" class="section level4" number="2.20.4.1">
<h4><span class="header-section-number">2.20.4.1</span> Paclitaxel</h4>
<ul>
<li>Paclitaxel: 225 mg/m2 IV over 3 hours on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Lilenbaum RC, et al. J Clin Oncol 2005;23:190–196.</p>
</blockquote>
<p>or
- Paclitaxel: 80–100 mg/m2 IV weekly for 3 weeks
- Repeat cycle every 28 days after 1-week rest.</p>
<blockquote>
<p>Tester WJ, et al. Cancer 1997;79:724–729.</p>
</blockquote>
</div>
<div id="nab-paclitaxel" class="section level4" number="2.20.4.2">
<h4><span class="header-section-number">2.20.4.2</span> Nab-Paclitaxel</h4>
<ul>
<li>Nab-Paclitaxel: 125 mg/m2 IV on days 1, 8, and 15</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Rizvi NA, et al. J Clin Oncol 2008;26:639–643.</p>
</blockquote>
</div>
<div id="docetaxel-6" class="section level4" number="2.20.4.3">
<h4><span class="header-section-number">2.20.4.3</span> Docetaxel</h4>
<ul>
<li>Docetaxel: 75 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Miller VA, et al. Semin Oncol 2000;27 (Suppl 3):3–10.</p>
</blockquote>
<p>or
- Docetaxel: 36 mg/m2 IV weekly for 6 weeks
- Repeat cycle every 8 weeks after 2-week rest. Premedicate with dexamethasone 8 mg PO at 12 hours and immediately before docetaxel infusion and 12 hours after each dose.</p>
<blockquote>
<p>Hainsworth JD, et al. Cancer 2000;89:328–333.</p>
</blockquote>
</div>
<div id="pemetrexed-2" class="section level4" number="2.20.4.4">
<h4><span class="header-section-number">2.20.4.4</span> Pemetrexed</h4>
<ul>
<li>Pemetrexed: 500 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days. Folic acid at 350–1,000 µg PO q day beginning 1 week prior to therapy and vitamin B12 at 1,000 µg IM beginning 1–2 weeks prior to first dose of therapy and repeated every 3 cycles.</li>
</ul>
<blockquote>
<p>Hanna N, et al. J Clin Oncol 2004;22:1589–1597.</p>
</blockquote>
</div>
<div id="gemcitabine-4" class="section level4" number="2.20.4.5">
<h4><span class="header-section-number">2.20.4.5</span> Gemcitabine</h4>
<ul>
<li>Gemcitabine: 1,000 mg/m2 IV on days 1, 8, and 15</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Manegold C, et al. Ann Oncol 1997;8:525–529.</p>
</blockquote>
</div>
<div id="vinorelbine-3" class="section level4" number="2.20.4.6">
<h4><span class="header-section-number">2.20.4.6</span> Vinorelbine</h4>
<ul>
<li>Vinorelbine: 25 mg/m2 IV on day 1</li>
<li>Repeat cycle every 7 days.</li>
</ul>
<blockquote>
<p>Furuse K, et al. Ann Oncol 1996;7:815–820.</p>
</blockquote>
</div>
<div id="gefitinib" class="section level4" number="2.20.4.7">
<h4><span class="header-section-number">2.20.4.7</span> Gefitinib</h4>
<ul>
<li>Gefitinib: 250 mg/day PO</li>
<li>Continue treatment until disease progression.</li>
</ul>
<blockquote>
<p>Herbst RS. Semin Oncol 2003;30 (Suppl 1):30–38.</p>
</blockquote>
</div>
<div id="erlotinib" class="section level4" number="2.20.4.8">
<h4><span class="header-section-number">2.20.4.8</span> Erlotinib</h4>
<ul>
<li>Erlotinib: 150 mg/day PO</li>
<li>Continue treatment until disease progression.</li>
</ul>
<blockquote>
<p>Shepherd FA, et al. J Clin Oncol 2004;22 (Suppl 1):14S (abstract 7022).</p>
</blockquote>
</div>
<div id="afatinib" class="section level4" number="2.20.4.9">
<h4><span class="header-section-number">2.20.4.9</span> Afatinib</h4>
<ul>
<li>Afatinib: 40 mg/day PO</li>
<li>Continue treatment until disease progression.</li>
</ul>
<blockquote>
<p>Sequist LV, et al. J Clin Oncol 2013;27:3327–3334.</p>
</blockquote>
</div>
<div id="sunitinib-2" class="section level4" number="2.20.4.10">
<h4><span class="header-section-number">2.20.4.10</span> Sunitinib</h4>
<ul>
<li>Sunitinib: 50 mg/day PO for 4 weeks</li>
<li>Repeat cycle every 6 weeks.</li>
</ul>
<blockquote>
<p>Socinski MA, et al. J Clin Oncol 2008;26:650–656.</p>
</blockquote>
</div>
<div id="cetuximab-3" class="section level4" number="2.20.4.11">
<h4><span class="header-section-number">2.20.4.11</span> Cetuximab</h4>
<ul>
<li>Cetuximab: 400 mg/m2 IV loading dose, then 250 mg/m2 IV weekly</li>
<li>Repeat cycle every week.</li>
</ul>
<blockquote>
<p>Hanna N, et al. J Clin Oncol 2006;24:5253–5258.</p>
</blockquote>
</div>
<div id="nivolumab-4" class="section level4" number="2.20.4.12">
<h4><span class="header-section-number">2.20.4.12</span> Nivolumab</h4>
<ul>
<li>Nivolumab: 240 mg IV on day 1</li>
<li>Repeat cycle every 2 weeks. May also administer 480 mg IV on day 1 with cycles every 4 weeks.</li>
</ul>
<blockquote>
<p>Brahmer J, et al. N Engl J Med 2015;373:123–135.</p>
</blockquote>
</div>
<div id="crizotinib" class="section level4" number="2.20.4.13">
<h4><span class="header-section-number">2.20.4.13</span> Crizotinib</h4>
<ul>
<li>Crizotinib: 250 mg PO bid</li>
<li>Continue treatment until disease progression.</li>
</ul>
<blockquote>
<p>Kwak EL, et al. N Engl J Med 2010;363:1693–1703.</p>
</blockquote>
</div>
<div id="ceritinib" class="section level4" number="2.20.4.14">
<h4><span class="header-section-number">2.20.4.14</span> Ceritinib</h4>
<ul>
<li>Ceritinib: 750 mg/day PO</li>
<li>Continue treatment until disease progression.</li>
</ul>
<blockquote>
<p>Shaw AT, et al. N Engl J Med 2014;370:1189–1197.</p>
</blockquote>
</div>
<div id="alectinib" class="section level4" number="2.20.4.15">
<h4><span class="header-section-number">2.20.4.15</span> Alectinib</h4>
<ul>
<li>Alectinib: 600 mg PO bid</li>
<li>Continue treatment until disease progression.</li>
</ul>
<blockquote>
<p>Shaw AT, et al. Lancet Oncol 2016;17:234–242.</p>
</blockquote>
</div>
<div id="brigatinib" class="section level4" number="2.20.4.16">
<h4><span class="header-section-number">2.20.4.16</span> Brigatinib</h4>
<ul>
<li>Brigatinib: 90 mg PO daily for 7 days and then 180 mg PO daily</li>
<li>Continue treatment until disease progression.</li>
</ul>
<blockquote>
<p>Kim DW, et al. J Clin Oncol 2017. doi: 10. 1200/JCO.2016.71.5904.</p>
</blockquote>
</div>
<div id="osimertinib" class="section level4" number="2.20.4.17">
<h4><span class="header-section-number">2.20.4.17</span> Osimertinib</h4>
<ul>
<li>Osimertinib: 80 mg/day PO</li>
<li>Continue treatment until disease progression.</li>
</ul>
<blockquote>
<p>Yang J, et al. J Thorac Oncl 2016;11:S152–153.</p>
</blockquote>
</div>
<div id="pembrolizumab-9" class="section level4" number="2.20.4.18">
<h4><span class="header-section-number">2.20.4.18</span> Pembrolizumab</h4>
<ul>
<li>Pembrolizumab: 200 mg IV on day 1</li>
<li>Repeat cycle every 3 weeks.</li>
</ul>
<blockquote>
<p>Mok T, et al. J Thorac Oncol 2016;11:S142.</p>
</blockquote>
</div>
<div id="durvalumab" class="section level4" number="2.20.4.19">
<h4><span class="header-section-number">2.20.4.19</span> Durvalumab</h4>
<ul>
<li>Durvalumab: 10 mg/kg IV on day 1</li>
<li>Repeat cycle every 14 days.</li>
</ul>
<blockquote>
<p>Antonia SJ, et al. N Engl J Med 2017;377:1919–1929.</p>
</blockquote>
</div>
</div>
<div id="small-cell-lung-cancer---combination-regimens" class="section level3" number="2.20.5">
<h3><span class="header-section-number">2.20.5</span> Small Cell Lung Cancer - Combination Regimens</h3>
<div id="ep-2" class="section level4" number="2.20.5.1">
<h4><span class="header-section-number">2.20.5.1</span> EP</h4>
<ul>
<li>Etoposide: 80 mg/m2 IV on days 1–3</li>
<li>Cisplatin: 80 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Ihde DC, et al. J Clin Oncol 1994;12:2022–2034.</p>
</blockquote>
</div>
<div id="ec" class="section level4" number="2.20.5.2">
<h4><span class="header-section-number">2.20.5.2</span> EC</h4>
<ul>
<li>Etoposide: 100 mg/m2 IV on days 1–3</li>
<li>Carboplatin: AUC of 6, IV on day 1</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Viren M, et al. Acta Oncol 1994;33:921–924.</p>
</blockquote>
</div>
<div id="irinotecan-cisplatin-1" class="section level4" number="2.20.5.3">
<h4><span class="header-section-number">2.20.5.3</span> Irinotecan + Cisplatin</h4>
<ul>
<li>Irinotecan: 60 mg/m2 IV on days 1, 8, and 15</li>
<li>Cisplatin: 60 mg/m2 IV on day 1</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Noda K, et al. N Engl J Med 2002;346:85–91.</p>
</blockquote>
</div>
<div id="topotecan-cisplatin" class="section level4" number="2.20.5.4">
<h4><span class="header-section-number">2.20.5.4</span> Topotecan + Cisplatin</h4>
<ul>
<li>Topotecan: 1.7 mg/m2/day PO on days 1–5</li>
<li>Cisplatin: 60 mg/m2 IV on day 5</li>
<li>Repeat cycle every 21 days up to 4 cycles or 2 cycles beyond best response.</li>
</ul>
<blockquote>
<p>Eckardt JR, et al. J Clin Oncol 2006;24:2044–2051.</p>
</blockquote>
</div>
<div id="carboplatin-paclitaxel-etoposide" class="section level4" number="2.20.5.5">
<h4><span class="header-section-number">2.20.5.5</span> Carboplatin + Paclitaxel + Etoposide</h4>
<ul>
<li>Carboplatin: AUC of 6, IV on day 1</li>
<li>Paclitaxel: 200 mg/m2 IV over 1 hour on day 1</li>
<li>Etoposide: 50 mg alternating with 100 mg PO on days 1–10</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Hainsworth JD, et al. J Clin Oncol 1997;15:3464–3470.</p>
</blockquote>
</div>
<div id="carboplatin-paclitaxel-1" class="section level4" number="2.20.5.6">
<h4><span class="header-section-number">2.20.5.6</span> Carboplatin + Paclitaxel</h4>
<ul>
<li>Carboplatin: AUC of 2, IV on days 1, 8, and 15</li>
<li>Paclitaxel: 80 mg/m2 IV on days 1, 8, and 15</li>
<li>Repeat cycle every 28 days for 6 cycles.</li>
</ul>
<blockquote>
<p>Neubauer M, et al. J Clin Oncol 2004;22:1872–1877.</p>
</blockquote>
</div>
<div id="cav" class="section level4" number="2.20.5.7">
<h4><span class="header-section-number">2.20.5.7</span> CAV</h4>
<ul>
<li>Cyclophosphamide: 1,000 mg/m2 IV on day 1</li>
<li>Doxorubicin: 40 mg/m2 IV on day 1</li>
<li>Vincristine: 1 mg/m2 IV on day 1 (maximum, 2 mg)</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Roth BJ, et al. J Clin Oncol 1992;10:282–291.</p>
</blockquote>
</div>
<div id="cae" class="section level4" number="2.20.5.8">
<h4><span class="header-section-number">2.20.5.8</span> CAE</h4>
<ul>
<li>Cyclophosphamide: 1,000 mg/m2 IV on day 1</li>
<li>Doxorubicin: 45 mg/m2 IV on day 1</li>
<li>Etoposide: 50 mg/m2 IV on days 1–5</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Aisner J, et al. Semin Oncol 1986;(Suppl 3):54–62.</p>
</blockquote>
</div>
</div>
<div id="small-cell-lung-cancer---single-agent-regimens" class="section level3" number="2.20.6">
<h3><span class="header-section-number">2.20.6</span> Small Cell Lung Cancer - Single-Agent Regimens</h3>
<div id="etoposide-1" class="section level4" number="2.20.6.1">
<h4><span class="header-section-number">2.20.6.1</span> Etoposide</h4>
<ul>
<li>Etoposide: 160 mg/m2 PO on days 1–5</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Johnson DH. Semin Oncol 1993;20:315–325.</p>
</blockquote>
<p>or
- Etoposide: 50 mg/m2/day PO on days 1–21
- Repeat cycle as tolerated.</p>
<blockquote>
<p>Johnson DH, et al. J Clin Oncol 1990;8:1013–1017.</p>
</blockquote>
</div>
<div id="paclitaxel-9" class="section level4" number="2.20.6.2">
<h4><span class="header-section-number">2.20.6.2</span> Paclitaxel</h4>
<ul>
<li>Paclitaxel: 80–100 mg/m2 IV weekly for 3 weeks</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Hainsworth JD, et al. Semin Oncol 1999;26 (Suppl 2):60–66.</p>
</blockquote>
</div>
<div id="topotecan-2" class="section level4" number="2.20.6.3">
<h4><span class="header-section-number">2.20.6.3</span> Topotecan</h4>
<ul>
<li>Topotecan: 1.5 mg/m2 IV on days 1–5</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Ardizzoni A, et al. J Clin Oncol 1997;15:2090–2096.</p>
</blockquote>
</div>
<div id="gemcitabine-5" class="section level4" number="2.20.6.4">
<h4><span class="header-section-number">2.20.6.4</span> Gemcitabine</h4>
<ul>
<li>Gemcitabine: 1,000 mg/m2 PO on days 1, 8, and 15</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Masters GA, et al. J Clin Oncol 2003;21:1550–1555.</p>
</blockquote>
</div>
</div>
</div>
<div id="lymphoma" class="section level2" number="2.21">
<h2><span class="header-section-number">2.21</span> LYMPHOMA</h2>
<div id="hodgkins-lymphoma---combination-regimens" class="section level3" number="2.21.1">
<h3><span class="header-section-number">2.21.1</span> Hodgkin’s Lymphoma - Combination Regimens</h3>
<div id="abvd" class="section level4" number="2.21.1.1">
<h4><span class="header-section-number">2.21.1.1</span> ABVD</h4>
<ul>
<li>Doxorubicin: 25 mg/m2 IV on days 1 and 15</li>
<li>Bleomycin: 10 U/m2 IV on days 1 and 15</li>
<li>Vinblastine: 6 mg/m2 IV on days 1 and 15</li>
<li>Dacarbazine: 375 mg/m2 IV on days 1 and 15</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Bonadonna G, et al. Cancer 1975;36:252–259.</p>
</blockquote>
</div>
<div id="a-avd" class="section level4" number="2.21.1.2">
<h4><span class="header-section-number">2.21.1.2</span> A + AVD</h4>
<ul>
<li>Brentuximab: 1.2 mg/kg IV on days 1 and 15</li>
<li>Doxorubicin: 25 mg/m2 IV on days 1 and 15</li>
<li>Vinblastine: 6 mg/m2 IV on days 1 and 15</li>
<li>Dacarbazine: 375 mg/m2 IV on days 1 and 15</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Connors JM, et al. N Engl J Med 2018;378:331–344.</p>
</blockquote>
</div>
<div id="mopp" class="section level4" number="2.21.1.3">
<h4><span class="header-section-number">2.21.1.3</span> MOPP</h4>
<ul>
<li>Nitrogen mustard: 6 mg/m2 IV on days 1 and 8</li>
<li>Vincristine: 1.4 mg/m2 IV on days 1 and 8</li>
<li>Procarbazine: 100 mg/m2 PO on days 1–14</li>
<li>Prednisone: 40 mg/m2 PO on days 1–14</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>DeVita VT Jr, et al. Ann Intern Med 1970;73:881–895.</p>
</blockquote>
</div>
<div id="moppabvd-hybrid" class="section level4" number="2.21.1.4">
<h4><span class="header-section-number">2.21.1.4</span> MOPP/ABVD Hybrid</h4>
<ul>
<li>Nitrogen mustard: 6 mg/m2 IV on days 1 and 8</li>
<li>Vincristine: 1.4 mg/m2 IV on day 1 (maximum dose, 2 mg)</li>
<li>Procarbazine: 100 mg/m2 PO on days 1–14</li>
<li>Prednisone: 40 mg/m2 PO on days 1–14</li>
<li>Doxorubicin: 35 mg/m2 IV on day 8</li>
<li>Bleomycin: 10 U/m2 IV on day 8</li>
<li>Hydrocortisone: 100 mg IV given before bleomycin</li>
<li>Vinblastine: 6 mg/m2 IV on day 8</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Klimo P, et al. J Clin Oncol 1985;3:1174–1182.</p>
</blockquote>
</div>
<div id="mopp-alternating-with-abvd" class="section level4" number="2.21.1.5">
<h4><span class="header-section-number">2.21.1.5</span> MOPP Alternating with ABVD</h4>
<ul>
<li>See MOPP and ABVD regimens outlined above.</li>
</ul>
</div>
<div id="stanford-v" class="section level4" number="2.21.1.6">
<h4><span class="header-section-number">2.21.1.6</span> Stanford V</h4>
<ul>
<li>Nitrogen mustard: 6 mg/m2 IV on day 1</li>
<li>Doxorubicin: 25 mg/m2 IV on days 1 and 15</li>
<li>Vinblastine: 6 mg/m2 IV on days 1 and 15</li>
<li>Vincristine: 1.4 mg/m2 IV on days 8 and 22</li>
<li>Bleomycin: 5 U/m2 IV on days 8 and 22</li>
<li>Etoposide: 60 mg/m2 IV on days 15 and 16</li>
<li>Prednisone: 40 mg PO every other day</li>
<li>Repeat cycle every 28 days. In patients &gt;50 years of age, vinblastine dose reduced to 4 mg/m2 and vincristine dose reduced to 1 mg/m2 on weeks 9 and 12.</li>
<li>Dose of prednisone tapered starting on week 10. Patient should be placed on prophylactic trimethoprim/sulfamethoxazole (Bactrim DS) PO bid and acyclovir 200 mg PO tid.</li>
</ul>
<blockquote>
<p>Bartlett NL, et al. J Clin Oncol 1995;13:1080–1088.</p>
</blockquote>
</div>
<div id="eva" class="section level4" number="2.21.1.7">
<h4><span class="header-section-number">2.21.1.7</span> EVA</h4>
<ul>
<li>Etoposide: 100 mg/m2 IV on days 1–3</li>
<li>Vinblastine: 6 mg/m2 IV on day 1</li>
<li>Doxorubicin: 50 mg/m2 IV on day 1</li>
<li>Repeat cycle every 28 days for up to 6 cycles.</li>
</ul>
<blockquote>
<p>Canellos GP, et al. Ann Oncol 2003;14:268–272.</p>
</blockquote>
</div>
<div id="evap" class="section level4" number="2.21.1.8">
<h4><span class="header-section-number">2.21.1.8</span> EVAP</h4>
<ul>
<li>Etoposide: 120 mg/m2 IV on days 1, 8, and 15</li>
<li>Vinblastine: 4 mg/m2 IV on days 1, 8, and 15</li>
<li>Cytarabine: 30 mg/m2 IV on days 1, 8, and 15</li>
<li>Cisplatin: 40 mg/m2 IV on days 1, 8, and 15</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Longo DL. Semin Oncol 1990;17:716–735.</p>
</blockquote>
</div>
<div id="mini-beam" class="section level4" number="2.21.1.9">
<h4><span class="header-section-number">2.21.1.9</span> Mini-BEAM</h4>
<ul>
<li>Carmustine: 60 mg/m2 IV on day 1</li>
<li>Etoposide: 75 mg/m2 IV on days 2–5</li>
<li>Ara-C: 100 mg/m2 IV every 12 hours on days 2–5</li>
<li>Melphalan: 30 mg/m2 IV on day 6</li>
<li>Repeat cycle every 4–6 weeks.</li>
</ul>
<blockquote>
<p>Colwill R, et al. J Clin Oncol 1995;13:396–402.</p>
</blockquote>
</div>
<div id="beacopp" class="section level4" number="2.21.1.10">
<h4><span class="header-section-number">2.21.1.10</span> BEACOPP</h4>
<ul>
<li>Bleomycin: 10 mg/m2 IV on day 8</li>
<li>Etoposide: 100 mg/m2 IV on days 1–3</li>
<li>Doxorubicin: 25 mg/m2 IV on day 1</li>
<li>Cyclophosphamide: 650 mg/m2 IV on day 1</li>
<li>Vincristine: 1.4 mg/m2 IV on day 8 (maximum, 2 mg)</li>
<li>Procarbazine: 100 mg/m2 PO on days 1–7</li>
<li>Prednisone: 40 mg/m2 PO on days 1–14</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Diehl V, et al. J Clin Oncol 1998;16:3810–3821.</p>
</blockquote>
</div>
<div id="beacopp-escalated" class="section level4" number="2.21.1.11">
<h4><span class="header-section-number">2.21.1.11</span> BEACOPP Escalated</h4>
<ul>
<li>Bleomycin: 10 mg/m2 IV on day 8</li>
<li>Etoposide: 200 mg/m2 IV on days 1–3</li>
<li>Doxorubicin: 35 mg/m2 IV on day 1</li>
<li>Cyclophosphamide: 1,200 mg/m2 IV on day 1</li>
<li>Vincristine: 1.4 mg/m2 IV on day 8 (maximum dose, 2 mg)</li>
<li>Procarbazine: 100 mg/m2 PO on days 1–7</li>
<li>Prednisone: 40 mg/m2 PO on days 1–14</li>
<li>Repeat cycle every 21 days. G-CSF support, at dose of 5 µg/kg/day SC, starting on day 8 and continue until neutrophil recovery.</li>
</ul>
<blockquote>
<p>Tesch H, et al. Blood 1998;15:4560–4567.</p>
</blockquote>
</div>
<div id="gvd" class="section level4" number="2.21.1.12">
<h4><span class="header-section-number">2.21.1.12</span> GVD</h4>
<p>For transplant-naïve patients:</p>
<ul>
<li>Gemcitabine: 1,000 mg/m2 IV on days 1 and 8</li>
<li>Vinorelbine: 20 mg/m2 IV on days 1 and 8</li>
<li>Doxil: 15 mg/m2 IV on days 1 and 8</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Bartlett NL, et al. Ann Oncol 2007;18:1071–1079.</p>
</blockquote>
<p>or
For post-transplant patients:</p>
<ul>
<li>Gemcitabine: 800 mg/m2 IV on days 1 and 8</li>
<li>Vinorelbine: 15 mg/m2 IV on days 1 and 8</li>
<li>Doxil: 10 mg/m2 IV on days 1 and 8</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Bartlett NL, et al. Ann Oncol 2007;18:1071–1079.</p>
</blockquote>
</div>
</div>
<div id="hodgkins-lymphoma---single-agent-regimens" class="section level3" number="2.21.2">
<h3><span class="header-section-number">2.21.2</span> Hodgkin’s Lymphoma - Single-Agent Regimens</h3>
<div id="gemcitabine-6" class="section level4" number="2.21.2.1">
<h4><span class="header-section-number">2.21.2.1</span> Gemcitabine</h4>
<ul>
<li>Gemcitabine: 1,250 mg/m2 IV on days 1, 8, and 15</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Santoro A, et al. J Clin Oncol 2000;18:2615–2619.</p>
</blockquote>
</div>
<div id="rituximab-1" class="section level4" number="2.21.2.2">
<h4><span class="header-section-number">2.21.2.2</span> Rituximab</h4>
<ul>
<li>Rituximab: 375 mg/m2 IV on day 1</li>
<li>Repeat weekly for 4 weeks.</li>
</ul>
<blockquote>
<p>Schulz H, et al. Blood 2008;111:109–111.</p>
</blockquote>
</div>
<div id="brentuximab" class="section level4" number="2.21.2.3">
<h4><span class="header-section-number">2.21.2.3</span> Brentuximab</h4>
<ul>
<li>Brentuximab: 1.8 mg/kg IV on day 1</li>
<li>Repeat cycle every 3 weeks for up to 16 cycles.</li>
</ul>
<blockquote>
<p>Younes A, et al. J Clin Oncol 2012;30:2183–2189.</p>
</blockquote>
</div>
<div id="nivolumab-5" class="section level4" number="2.21.2.4">
<h4><span class="header-section-number">2.21.2.4</span> Nivolumab</h4>
<ul>
<li>Nivolumab: 240 mg IV on day 1</li>
<li>Repeat cycle every 2 weeks. May also administer 480 mg IV with cycles repeated every 4 weeks.</li>
</ul>
<blockquote>
<p>Ansell SM, et al. N Engl J Med 2015;372:311–318.</p>
</blockquote>
</div>
<div id="pembrolizumab-10" class="section level4" number="2.21.2.5">
<h4><span class="header-section-number">2.21.2.5</span> Pembrolizumab</h4>
<ul>
<li>Pembrolizumab: 200 mg IV on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Armand P, et al. J Clin Oncol 2016;34:3733–3739.</p>
</blockquote>
</div>
<div id="bendamustine-1" class="section level4" number="2.21.2.6">
<h4><span class="header-section-number">2.21.2.6</span> Bendamustine</h4>
<ul>
<li>Bendamustine: 70–120 mg/m2 IV on days 1 and 2</li>
<li>Repeat weekly for 4 weeks.</li>
</ul>
<blockquote>
<p>Moskowitz AJ, et al. J Clin Oncol 2013;31:456–460.</p>
</blockquote>
</div>
<div id="everolimus-1" class="section level4" number="2.21.2.7">
<h4><span class="header-section-number">2.21.2.7</span> Everolimus</h4>
<ul>
<li>Everolimus: 10 mg PO daily</li>
<li>Continue until disease progression.</li>
</ul>
<blockquote>
<p>Johnston PB, et al. Am J Hematol 2010;85:320–324.</p>
</blockquote>
</div>
<div id="lenalidomide-1" class="section level4" number="2.21.2.8">
<h4><span class="header-section-number">2.21.2.8</span> Lenalidomide</h4>
<ul>
<li>Lenalidomide: 25 mg PO daily</li>
<li>Continue until disease progression.</li>
</ul>
<blockquote>
<p>Fehniger TA, et al. Blood 2011;118:5119–5125.</p>
</blockquote>
</div>
</div>
<div id="non-hodgkins-lymphoma---low-grade-lymphoma---combination-regimens" class="section level3" number="2.21.3">
<h3><span class="header-section-number">2.21.3</span> Non-Hodgkin’s Lymphoma - Low-Grade Lymphoma - Combination Regimens</h3>
<div id="cvp-1" class="section level4" number="2.21.3.1">
<h4><span class="header-section-number">2.21.3.1</span> CVP</h4>
<ul>
<li>Cyclophosphamide: 400 mg/m2 PO on days 1–5 (or 800 mg/m2 IV on day 1)</li>
<li>Vincristine: 1.4 mg/m2 IV on day 1 (maximum, 2 mg)</li>
<li>Prednisone: 100 mg/m2 PO on days 1–5</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Bagley CM Jr, et al. Ann Intern Med 1972;76:227–234.</p>
</blockquote>
</div>
<div id="chop" class="section level4" number="2.21.3.2">
<h4><span class="header-section-number">2.21.3.2</span> CHOP</h4>
<ul>
<li>Cyclophosphamide: 750 mg/m2 IV on day 1</li>
<li>Doxorubicin: 50 mg/m2 IV on day 1</li>
<li>Vincristine: 1.4 mg/m2 IV on day 1 (maximum, 2 mg)</li>
<li>Prednisone: 100 mg/m2 PO on days 1–5</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Urba WJ, et al. J Natl Cancer Inst Monogr 1990;10:29–37.</p>
</blockquote>
</div>
<div id="cnop" class="section level4" number="2.21.3.3">
<h4><span class="header-section-number">2.21.3.3</span> CNOP</h4>
<ul>
<li>Cyclophosphamide: 750 mg/m2 IV on day 1</li>
<li>Mitoxantrone: 10 mg/m2 IV on day 1</li>
<li>Vincristine: 1.4 mg/m2 IV on day 1 (maximum, 2 mg)</li>
<li>Prednisone: 50 mg/m2 PO on days 1–5</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Sonnevald P, et al. J Clin Oncol 1995;13:2530–2539.</p>
</blockquote>
</div>
<div id="fnd" class="section level4" number="2.21.3.4">
<h4><span class="header-section-number">2.21.3.4</span> FND</h4>
<ul>
<li>Fludarabine: 25 mg/m2 IV on days 1–3</li>
<li>Mitoxantrone: 10 mg/m2 IV on day 1</li>
<li>Dexamethasone: 20 mg PO on days 1–5</li>
<li>Trimethoprim/sulfamethoxazole (Bactrim DS): 1 tablet PO bid, 3 times per week</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>McLaughlin P, et al. J Clin Oncol 1996;14:1262–1268.</p>
</blockquote>
</div>
<div id="fc" class="section level4" number="2.21.3.5">
<h4><span class="header-section-number">2.21.3.5</span> FC</h4>
<ul>
<li>Fludarabine: 20 mg/m2 IV on days 1–5</li>
<li>Cyclophosphamide: 1,000 mg/m2 IV on day 1</li>
<li>Trimethoprim/sulfamethoxazole (Bactrim DS): 1 tablet PO bid</li>
<li>Repeat cycle every 21–28 days.</li>
</ul>
<blockquote>
<p>Hochster H, et al. Blood 1994;84 (Suppl 1):383a.</p>
</blockquote>
</div>
<div id="fcr-1" class="section level4" number="2.21.3.6">
<h4><span class="header-section-number">2.21.3.6</span> FCR</h4>
<ul>
<li>Fludarabine: 25 mg/m2 IV on days 1–3</li>
<li>Cyclophosphamide: 300 mg/m2 IV on days 1–3</li>
<li>Rituximab: 375 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days for 4 cycles.</li>
</ul>
<blockquote>
<p>Sacchi S, et al. Cancer 2007;110:121–128.</p>
</blockquote>
</div>
<div id="r-chop" class="section level4" number="2.21.3.7">
<h4><span class="header-section-number">2.21.3.7</span> R-CHOP</h4>
<ul>
<li>Cyclophosphamide: 750 mg/m2 IV on day 1</li>
<li>Doxorubicin: 50 mg/m2 IV on day 1</li>
<li>Vincristine: 1.4 mg/m2 IV on day 1 (maximum, 2 mg)</li>
<li>Prednisone: 100 mg/day PO on days 1–5</li>
<li>Repeat cycle every 21 days up to 6 cycles. Patients who experience a response to therapy can then receive maintenance therapy with</li>
<li>Rituximab: 375 mg/m2 IV on day 1</li>
<li>Repeat cycle every 3 months up to a maximum of 2 years.</li>
</ul>
<blockquote>
<p>van Oers MHJ, et al. Blood 2006;108:3295–3301.</p>
</blockquote>
</div>
<div id="r-fcm" class="section level4" number="2.21.3.8">
<h4><span class="header-section-number">2.21.3.8</span> R-FCM</h4>
<ul>
<li>Rituximab: 375 mg/m2 IV on day 0</li>
<li>Fludarabine: 25 mg/m2 IV on days 1–3</li>
<li>Cyclophosphamide: 200 mg/m2 IV on days 1–3</li>
<li>Mitoxantrone: 8 mg/m2 IV on day 1</li>
<li>Repeat cycle every 4 weeks for a total of 4 cycles. Patients who experience a response can then receive maintenance therapy at 3 and 9 months after completion of therapy with</li>
<li>Rituximab: 375 mg/m2 IV weekly for 4 weeks</li>
</ul>
<blockquote>
<p>Forstpointer R, et al. Blood 2006;108:4003–4008.</p>
</blockquote>
</div>
<div id="bendamustine-rituximab-1" class="section level4" number="2.21.3.9">
<h4><span class="header-section-number">2.21.3.9</span> Bendamustine + Rituximab</h4>
<ul>
<li>Bendamustine: 90 mg/m2 IV on days 1 and 2</li>
<li>Rituximab: 375 mg/m2 IV on day 1</li>
<li>Repeat cycle every 28 days for 4 cycles.</li>
</ul>
<blockquote>
<p>Rummel MJ, et al. J Clin Oncol 2005;23:3383–3389.</p>
</blockquote>
<p>or</p>
<ul>
<li>Rituximab: 375 mg/m2 IV on day 1</li>
<li>Bendamustine: 90 mg/m2 IV on days 2 and 3</li>
<li>Repeat cycle every 28 days for 4–6 cycles. An additional dose of rituximab is administered 1 week prior to the first cycle and 4 weeks after the last cycle.</li>
</ul>
<blockquote>
<p>Robinson KS, et al. J Clin Oncol 2008;26:4473–4479.</p>
</blockquote>
</div>
<div id="bortezomib-mantle-cell-lymphoma" class="section level4" number="2.21.3.10">
<h4><span class="header-section-number">2.21.3.10</span> Bortezomib (mantle cell lymphoma)</h4>
<ul>
<li>Bortezomib: 1.3 mg/m2 IV or SC on days 1, 4, 8, and 11</li>
<li>Repeat cycle every 21 days for up to 17 cycles.</li>
</ul>
<blockquote>
<p>Fisher RI, et al. J Clin Oncol 2006;24:4867–4874.</p>
</blockquote>
</div>
<div id="ibrutinib-mantle-cell-lymphoma" class="section level4" number="2.21.3.11">
<h4><span class="header-section-number">2.21.3.11</span> Ibrutinib (mantle cell lymphoma)</h4>
<ul>
<li>Ibrutinib: 560 mg/day PO</li>
<li>Continue treatment until disease progression.</li>
</ul>
<blockquote>
<p>Wang ML, et al. N Engl J Med 2013;369:507–516.</p>
</blockquote>
</div>
<div id="acalabrutinib-mantle-cell-lymphoma" class="section level4" number="2.21.3.12">
<h4><span class="header-section-number">2.21.3.12</span> Acalabrutinib (mantle cell lymphoma)</h4>
<ul>
<li>Acalabrutinib: 100 mg PO bid</li>
<li>Continue treatment until disease progression.</li>
</ul>
<blockquote>
<p>Wang M, et al. Lancet 2018;391:659–667.</p>
</blockquote>
</div>
<div id="copanlisib" class="section level4" number="2.21.3.13">
<h4><span class="header-section-number">2.21.3.13</span> Copanlisib</h4>
<ul>
<li>Copanlisib: 60 mg IV on days 1, 8, and 15</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Dreyling M, et al. Ann Oncol 2017;28:2169–2178.</p>
</blockquote>
</div>
<div id="bendamustine-obinutuzumab" class="section level4" number="2.21.3.14">
<h4><span class="header-section-number">2.21.3.14</span> Bendamustine + Obinutuzumab</h4>
<ul>
<li>Bendamustine: 90 mg/m2 IV on days 1 and 2</li>
<li>Obinutuzumab: 1,000 mg IV on days 1, 8, and 15</li>
<li>First cycle is administered over 28 days followed by</li>
<li>Bendamustine: 90 mg/m2 IV on days 1 and 2</li>
<li>Obinutuzumab: 1,000 mg IV on day 1</li>
<li>Repeat cycle every 28 days for a total of 5 cycles.</li>
</ul>
<blockquote>
<p>Sehn LH, et al. J Clin Oncol 2015;33:LBA8502.</p>
</blockquote>
</div>
</div>
<div id="non-hodgkins-lymphoma---intermediate-grade-lymphoma" class="section level3" number="2.21.4">
<h3><span class="header-section-number">2.21.4</span> Non-Hodgkin’s Lymphoma - Intermediate-Grade Lymphoma</h3>
<div id="chop-1" class="section level4" number="2.21.4.1">
<h4><span class="header-section-number">2.21.4.1</span> CHOP</h4>
<ul>
<li>Cyclophosphamide: 750 mg/m2 IV on day 1</li>
<li>Doxorubicin: 50 mg/m2 IV on day 1</li>
<li>Vincristine: 1.4 mg/m2 IV on day 1 (maximum, 2 mg)</li>
<li>Prednisone: 100 mg PO on days 1–5</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Klimo P, et al. J Clin Oncol 1985;3:1174–1182.</p>
</blockquote>
</div>
<div id="chop-rituximab" class="section level4" number="2.21.4.2">
<h4><span class="header-section-number">2.21.4.2</span> CHOP + Rituximab</h4>
<ul>
<li>Cyclophosphamide: 750 mg/m2 IV on day 1</li>
<li>Doxorubicin: 50 mg/m2 IV on day 1</li>
<li>Vincristine: 1.4 mg/m2 IV on day 1 (maximum, 2 mg)</li>
<li>Prednisone: 40 mg/m2 PO on days 1–5</li>
<li>Rituximab: 375 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days. Rituximab is to be administered first, followed by cyclophosphamide, doxorubicin, and vincristine.</li>
</ul>
<blockquote>
<p>Coiffier B, et al. N Engl J Med 2002;346:235–242.</p>
</blockquote>
<p>or</p>
</div>
<div id="r-chop-14" class="section level4" number="2.21.4.3">
<h4><span class="header-section-number">2.21.4.3</span> R-CHOP-14</h4>
<ul>
<li>Cyclophosphamide: 750 mg/m2 IV on day 1</li>
<li>Doxorubicin: 50 mg/m2 IV on day 1</li>
<li>Vincristine: 1.4 mg/m2 IV on day 1 (maximum, 2 mg)</li>
<li>Prednisone: 100 mg/day PO on days 1–5</li>
<li>Rituximab: 375 mg/m2 IV on day 1</li>
<li>Repeat cycle every 2 weeks up to 6 cycles. G-CSF support to start on day 4 of each cycle.</li>
</ul>
<blockquote>
<p>Pfreundschuh M, et al. Lancet Oncol 2008;9:105–116.</p>
</blockquote>
</div>
<div id="cnop-1" class="section level4" number="2.21.4.4">
<h4><span class="header-section-number">2.21.4.4</span> CNOP</h4>
<ul>
<li>Cyclophosphamide: 750 mg/m2 IV on day 1</li>
<li>Mitoxantrone: 10 mg/m2 IV on day 1</li>
<li>Vincristine: 1.4 mg/m2 IV on day 1 (maximum, 2 mg)</li>
<li>Prednisone: 100 mg PO on days 1–5</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Vose JM, et al. Leuk Lymphoma 2002;43:799–804.</p>
</blockquote>
</div>
<div id="epoch" class="section level4" number="2.21.4.5">
<h4><span class="header-section-number">2.21.4.5</span> EPOCH</h4>
<ul>
<li>Etoposide: 50 mg/m2/day IV continuous infusion on days 1–4</li>
<li>Prednisone: 60 mg/m2 PO on days 1–5</li>
<li>Vincristine: 0.4 mg/m2/day IV continuous infusion on days 1–4</li>
<li>Cyclophosphamide: 750 mg/m2 IV on day 5, begin after infusion</li>
<li>Doxorubicin: 10 mg/m2/day IV continuous infusion on days 1–4</li>
<li>Trimethoprim/sulfamethoxazole (Bactrim DS): 1 tablet PO bid, 3 times per week</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Wilson WH, et al. J Clin Oncol 1993;11:1573–1582.</p>
</blockquote>
</div>
<div id="epoch-rituximab" class="section level4" number="2.21.4.6">
<h4><span class="header-section-number">2.21.4.6</span> EPOCH + Rituximab</h4>
<ul>
<li>Etoposide: 50 mg/m2/day IV continuous infusion on days 1–4</li>
<li>Prednisone: 60 mg/m2 PO bid on days 1–5</li>
<li>Vincristine: 0.4 mg/m2/day IV continuous infusion on days 1–4</li>
<li>Cyclophosphamide: 750 mg/m2 IV on day 5, begin after infusion</li>
<li>Doxorubicin: 10 mg/m2/day IV continuous infusion on days 1–4</li>
<li>Rituximab: 375 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days. Rituximab is to be administered first followed by infusions of etoposide, doxorubicin, and vincristine. Prophylaxis with trimethoprim/sulfamethoxazole (Bactrim DS) 1 tablet PO bid, 3 times per week to reduce the risk of Pneumocystis carinii infection.</li>
</ul>
<blockquote>
<p>Wilson WH. Semin Oncol 2000;27 (Suppl 12):30–36.</p>
</blockquote>
</div>
<div id="macop-b" class="section level4" number="2.21.4.7">
<h4><span class="header-section-number">2.21.4.7</span> MACOP-B</h4>
<ul>
<li>Methotrexate: 400 mg/m2 IV on weeks 2, 6, and 10</li>
<li>Leucovorin: 15 mg/m2 PO every 6 hours for 6 doses, beginning 24 hours after methotrexate</li>
<li>Doxorubicin: 50 mg/m2 IV on weeks 1, 3, 5, 7, 9, and 11</li>
<li>Cyclophosphamide: 350 mg/m2 IV on weeks 1, 3, 5, 7, 9, and 11</li>
<li>Vincristine: 1.4 mg/m2 IV on weeks 2, 4, 6, 8, 10, and 12</li>
<li>Prednisone: 75 mg/day PO for 12 weeks with taper over the last 2 weeks</li>
<li>Bleomycin: 10 U/m2 IV on weeks 4, 8, and 12</li>
<li>Bactrim DS: 1 tablet PO bid</li>
<li>Ketoconazole: 200 mg/day PO</li>
<li>Administer one cycle.</li>
</ul>
<blockquote>
<p>Klimo P, et al. Ann Intern Med 1985;102:596–602.</p>
</blockquote>
</div>
<div id="m-bacod" class="section level4" number="2.21.4.8">
<h4><span class="header-section-number">2.21.4.8</span> m-BACOD</h4>
<ul>
<li>Methotrexate: 200 mg/m2 IV on days 8 and 15</li>
<li>Leucovorin: 10 mg/m2 PO every 6 hours for 8 doses, beginning 24 hours after methotrexate</li>
<li>Bleomycin: 4 U/m2 IV on day 1</li>
<li>Doxorubicin: 45 mg/m2 IV on day 1</li>
<li>Cyclophosphamide: 600 mg/m2 IV on day 1</li>
<li>Vincristine: 1 mg/m2 IV on day 1 (maximum, 2 mg)</li>
<li>Dexamethasone: 6 mg/m2 PO on days 1–5</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Shipp MA, et al. Ann Intern Med 1986;104:757–765.</p>
</blockquote>
</div>
<div id="promacecytabom" class="section level4" number="2.21.4.9">
<h4><span class="header-section-number">2.21.4.9</span> ProMACE/CytaBOM</h4>
<ul>
<li>Prednisone: 60 mg/m2 PO on days 1–14</li>
<li>Doxorubicin: 25 mg/m2 IV on day 1</li>
<li>Cyclophosphamide: 650 mg/m2 IV on day 1</li>
<li>Etoposide: 120 mg/m2 IV on day 1</li>
<li>Cytarabine: 300 mg/m2 IV on day 8</li>
<li>Bleomycin: 5 U/m2 IV on day 8</li>
<li>Vincristine: 1.4 mg/m2 IV on day 8</li>
<li>Methotrexate: 120 mg/m2 IV on day 8</li>
<li>Leucovorin rescue: 25 mg/m2 PO every 6 hours for 6 doses, beginning 24 hours after methotrexate</li>
<li>Trimethoprim/sulfamethoxazole: 1 tablet PO bid on days 1–21</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Longo DL, et al. J Clin Oncol 1991;9:25–38.</p>
</blockquote>
</div>
<div id="eshap-salvage-regimen" class="section level4" number="2.21.4.10">
<h4><span class="header-section-number">2.21.4.10</span> ESHAP (salvage regimen)</h4>
<ul>
<li>Etoposide: 40 mg/m2 IV on days 1–4</li>
<li>Methylprednisolone: 500 mg IV on days 1–4</li>
<li>Cisplatin: 25 mg/m2/day IV continuous infusion on days 1–4</li>
<li>Cytarabine: 2,000 mg/m2 IV on day 5 after completion of cisplatin and etoposide</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Velasquez WS, et al. J Clin Oncol 1994;12:1169–1176.</p>
</blockquote>
</div>
<div id="dhap-salvage-regimen" class="section level4" number="2.21.4.11">
<h4><span class="header-section-number">2.21.4.11</span> DHAP (salvage regimen)</h4>
<ul>
<li>Cisplatin: 100 mg/m2 IV continuous infusion over 24 hours on day 1</li>
<li>Cytarabine: 2,000 mg/m2 IV over 3 hours every 12 hours for 2 doses on day 2 after completion of cisplatin infusion</li>
<li>Dexamethasone: 40 mg PO or IV on days 1–4</li>
<li>Repeat cycle every 3–4 weeks.</li>
</ul>
<blockquote>
<p>Velasquez WS, et al. Blood 1988;71:117–122.</p>
</blockquote>
</div>
<div id="ice-salvage-regimen" class="section level4" number="2.21.4.12">
<h4><span class="header-section-number">2.21.4.12</span> ICE (salvage regimen)</h4>
<ul>
<li>Ifosfamide: 5,000 mg/m2 IV continuous infusion for 24 hours on day 2</li>
<li>Etoposide: 100 mg/m2 IV on days 1–3</li>
<li>Carboplatin: AUC of 5, IV on day 2</li>
<li>Mesna: 5,000 mg/m2 IV in combination with ifosfamide dose</li>
<li>Repeat cycle every 14 days. G-CSF support is administered at 5 µg/kg/day on days 5–12.</li>
</ul>
<blockquote>
<p>Moskowitz C, et al. J Clin Oncol 1999;17:3776–3785.</p>
</blockquote>
</div>
<div id="rice-salvage-regimen" class="section level4" number="2.21.4.13">
<h4><span class="header-section-number">2.21.4.13</span> RICE (salvage regimen)</h4>
<ul>
<li>Rituximab: 375 mg/m2 IV on day 1</li>
<li>Ifosfamide: 5,000 mg/m2 IV continuous infusion for 24 hours on day 4</li>
<li>Etoposide: 100 mg/m2 IV on days 3–5</li>
<li>Carboplatin: AUC of 5, IV on day 4</li>
<li>Mesna: 5,000 mg/m2 IV in combination with ifosfamide dose</li>
<li>Repeat cycle every 14 days. Rituximab is also given at 48 hours before the start of the first cycle. G-CSF is administered at 5 µg/kg/day SC on days 7–14 after the first 2 cycles and at 10 µg/kg/day SC after the third cycle.</li>
</ul>
<blockquote>
<p>Kewairamani T, et al. Blood 2004;103; 3684–3688.</p>
</blockquote>
</div>
<div id="mine-salvage-regimen" class="section level4" number="2.21.4.14">
<h4><span class="header-section-number">2.21.4.14</span> MINE (salvage regimen)</h4>
<ul>
<li>Mesna: 1,330 mg/m2 IV administered at same time as ifosfamide on days 1–3, then 500 mg IV 4 hours after ifosfamide on days 1–3</li>
<li>Ifosfamide: 1,330 mg/m2 IV on days 1–3</li>
<li>Mitoxantrone: 8 mg/m2 IV on day 1</li>
<li>Etoposide: 65 mg/m2 IV on days 1–3</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Rodriguez MA, et al. Ann Oncol 1995;6:609–611.</p>
</blockquote>
</div>
<div id="r-gemox" class="section level4" number="2.21.4.15">
<h4><span class="header-section-number">2.21.4.15</span> R-GemOx</h4>
<ul>
<li>Rituximab: 375 mg/m2 IV on day 1</li>
<li>Gemcitabine: 1,000 mg/m2 IV on day 2</li>
<li>Oxaliplatin: 50 mg/m2 IV on day 2</li>
<li>Repeat cycle every 2 weeks for a total of 8 cycles.</li>
</ul>
<blockquote>
<p>El Gnaoui T, et al. Ann Oncol 2007;18:1363–1368.</p>
</blockquote>
<p>or</p>
<ul>
<li>Rituximab: 375 mg/m2 IV on day 0</li>
<li>Gemcitabine: 1,000 mg/m2 IV on day 1</li>
<li>Oxaliplatin: 100 mg/m2 IV on day 1</li>
<li>Repeat cycle every 2 weeks for a total of 6 cycles.</li>
</ul>
<blockquote>
<p>Shen QD, et al. Lancet Hematol 2018. <a href="doi:10.1016/S2352-3026" class="uri">doi:10.1016/S2352-3026</a> (18)30054-1.</p>
</blockquote>
</div>
</div>
<div id="non-hodgkins-lymphoma---high-grade-lymphoma" class="section level3" number="2.21.5">
<h3><span class="header-section-number">2.21.5</span> Non-Hodgkin’s Lymphoma - High-Grade Lymphoma</h3>
<div id="magrath-protocol-burkitts-lymphoma" class="section level4" number="2.21.5.1">
<h4><span class="header-section-number">2.21.5.1</span> Magrath Protocol (Burkitt’s lymphoma)</h4>
<ul>
<li>Cyclophosphamide: 1,200 mg/m2 IV on day 1</li>
<li>Doxorubicin: 40 mg/m2 IV on day 1</li>
<li>Vincristine: 1.4 mg/m2 IV on day 1 (maximum, 2 mg)</li>
<li>Prednisone: 40 mg/m2 PO on days 1–5</li>
<li>Methotrexate: 300 mg/m2 IV on day 10 for 1 hour, then 60 mg/m2 IV on days 10 and 11 for 41 hours</li>
<li>Leucovorin rescue: 15 mg/m2 IV every 6 hours for 8 doses, starting 24 hours after methotrexate on day 12</li>
<li>Intrathecal ara-C: 30 mg/m2 IT on day 7, cycle 1 only; 45 mg/m2 IT on day 7, all subsequent cycles</li>
<li>Intrathecal methotrexate: 12.5 mg IT on day 10, all cycles</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Magrath I, et al. Blood 1984;63:1102–1111.</p>
</blockquote>
<p>or</p>
</div>
<div id="regimen-a-codox-m" class="section level4" number="2.21.5.2">
<h4><span class="header-section-number">2.21.5.2</span> Regimen A (CODOX-M)</h4>
<ul>
<li>Cyclophosphamide: 800 mg/m2 IV on day 1 and 200 mg/m2 IV on days 2–5</li>
<li>Doxorubicin: 40 mg/m2 IV on day 1</li>
<li>Vincristine: 1.5 mg/m2 IV on days 1 and 8 in cycle 1 and on days 1, 8, and 15 in cycle 3</li>
<li>Methotrexate: 1,200 mg/m2 IV over 1 hour, followed by 240 mg/m2/hour for the next 23 hours on day 10</li>
<li>Leucovorin: 192 mg/m2 IV starting at hour 36 after the start of the infusion and 12 mg/m2 IV every 6 hours thereafter until serum methotrexate levels &lt;50 nM</li>
</ul>
<blockquote>
<p>Magrath I, et al. J Clin Oncol 1996;14:925.</p>
</blockquote>
</div>
<div id="cns-prophylaxis-2" class="section level4" number="2.21.5.3">
<h4><span class="header-section-number">2.21.5.3</span> CNS Prophylaxis</h4>
<ul>
<li>Cytarabine: 70 mg IT on days 1 and 3</li>
<li>Methotrexate: 12 mg IT on day 15</li>
</ul>
</div>
<div id="regimen-b-ivac" class="section level4" number="2.21.5.4">
<h4><span class="header-section-number">2.21.5.4</span> Regimen B (IVAC)</h4>
<ul>
<li>Ifosfamide: 1,500 mg/m2 IV on days 1–5</li>
<li>Etoposide: 60 mg/m2 IV on days 1–5</li>
<li>Cytarabine: 2 g/m2 IV every 12 hours on days 1 and 2 for a total of 4 doses</li>
<li>Methotrexate: 12 mg IT on day 5</li>
</ul>
</div>
<div id="stanford-regimen-small-noncleaved-cell-and-burkitts-lymphoma" class="section level4" number="2.21.5.5">
<h4><span class="header-section-number">2.21.5.5</span> Stanford Regimen (small noncleaved cell and Burkitt’s lymphoma)</h4>
<ul>
<li>Cyclophosphamide: 1,200 mg/m2 IV on day 1</li>
<li>Doxorubicin: 40 mg/m2 IV on day 1</li>
<li>Vincristine: 1.4 mg/m2 IV on day 1 (maximum, 2 mg)</li>
<li>Prednisone: 40 mg/m2 PO on days 1–5</li>
<li>Methotrexate: 3 g/m2 IV over 6 hours on day 10</li>
<li>Leucovorin rescue: 25 mg/m2 IV or PO every 6 hours for 12 doses, beginning 24 hours after methotrexate</li>
<li>Intrathecal methotrexate: 12 mg IT on days 1 and 10</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Berstein JI, et al. J Clin Oncol 1986;4:847–858.</p>
</blockquote>
</div>
<div id="hyper-cvadmethotrexate-ara-c" class="section level4" number="2.21.5.6">
<h4><span class="header-section-number">2.21.5.6</span> Hyper-CVAD/Methotrexate-Ara-C</h4>
<ul>
<li>Cyclophosphamide: 300 mg/m2 IV every 12 hours for 6 doses on days 1–3</li>
<li>Mesna: 600 mg/m2/day continuous infusion on days 1–3 to start 1 hour before cyclophosphamide until 12 hours after completion of cyclophosphamide</li>
<li>Vincristine: 2 mg IV on days 4 and 11</li>
<li>Doxorubicin: 50 mg/m2 IV over 24 hours on day 4</li>
<li>Dexamethasone: 40 mg PO or IV on days 1–4 and days 11–14</li>
<li>Administer every 3–4 weeks on cycles 1, 3, 5, and 7.</li>
<li>Methotrexate: 200 mg/m2 IV over 2 hours followed by 800 mg/m2 continuous infusion over 22 hours on day 1</li>
<li>Cytarabine: 3,000 mg/m2 IV over 2 hours every 12 hours for 4 doses on days 2–3 (1 g/m2 for patients &gt;60 years old)</li>
<li>Leucovorin: 50 mg IV every 6 hours starting 12 hours after completion of methotrexate until methotrexate level &lt;50 nM</li>
<li>Administer every 3–4 weeks on cycles 2, 4, 6, and 8</li>
</ul>
<blockquote>
<p>Thomas DA, et al. Blood 2004;104:1624–1630.</p>
</blockquote>
</div>
<div id="intrathecal-chemotherapy-prophylaxis" class="section level4" number="2.21.5.7">
<h4><span class="header-section-number">2.21.5.7</span> Intrathecal Chemotherapy Prophylaxis</h4>
<ul>
<li>Methotrexate: 12 mg IT on day 2 of each cycle for a total of 3–4 treatments</li>
<li>Cytarabine: 100 mg IT on day 8 of each cycle for a total of 3–4 treatments</li>
<li>Intrathecal Chemotherapy: Administer intrathecal chemotherapy twice a week with methotrexate 12 mg and cytarabine 100 mg, respectively, until no more cancer cells in CSF, then decrease intrathecal chemotherapy to once a week for 4 weeks, followed by methotrexate 12 mg on day 2 and cytarabine 100 mg on day 8 for the remaining chemotherapy cycles.</li>
</ul>
</div>
<div id="axicabtagene-ciloceucel" class="section level4" number="2.21.5.8">
<h4><span class="header-section-number">2.21.5.8</span> Axicabtagene ciloceucel</h4>
<ul>
<li>Cyclophosphamide: 500 mg/m2 IV on days -5, -4, and -3</li>
<li>Fludarabine: 30 mg/m2 IV on days -5, -4, and -3</li>
<li>Axicabtagene ciloceucel: 2 x 106 CAR-positive T cells/kg body weight IV on day 1</li>
</ul>
<blockquote>
<p>Neelapu SS, et al. N Engl J Med 2017;377:2531–2544.</p>
</blockquote>
</div>
<div id="tisagenlecleucel" class="section level4" number="2.21.5.9">
<h4><span class="header-section-number">2.21.5.9</span> Tisagenlecleucel</h4>
<ul>
<li>Cyclophosphamide: 250 mg/m2 IV on days -5, -4, and -3</li>
<li>Fludarabine: 25 mg/m2 IV on day -5, -4, and -3</li>
<li>Tisagenlecleucel: 0.6–6.0 × 108 CAR-positive T cells/kg body weight IV on day 1</li>
</ul>
<blockquote>
<p>Schuster SJ, et al. N Engl J Med 2017;377:2545–2554.</p>
</blockquote>
</div>
</div>
<div id="non-hodgkins-lymphoma---single-agent-regimens" class="section level3" number="2.21.6">
<h3><span class="header-section-number">2.21.6</span> Non-Hodgkin’s Lymphoma - Single-Agent Regimens</h3>
<div id="rituximab-2" class="section level4" number="2.21.6.1">
<h4><span class="header-section-number">2.21.6.1</span> Rituximab</h4>
<ul>
<li>Rituximab: 375 mg/m2 IV on days 1, 8, 15, and 22</li>
<li>Repeat one additional cycle.</li>
</ul>
<blockquote>
<p>McLaughlin P, et al. J Clin Oncol 1998;16:2825–2833.</p>
</blockquote>
<p>or</p>
<ul>
<li>Rituximab: 375 mg/m2 IV on days 1, 8, 15, and 22 followed by 375 mg/m2 IV at week 12 and at months 5, 7, and 9.</li>
</ul>
<blockquote>
<p>Ghielmini M, et al. Blood 2004;103:4416–4423.</p>
</blockquote>
</div>
<div id="ibritumomab-tiuxetan-regimen" class="section level4" number="2.21.6.2">
<h4><span class="header-section-number">2.21.6.2</span> Ibritumomab Tiuxetan Regimen</h4>
<ul>
<li>Rituximab: 250 mg/m2 IV on days 1 and 8</li>
<li>111In-Ibritumomab tiuxetan: 5 mCi of 111In, 1.6 mg of ibritumomab tiuxetan IV on day 1</li>
<li>90Y-Ibritumomab tiuxetan: 0.4 mCi/kg IV over 10 min on day 8 after the day 8 rituximab dose</li>
<li>The dose of 90Y-ibritumomab tiuxetan is capped at 32 mCi.</li>
</ul>
<blockquote>
<p>Witzig TE, et al. J Clin Oncol 2002;20:2453–2463.</p>
</blockquote>
</div>
<div id="fludarabine-1" class="section level4" number="2.21.6.3">
<h4><span class="header-section-number">2.21.6.3</span> Fludarabine</h4>
<ul>
<li>Fludarabine: 25 mg/m2 IV on days 1–5</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Falkson CI. Am J Clin Oncol 1996;19:268–270.</p>
</blockquote>
</div>
<div id="cladribine-3" class="section level4" number="2.21.6.4">
<h4><span class="header-section-number">2.21.6.4</span> Cladribine</h4>
<ul>
<li>Cladribine: 0.5–0.7 mg/kg SC on days 1–5 or 0.1 mg/kg IV on days 1–7</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Betticher DC, et al. J Clin Oncol 1998;16:850–858.</p>
</blockquote>
</div>
<div id="bendamustine-2" class="section level4" number="2.21.6.5">
<h4><span class="header-section-number">2.21.6.5</span> Bendamustine</h4>
<ul>
<li>Bendamustine: 120 mg/m2 IV on days 1 and 2</li>
<li>Repeat cycle every 21 days up to 8 cycles.</li>
</ul>
<blockquote>
<p>Friedberg JW, et al. J Clin Oncol 2008;26:204–210.</p>
</blockquote>
</div>
<div id="vorinostat-peripheral-t-cell-lymphoma" class="section level4" number="2.21.6.6">
<h4><span class="header-section-number">2.21.6.6</span> Vorinostat (peripheral T-cell lymphoma)</h4>
<ul>
<li>Vorinostat: 400 mg PO daily</li>
<li>Continue therapy until disease progression. If toxicity is observed, dose may be reduced to 300 mg PO daily.</li>
</ul>
<blockquote>
<p>Mann BS, et al. Oncologist 2007;12:1247–1252.</p>
</blockquote>
</div>
<div id="pralatrexate" class="section level4" number="2.21.6.7">
<h4><span class="header-section-number">2.21.6.7</span> Pralatrexate</h4>
<ul>
<li>Pralatrexate: 30 mg/m2 IV weekly for 6 weeks</li>
<li>Repeat cycle every 7 weeks. Folic acid at 1–1.25 mg PO q day beginning 10 days prior to therapy and vitamin B12 at 1 mg IM beginning no more than 10 weeks prior to first dose of therapy and repeated every 8–10 weeks.</li>
</ul>
<blockquote>
<p>O’Connor OA, et al. J Clin Oncol 2009;27:4357–4364.</p>
</blockquote>
</div>
<div id="brentuximab-1" class="section level4" number="2.21.6.8">
<h4><span class="header-section-number">2.21.6.8</span> Brentuximab</h4>
<ul>
<li>Brentuximab: 1.8 mg/kg IV on day 1</li>
<li>Repeat cycle every 3 weeks for up to 16 cycles.</li>
</ul>
<blockquote>
<p>Pro B, et al. J Clin Oncol 2012;30:2190–2196.</p>
</blockquote>
</div>
<div id="romidepsin-peripheral-t-cell-lymphoma" class="section level4" number="2.21.6.9">
<h4><span class="header-section-number">2.21.6.9</span> Romidepsin (peripheral T-cell lymphoma)</h4>
<ul>
<li>Romidespsin: 14 mg/m2 IV on days 1, 8, and 15</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Piekarz RI, et al. Blood 2011;117:5827–5834.</p>
</blockquote>
</div>
<div id="belinostat-peripheral-t-cell-lymphoma" class="section level4" number="2.21.6.10">
<h4><span class="header-section-number">2.21.6.10</span> Belinostat (peripheral T-cell lymphoma)</h4>
<ul>
<li>Belinostat: 1,000 mg/m2 IV on days 1–5</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>O’Connor OA, et al. J Clin Oncol 2015;33:2492–2499.</p>
</blockquote>
</div>
<div id="bortezomib-mantle-cell-lymphoma-1" class="section level4" number="2.21.6.11">
<h4><span class="header-section-number">2.21.6.11</span> Bortezomib (mantle cell lymphoma)</h4>
<ul>
<li>Bortezomib: 1.3–1.5 mg/m2 IV on days 1, 4, 8, and 11</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Strauss SJ, et al. J Clin Oncol 2006;24:2105–2112.</p>
</blockquote>
</div>
<div id="lenalidomide-mantle-cell-lymphoma" class="section level4" number="2.21.6.12">
<h4><span class="header-section-number">2.21.6.12</span> Lenalidomide (mantle cell lymphoma)</h4>
<ul>
<li>Lenalidomide: 25 mg/day PO on days 1–21</li>
<li>Repeat cycle every 28 days for up to 52 weeks.</li>
</ul>
<blockquote>
<p>Habermann TM, et al. Br J Haematol 2009;145:344–349.</p>
</blockquote>
</div>
<div id="pembrolizumab-11" class="section level4" number="2.21.6.13">
<h4><span class="header-section-number">2.21.6.13</span> Pembrolizumab</h4>
<ul>
<li>Pembrolizumab: 200 mg IV on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Zinzani PL, et al. Blood 2017;130:267–270.</p>
</blockquote>
</div>
</div>
<div id="primary-cns-lymphoma---combination-regimens" class="section level3" number="2.21.7">
<h3><span class="header-section-number">2.21.7</span> Primary Cns Lymphoma - Combination Regimens</h3>
<ul>
<li>Methotrexate: 3,500 mg/m2 IV over 2 hours every other week for 5 doses</li>
<li>Intrathecal methotrexate: 12 mg IT weekly every other week after IV methotrexate</li>
<li>Leucovorin: 10 mg IV every 6 hours for 12 doses starting 24 hours after IV methotrexate; 10 mg IV every 12 hours for 8 doses starting 24 hours after IT methotrexate</li>
<li>Vincristine: 1.4 mg/m2 IV every other week along with IV methotrexate</li>
<li>Procarbazine: 100 mg/m2/day PO for 7 days on first, third, and fifth cycle of IV methotrexate</li>
<li>Once chemotherapy is completed, whole-brain radiation therapy is administered
to a total dose of 45 cGy.</li>
</ul>
<blockquote>
<p>Abrey LE, et al. J Clin Oncol 2002;18:3144–3150.</p>
</blockquote>
<div id="r-mpv-radiation-therapy-cytarabine" class="section level4" number="2.21.7.1">
<h4><span class="header-section-number">2.21.7.1</span> R-MPV + Radiation Therapy + Cytarabine</h4>
<ul>
<li>Rituximab: 500 mg/m2 IV on day 1</li>
<li>Methotrexate: 3,500 mg/m2 IV on day 2</li>
<li>Leucovorin: 20–25 mg every 6 hours starting 24 hours after methotrexate infusion for 72 hours or until serum methotrexate level, 1 × 10-8 mg/dL.</li>
<li>Increase leucovorin to 40 mg every 4 hours IV, if methotrexate level &gt; 1 × 10–8 mg/dL at 48 hours or &gt;1 × 10–8 mg/dL at 72 hours</li>
<li>Vincristine: 1.4 mg/m2 (maximum, 2.8 mg) IV on day 2</li>
<li>Procarbazine: 100 mg/m2 PO on days 1–7 of odd-numbered cycles only</li>
<li>If positive CSF cytology, administer 12 mg methotrexate IT between days 5 and 12 of each cycle</li>
<li>Repeat cycle every 2 weeks for 5 cycles.</li>
<li>After 5 cycles of R-MPV:</li>
<li>If CR, whole-brain radiotherapy (WBRT) 180 cGy/day for 13 days to a total of 2340 cGy beginning 3–5 weeks after the completion of R-MPV.</li>
<li>If PR, administer 2 additional cycles of R-MPV. If CR is achieved after 7 cycles of R-MPV, administer WBRT 180 cGy/day × 13 days to a total of 2,340 cGy beginning 3–5 weeks after completion of R-MPV.</li>
<li>If persistent disease exists after 7 cycles of R-MPV, administer WBRT 180 cGy/day × 25 days to a total of 4,500 cGy beginning 3–5 weeks after the completion of R-MPV.</li>
<li>If stable or progressive disease after 5 cycles of R-MPV, administer WBRT 180 cGy/day for 25 days to a total of 4,500 cGy beginning 3–5 weeks after the completion of R-MPV. Three weeks after the completion of WBRT, consolidation therapy is given with cytarabine 3 g/m2/day (maximum, 6 g) IV over 3 hours for 2 days. A second cycle of cytarabine is given 1 month later.</li>
</ul>
<blockquote>
<p>Shah GD, et al. J Clin Oncol 2007;25:4730–4735.</p>
</blockquote>
</div>
</div>
<div id="primary-cns-lymphoma---single-agent-regimens" class="section level3" number="2.21.8">
<h3><span class="header-section-number">2.21.8</span> Primary Cns Lymphoma - Single-Agent Regimens</h3>
<div id="high-dose-methotrexate" class="section level4" number="2.21.8.1">
<h4><span class="header-section-number">2.21.8.1</span> High-Dose Methotrexate</h4>
<ul>
<li>Methotrexate: 8,000 mg/m2 IV on day 1</li>
<li>Repeat cycle every 2 weeks up to 8 cycles, followed by 8,000 mg/m2 IV on day 1 every month up to 100 months.</li>
</ul>
<blockquote>
<p>Batchelor T, et al. J Clin Oncol 2003;21:1044–1049.</p>
</blockquote>
</div>
<div id="temozolomide-1" class="section level4" number="2.21.8.2">
<h4><span class="header-section-number">2.21.8.2</span> Temozolomide</h4>
<ul>
<li>Temozolomide: 150 mg/m2/day PO on days 1–5</li>
<li>Repeat cycle every 4 weeks.</li>
</ul>
<blockquote>
<p>Reni M, et al. Br J Cancer 2007;96:864–867.</p>
</blockquote>
</div>
<div id="topotecan-3" class="section level4" number="2.21.8.3">
<h4><span class="header-section-number">2.21.8.3</span> Topotecan</h4>
<ul>
<li>Topotecan: 1.5 mg/m2 IV on days 1–5</li>
<li>Repeat cycle every 3 weeks.</li>
</ul>
<blockquote>
<p>Fischer L, et al. Ann Oncol 2006;17:1141–1145.</p>
</blockquote>
</div>
</div>
</div>
<div id="malignant-melanoma" class="section level2" number="2.22">
<h2><span class="header-section-number">2.22</span> MALIGNANT MELANOMA</h2>
<div id="adjuvant-therapy---combination-regimens-2" class="section level3" number="2.22.1">
<h3><span class="header-section-number">2.22.1</span> Adjuvant Therapy - Combination Regimens</h3>
<div id="dabrafenib-trametinib-1" class="section level4" number="2.22.1.1">
<h4><span class="header-section-number">2.22.1.1</span> Dabrafenib + Trametinib</h4>
<ul>
<li>Dabrafenib: 150 mg PO bid</li>
<li>Trametinib: 2 mg PO daily</li>
<li>Continue treatment for up to 12 months.</li>
</ul>
<blockquote>
<p>Hauschild LA, et al. N Engl J Med 2017;377:1813–1823.</p>
</blockquote>
</div>
</div>
<div id="adjuvant-therapy---single-agent-regimens-2" class="section level3" number="2.22.2">
<h3><span class="header-section-number">2.22.2</span> Adjuvant Therapy - Single-Agent Regimens</h3>
<div id="interferon-alpha-2b" class="section level4" number="2.22.2.1">
<h4><span class="header-section-number">2.22.2.1</span> Interferon alpha-2b</h4>
<ul>
<li>Interferon alpha-2b: 20 million U/m2 IV, 5 times weekly for 4 weeks, then 10 million IU/m2 SC, 3 times weekly for 48 weeks</li>
<li>Treatment is for a total of 1 year.</li>
</ul>
<blockquote>
<p>Kirkwood JM, et al. J Clin Oncol 1996;14:7–17.</p>
</blockquote>
</div>
<div id="peg-interferon-alpha-2b" class="section level4" number="2.22.2.2">
<h4><span class="header-section-number">2.22.2.2</span> Peg-Interferon alpha-2b</h4>
<ul>
<li>Peg-Interferon a-2b: 6 µg/kg SC weekly for 8 weeks, then 3 µg/kg SC weekly for up to 5 years</li>
<li>Treatment is for up to a total of 5 years.</li>
</ul>
<blockquote>
<p>Eggermont AM, et al. Lancet 2008;372:117–126.</p>
</blockquote>
</div>
<div id="nivolumab-6" class="section level4" number="2.22.2.3">
<h4><span class="header-section-number">2.22.2.3</span> Nivolumab</h4>
<ul>
<li>Nivolumab: 240 mg IV on day 1</li>
<li>Repeat cycle every 2 weeks.
or</li>
<li>Nivolumab: 480 mg IV on day 1</li>
<li>Repeat cycle every 4 weeks.</li>
</ul>
<blockquote>
<p>Weber J, et al. N Engl J Med 2017;377:1824–1835.</p>
</blockquote>
</div>
<div id="ipilimumab-1" class="section level4" number="2.22.2.4">
<h4><span class="header-section-number">2.22.2.4</span> Ipilimumab</h4>
<ul>
<li>Ipilimumab: 10 mg/kg IV on day 1</li>
<li>Repeat cycle every 3 weeks for 4 doses followed by 10 mg/kg on day 1 every 12 weeks for up to 3 years.</li>
</ul>
<blockquote>
<p>Eggermont AM, et al. Lancet Oncol 2015;16:522–530.</p>
</blockquote>
</div>
</div>
<div id="metastatic-disease---combination-regimens-4" class="section level3" number="2.22.3">
<h3><span class="header-section-number">2.22.3</span> Metastatic Disease - Combination Regimens</h3>
<div id="dtic-carmustine-cisplatin" class="section level4" number="2.22.3.1">
<h4><span class="header-section-number">2.22.3.1</span> DTIC + Carmustine + Cisplatin</h4>
<ul>
<li>Dacarbazine: 220 mg/m2 IV on days 1–3</li>
<li>Carmustine: 150 mg/m2 IV on day 1</li>
<li>Cisplatin: 25 mg/m2 IV on days 1–3</li>
<li>Repeat cycle with dacarbazine and cisplatin every 21 days and carmustine every 42 days.</li>
</ul>
<blockquote>
<p>Creagen ET, et al. J Clin Oncol 1999;17:1884–1890.</p>
</blockquote>
</div>
<div id="ifn-dtic" class="section level4" number="2.22.3.2">
<h4><span class="header-section-number">2.22.3.2</span> IFN + DTIC</h4>
<ul>
<li>Interferon alpha-2b: 15 million IU/m2 IV on days 1–5, 8–12, and 15–19 as induction therapy</li>
<li>Interferon alpha-2b: 10 million IU/m2 SC 3 times weekly after induction therapy</li>
<li>Dacarbazine: 200 mg/m2 IV on days 22–26</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Falkson CI, et al. J Clin Oncol 1998;16:1743–1751.</p>
</blockquote>
</div>
<div id="temozolomide-thalidomide" class="section level4" number="2.22.3.3">
<h4><span class="header-section-number">2.22.3.3</span> Temozolomide + Thalidomide</h4>
<ul>
<li>Temozolomide: 75 mg/m2/day PO for 6 weeks</li>
<li>Thalidomide: 200 mg/day PO for 6 weeks</li>
<li>Repeat cycle every 8 weeks. Consider dose escalation to 400 mg/day for patients &lt;70 years and starting at a lower dose of 100 mg/day with dose escalation to 250 mg/day for patient &gt;70 years.</li>
</ul>
<blockquote>
<p>Hwu WJ, et al. J Clin Oncol 2003;21:3351–3356.</p>
</blockquote>
</div>
<div id="dabrafenib-trametinib-2" class="section level4" number="2.22.3.4">
<h4><span class="header-section-number">2.22.3.4</span> Dabrafenib + Trametinib</h4>
<ul>
<li>Dabrafenib: 150 mg PO bid</li>
<li>Trametinib: 2 mg PO daily</li>
<li>Continue treatment until disease progression.</li>
</ul>
<blockquote>
<p>Flaherty KT, et al. N Engl J Med 2012;367:1694–1703</p>
</blockquote>
</div>
<div id="cobimetinib-vemurafenib" class="section level4" number="2.22.3.5">
<h4><span class="header-section-number">2.22.3.5</span> Cobimetinib + Vemurafenib</h4>
<ul>
<li>Cobimetinib: 60 mg/day PO on days 1–21</li>
<li>Vemurafenib: 960 mg PO bid daily</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Larkin J, et al. N Engl J Med 2014;371:1867–1876.</p>
</blockquote>
</div>
<div id="binimetinib-encorafenib" class="section level4" number="2.22.3.6">
<h4><span class="header-section-number">2.22.3.6</span> Binimetinib + Encorafenib</h4>
<ul>
<li>Binimetinib: 45 mg PO bid</li>
<li>Encorafenib: 300 mg PO daily</li>
<li>Continue treatment until disease progression.</li>
</ul>
<blockquote>
<p>Dummer R, et al. Lancet Oncol 2018;19:603–615.</p>
</blockquote>
</div>
<div id="nivolumab-ipilimumab-1" class="section level4" number="2.22.3.7">
<h4><span class="header-section-number">2.22.3.7</span> Nivolumab + Ipilimumab</h4>
<ul>
<li>Ipilimumab: 1 mg/kg IV on day 1</li>
<li>Nivolumab: 1 mg/kg IV on day 1</li>
<li>Repeat cycle every 21 days for 4 cycles followed by</li>
<li>Nivolumab: 240 mg IV on day 1</li>
<li>Repeat cycle every 14 days until disease progression.</li>
</ul>
<blockquote>
<p>Larkin J, et al. N Engl J Med 2015;373:23–34.</p>
</blockquote>
</div>
</div>
<div id="metastatic-disease---single-agent-regimens-6" class="section level3" number="2.22.4">
<h3><span class="header-section-number">2.22.4</span> Metastatic Disease - Single-Agent Regimens</h3>
<div id="dacarbazine" class="section level4" number="2.22.4.1">
<h4><span class="header-section-number">2.22.4.1</span> Dacarbazine</h4>
<ul>
<li>Dacarbazine: 250 mg/m2 IV on days 1–5</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Luce JK, et al. Cancer Chemother Rep 1970;54:119–124.</p>
</blockquote>
<p>or</p>
<ul>
<li>Dacarbazine: 850 mg/m2 IV on day 1</li>
<li>Repeat cycle every 3–6 weeks.</li>
</ul>
<blockquote>
<p>Pritchard KI, et al. Cancer Treat Rep 1980;64:1123–1126.</p>
</blockquote>
</div>
<div id="interferon-alpha-1" class="section level4" number="2.22.4.2">
<h4><span class="header-section-number">2.22.4.2</span> Interferon-alpha</h4>
<ul>
<li>Interferon alpha-2b: 20 million IU/m2 IM, 3 times weekly for 12 weeks.</li>
</ul>
<blockquote>
<p>Kirkwood JM, et al. Semin Oncol 1997;24 (Suppl 4):1–48.</p>
</blockquote>
</div>
<div id="aldesleukin" class="section level4" number="2.22.4.3">
<h4><span class="header-section-number">2.22.4.3</span> Aldesleukin</h4>
<ul>
<li>Aldesleukin (IL-2): 720,000 IU/kg IV every 8 hours on days 1–5 and 15–19</li>
<li>Repeat cycle in 6- to 12-week intervals.</li>
</ul>
<blockquote>
<p>Atkins MB, et al. J Clin Oncol 1999;17:2105–2116.</p>
</blockquote>
<p>or</p>
<ul>
<li>Aldesleukin (IL-2): 100,000 IU/kg IV every 4 hours on days 1–5 and 15–19</li>
<li>Repeat cycle in 12-week intervals up to a total of 3 cycles.</li>
</ul>
<blockquote>
<p>Parkinson DR, et al. J Clin Oncol 1990;8:1650–1656.</p>
</blockquote>
<p>or</p>
<ul>
<li>Aldesleukin (IL-2): 720,000 IU/kg IV at 8 am and 6 pm on days 1–5 and 15–19</li>
<li>Treat up to a maximum of 8 total doses on days 1–5 and repeat on days 15–19.</li>
<li>Repeat cycle in 8- to 12-week intervals.</li>
</ul>
<blockquote>
<p>Acquavella N, et al. J Immunother 2008;31:569–576.</p>
</blockquote>
</div>
<div id="ipilimumab-2" class="section level4" number="2.22.4.4">
<h4><span class="header-section-number">2.22.4.4</span> Ipilimumab</h4>
<ul>
<li>Ipilimumab: 3 mg/kg IV on day 1</li>
<li>Repeat cycle every 3 weeks for a total of 4 doses.</li>
</ul>
<blockquote>
<p>Wolchok JD, et al. Lancet Oncology 2010;11:155–164.</p>
</blockquote>
</div>
<div id="pembrolizumab-12" class="section level4" number="2.22.4.5">
<h4><span class="header-section-number">2.22.4.5</span> Pembrolizumab</h4>
<ul>
<li>Pembrolizumab: 200 mg IV on day 1</li>
<li>Repeat cycle every 3 weeks.</li>
</ul>
<blockquote>
<p>Robert C, et al. N Engl J Med 2015;372:2521–2532.</p>
</blockquote>
</div>
<div id="nivolumab-7" class="section level4" number="2.22.4.6">
<h4><span class="header-section-number">2.22.4.6</span> Nivolumab</h4>
<ul>
<li>Nivolumab: 240 mg IV on day 1</li>
<li>Repeat cycle every 2 weeks.</li>
</ul>
<blockquote>
<p>Weber JS, et al. Lancet Oncol 2015;16:375–384.</p>
</blockquote>
</div>
<div id="temozolomide-2" class="section level4" number="2.22.4.7">
<h4><span class="header-section-number">2.22.4.7</span> Temozolomide</h4>
<ul>
<li>Temozolomide: 150 mg/m2 PO on days 1–5</li>
<li>Repeat cycle every 28 days. If tolerated, can increase dose to 200 mg/m2 PO on days 1–5.</li>
</ul>
<blockquote>
<p>Middleton MR, et al. J Clin Oncol 2000;18:158–166.</p>
</blockquote>
</div>
<div id="vemurafenib-1" class="section level4" number="2.22.4.8">
<h4><span class="header-section-number">2.22.4.8</span> Vemurafenib</h4>
<ul>
<li>Vemurafenib: 960 mg PO bid</li>
<li>Continue treatment until disease progression.</li>
</ul>
<blockquote>
<p>Sosman JA, et al. N Engl J Med 2012;366:707–714.</p>
</blockquote>
</div>
<div id="dabrafenib-1" class="section level4" number="2.22.4.9">
<h4><span class="header-section-number">2.22.4.9</span> Dabrafenib</h4>
<ul>
<li>Dabrafenib: 150 mg PO bid</li>
<li>Continue treatment until disease progression.</li>
</ul>
<blockquote>
<p>Falchook GS, et al. Lancet 2012;379:1893–1901.</p>
</blockquote>
</div>
<div id="trametinib-1" class="section level4" number="2.22.4.10">
<h4><span class="header-section-number">2.22.4.10</span> Trametinib</h4>
<ul>
<li>Trametinib: 2 mg PO daily</li>
<li>Continue treatment until disease progression.</li>
</ul>
<blockquote>
<p>Kim KB, et al. J Clin Oncol 2013;31:482–489.</p>
</blockquote>
</div>
</div>
</div>
<div id="malignant-mesothelioma" class="section level2" number="2.23">
<h2><span class="header-section-number">2.23</span> MALIGNANT MESOTHELIOMA</h2>
<div id="combination-regimens-10" class="section level3" number="2.23.1">
<h3><span class="header-section-number">2.23.1</span> Combination Regimens</h3>
<div id="doxorubicin-cisplatin" class="section level4" number="2.23.1.1">
<h4><span class="header-section-number">2.23.1.1</span> Doxorubicin + Cisplatin</h4>
<ul>
<li>Doxorubicin: 60 mg/m2 IV on day 1</li>
<li>Cisplatin: 60 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21–28 days.</li>
</ul>
<blockquote>
<p>Ardizzoni A, et al. Cancer 1991;67:2984–2987.</p>
</blockquote>
</div>
<div id="cap-2" class="section level4" number="2.23.1.2">
<h4><span class="header-section-number">2.23.1.2</span> CAP</h4>
<ul>
<li>Cyclophosphamide: 500 mg/m2 IV on day 1</li>
<li>Doxorubicin: 50 mg/m2 IV on day 1</li>
<li>Cisplatin: 80 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Shin DM, et al. Cancer 1995;76:2230–2236.</p>
</blockquote>
</div>
<div id="gemcitabine-cisplatin-3" class="section level4" number="2.23.1.3">
<h4><span class="header-section-number">2.23.1.3</span> Gemcitabine + Cisplatin</h4>
<ul>
<li>Gemcitabine: 1,000 mg/m2 IV on days 1, 8, and 15</li>
<li>Cisplatin: 100 mg/m2 IV on day 1</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Nowak AK, et al. Br J Cancer 2002;87:491–496.</p>
</blockquote>
</div>
<div id="gemcitabine-carboplatin-2" class="section level4" number="2.23.1.4">
<h4><span class="header-section-number">2.23.1.4</span> Gemcitabine + Carboplatin</h4>
<ul>
<li>Gemcitabine: 1,000 mg/m2 IV on days 1, 8, and 15</li>
<li>Carboplatin: AUC of 5, IV on day 1</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Favaretto AG, et al. Cancer 2003;97:2791–2797.</p>
</blockquote>
</div>
<div id="pemetrexed-cisplatin-2" class="section level4" number="2.23.1.5">
<h4><span class="header-section-number">2.23.1.5</span> Pemetrexed + Cisplatin</h4>
<ul>
<li>Pemetrexed: 500 mg/m2 IV on day 1</li>
<li>Cisplatin: 75 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days. Folic acid at 350–1,000 µg PO q day beginning 1 week prior to therapy and vitamin B12 at 1,000 µg IM to start 1–2 weeks prior to first dose of therapy and repeated every 3 cycles.</li>
</ul>
<blockquote>
<p>Vogelzang NJ, et al. J Clin Oncol 2003;21:2636–2644.</p>
</blockquote>
</div>
<div id="gemcitabine-vinorelbine-1" class="section level4" number="2.23.1.6">
<h4><span class="header-section-number">2.23.1.6</span> Gemcitabine + Vinorelbine</h4>
<ul>
<li>Gemcitabine: 1,000 mg/m2 IV on days 1 and 8</li>
<li>Vinorelbine: 25 mg/m2 IV on days 1 and 8</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Zucali PA, et al. Cancer 2008;112:1555–1561.</p>
</blockquote>
</div>
<div id="pemetrexed-gemcitabine" class="section level4" number="2.23.1.7">
<h4><span class="header-section-number">2.23.1.7</span> Pemetrexed + Gemcitabine</h4>
<ul>
<li>Pemetrexed: 500 mg/m2 IV on day 8</li>
<li>Gemcitabine: 1,250 mg/m2 IV on days 1 and 8</li>
<li>Repeat cycle every 21 days. Folic acid at 350–1,000 µg PO q day beginning 1–2 weeks prior to therapy and vitamin B12 at 1,000 µg IM to start 1–2 weeks prior to first dose of therapy and repeated every 3 cycles.</li>
</ul>
<blockquote>
<p>Simon GR, et al. J Clin Oncol 2008;21:3567–3572.</p>
</blockquote>
</div>
</div>
<div id="single-agent-regimens-9" class="section level3" number="2.23.2">
<h3><span class="header-section-number">2.23.2</span> Single-Agent Regimens</h3>
<div id="pemetrexed-3" class="section level4" number="2.23.2.1">
<h4><span class="header-section-number">2.23.2.1</span> Pemetrexed</h4>
<ul>
<li>Pemetrexed: 500 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days. Folic acid at 350–1,000 µg PO q day beginning 1 week prior to therapy and vitamin B12 at 1,000 µg IM to start 1–2 weeks prior to first dose of therapy and repeated every 3 cycles.</li>
<li>Dexamethasone 4 mg PO bid on the day before, day of, and day after each dose of pemetrexed.</li>
</ul>
<blockquote>
<p>Jassem J, et al. J Clin Oncol 2008;26:1698–1704.</p>
</blockquote>
</div>
<div id="vinorelbine-4" class="section level4" number="2.23.2.2">
<h4><span class="header-section-number">2.23.2.2</span> Vinorelbine</h4>
<ul>
<li>Vinorelbine: 30 mg/m2 IV weekly</li>
<li>One cycle consists of 6 weekly injections. Continue until disease progression.</li>
</ul>
<blockquote>
<p>Steele JPC, et al. J Clin Oncol 2000;18:3912–3917.</p>
</blockquote>
</div>
<div id="gemcitabine-7" class="section level4" number="2.23.2.3">
<h4><span class="header-section-number">2.23.2.3</span> Gemcitabine</h4>
<ul>
<li>Gemcitabine: 1,250 mg/m2 IV on days 1, 8, and 15</li>
<li>Repeat cycle every 28 days up to a total of 10 cycles.</li>
</ul>
<blockquote>
<p>van Meerbeeck JP, et al. Cancer 1999;85:2577–2582.</p>
</blockquote>
</div>
<div id="pembrolizumab-13" class="section level4" number="2.23.2.4">
<h4><span class="header-section-number">2.23.2.4</span> Pembrolizumab</h4>
<ul>
<li>Pembrolizumab: 10 mg/kg IV on day 1</li>
<li>Repeat cycle every 14 days.</li>
</ul>
<blockquote>
<p>Alley EW, et al. Lancet Oncol 2017;18:623–630.</p>
</blockquote>
</div>
<div id="nivolumab-8" class="section level4" number="2.23.2.5">
<h4><span class="header-section-number">2.23.2.5</span> Nivolumab</h4>
<ul>
<li>Nivolumab: 3 mg/kg IV on day 1</li>
<li>Repeat cycle every 14 days.</li>
</ul>
<blockquote>
<p>Quispel-Janssen J, et al. J Thorac Oncol 2018. doi: 10.1016/j.jtho.2018.038.</p>
</blockquote>
</div>
</div>
</div>
<div id="merkel-cell-cancer" class="section level2" number="2.24">
<h2><span class="header-section-number">2.24</span> MERKEL CELL CANCER</h2>
<div id="combination-regimens-11" class="section level3" number="2.24.1">
<h3><span class="header-section-number">2.24.1</span> Combination Regimens</h3>
<div id="ep-3" class="section level4" number="2.24.1.1">
<h4><span class="header-section-number">2.24.1.1</span> EP</h4>
<ul>
<li>Etoposide: 80 mg/m2 IV on days 1–3</li>
<li>Cisplatin: 80 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Ihde DC, et al. J Clin Oncol 1994;12:2022–2034.</p>
</blockquote>
</div>
<div id="ec-1" class="section level4" number="2.24.1.2">
<h4><span class="header-section-number">2.24.1.2</span> EC</h4>
<ul>
<li>Etoposide: 100 mg/m2 IV on days 1–3</li>
<li>Carboplatin: AUC of 6, IV on day 1</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Viren M, et al. Acta Oncol 1994;33:921–924</p>
</blockquote>
</div>
<div id="cav-1" class="section level4" number="2.24.1.3">
<h4><span class="header-section-number">2.24.1.3</span> CAV</h4>
<ul>
<li>Cyclophosphamide: 1,000 mg/m2 IV on day 1</li>
<li>Doxorubicin: 40 mg/m2 IV on day 1</li>
<li>Vincristine: 1 mg/m2 IV on day 1 (maximum, 2 mg)</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Roth BJ, et al. J Clin Oncol 1992;10:282–291.</p>
</blockquote>
</div>
</div>
<div id="single-agent-regimens-10" class="section level3" number="2.24.2">
<h3><span class="header-section-number">2.24.2</span> Single-Agent Regimens</h3>
<div id="avelumab-1" class="section level4" number="2.24.2.1">
<h4><span class="header-section-number">2.24.2.1</span> Avelumab</h4>
<ul>
<li>Avelumab: 10 mg/kg IV on day 1</li>
<li>Repeat cycle every 2 weeks.</li>
</ul>
<blockquote>
<p>Kaufman HL, et al. Lancet Oncol 2016;10:1374–1385.</p>
</blockquote>
</div>
</div>
</div>
<div id="multiple-myeloma" class="section level2" number="2.25">
<h2><span class="header-section-number">2.25</span> MULTIPLE MYELOMA</h2>
<div id="combination-regimens-12" class="section level3" number="2.25.1">
<h3><span class="header-section-number">2.25.1</span> Combination Regimens</h3>
<div id="mp" class="section level4" number="2.25.1.1">
<h4><span class="header-section-number">2.25.1.1</span> MP</h4>
<ul>
<li>Melphalan: 8–10 mg/m2 PO on days 1–4</li>
<li>Prednisone: 60 mg/m2 on days 1–4</li>
<li>Repeat cycle every 42 days.</li>
</ul>
<blockquote>
<p>Southwest Oncology Group Study. Arch Intern Med 1975;135:147–152.</p>
</blockquote>
</div>
<div id="mpt" class="section level4" number="2.25.1.2">
<h4><span class="header-section-number">2.25.1.2</span> MPT</h4>
<ul>
<li>Melphalan: 0.25 mg/kg PO on days 1–4</li>
<li>Prednisone: 1.5 mg/kg PO on days 1–4</li>
<li>Thalidomide: 50–100 mg/day PO q day</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Palumbo A, et al. Lancet 2006;367:835.</p>
</blockquote>
<p>or</p>
<ul>
<li>Melphalan: 0.25 mg/kg/day PO on days 1–4</li>
<li>Prednisone: 2 mg/kg/day PO on days 1–4</li>
<li>Thalidomide: 100–400 mg PO q day</li>
<li>Repeat cycle every 42 days.</li>
</ul>
<blockquote>
<p>Facon T, et al. Proc Am Soc Clin Oncol 2006;24 (abstract 1)</p>
</blockquote>
</div>
<div id="mpl" class="section level4" number="2.25.1.3">
<h4><span class="header-section-number">2.25.1.3</span> MPL</h4>
<ul>
<li>Melphalan: 0.18 mg/kg PO on days 1–4</li>
<li>Prednisone: 2 mg/kg PO on days 1–4</li>
<li>Lenalidomide: 10 mg/day PO on days 1–21</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Palumbo A, et al. J Clin Oncol 2007;25:4459–4465.</p>
</blockquote>
</div>
<div id="vad" class="section level4" number="2.25.1.4">
<h4><span class="header-section-number">2.25.1.4</span> VAD</h4>
<ul>
<li>Vincristine: 0.4 mg/day IV continuous infusion on days 1–4</li>
<li>Doxorubicin: 9 mg/m2/day IV continuous infusion on days 1–4</li>
<li>Dexamethasone: 40 mg PO on days 1–4, 9–12, and 17–20</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<blockquote>
<p>Barlogie B, et al. N Engl J Med 1984;310:1353–1356.</p>
</blockquote>
</blockquote>
</div>
<div id="thalidomide-dexamethasone" class="section level4" number="2.25.1.5">
<h4><span class="header-section-number">2.25.1.5</span> Thalidomide + Dexamethasone</h4>
<ul>
<li>Thalidomide: 200 mg/day PO</li>
<li>Dexamethasone: 40 mg/day PO on days 1–4, 9–12, and 17–20 for first 4 cycles and then 40 mg/day PO on days 1–4</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Rajkumar SV, et al. J Clin Oncol 2002;20:4319–4323.</p>
</blockquote>
</div>
<div id="lenalidomide-dexamethasone" class="section level4" number="2.25.1.6">
<h4><span class="header-section-number">2.25.1.6</span> Lenalidomide + Dexamethasone</h4>
<ul>
<li>Lenalidomide: 25 mg/day PO on days 1–21</li>
<li>Dexamethasone: 40 mg/day PO on days 1–4, 9–12, and 17–20 (first 4 cycles) and then 40 mg/day PO on days 1–4 with future cycles</li>
<li>Repeat cycles every 28 days.</li>
</ul>
<blockquote>
<p>Richardson PG, et al. Blood 2006;108:3458–3464.</p>
</blockquote>
<p>or</p>
<ul>
<li>Lenalidomide: 25 mg/day PO on days 1–21</li>
<li>Dexamethasone: 40 mg/m2/day PO on days 1, 8, 15, and 22</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Rajkumar SV, et al. Proc Am Soc Clin Oncol 2007;25 (LBA8025).</p>
</blockquote>
</div>
<div id="rvd" class="section level4" number="2.25.1.7">
<h4><span class="header-section-number">2.25.1.7</span> RVD</h4>
<ul>
<li>Lenalidomide: 25 mg/day PO on days 1–14</li>
<li>Bortezomib: 1.3 mg/m2 IV or SC on days 1, 4, 8, and 11</li>
<li>Dexamethasone: 20 mg/day PO on days 1, 2, 4, 5, 8, 9, 11, and 12</li>
<li>Repeat cycle every 21 days for 8 cycles.</li>
</ul>
<blockquote>
<p>Richardson PG, et al. Blood 2010;116:679–686.</p>
</blockquote>
</div>
<div id="panobinostat-bortezomib-dexamethasone" class="section level4" number="2.25.1.8">
<h4><span class="header-section-number">2.25.1.8</span> Panobinostat + Bortezomib + Dexamethasone</h4>
<ul>
<li>Panobinostat: 20 mg/day PO on days 1, 3, 5, 8, 10, and 12</li>
<li>Bortezomib: 1.3 mg/m2 IV on days 1, 4, 8, and 11</li>
<li>Dexamethasone: 20 mg/day PO on days 1, 2, 4, 5, 8, 9, 11, and 12</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>San-Miguel JF, et al. Lancet Oncol 2014;15:1195–1206.</p>
</blockquote>
</div>
<div id="pd" class="section level4" number="2.25.1.9">
<h4><span class="header-section-number">2.25.1.9</span> PD</h4>
<ul>
<li>Pomalidomide: 4 mg/day PO on days 1–21</li>
<li>Dexamethasone: 40 mg/day PO on day 1</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Leleu X, et al. Blood 2013;121:1968–1975.</p>
</blockquote>
<p>or</p>
<ul>
<li>Pomalidomide: 2 mg/day PO on days 1–21</li>
<li>Dexamethasone: 40 mg/day PO on days 1, 8, 15, and 22</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Lacy MQ, et al. Blood 2009;27:5008–5014.</p>
</blockquote>
</div>
<div id="dvd" class="section level4" number="2.25.1.10">
<h4><span class="header-section-number">2.25.1.10</span> DVD</h4>
<ul>
<li>Doxorubicin liposome: 40 mg/m2 IV on day 1</li>
<li>Vincristine: 2 mg IV on day 1</li>
<li>Dexamethasone: 40 mg PO on days 1–4</li>
<li>Repeat cycles every 28 days.</li>
</ul>
<blockquote>
<p>Hussein MA, et al. Cancer 2002;95:2160–2168.</p>
</blockquote>
</div>
<div id="bortezomib-doxorubicin-liposome" class="section level4" number="2.25.1.11">
<h4><span class="header-section-number">2.25.1.11</span> Bortezomib + Doxorubicin liposome</h4>
<ul>
<li>Bortezomib: 1.3 mg/m2 IV or SC on days 1, 4, 8, and 11</li>
<li>Doxorubicin liposome: 30 mg/m2 IV infusion on day 4</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Orlowski RZ, et al. Proc Am Soc Hematol 2006 (abstract 404).</p>
</blockquote>
</div>
<div id="bortezomib-melphalan" class="section level4" number="2.25.1.12">
<h4><span class="header-section-number">2.25.1.12</span> Bortezomib + Melphalan</h4>
<ul>
<li>Bortezomib: 1.0 mg/m2 IV or SC on days 1, 4, 8, and 11</li>
<li>Melphalan: 0.10 mg/kg PO on days 1–4</li>
<li>Repeat cycle every 28 days up to 8 cycles.</li>
</ul>
<blockquote>
<p>Berenson JR, et al. J Clin Oncol 2006;24:937–944.</p>
</blockquote>
</div>
<div id="bmp" class="section level4" number="2.25.1.13">
<h4><span class="header-section-number">2.25.1.13</span> BMP</h4>
<ul>
<li>Bortezomib: 1.3 mg/m2 IV or SC on days 1, 4, 8, 11, 22, 25, 29, and 32</li>
<li>Melphalan: 9 mg/m2 PO on days 1–4</li>
<li>Prednisone: 60 mg/m2 PO on days 1–4</li>
<li>Repeat cycle every 6 weeks for 4 cycles, then</li>
<li>Bortezomib: 1.3 mg/m2 IV on days 1, 8, 22, and 29</li>
<li>Melphalan: 9 mg/m2 PO on days 1–4</li>
<li>Prednisone: 60 mg/m2 PO on days 1–4</li>
<li>Repeat cycle every 6 weeks for 5 cycles.</li>
</ul>
<blockquote>
<p>San Miguel JF, et al. N Engl J Med 2008;359:906–917.</p>
</blockquote>
</div>
<div id="bmpt" class="section level4" number="2.25.1.14">
<h4><span class="header-section-number">2.25.1.14</span> BMPT</h4>
<ul>
<li>Bortezomib: 1–1.3 mg/m2 IV or SC on days 1, 4, 15, and 22</li>
<li>Melphalan: 6 mg/m2 PO on days 1–5</li>
<li>Prednisone: 60 mg/m2 PO on days 1–5</li>
<li>Thalidomide: 50 mg PO daily</li>
<li>Repeat cycle every 5 weeks for 6 cycles.</li>
</ul>
<blockquote>
<p>Palumbo A, et al. Blood 2007;109:2757–2762.</p>
</blockquote>
</div>
<div id="rmpt" class="section level4" number="2.25.1.15">
<h4><span class="header-section-number">2.25.1.15</span> RMPT</h4>
<ul>
<li>Lenalidomide: 10 mg PO on days 1–21</li>
<li>Melphalan: 0.18 mg/kg PO on days 1–4</li>
<li>Prednisone: 2 mg/kg PO on days 1–4</li>
<li>Thalidomide: 50 mg PO daily on days 1–28</li>
<li>Repeat cycle every 28 days for 6 cycles followed by maintenance lenalidomide 10 mg PO on days 1–21 until progression or toxicity.</li>
</ul>
<blockquote>
<p>Palumbo A, et al. Leukemia 2010;24:1037–1042.</p>
</blockquote>
</div>
<div id="carfilzomib-lenalidomide-dexamethasone-cld" class="section level4" number="2.25.1.16">
<h4><span class="header-section-number">2.25.1.16</span> Carfilzomib + Lenalidomide + Dexamethasone (CLD)</h4>
<ul>
<li>Carfilzomib: 20 mg/m2 IV on days 1 and 2 of cycle 1, and if tolerated, then 27 mg/m2 IV on days 8, 9, 15, and 16 during cycles
1 through 12 and 27 mg/m2 IV on days 1, 2, 15, and 16 during cycles 13 through 18 after which carfilzomib is discontinued</li>
<li>Lenalidomide: 25 mg PO on days 1–21</li>
<li>Dexamethasone: 40 mg PO on days 1, 8, 15, and 22</li>
<li>Repeat cycle every 28 days for up to 9 cycles.</li>
</ul>
<blockquote>
<p>Stewart AK, et al. N Engl J Med 2015;372:142–152.</p>
</blockquote>
</div>
<div id="carfilzomib-dexamethasone-cd" class="section level4" number="2.25.1.17">
<h4><span class="header-section-number">2.25.1.17</span> Carfilzomib + Dexamethasone (CD)</h4>
<ul>
<li>Carfilzomib: 20 mg/m2 IV on days 1, 8, and 15 of cycle 1, and then 70 mg/m2 IV on days 1, 8, and 15 for all subsequent cycles</li>
<li>Dexamethasone: 40 mg PO on days 1, 8, and 15 for all cycles 40 mg PO on days 1, 8, 15, and 22 (cycles 1–9 only)</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Moreau P, et al. Lancet Oncol 2018;dx. doi.org/10.1016/S1470-2045(18)30354-1.</p>
</blockquote>
</div>
<div id="lenalidomide-dexamethasone-ixazomib" class="section level4" number="2.25.1.18">
<h4><span class="header-section-number">2.25.1.18</span> Lenalidomide + Dexamethasone + Ixazomib</h4>
<ul>
<li>Lenalidomide: 25 mg/day PO on days 1–21</li>
<li>Dexamethasone: 40 mg/day PO on days 1, 8, 15, and 22</li>
<li>Ixazomib: 4 mg/day PO on days 1, 8, and 15</li>
<li>Repeat cycle every 28 days until disease progression.</li>
</ul>
<blockquote>
<p>Moreau P, et al. Blood 2015;126:727.</p>
</blockquote>
</div>
<div id="daratumumab-bortezomib-dexamethasone" class="section level4" number="2.25.1.19">
<h4><span class="header-section-number">2.25.1.19</span> Daratumumab + Bortezomib + Dexamethasone</h4>
<ul>
<li>Daratumumab: 16 mg/kg IV weekly on cycles 1–3, 16 mg/kg IV on day 1 of cycles 4–8, 16 mg/kg IV on day 1 of cycles 9+</li>
<li>Bortezomib: 1.3 mg/m2 IV on days 1, 4, 8, and 11 on cycles 1–8</li>
<li>Dexamethasone: 20 mg PO on days 1, 2, 4, 5, 8, 9, 11, and 12 on cycles 1–8</li>
<li>Continue treatment until disease progression or toxicity.</li>
</ul>
<blockquote>
<p>Lokhorst HM, et al. N Engl J Med 2015;373:1207–1219.</p>
</blockquote>
</div>
<div id="elotuzumab-lenalidomide-dexamethasone" class="section level4" number="2.25.1.20">
<h4><span class="header-section-number">2.25.1.20</span> Elotuzumab + Lenalidomide + Dexamethasone</h4>
<ul>
<li>Elotuzumab: 10 mg/kg IV on days 1, 8, 15, and 22</li>
<li>Lenalidomide: 25 mg PO on days 1–21</li>
<li>Dexamethasone: 8 mg IV prior to elotuzumab infusion and 28 mg PO on days 1, 8, 15, and 22 and 40 mg PO on day 28</li>
<li>Repeat cycle every 28 days for two cycles followed by:</li>
<li>Elotuzumab: 10 mg/kg IV on days 1 and 15</li>
<li>Lenalidomide: 25 mg PO on days 1–21</li>
<li>Dexamethasone: 8 mg IV prior to elotuzumab infusion and 28 mg PO on days 1 and 15, and 40 mg PO on days 22 and 28</li>
<li>Repeat cycle every 28 days until disease progression.</li>
</ul>
<blockquote>
<p>Lonial S, et al. N Engl J Med 2015;373:621–631.</p>
</blockquote>
</div>
</div>
<div id="single-agent-regimens-11" class="section level3" number="2.25.2">
<h3><span class="header-section-number">2.25.2</span> Single-Agent Regimens</h3>
<div id="dexamethasone" class="section level4" number="2.25.2.1">
<h4><span class="header-section-number">2.25.2.1</span> Dexamethasone</h4>
<ul>
<li>Dexamethasone: 40 mg IV or PO on days 1–4, 9–12, and 17–20</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Alexanian R, et al. Ann Intern Med 1986;105:8–11.</p>
</blockquote>
</div>
<div id="melphalan" class="section level4" number="2.25.2.2">
<h4><span class="header-section-number">2.25.2.2</span> Melphalan</h4>
<ul>
<li>Melphalan: 90–140 mg/m2 IV on day 1</li>
<li>Repeat cycle every 28–42 days.</li>
</ul>
<blockquote>
<p>Cunningham D, et al. J Clin Oncol 1994;12:764–768.</p>
</blockquote>
</div>
<div id="thalidomide" class="section level4" number="2.25.2.3">
<h4><span class="header-section-number">2.25.2.3</span> Thalidomide</h4>
<ul>
<li>Thalidomide: 200–800 mg PO daily</li>
<li>Continue treatment until disease progression or undue toxicity.</li>
</ul>
<blockquote>
<p>Singhal S, et al. N Engl J Med 1999;341:1565–1571.</p>
</blockquote>
</div>
<div id="lenalidomide-2" class="section level4" number="2.25.2.4">
<h4><span class="header-section-number">2.25.2.4</span> Lenalidomide</h4>
<ul>
<li>Lenalidomide: 30 mg PO daily on days 1–21</li>
<li>Repeat cycle every 28 days until disease progression or undue toxicity.</li>
</ul>
<blockquote>
<p>Richardson PG, et al. Blood 2006;108:3458–3464.</p>
</blockquote>
<p>or</p>
</div>
<div id="lenalidomide-3" class="section level4" number="2.25.2.5">
<h4><span class="header-section-number">2.25.2.5</span> Lenalidomide</h4>
<ul>
<li>Lenalidomide: 10 mg PO daily on days 1–21</li>
<li>For maintenance therapy after autologous stem-cell transplantation, repeat cycle every 28 days until disease progression or undue toxicity.</li>
</ul>
<blockquote>
<p>Palumbo A, et al. N Engl J Med 2014;371:895–905.</p>
</blockquote>
</div>
<div id="bortezomib" class="section level4" number="2.25.2.6">
<h4><span class="header-section-number">2.25.2.6</span> Bortezomib</h4>
<ul>
<li>Bortezomib: 1.3 mg/m2 IV or SC on days 1, 4, 8, and 11</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Richardson P, et al. N Engl J Med 2003;348:2609–2617.</p>
</blockquote>
</div>
<div id="carfilzomib" class="section level4" number="2.25.2.7">
<h4><span class="header-section-number">2.25.2.7</span> Carfilzomib</h4>
<ul>
<li>Carfilzomib: 20 mg/m2 IV on days 1, 2, 8, 9, 15, and 16. After cycle 1, increase dose to 27 mg/m2 IV</li>
<li>Repeat cycle every 28 days for up to 12 cycles.</li>
</ul>
<blockquote>
<p>Vij R, et al. Blood 2012;119:5661–5670.</p>
</blockquote>
</div>
<div id="daratumumab" class="section level4" number="2.25.2.8">
<h4><span class="header-section-number">2.25.2.8</span> Daratumumab</h4>
<ul>
<li>Daratumumab: 16 mg/kg IV on days 1, 8, 15, 22, 29, 36, 42, and 49; followed by once every 2 weeks for 16 weeks; followed by once every 4 weeks</li>
<li>Continue treatment until disease progression.</li>
</ul>
<blockquote>
<p>Lonial S, et al. Lancet 2016;387:1551–1560.</p>
</blockquote>
</div>
<div id="ibrutinib-1" class="section level4" number="2.25.2.9">
<h4><span class="header-section-number">2.25.2.9</span> Ibrutinib</h4>
<ul>
<li>Ibrutinib: 420 mg/day PO daily</li>
<li>Continue treatment until disease progression.</li>
</ul>
<blockquote>
<p>Treon SP, et al. N Engl J Med 2015;372:1430–1400.</p>
</blockquote>
</div>
</div>
</div>
<div id="myelodysplastic-syndrome" class="section level2" number="2.26">
<h2><span class="header-section-number">2.26</span> MYELODYSPLASTIC SYNDROME</h2>
<div id="single-agent-regimens-12" class="section level3" number="2.26.1">
<h3><span class="header-section-number">2.26.1</span> Single-Agent Regimens</h3>
<div id="azacitidine-1" class="section level4" number="2.26.1.1">
<h4><span class="header-section-number">2.26.1.1</span> Azacitidine</h4>
<ul>
<li>Azacitidine: 75 mg/m2 SC daily for 7 days</li>
<li>Repeat cycle every 4 weeks. Patients should be treated for at least 4 cycles.</li>
</ul>
<blockquote>
<p>Silverman LR, et al. J Clin Oncol 2006;24:3895–3903.</p>
</blockquote>
</div>
<div id="decitabine-1" class="section level4" number="2.26.1.2">
<h4><span class="header-section-number">2.26.1.2</span> Decitabine</h4>
<ul>
<li>Decitabine: 15 mg/m2 IV continuous infusion over 3 hours every 8 hours for 3 days</li>
<li>Repeat cycle every 4 weeks. Patients should be treated for at least 4 cycles.</li>
</ul>
<blockquote>
<p>Kantarjian HM, et al. Cancer 2006;106:1794–1803.</p>
</blockquote>
<p>or</p>
<ul>
<li>Decitabine: 20 mg/m2 IV continuous infusion over 1 hour for 5 days</li>
<li>Repeat cycle every 4–6 weeks. Patients should be treated for at least 4 cycles.</li>
</ul>
<blockquote>
<p>Kantarjian HM, et al. Semin Hematology 2005;32 (Suppl 2): S17–S22.</p>
</blockquote>
</div>
<div id="lenalidomide-4" class="section level4" number="2.26.1.3">
<h4><span class="header-section-number">2.26.1.3</span> Lenalidomide</h4>
<ul>
<li>Lenalidomide: 10 mg PO daily</li>
<li>Continue until disease progression.</li>
</ul>
<p>or</p>
<ul>
<li>Lenalidomide: 10 mg PO daily for 21 days</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Galili N, et al. Expert Opin Investig Drugs 2006;15:805–813.</p>
</blockquote>
</div>
<div id="imatinib-4" class="section level4" number="2.26.1.4">
<h4><span class="header-section-number">2.26.1.4</span> Imatinib</h4>
<ul>
<li>Imatinib: 400 mg PO daily</li>
<li>Continue until disease progression.</li>
</ul>
<blockquote>
<p>David M, et al. Blood 2007;109:61–64.</p>
</blockquote>
</div>
<div id="antithymocyte-globulin-atg-cyclosporine" class="section level4" number="2.26.1.5">
<h4><span class="header-section-number">2.26.1.5</span> Antithymocyte globulin (ATG) + Cyclosporine</h4>
<ul>
<li>ATG: 15 mg/kg IV on days 1–5</li>
<li>Cyclosporine: 5–6 mg/kg PO bid</li>
<li>Adjust cyclosporine dose to maintain blood levels between 100 and 300 ng/mL.</li>
</ul>
<blockquote>
<p>Passweg JR, et al. J Clin Oncol 2011;29:303–309.</p>
</blockquote>
</div>
</div>
</div>
<div id="osteogenic-sarcoma" class="section level2" number="2.27">
<h2><span class="header-section-number">2.27</span> OSTEOGENIC SARCOMA</h2>
<div id="combination-regimens-13" class="section level3" number="2.27.1">
<h3><span class="header-section-number">2.27.1</span> Combination Regimens</h3>
<div id="etoposide-ifosfamide" class="section level4" number="2.27.1.1">
<h4><span class="header-section-number">2.27.1.1</span> Etoposide + Ifosfamide</h4>
<ul>
<li>Etoposide: 100 mg/m2/day IV on days 1–5</li>
<li>Ifosfamide: 3,500 mg/m2/day IV on days 1–5</li>
<li>Mesna: 700 mg/m2 IV with first ifosfamide dose, then 3, 6, and 9 hours later on
days 1–5</li>
<li>Repeat cycle every 21 days for 2 cycles. Start G-CSF support at 5 µg/kg/day SC to start on day 6. Followed by surgical resection of primary tumor and then intensive maintenance chemotherapy.</li>
<li>Methotrexate: 1,200 mg/m2 IV on weeks 1, 2, 6, 7, 11, 12, 16, 17, 30, and 31</li>
<li>Leucovorin: 15 mg IV every 6 hours for 10 doses starting 24 hours after start of highdose methotrexate
or</li>
<li>L-Leucovorin: 7.5 mg IV every 6 hours for 10 doses starting 24 hours after start of highdose methotrexate</li>
<li>Doxorubicin: 37.5 mg/m2/day IV on days 1–2 on weeks 3, 13, 21, 27, and 32</li>
<li>Cisplatin: 60 mg/m2/day IV on days 1–2 on weeks 3, 13, 21, and 27</li>
<li>Ifosfamide: 2,400 mg/m2/day IV on days 1–5 on weeks 8, 18, and 24</li>
<li>Administer G-CSF support at 5 µg/kg/day SC on weeks 8, 18, and 24.</li>
</ul>
<blockquote>
<p>Goorin A, et al. Med Pediatr Oncol 1995;24:362–367.</p>
</blockquote>
</div>
<div id="cisplatin-doxorubicin-high-dose-methotrexate" class="section level4" number="2.27.1.2">
<h4><span class="header-section-number">2.27.1.2</span> Cisplatin + Doxorubicin + High-Dose Methotrexate</h4>
<ul>
<li>Doxorubicin: 25 mg/m2/day IV on days 1–3 on weeks 0 and 5</li>
<li>Cisplatin: 120 mg/m2 IV on day 1 on weeks 0 and 5</li>
<li>Methotrexate: 1,200 mg/m2 IV on day 1 on weeks 3, 4, 8, and 9</li>
<li>Leucovorin: 10 mg IV every 6 hours for 10 doses starting 24 hours after start of highdose methotrexate
or</li>
<li>L-Leucovorin: 7.5 mg IV every 6 hours for 10 doses starting 24 hours after start of highdose methotrexate</li>
<li>Induction chemotherapy is followed by surgical resection of primary tumor and then maintenance chemotherapy to begin on week 12 and continuing until week 31.</li>
<li>Doxorubicin: 25 mg/m2/day IV on days 1–3 on weeks 12, 17, 22, and 27</li>
<li>Cisplatin: 120 mg/m2 IV on day 1 on weeks 12 and 17</li>
<li>Methotrexate: 1,200 mg/m2 IV on day 1 on weeks 15, 16, 20, 21, 25, 26, 30, and 31</li>
<li>Leucovorin: 10 mg IV every 6 hours for 10 doses starting 24 hours after start of highdose methotrexate
or
L-Leucovorin: 7.5 mg IV every 6 hours for 10 doses starting 24 hours after start of highdose methotrexate</li>
</ul>
<blockquote>
<p>Meyers PA, et al. J Clin Oncol 2005;23:2004–2011.</p>
</blockquote>
</div>
</div>
</div>
<div id="ovarian-cancer-epithelial" class="section level2" number="2.28">
<h2><span class="header-section-number">2.28</span> OVARIAN CANCER (EPITHELIAL)</h2>
<div id="combination-regimens-14" class="section level3" number="2.28.1">
<h3><span class="header-section-number">2.28.1</span> Combination Regimens</h3>
<div id="cc" class="section level4" number="2.28.1.1">
<h4><span class="header-section-number">2.28.1.1</span> CC</h4>
<ul>
<li>Carboplatin: 300 mg/m2 IV on day 1</li>
<li>Cyclophosphamide: 600 mg/m2 IV on day 1</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Swenerton K, et al. J Clin Oncol 1992;10:718–726.</p>
</blockquote>
</div>
<div id="cc-1" class="section level4" number="2.28.1.2">
<h4><span class="header-section-number">2.28.1.2</span> CC</h4>
<ul>
<li>Cisplatin: 100 mg/m2 IV on day 1</li>
<li>Cyclophosphamide: 600 mg/m2 IV on day 1</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Alberts D, et al. J Clin Oncol 1992;10:706–717.</p>
</blockquote>
</div>
<div id="cp-1" class="section level4" number="2.28.1.3">
<h4><span class="header-section-number">2.28.1.3</span> CP</h4>
<ul>
<li>Cisplatin: 75 mg/m2 IV on day 2</li>
<li>Paclitaxel: 135 mg/m2 IV over 24 hours on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>McGuire WP, et al. N Engl J Med 1996;334:1–6.</p>
</blockquote>
</div>
<div id="carboplatin-paclitaxel-2" class="section level4" number="2.28.1.4">
<h4><span class="header-section-number">2.28.1.4</span> Carboplatin + Paclitaxel</h4>
<ul>
<li>Carboplatin: AUC of 6–7.5, IV on day 1</li>
<li>Paclitaxel: 175 mg/m2 IV over 3 hours on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Ozols RE. Semin Oncol 1995;22 (Suppl 15):1–6.</p>
</blockquote>
<p>or</p>
<ul>
<li>Carboplatin: AUC of 2, IV on days 1, 8, and 15</li>
<li>Paclitaxel: 60 mg/m2 IV on days 1, 8, and 15</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Pignata S, et al. Crit Rev Oncol Hematol 2008;66:229–236.</p>
</blockquote>
</div>
<div id="carboplatin-paclitaxel-bevacizumab" class="section level4" number="2.28.1.5">
<h4><span class="header-section-number">2.28.1.5</span> Carboplatin + Paclitaxel + Bevacizumab</h4>
<ul>
<li>Carboplatin: AUC of 6, IV on day 1</li>
<li>Paclitaxel: 175 mg/m2 IV over 3 hours on day 1</li>
<li>Bevacizumab: 15 mg/kg IV on day 1</li>
<li>Repeat cycle every 21 days for 6 cycles, then maintenance bevacizumab for cycles 7–22.</li>
</ul>
<blockquote>
<p>Burger RA, et al. J Clin Oncol 2010:28:946S (LBA1).</p>
</blockquote>
</div>
<div id="carboplatin-docetaxel-2" class="section level4" number="2.28.1.6">
<h4><span class="header-section-number">2.28.1.6</span> Carboplatin + Docetaxel</h4>
<ul>
<li>Carboplatin: AUC of 6, IV on day 1</li>
<li>Docetaxel: 60 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Markman M, et al. J Clin Oncol 2001;19:1901–1905.</p>
</blockquote>
</div>
<div id="carboplatin-doxorubicin-liposome-1" class="section level4" number="2.28.1.7">
<h4><span class="header-section-number">2.28.1.7</span> Carboplatin + Doxorubicin liposome</h4>
<ul>
<li>Carboplatin: AUC of 5, IV on day 1</li>
<li>Doxorubicin liposome: 30 mg/m2 IV on day 1</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Pignant S, et al. J Clin Oncol 2009;27:18S (LBA5509).</p>
</blockquote>
</div>
<div id="gemcitabine-doxorubicin-liposome" class="section level4" number="2.28.1.8">
<h4><span class="header-section-number">2.28.1.8</span> Gemcitabine + Doxorubicin liposome</h4>
<ul>
<li>Gemcitabine: 1,000 mg/m2 IV on days 1 and 8</li>
<li>Doxorubicin liposome: 30 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>D’Agostino G, et al. Br J Cancer 2003;89:1180–1184.</p>
</blockquote>
</div>
<div id="gemcitabine-cisplatin-4" class="section level4" number="2.28.1.9">
<h4><span class="header-section-number">2.28.1.9</span> Gemcitabine + Cisplatin</h4>
<ul>
<li>Gemcitabine: 800–1,000 mg/m2 IV on days 1 and 8</li>
<li>Cisplatin: 30 mg/m2 IV on days 1 and 8</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Nagourney RA, et al. Gynecol Oncol 2003;88:35–39.</p>
</blockquote>
</div>
<div id="gemcitabine-carboplatin-3" class="section level4" number="2.28.1.10">
<h4><span class="header-section-number">2.28.1.10</span> Gemcitabine + Carboplatin</h4>
<ul>
<li>Gemcitabine: 1,000 mg/m2 IV on days 1 and 8</li>
<li>Carboplatin: AUC of 4, IV on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Thigpen T. Semin Oncol 2006;33 (Suppl 6):S26–S32.</p>
</blockquote>
</div>
<div id="paclitaxel-ip-cisplatin-ip-paclitaxel" class="section level4" number="2.28.1.11">
<h4><span class="header-section-number">2.28.1.11</span> Paclitaxel + IP Cisplatin + IP Paclitaxel</h4>
<ul>
<li>Paclitaxel: 135 mg/m2 IV over 24 hours on day 1</li>
<li>Cisplatin: 100 mg/m2 IP on day 2</li>
<li>Paclitaxel: 60 mg/m2 IP on day 8</li>
<li>Repeat cycle every 21 days up to 6 cycles.</li>
</ul>
<blockquote>
<p>Armstrong DK, et al. N Engl J Med 2006;354:34–43.</p>
</blockquote>
</div>
<div id="pemetrexed-carboplatin-1" class="section level4" number="2.28.1.12">
<h4><span class="header-section-number">2.28.1.12</span> Pemetrexed + Carboplatin</h4>
<ul>
<li>Pemetrexed: 500 mg/m2 IV on day 1</li>
<li>Carboplatin: AUC of 5, IV on day 1</li>
<li>Repeat cycle every 21 days. Folic acid at 350–1,000 µg PO q day beginning 1–2 weeks prior to therapy and vitamin B12 at 1,000 µg IM to start 1–2 weeks prior to first dose of therapy and repeated every 3 cycles. Dexamethasone 4 mg PO bid on the day before, day of, and day after each dose of pemetrexed.</li>
</ul>
<blockquote>
<p>Matulonis UA, et al. J Clin Oncol 2008;26:5761–5766.</p>
</blockquote>
</div>
</div>
<div id="single-agent-regimens-13" class="section level3" number="2.28.2">
<h3><span class="header-section-number">2.28.2</span> Single-Agent Regimens</h3>
<div id="altretamine" class="section level4" number="2.28.2.1">
<h4><span class="header-section-number">2.28.2.1</span> Altretamine</h4>
<ul>
<li>Altretamine: 260 mg/m2/day PO in 4 divided doses after meals and at bedtime</li>
<li>Repeat cycle every 14–21 days.</li>
</ul>
<blockquote>
<p>Markman M. Gynecol Oncol 1998;69:226–229.</p>
</blockquote>
</div>
<div id="doxorubicin-liposome-2" class="section level4" number="2.28.2.2">
<h4><span class="header-section-number">2.28.2.2</span> Doxorubicin liposome</h4>
<ul>
<li>Doxorubicin liposome: 40–50 mg/m2 IV over 1 hour on day 1</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Rose PG, et al. Gynecol Oncol 2001;82:323–328.</p>
</blockquote>
</div>
<div id="paclitaxel-10" class="section level4" number="2.28.2.3">
<h4><span class="header-section-number">2.28.2.3</span> Paclitaxel</h4>
<ul>
<li>Paclitaxel: 135 mg/m2 IV over 3 hours on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>McGuire WP, et al. Ann Intern Med 1989;111:273–279.</p>
</blockquote>
</div>
<div id="ixabepilone-1" class="section level4" number="2.28.2.4">
<h4><span class="header-section-number">2.28.2.4</span> Ixabepilone</h4>
<ul>
<li>Ixabepilone: 20 mg/m2 IV on days 1, 8, and 15</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>DeGeest K, et al. J Clin Oncol 2010:28:149–153.</p>
</blockquote>
</div>
<div id="topotecan-4" class="section level4" number="2.28.2.5">
<h4><span class="header-section-number">2.28.2.5</span> Topotecan</h4>
<ul>
<li>Topotecan: 1.5 mg/m2 IV on days 1–5</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Kudelka AP, et al. J Clin Oncol 1996;14:1552–1557.</p>
</blockquote>
</div>
<div id="gemcitabine-8" class="section level4" number="2.28.2.6">
<h4><span class="header-section-number">2.28.2.6</span> Gemcitabine</h4>
<ul>
<li>Gemcitabine: 800 mg/m2 IV weekly for 3 weeks</li>
<li>Repeat cycle every 4 weeks.</li>
</ul>
<blockquote>
<p>Lund B, et al. J Natl Cancer Inst 1994;86:1530–1533.</p>
</blockquote>
</div>
<div id="etoposide-2" class="section level4" number="2.28.2.7">
<h4><span class="header-section-number">2.28.2.7</span> Etoposide</h4>
<ul>
<li>Etoposide: 50 mg/m2/day PO on days 1–21</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Ozols RF. Drugs 1999;58 (Suppl 3):43–49.</p>
</blockquote>
</div>
<div id="vinorelbine-5" class="section level4" number="2.28.2.8">
<h4><span class="header-section-number">2.28.2.8</span> Vinorelbine</h4>
<ul>
<li>Vinorelbine: 30 mg/m2 IV on days 1 and 8</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Sorensen P, et al. Gynecol Oncol 2001;81:58–62.</p>
</blockquote>
</div>
<div id="pemetrexed-4" class="section level4" number="2.28.2.9">
<h4><span class="header-section-number">2.28.2.9</span> Pemetrexed</h4>
<ul>
<li>Pemetrexed: 900 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days. Folic acid at 350–1,000 µg PO q day beginning 1 week prior to therapy and vitamin B12 at 1,000 µg IM to start 1–2 weeks prior to first dose of therapy and repeated every 3 cycles. Dexamethasone 4 mg PO bid on
the day before, day of, and day after each dose of pemetrexed.</li>
</ul>
<blockquote>
<p>Miller DS, et al. J Clin Oncol 2009;27:2686–2691.</p>
</blockquote>
</div>
<div id="bevacizumab-3" class="section level4" number="2.28.2.10">
<h4><span class="header-section-number">2.28.2.10</span> Bevacizumab</h4>
<ul>
<li>Bevacizumab: 15 mg/kg IV on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Burger RA, et al. J Clin Oncol 2007;25:5165–5171.</p>
</blockquote>
</div>
<div id="capecitabine-6" class="section level4" number="2.28.2.11">
<h4><span class="header-section-number">2.28.2.11</span> Capecitabine</h4>
<ul>
<li>Capecitabine: 1,000 mg/m2 PO bid on days 1–14</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Wolf JK, et al. Gynecol Oncol 2006;102:468–474.</p>
</blockquote>
</div>
<div id="olaparib-1" class="section level4" number="2.28.2.12">
<h4><span class="header-section-number">2.28.2.12</span> Olaparib</h4>
<ul>
<li>Olaparib: 400 PO bid</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Ledermann J, et al. Lancet Oncol 2014;15:852–861.</p>
</blockquote>
</div>
<div id="rucaparib" class="section level4" number="2.28.2.13">
<h4><span class="header-section-number">2.28.2.13</span> Rucaparib</h4>
<ul>
<li>Rucaparib: 600 PO daily</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Swisher E, et al. Lancet Oncol 2017;18:75–87.</p>
</blockquote>
</div>
<div id="niraparib" class="section level4" number="2.28.2.14">
<h4><span class="header-section-number">2.28.2.14</span> Niraparib</h4>
<ul>
<li>Niraparib: 300 PO daily</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Mirza M, et al. N Engl J Med 2016;375:2154–2164.</p>
</blockquote>
</div>
</div>
</div>
<div id="ovarian-cancer-germ-cell" class="section level2" number="2.29">
<h2><span class="header-section-number">2.29</span> OVARIAN CANCER (GERM CELL)</h2>
<div id="combination-regimens-15" class="section level3" number="2.29.1">
<h3><span class="header-section-number">2.29.1</span> Combination Regimens</h3>
<div id="bep" class="section level4" number="2.29.1.1">
<h4><span class="header-section-number">2.29.1.1</span> BEP</h4>
<ul>
<li>Bleomycin: 30 U IV on days 2, 9, and 16</li>
<li>Etoposide: 100 mg/m2 IV on days 1–5</li>
<li>Cisplatin: 20 mg/m2 IV on days 1–5</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Dimopoulos MA, et al. Gynecol Oncol 2004;95:695–700.</p>
</blockquote>
</div>
</div>
</div>
<div id="pancreatic-cancer" class="section level2" number="2.30">
<h2><span class="header-section-number">2.30</span> PANCREATIC CANCER</h2>
<div id="adjuvant-therapy---combination-regimens-3" class="section level3" number="2.30.1">
<h3><span class="header-section-number">2.30.1</span> Adjuvant Therapy - Combination Regimens</h3>
<div id="gemcitabine-capecitabine-gem-cap" class="section level4" number="2.30.1.1">
<h4><span class="header-section-number">2.30.1.1</span> Gemcitabine + Capecitabine (GEM-CAP)</h4>
<ul>
<li>Gemcitabine: 1,000 mg/m2 IV on days 1, 8, and 15</li>
<li>Capecitabine: 880 mg/m2 PO bid on days 1–21</li>
<li>Repeat cycle every 28 days for a total of 6 cycles.</li>
</ul>
<blockquote>
<p>Neoptolemos JP, et al. Lancet 2017;389:1011–1024.</p>
</blockquote>
</div>
<div id="folfirinox" class="section level4" number="2.30.1.2">
<h4><span class="header-section-number">2.30.1.2</span> FOLFIRINOX</h4>
<ul>
<li>Oxaliplatin: 85 mg/m2 IV on day 1</li>
<li>Irinotecan: 150 mg/m2 IV on day 1</li>
<li>Leucovorin: 400 mg/m2 IV on day 1</li>
<li>5-Fluorouracil: 2,400 mg/m2 IV continuous infusion over 46 hours on days 1 and 2</li>
<li>Repeat cycle every 2 weeks for a total of 12 cycles.</li>
</ul>
<blockquote>
<p>Conroy T, et al. J Clin Oncol 2018;36:18S (abstract LBA4001).</p>
</blockquote>
</div>
</div>
<div id="adjuvant-therapy---single-agent-regimens-3" class="section level3" number="2.30.2">
<h3><span class="header-section-number">2.30.2</span> Adjuvant Therapy - Single-Agent Regimens</h3>
<div id="fluorouracil-leucovorin-1" class="section level4" number="2.30.2.1">
<h4><span class="header-section-number">2.30.2.1</span> 5-Fluorouracil + Leucovorin</h4>
<ul>
<li>5-Fluorouracil: 425 mg/m2 IV on days 1–5</li>
<li>Leucovorin: 20 mg/m2 IV on days 1–5</li>
<li>Repeat cycle every 28 days for a total of 6 cycles.</li>
</ul>
<blockquote>
<p>Neoptolemos J, et al. J Clin Oncol 2009;27:18S (abstract LBA4505).</p>
</blockquote>
</div>
<div id="gemcitabine-9" class="section level4" number="2.30.2.2">
<h4><span class="header-section-number">2.30.2.2</span> Gemcitabine</h4>
<ul>
<li>Gemcitabine: 1,000 mg/m2 IV on days 1, 8, and 15</li>
<li>Repeat cycle every 28 days for a total of 6 cycles.</li>
</ul>
<blockquote>
<p>Oettle H, et al. JAMA 2007;297:267–277.</p>
</blockquote>
</div>
</div>
<div id="locally-advanced-disease---combination-regimens" class="section level3" number="2.30.3">
<h3><span class="header-section-number">2.30.3</span> Locally Advanced Disease - Combination Regimens</h3>
<div id="fluorouracil-radiation-therapy-gitsg-regimen" class="section level4" number="2.30.3.1">
<h4><span class="header-section-number">2.30.3.1</span> 5-Fluorouracil + Radiation Therapy (GITSG regimen)</h4>
<ul>
<li>5-Fluorouracil: 500 mg/m2/day IV on days 1–3 and 29–31, then weekly beginning on day 71</li>
<li>Radiation therapy: Total dose, 4,000 cGy</li>
<li>Chemotherapy and radiation therapy started on the same day and given concurrently.</li>
</ul>
<blockquote>
<p>Gastrointestinal Tumor Study Group. Int J Radiat Oncol Biol Phys 1979;5:1643–1647.</p>
</blockquote>
</div>
<div id="rtog-chemoradiation-regimen" class="section level4" number="2.30.3.2">
<h4><span class="header-section-number">2.30.3.2</span> RTOG Chemoradiation Regimen</h4>
<ul>
<li>Gemcitabine: 1,000 mg/m2 IV on days 1, 8, and 15</li>
<li>Followed by concurrent chemoradiation:</li>
<li>5-Fluorouracil: 250 mg/m2/day IV continuous infusion during radiation therapy</li>
<li>Radiation therapy: 180 cGy/day to a total dose of 5,040 cGy</li>
<li>Chemotherapy and radiation therapy started on the same day and given concurrently.</li>
<li>After chemoradiation:</li>
<li>Gemcitabine: 1,000 mg/m2 IV on days 1, 8, and 15</li>
<li>Repeat cycle every 4 weeks for a total of 3 cycles.</li>
</ul>
<blockquote>
<p>Regine WF, et al. J Clin Oncol 2006;25 (abstract 4007).</p>
</blockquote>
</div>
<div id="gemcitabine-radiation-therapy-ecog-regimen" class="section level4" number="2.30.3.3">
<h4><span class="header-section-number">2.30.3.3</span> Gemcitabine + Radiation Therapy (ECOG regimen)</h4>
<ul>
<li>Gemcitabine: 600 mg/m2 IV weekly for 6 weeks</li>
<li>Radiation therapy: 180 cGy/day to a total dose of 5,040 cGy. Chemotherapy and radiation therapy started on the same day and given concurrently.</li>
<li>Four weeks after the completion of chemoradiation:</li>
<li>Gemcitabine: 1,000 mg/m2 IV on days 1, 8, and 15</li>
<li>Repeat cycle every 4 weeks for a total of 5 cycles.</li>
</ul>
<blockquote>
<p>Loehrer PJ, et al. J Clin Oncol 2008;26 (abstract 4506).</p>
</blockquote>
</div>
</div>
<div id="metastatic-disease---combination-regimens-5" class="section level3" number="2.30.4">
<h3><span class="header-section-number">2.30.4</span> Metastatic Disease - Combination Regimens</h3>
<div id="fluorouracil-leucovorin-2" class="section level4" number="2.30.4.1">
<h4><span class="header-section-number">2.30.4.1</span> 5-Fluorouracil + Leucovorin</h4>
<ul>
<li>5-Fluorouracil: 425 mg/m2 IV on days 1–5</li>
<li>Leucovorin: 20 mg/m2 IV on days 1–5</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>DeCaprio JA, et al. J Clin Oncol 1991;9:2128–2133.</p>
</blockquote>
</div>
<div id="gemcitabine-capecitabine-gem-cap-1" class="section level4" number="2.30.4.2">
<h4><span class="header-section-number">2.30.4.2</span> Gemcitabine + Capecitabine (GEM-CAP)</h4>
<ul>
<li>Gemcitabine: 1,000 mg/m2 IV on days 1 and 8</li>
<li>Capecitabine: 650 mg/m2 PO bid on days 1–14</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Hess V, et al. J Clin Oncol 2003;21:66–68.</p>
</blockquote>
<p>or</p>
<ul>
<li>Gemcitabine: 1,000 mg/m2 IV on days 1, 8, and 15</li>
<li>Capecitabine: 830 mg/m2 PO bid on days 1–21</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Hubner RA, et al. Pancreas 2013;42:511–515.</p>
</blockquote>
</div>
<div id="gemcitabine-docetaxel-capecitabine-gtx" class="section level4" number="2.30.4.3">
<h4><span class="header-section-number">2.30.4.3</span> Gemcitabine + Docetaxel + Capecitabine (GTX)</h4>
<ul>
<li>Gemcitabine: 750 mg/m2 IV over 75 minutes on days 4 and 11</li>
<li>Docetaxel: 30 mg/m2 IV on days 4 and 11</li>
<li>Capecitabine: 750 mg/m2 PO bid on days 1–14</li>
<li>Repeat cycle every 3 weeks.</li>
</ul>
<blockquote>
<p>Fine RL, et al. Cancer Chemother Pharmacol 2008;61:167–175.</p>
</blockquote>
</div>
<div id="gemcitabine-oxaliplatin-1" class="section level4" number="2.30.4.4">
<h4><span class="header-section-number">2.30.4.4</span> Gemcitabine + Oxaliplatin</h4>
<ul>
<li>Gemcitabine: 1,000 mg/m2 IV over 100 minutes on day 1</li>
<li>Oxaliplatin: 100 mg/m2 over 2 hours on day 2</li>
<li>Repeat cycle every 2 weeks.</li>
</ul>
<blockquote>
<p>Louvet C, et al. J Clin Oncol 2002;20:1512–1518.</p>
</blockquote>
<p>or</p>
<ul>
<li>Gemcitabine: 1,000 mg/m2 IV over 100 minutes on day 1</li>
<li>Oxaliplatin: 100 mg/m2 over 2 hours on day 1</li>
<li>Repeat cycle every 2 weeks.</li>
</ul>
<blockquote>
<p>Louvet C, et al. J Clin Oncol 2007;25:18S (abstract 4592).</p>
</blockquote>
</div>
<div id="gemcitabine-erlotinib" class="section level4" number="2.30.4.5">
<h4><span class="header-section-number">2.30.4.5</span> Gemcitabine + Erlotinib</h4>
<ul>
<li>Gemcitabine: 1,000 mg/m2 IV weekly for 7 weeks, then 1-week rest; subsequent cycles 1,000 mg/m2 IV weekly for 3 weeks with 1-week rest</li>
<li>Erlotinib: 100 mg PO daily</li>
<li>Repeat 3-week cycles every 28 days.</li>
</ul>
<blockquote>
<p>Moore MJ, et al. J Clin Oncol 2005;23:16S (abstract 1).</p>
</blockquote>
</div>
<div id="capecitabine-erlotinib" class="section level4" number="2.30.4.6">
<h4><span class="header-section-number">2.30.4.6</span> Capecitabine + Erlotinib</h4>
<ul>
<li>Capecitabine: 1,000 mg/m2 PO bid on days 1–14</li>
<li>Erlotinib: 150 mg PO daily</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Kulke MH, et al. J Clin Oncol 2007;25:4787–4792.</p>
</blockquote>
</div>
<div id="folfirinox-1" class="section level4" number="2.30.4.7">
<h4><span class="header-section-number">2.30.4.7</span> FOLFIRINOX</h4>
<ul>
<li>Oxaliplatin: 85 mg/m2 IV on day 1</li>
<li>Irinotecan: 180 mg/m2 IV on day 1</li>
<li>Leucovorin: 400 mg/m2 IV on day 1</li>
<li>5-Fluorouracil: 400 mg/m2 IV on day 1</li>
<li>5-Fluorouracil: 2,400 mg/m2 IV continuous infusion over 46 hours on days 1 and 2</li>
<li>Repeat cycle every 2 weeks.</li>
</ul>
<blockquote>
<p>Conroy T, et al. J Clin Oncol 2010;28:302S (abstract 4010).</p>
</blockquote>
</div>
<div id="nab-paclitaxel-gemcitabine" class="section level4" number="2.30.4.8">
<h4><span class="header-section-number">2.30.4.8</span> Nab-Paclitaxel + Gemcitabine</h4>
<ul>
<li>Nab-Paclitaxel: 125 mg/m2 IV on days 1, 8, and 15</li>
<li>Gemcitabine: 1,000 mg/m2 IV on days 1, 8, and 15</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Von Hoff DD, et al. N Engl J Med 2013;369:1691–1703.</p>
</blockquote>
</div>
<div id="liposomal-irinotecan-5-fluorouracil-leucovorin" class="section level4" number="2.30.4.9">
<h4><span class="header-section-number">2.30.4.9</span> Liposomal Irinotecan + 5-Fluorouracil + Leucovorin</h4>
<ul>
<li>Liposomal Irinotecan: 70 mg/m2 IV on day 1</li>
<li>5-Fluorouracil: 2,400 mg/m2 IV continuous infusion over 46 hours on days 1 and 2</li>
<li>Leucovorin: 400 mg/m2 IV on day 1</li>
<li>Repeat cycle every 2 weeks.</li>
</ul>
<blockquote>
<p>Wang-Gilam A, et al. Lancet 2016;387:545–557.</p>
</blockquote>
</div>
</div>
<div id="metastatic-disease---single-agent-regimens-7" class="section level3" number="2.30.5">
<h3><span class="header-section-number">2.30.5</span> Metastatic Disease - Single-Agent Regimens</h3>
<div id="gemcitabine-10" class="section level4" number="2.30.5.1">
<h4><span class="header-section-number">2.30.5.1</span> Gemcitabine</h4>
<ul>
<li>Gemcitabine: 1,000 mg/m2 IV weekly for 7 weeks, then 1-week rest; subsequent cycles 1,000 mg/m2 IV weekly for 3 weeks
with 1-week rest</li>
<li>Repeat 3-week cycle every 28 days.</li>
</ul>
<blockquote>
<p>Burris HA, et al. J Clin Oncol 1997;15:2403–2413.</p>
</blockquote>
<p>or</p>
<ul>
<li>Gemcitabine: 1,000 mg/m2 IV over 100 min at 10 mg/m2/min on days 1, 8, and 5</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Brand R, et al. Invest New Drugs 1997;15:331–341.</p>
</blockquote>
</div>
<div id="capecitabine-7" class="section level4" number="2.30.5.2">
<h4><span class="header-section-number">2.30.5.2</span> Capecitabine</h4>
<ul>
<li>Capecitabine: 1,250 mg/m2 PO bid on days 1–14</li>
<li>May decrease dose to 850–1,000 mg/m2 PO bid on days 1–14 to reduce the risk of toxicity without compromising clinical efficacy.</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Cartwright TH, et al. J Clin Oncol 2002;20:160–164.</p>
</blockquote>
</div>
</div>
</div>
<div id="prostate-cancer" class="section level2" number="2.31">
<h2><span class="header-section-number">2.31</span> PROSTATE CANCER</h2>
<div id="combination-regimens-16" class="section level3" number="2.31.1">
<h3><span class="header-section-number">2.31.1</span> Combination Regimens</h3>
<div id="flutamide-leuprolide" class="section level4" number="2.31.1.1">
<h4><span class="header-section-number">2.31.1.1</span> Flutamide + Leuprolide</h4>
<ul>
<li>Flutamide: 250 mg PO tid</li>
<li>Leuprolide: 7.5 mg IM every 28 days or 22.5 mg IM every 12 weeks</li>
</ul>
<blockquote>
<p>Eisenberger MA, et al. Semin Oncol 1994;21:613–619.</p>
</blockquote>
</div>
<div id="flutamide-goserelin" class="section level4" number="2.31.1.2">
<h4><span class="header-section-number">2.31.1.2</span> Flutamide + Goserelin</h4>
<ul>
<li>Flutamide: 250 mg PO tid</li>
<li>Goserelin: 10.8 mg SC every 12 weeks</li>
</ul>
<blockquote>
<p>Jurincic CD, et al. Semin Oncol 1991;18 (Suppl 6):21–25.</p>
</blockquote>
</div>
<div id="estramustine-etoposide" class="section level4" number="2.31.1.3">
<h4><span class="header-section-number">2.31.1.3</span> Estramustine + Etoposide</h4>
<ul>
<li>Estramustine: 15 mg/kg/day PO in 4 divided doses on days 1–21</li>
<li>Etoposide: 50 mg/m2/day PO in 2 divided doses on days 1–21</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Pienta KJ, et al. J Clin Oncol 1994;12:2005–2012.</p>
</blockquote>
</div>
<div id="estramustine-vinblastine" class="section level4" number="2.31.1.4">
<h4><span class="header-section-number">2.31.1.4</span> Estramustine + Vinblastine</h4>
<ul>
<li>Estramustine: 600 mg/m2 PO daily on days 1–42</li>
<li>Vinblastine: 4 mg/m2 IV weekly for 6 weeks</li>
<li>Repeat cycle every 8 weeks.</li>
</ul>
<blockquote>
<p>Hudes GR, et al. J Clin Oncol 1992;11:1754–1761.</p>
</blockquote>
</div>
<div id="paclitaxel-estramustine" class="section level4" number="2.31.1.5">
<h4><span class="header-section-number">2.31.1.5</span> Paclitaxel + Estramustine</h4>
<ul>
<li>Paclitaxel: 120 mg/m2 IV continuous infusion on days 1–4</li>
<li>Estramustine: 600 mg/m2 PO daily, starting 24 hours before paclitaxel</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Hudes GR, et al. J Clin Oncol 1997;15:3156–3163.</p>
</blockquote>
<p>or</p>
<ul>
<li>Paclitaxel: 90 mg/m2 IV weekly for 3 weeks</li>
<li>Estramustine: 140 mg PO tid, starting day before, day of, and day after paclitaxel</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Vaughn DJ, et al. Cancer 2004;100:746–750.</p>
</blockquote>
</div>
<div id="mitoxantrone-prednisone" class="section level4" number="2.31.1.6">
<h4><span class="header-section-number">2.31.1.6</span> Mitoxantrone + Prednisone</h4>
<ul>
<li>Mitoxantrone: 12 mg/m2 IV on day 1</li>
<li>Prednisone: 5 mg PO bid daily</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Tannock IF, et al. J Clin Oncol 1996;14:1756–1764.</p>
</blockquote>
</div>
<div id="docetaxel-estramustine" class="section level4" number="2.31.1.7">
<h4><span class="header-section-number">2.31.1.7</span> Docetaxel + Estramustine</h4>
<ul>
<li>Docetaxel: 35 mg/m2 IV on day 2 of weeks 1 and 2</li>
<li>Estramustine: 420 mg PO for the first 4 doses and 280 mg PO for the next 5 doses on days 1–3 of weeks 1 and 2</li>
<li>Repeat cycle every 21 days. Dexamethasone is administered at 4 mg PO bid on days 1–3 of weeks 1 and 2.</li>
</ul>
<blockquote>
<p>Copur MS, et al. Semin Oncol 2001;28:16–21.</p>
</blockquote>
<p>or</p>
<ul>
<li>Docetaxel: 60 mg/m2 IV on day 2</li>
<li>Estramustine: 280 mg PO tid on days 1–5</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Petrylak DP, et al. N Engl J Med 2004;351:1513–1520.</p>
</blockquote>
</div>
<div id="docetaxel-prednisone" class="section level4" number="2.31.1.8">
<h4><span class="header-section-number">2.31.1.8</span> Docetaxel + Prednisone</h4>
<ul>
<li>Docetaxel: 75 mg/m2 IV on day 1</li>
<li>Prednisone: 5 mg PO bid</li>
<li>Repeat cycle every 21 days for up to a total of 10 cycles.</li>
</ul>
<blockquote>
<p>Tannock IF, et al. N Engl J Med 2004;351:1502–1512.</p>
</blockquote>
</div>
<div id="docetaxel-prednisone-bevacizumab" class="section level4" number="2.31.1.9">
<h4><span class="header-section-number">2.31.1.9</span> Docetaxel + Prednisone + Bevacizumab</h4>
<ul>
<li>Docetaxel: 75 mg/m2 IV on day 1</li>
<li>Prednisone: 5 mg PO bid</li>
<li>Bevacizumab: 15 mg/kg IV on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Halabi S, et al. J Clin Oncol 2010;28:951S (LBA 4511).</p>
</blockquote>
</div>
<div id="cabazitaxel-prednisone" class="section level4" number="2.31.1.10">
<h4><span class="header-section-number">2.31.1.10</span> Cabazitaxel + Prednisone</h4>
<ul>
<li>Cabazitaxel: 25 mg/m2 IV on day 1</li>
<li>Prednisone: 10 mg PO daily</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>DeBono JS, et al. J Clin Oncol 2010;28:344S (abstract 4508).</p>
</blockquote>
<p>or</p>
<ul>
<li>Cabazitaxel: 20 mg/m2 IV on day 1</li>
<li>Prednisone: 10 mg PO daily</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Eisenberger M, et al. J Clin Oncol 2017;35:3198–3206.</p>
</blockquote>
<p>or</p>
<ul>
<li>Cabazitaxel: 10 mg/m2 IV on days 1, 8, 15, and 22</li>
<li>Prednisone: 5 mg PO bid</li>
<li>Repeat cycle every 5 weeks.</li>
</ul>
<blockquote>
<p>Climent MA, et al. Eur J Cancer 2017;878:30–37.</p>
</blockquote>
</div>
<div id="abiraterone-prednisone" class="section level4" number="2.31.1.11">
<h4><span class="header-section-number">2.31.1.11</span> Abiraterone + Prednisone</h4>
<ul>
<li>Abiraterone: 1,000 mg PO daily</li>
<li>Prednisone: 5 mg PO bid</li>
<li>Continue until disease progression.</li>
</ul>
<blockquote>
<p>DeBono JS, et al. N Engl J Med 2011;364:1995–2005.</p>
</blockquote>
</div>
<div id="docetaxel-leuprolide" class="section level4" number="2.31.1.12">
<h4><span class="header-section-number">2.31.1.12</span> Docetaxel + Leuprolide</h4>
<ul>
<li>Docetaxel: 75 mg/m2 IV on day 1 every 28 days</li>
<li>Leuprolide: 7.5 mg IM on day 1 every 21 days</li>
<li>Continue until disease progression.</li>
</ul>
<blockquote>
<p>Sweeney C, et al. J Clin Oncol 2014;32:5S (LBA2).</p>
</blockquote>
</div>
</div>
<div id="single-agent-regimens-14" class="section level3" number="2.31.2">
<h3><span class="header-section-number">2.31.2</span> Single-Agent Regimens</h3>
<div id="paclitaxel-11" class="section level4" number="2.31.2.1">
<h4><span class="header-section-number">2.31.2.1</span> Paclitaxel</h4>
<ul>
<li>Paclitaxel: 135–170 mg/m2 IV as a 24-hour infusion on day 1</li>
<li>Repeat cycle every 3 weeks.</li>
</ul>
<blockquote>
<p>Roth BJ, et al. Cancer 1993;72:2457–2460.</p>
</blockquote>
<p>or</p>
<ul>
<li>Paclitaxel: 150 mg/m2 IV as a 1-hour infusion weekly for 6 weeks</li>
<li>Repeat cycle every 8 weeks.</li>
</ul>
<blockquote>
<p>Ahmed S, et al. Proc Am Soc Clin Oncol 1998;17:325a.</p>
</blockquote>
</div>
<div id="docetaxel-7" class="section level4" number="2.31.2.2">
<h4><span class="header-section-number">2.31.2.2</span> Docetaxel</h4>
<ul>
<li>Docetaxel: 75 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Petrylak DP. Semin Oncol 2000;27 (Suppl 3):24–29.</p>
</blockquote>
<p>or</p>
<ul>
<li>Docetaxel: 20–40 mg/m2 weekly for 3 weeks</li>
<li>Repeat cycle every 4 weeks.</li>
</ul>
<blockquote>
<p>Dreicer R. Hematol Oncol Clin North Am 2006;20:935–946.</p>
</blockquote>
</div>
<div id="estramustine" class="section level4" number="2.31.2.3">
<h4><span class="header-section-number">2.31.2.3</span> Estramustine</h4>
<ul>
<li>Estramustine: 14 mg/kg/day PO in 3–4 divided doses.</li>
</ul>
<blockquote>
<p>Neoptolemos JP, et al. Lancet 2017;389:1011–1024.</p>
</blockquote>
</div>
<div id="goserelin" class="section level4" number="2.31.2.4">
<h4><span class="header-section-number">2.31.2.4</span> Goserelin</h4>
<ul>
<li>Goserelin: 3.6 mg SC on day 1</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Murphy GP, et al. Urology 1984;23:54–63.</p>
</blockquote>
<p>or</p>
<ul>
<li>Goserelin: 10.8 mg SC on day 1</li>
<li>Repeat cycle every 12 weeks.</li>
</ul>
<blockquote>
<p>Dijkman GA, et al. Eur Urol 1995;27:43–46.</p>
</blockquote>
</div>
<div id="goserelin-adjuvant-therapy" class="section level4" number="2.31.2.5">
<h4><span class="header-section-number">2.31.2.5</span> Goserelin (adjuvant therapy)</h4>
<ul>
<li>Goserelin: 3.6 mg SC on day 1</li>
<li>Repeat cycle every 28 days for 24 months.</li>
</ul>
<blockquote>
<p>Hanks GE, et al. J Clin Oncol 2003;21:3972–3978.</p>
</blockquote>
</div>
<div id="degarelix" class="section level4" number="2.31.2.6">
<h4><span class="header-section-number">2.31.2.6</span> Degarelix</h4>
<ul>
<li>Degarelix: 240 mg SC starting dose followed 28 days later by the first maintenance dose of 80 mg SC</li>
<li>Repeat maintenance dose every 28 days.</li>
</ul>
<blockquote>
<p>Klotz L, et al. BJU Int 2008;10:1531–1538.</p>
</blockquote>
</div>
<div id="leuprolide" class="section level4" number="2.31.2.7">
<h4><span class="header-section-number">2.31.2.7</span> Leuprolide</h4>
<ul>
<li>Leuprolide: 7.5 mg SC on day 1</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>The Leuprolide Study Group. N Engl J Med 1984;311:1281–1286.</p>
</blockquote>
<p>or</p>
<ul>
<li>Leuprolide: 22.5 mg SC on day 1</li>
<li>Repeat cycle every 12 weeks.</li>
</ul>
<blockquote>
<p>Sharifi R, et al. Clin Ther 1996;18:647–657.</p>
</blockquote>
<p>or</p>
<ul>
<li>Leuprolide: 30 mg SC on day 1</li>
<li>Repeat cycle every 16 weeks.</li>
</ul>
<blockquote>
<p>Sartor O, et al. Urology 2003;62:319–323.</p>
</blockquote>
</div>
<div id="bicalutamide" class="section level4" number="2.31.2.8">
<h4><span class="header-section-number">2.31.2.8</span> Bicalutamide</h4>
<ul>
<li>Bicalutamide: 50 mg PO daily.</li>
</ul>
<p>In patients refractory to other anti-androgen agents, may start with a higher dose of 150 mg PO daily.</p>
<blockquote>
<p>Schellhammer PF, et al. Urology 1997;50:330–336.</p>
</blockquote>
</div>
<div id="flutamide" class="section level4" number="2.31.2.9">
<h4><span class="header-section-number">2.31.2.9</span> Flutamide</h4>
<ul>
<li>Flutamide: 250 mg PO tid.</li>
</ul>
<blockquote>
<p>McLeod DG, et al. Cancer 1993;72:3870–3873.</p>
</blockquote>
</div>
<div id="nilutamide" class="section level4" number="2.31.2.10">
<h4><span class="header-section-number">2.31.2.10</span> Nilutamide</h4>
<ul>
<li>Nilutamide: 300 mg PO on days 1–30, then 150 mg PO daily.</li>
</ul>
<blockquote>
<p>Janknegt RA, et al. J Urol 1993;149:77–82.</p>
</blockquote>
</div>
<div id="apalutamide" class="section level4" number="2.31.2.11">
<h4><span class="header-section-number">2.31.2.11</span> Apalutamide</h4>
<ul>
<li>Apalutamide: 240 mg PO daily.</li>
</ul>
<blockquote>
<p>Smith MR, et al. N Engl J Med 2018;378:1408–1418.</p>
</blockquote>
</div>
<div id="prednisone-1" class="section level4" number="2.31.2.12">
<h4><span class="header-section-number">2.31.2.12</span> Prednisone</h4>
<ul>
<li>Prednisone: 5 mg PO bid.</li>
</ul>
<blockquote>
<p>Tannock IF, et al. J Clin Oncol 1989;7:590–597.</p>
</blockquote>
<p>or</p>
<ul>
<li>Prednisone: 5 mg PO qid.</li>
</ul>
<blockquote>
<p>Fossa SD, et al. J Clin Oncol 2001;19:62–71.</p>
</blockquote>
</div>
<div id="ketoconazole" class="section level4" number="2.31.2.13">
<h4><span class="header-section-number">2.31.2.13</span> Ketoconazole</h4>
<ul>
<li>Ketoconazole: 1,200 mg PO daily</li>
</ul>
<blockquote>
<p>Johnson DE, et al. Urology 1988;31:132–134.</p>
</blockquote>
</div>
<div id="aminoglutethimide" class="section level4" number="2.31.2.14">
<h4><span class="header-section-number">2.31.2.14</span> Aminoglutethimide</h4>
<ul>
<li>Aminoglutethimide: 250 mg PO qid, if tolerated may increase to 500 mg PO qid</li>
</ul>
<blockquote>
<p>Havlin KA, et al. Cancer Treat Res 1988;39:83–96.</p>
</blockquote>
</div>
<div id="sipuleucel-t" class="section level4" number="2.31.2.15">
<h4><span class="header-section-number">2.31.2.15</span> Sipuleucel-T</h4>
<ul>
<li>Sipuleucel-T: Administer contents of infusion bag IV over 60 minutes on day 1</li>
<li>Repeat cycle every 2 weeks for a total of 3 doses.</li>
</ul>
<blockquote>
<p>Kantoff PW, et al. N Engl J Med 2010;363:411–422.</p>
</blockquote>
</div>
<div id="enzalutamide" class="section level4" number="2.31.2.16">
<h4><span class="header-section-number">2.31.2.16</span> Enzalutamide</h4>
<ul>
<li>Enzalutamide: 160 mg PO daily</li>
</ul>
<blockquote>
<p>Scher HI, et al. N Engl J Med 2012;367:1187–1197.</p>
</blockquote>
</div>
</div>
</div>
<div id="renal-cell-cancer" class="section level2" number="2.32">
<h2><span class="header-section-number">2.32</span> RENAL CELL CANCER</h2>
<div id="adjuvant-therapy---single-agent-regimens-4" class="section level3" number="2.32.1">
<h3><span class="header-section-number">2.32.1</span> Adjuvant Therapy - Single-Agent Regimens</h3>
<div id="sunitinib-3" class="section level4" number="2.32.1.1">
<h4><span class="header-section-number">2.32.1.1</span> Sunitinib</h4>
<ul>
<li>Sunitinib: 50 mg PO daily for 4 weeks</li>
<li>Repeat cycle every 6 weeks.</li>
</ul>
<blockquote>
<p>Ravaud A, et al. N Engl J Med 2016;375:2246–2254.</p>
</blockquote>
</div>
</div>
<div id="metastatic-disease---combination-regimens-6" class="section level3" number="2.32.2">
<h3><span class="header-section-number">2.32.2</span> Metastatic Disease - Combination Regimens</h3>
<div id="bevacizumab-interferon-alpha" class="section level4" number="2.32.2.1">
<h4><span class="header-section-number">2.32.2.1</span> Bevacizumab + Interferon-alpha</h4>
<ul>
<li>Bevacizumab: 10 mg/kg IV every 2 weeks</li>
<li>Interferon alpha-2a: 9 million U SC, 3 times per week, for 1 year</li>
<li>Continue treatment until disease progression.</li>
</ul>
<blockquote>
<p>Escudier B, et al. Lancet 2007;370:2103–2111.</p>
</blockquote>
</div>
<div id="interferon-alpha-il-2" class="section level4" number="2.32.2.2">
<h4><span class="header-section-number">2.32.2.2</span> Interferon-alpha + IL-2</h4>
<ul>
<li>Interferon a-2a: 9 million U SC on days 1–4, weeks 1–4</li>
<li>Interleukin-2: 12 million U SC on days 1–4, weeks 1–4</li>
<li>Repeat cycle every 6 weeks.</li>
</ul>
<blockquote>
<p>Atzpodien J, et al. Semin Oncol 1993;20 (Suppl 9):22.</p>
</blockquote>
</div>
<div id="lenvatinib-everolimus" class="section level4" number="2.32.2.3">
<h4><span class="header-section-number">2.32.2.3</span> Lenvatinib + Everolimus</h4>
<ul>
<li>Lenvatinib: 18 mg/day PO daily</li>
<li>Everolimus: 5 mg/day PO daily</li>
<li>Continue treatment until disease progression.</li>
</ul>
<blockquote>
<p>Motzer RJ, et al. Lancet Oncol 2015;16:1473–1482.</p>
</blockquote>
</div>
<div id="nivolumab-ipilimumab-2" class="section level4" number="2.32.2.4">
<h4><span class="header-section-number">2.32.2.4</span> Nivolumab + Ipilimumab</h4>
<ul>
<li>Ipilimumab: 1 mg/kg IV on day 1</li>
<li>Nivolumab: 3 mg/kg IV on day 1</li>
<li>Repeat cycle every 21 days for 4 cycles followed by</li>
<li>Nivolumab: 240 mg IV on day 1</li>
<li>Repeat cycle every 14 days until disease progression. May also administer 480 mg IV on day 1 with cycles repeated every 28 days.</li>
</ul>
<blockquote>
<p>Motzer RJ, et al. N Engl J Med 2018;378:1277–1290.</p>
</blockquote>
</div>
<div id="bevacizumab-everolimus" class="section level4" number="2.32.2.5">
<h4><span class="header-section-number">2.32.2.5</span> Bevacizumab + Everolimus</h4>
<ul>
<li>Bevacizumab: 10 mg/kg IV on day 1</li>
<li>Everolimus: 10 mg/day PO daily</li>
<li>Repeat cycle every 14 days.</li>
</ul>
<blockquote>
<p>Voss MH, et al. J Clin Oncol 2016;34:3846–3853.</p>
</blockquote>
</div>
</div>
<div id="metastatic-disease---single-agent-regimens-8" class="section level3" number="2.32.3">
<h3><span class="header-section-number">2.32.3</span> Metastatic Disease - Single-Agent Regimens</h3>
<div id="bevacizumab-4" class="section level4" number="2.32.3.1">
<h4><span class="header-section-number">2.32.3.1</span> Bevacizumab</h4>
<ul>
<li>Bevacizumab: 10 mg/kg IV on day 1</li>
<li>Repeat cycle every 2 weeks.</li>
</ul>
<blockquote>
<p>Yang JC, et al. N Engl J Med 2003;349:427–434.</p>
</blockquote>
</div>
<div id="sunitinib-4" class="section level4" number="2.32.3.2">
<h4><span class="header-section-number">2.32.3.2</span> Sunitinib</h4>
<ul>
<li>Sunitinib: 50 mg PO daily for 4 weeks</li>
<li>Repeat cycle every 6 weeks.</li>
</ul>
<blockquote>
<p>Motzer RJ, et al. J Clin Oncol 2006;24:16–24.</p>
</blockquote>
<p>or</p>
<ul>
<li>Sunitinib: 50 mg PO daily for 2 weeks</li>
<li>Repeat cycle every 3 weeks.</li>
</ul>
<blockquote>
<p>Najjar YG, et al. Eur J Cancer 2014;50:1084–1089.</p>
</blockquote>
</div>
<div id="sorafenib-3" class="section level4" number="2.32.3.3">
<h4><span class="header-section-number">2.32.3.3</span> Sorafenib</h4>
<ul>
<li>Sorafenib: 400 mg PO bid</li>
<li>Continue treatment until disease progression.</li>
</ul>
<blockquote>
<p>Ratain MJ, et al. J Clin Oncol 2006;24:2505–2512.</p>
</blockquote>
</div>
<div id="pazopanib" class="section level4" number="2.32.3.4">
<h4><span class="header-section-number">2.32.3.4</span> Pazopanib</h4>
<ul>
<li>Pazopanib: 800 mg PO daily</li>
<li>Continue treatment until disease progression.</li>
</ul>
<blockquote>
<p>Sternberg CN, et al. J Clin Oncol 2010;28:1061–1068.</p>
</blockquote>
</div>
<div id="axitinib" class="section level4" number="2.32.3.5">
<h4><span class="header-section-number">2.32.3.5</span> Axitinib</h4>
<ul>
<li>Axitinib: 5 mg PO bid; after 2 weeks may increase dose to 7 mg PO bid; after 2 weeks may increase dose to 10 mg PO bid
Continue cycle every 6 weeks.</li>
</ul>
<blockquote>
<p>Rini Bl, et al., et al. Lancet 2011;378:1931–1939.</p>
</blockquote>
</div>
<div id="temsirolimus-1" class="section level4" number="2.32.3.6">
<h4><span class="header-section-number">2.32.3.6</span> Temsirolimus</h4>
<ul>
<li>Temsirolimus: 25 mg IV weekly</li>
<li>Continue treatment disease progression.</li>
</ul>
<blockquote>
<p>Hudes G, et al. N Engl J Med 2007;356:2271–2281.</p>
</blockquote>
</div>
<div id="everolimus-2" class="section level4" number="2.32.3.7">
<h4><span class="header-section-number">2.32.3.7</span> Everolimus</h4>
<ul>
<li>Everolimus: 10 mg PO daily</li>
<li>Continue treatment until disease progression.</li>
</ul>
<blockquote>
<p>Motzer RJ, et al. Lancet 2008;372:449–456.</p>
</blockquote>
</div>
<div id="aldesleukin-1" class="section level4" number="2.32.3.8">
<h4><span class="header-section-number">2.32.3.8</span> Aldesleukin</h4>
<ul>
<li>Interleukin-2: 720,000 IU/kg IV every 8 hours on days 1–5 and 15–19</li>
<li>Repeat cycles in 6- to 12-week intervals up to a total of 3 cycles.</li>
</ul>
<blockquote>
<p>Fyfe G, et al. J Clin Oncol 1995;13:688–696.</p>
</blockquote>
<p>or</p>
<ul>
<li>Interleukin-2: 720,000 IU/kg IV at 8 am and 6 pm on days 1–5 and 15–19</li>
<li>Treat up to a maximum of 8 total doses on days 1–5 and repeat on days 15–19.</li>
<li>Repeat cycles in 8- to 12-week intervals.</li>
</ul>
<blockquote>
<p>Acquavella N, et al. J Immunother 2008;31:569–576.</p>
</blockquote>
</div>
<div id="interferon-alpha-2" class="section level4" number="2.32.3.9">
<h4><span class="header-section-number">2.32.3.9</span> Interferon-alpha</h4>
<ul>
<li>Interferon a-2a: 5–15 million U SC daily or 3–5 times per week Continue treatment until disease progression.</li>
</ul>
<blockquote>
<p>Minasian LM, et al. J Clin Oncol 1993;11:1368–1375.</p>
</blockquote>
</div>
<div id="cabozantinib" class="section level4" number="2.32.3.10">
<h4><span class="header-section-number">2.32.3.10</span> Cabozantinib</h4>
<ul>
<li>Cabozantinib: 60 mg PO daily</li>
<li>Continue treatment until disease progression.</li>
</ul>
<blockquote>
<p>Choueiri TK, et al. N Engl J Med 2015:373:1814–1822.</p>
</blockquote>
</div>
<div id="nivolumab-9" class="section level4" number="2.32.3.11">
<h4><span class="header-section-number">2.32.3.11</span> Nivolumab</h4>
<ul>
<li>Nivolumab: 240 mg IV on day 1</li>
<li>Repeat cycle every 2 weeks. May also administer 480 mg IV on day 1 with cycles repeated every 4 weeks.</li>
</ul>
<blockquote>
<p>Motzer RJ et al. Lancet Oncol 2015;16:1473–1482.</p>
</blockquote>
</div>
</div>
</div>
<div id="soft-tissue-sarcomas" class="section level2" number="2.33">
<h2><span class="header-section-number">2.33</span> SOFT TISSUE SARCOMAS</h2>
<div id="combination-regimens-17" class="section level3" number="2.33.1">
<h3><span class="header-section-number">2.33.1</span> Combination Regimens</h3>
<div id="ad" class="section level4" number="2.33.1.1">
<h4><span class="header-section-number">2.33.1.1</span> AD</h4>
<ul>
<li>Doxorubicin: 15 mg/m2/day IV continuous infusion on days 1–4</li>
<li>Dacarbazine: 250 mg/m2/day IV continuous infusion on days 1–4</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Antman K, et al. J Clin Oncol 1993;11:1276–1285.</p>
</blockquote>
</div>
<div id="ai" class="section level4" number="2.33.1.2">
<h4><span class="header-section-number">2.33.1.2</span> AI</h4>
<ul>
<li>Doxorubicin: 20 mg/m2/day IV continuous infusion on days 1–3</li>
<li>Ifosfamide: 1,500 mg/m2/day IV continuous infusion on days 1–4</li>
<li>Mesna: 225 mg/m2 IV over 1 hour before ifosfamide and at 4 and 8 hours after ifosfamide</li>
<li>Repeat cycle every 21 days. On day 5, G-CSF support should be started at 5 µg/kg/day for 10 days starting on day 5.</li>
</ul>
<blockquote>
<p>Worden FP, et al. J Clin Oncol 2005;23:105–112.</p>
</blockquote>
</div>
<div id="maid" class="section level4" number="2.33.1.3">
<h4><span class="header-section-number">2.33.1.3</span> MAID</h4>
<ul>
<li>Mesna: 2,500 mg/m2/day IV continuous infusion on days 1–4</li>
<li>Doxorubicin: 20 mg/m2/day IV continuous infusion on days 1–3</li>
<li>Ifosfamide: 2,500 mg/m2/day IV continuous infusion on days 1–3</li>
<li>Dacarbazine: 300 mg/m2/day IV continuous infusion on days 1–3</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Elias A, et al. J Clin Oncol 1989;7:1208–1216.</p>
</blockquote>
</div>
<div id="cyvadic" class="section level4" number="2.33.1.4">
<h4><span class="header-section-number">2.33.1.4</span> CYVADIC</h4>
<ul>
<li>Cyclophosphamide: 500 mg/m2 IV on day 1</li>
<li>Vincristine: 1.5 mg/m2 IV on day 1 (maximum, 2 mg)</li>
<li>Doxorubicin: 50 mg/m2 IV on day 1</li>
<li>Dacarbazine: 750 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Santoro A, et al. J Clin Oncol 1995;13:1537–1545.</p>
</blockquote>
</div>
<div id="gemcitabine-docetaxel-2" class="section level4" number="2.33.1.5">
<h4><span class="header-section-number">2.33.1.5</span> Gemcitabine + Docetaxel</h4>
<ul>
<li>Gemcitabine: 900 mg/m2 IV over 90 minutes on days 1 and 8</li>
<li>Docetaxel: 100 mg/m2 IV on day 8</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Maki RG, et al. J Clin Oncol 2007;25:2755–2763.</p>
</blockquote>
</div>
<div id="gemcitabine-navelbine" class="section level4" number="2.33.1.6">
<h4><span class="header-section-number">2.33.1.6</span> Gemcitabine + Navelbine</h4>
<ul>
<li>Gemcitabine: 800 mg/m2 IV over 90 minutes on days 1 and 8</li>
<li>Vinorelbine: 25 mg/m2 IV on days 1 and 8</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Dileo P, et al. Cancer 2007;109:1863–1869.</p>
</blockquote>
</div>
<div id="doxorubicin-olaratumab" class="section level4" number="2.33.1.7">
<h4><span class="header-section-number">2.33.1.7</span> Doxorubicin + Olaratumab</h4>
<ul>
<li>Doxorubicin: 75 mg/m2 IV on day 1</li>
<li>Olaratumab: 15 mg/kg IV on days 1 and 8</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Tap WD, et al. Lancet 2016;388:488–497.</p>
</blockquote>
</div>
<div id="cav-alternating-with-ie-ewings-sarcoma" class="section level4" number="2.33.1.8">
<h4><span class="header-section-number">2.33.1.8</span> CAV Alternating with IE (Ewing’s sarcoma)</h4>
<ul>
<li>Cyclophosphamide: 1,200 mg/m2 IV on day 1</li>
<li>Doxorubicin: 75 mg/m2 IV on day 1</li>
<li>Vincristine: 2 mg IV on day 1</li>
<li>Ifosfamide: 1,800 mg/m2 IV on days 1–5</li>
<li>Etoposide: 100 mg/m2 IV on days 1–5</li>
<li>Alternate CAV with IE every 21 days for a total of 17 cycles. When the cumulative dose of doxorubicin reaches 375 mg/m2, switch to dactinomycin at 1.25 mg/m2.</li>
</ul>
<blockquote>
<p>Holcombe E, et al. N Engl J Med 2003;348:694–701.</p>
</blockquote>
</div>
</div>
<div id="single-agent-regimens-15" class="section level3" number="2.33.2">
<h3><span class="header-section-number">2.33.2</span> Single-Agent Regimens</h3>
<div id="doxorubicin-3" class="section level4" number="2.33.2.1">
<h4><span class="header-section-number">2.33.2.1</span> Doxorubicin</h4>
<ul>
<li>Doxorubicin: 75 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Santoro A, et al. J Clin Oncol 1995;13:1537–1545.</p>
</blockquote>
</div>
<div id="gemcitabine-11" class="section level4" number="2.33.2.2">
<h4><span class="header-section-number">2.33.2.2</span> Gemcitabine</h4>
<ul>
<li>Gemcitabine: 1,200 mg/m2 IV on days 1 and 8</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Maki RG, et al. J Clin Oncol 2007;25:2755–2763.</p>
</blockquote>
</div>
<div id="ifosfamide" class="section level4" number="2.33.2.3">
<h4><span class="header-section-number">2.33.2.3</span> Ifosfamide</h4>
<ul>
<li>Ifosfamide: 3,000 mg/m2/day IV on days 1–3</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>van Oosterom AT, et al. Eur J Cancer 2002;38:2397–2406.</p>
</blockquote>
</div>
<div id="doxorubicin-liposome-3" class="section level4" number="2.33.2.4">
<h4><span class="header-section-number">2.33.2.4</span> Doxorubicin Liposome</h4>
<ul>
<li>Doxorubicin liposome: 50 mg/m2 IV on day 1</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Judson I, et al. Eur J Cancer 2001;37:870–877.</p>
</blockquote>
</div>
<div id="pazopanib-1" class="section level4" number="2.33.2.5">
<h4><span class="header-section-number">2.33.2.5</span> Pazopanib</h4>
<ul>
<li>Pazopanib: 800 mg PO daily</li>
<li>Continue treatment until disease progression.</li>
</ul>
<blockquote>
<p>van Der Graaf, et al. J Clin Oncol 2011;29:18S (LBA 10002).</p>
</blockquote>
</div>
<div id="trabectedin" class="section level4" number="2.33.2.6">
<h4><span class="header-section-number">2.33.2.6</span> Trabectedin</h4>
<ul>
<li>Trabectedin: 1.5 mg/kg IV on day 1</li>
<li>Repeat cycles every 21 days.</li>
</ul>
<blockquote>
<p>Demetri GD, et al. J Clin Oncol 2016;34:786–793.</p>
</blockquote>
</div>
<div id="eribulin-1" class="section level4" number="2.33.2.7">
<h4><span class="header-section-number">2.33.2.7</span> Eribulin</h4>
<ul>
<li>Eribulin: 1.4 mg/m2 IV on days 1 and 8</li>
<li>Repeat cycles every 21 days.</li>
</ul>
<blockquote>
<p>Schoffski P, et al. Lancet 2016;387:1629–1637.</p>
</blockquote>
</div>
</div>
</div>
<div id="testicular-cancer" class="section level2" number="2.34">
<h2><span class="header-section-number">2.34</span> TESTICULAR CANCER</h2>
<div id="adjuvant-therapy-2" class="section level3" number="2.34.1">
<h3><span class="header-section-number">2.34.1</span> Adjuvant Therapy</h3>
<div id="peb-1" class="section level4" number="2.34.1.1">
<h4><span class="header-section-number">2.34.1.1</span> PEB</h4>
<ul>
<li>Cisplatin: 20 mg/m2/day IV on days 1–5</li>
<li>Etoposide: 100 mg/m2/day IV on days 1–5</li>
<li>Bleomycin: 30 U IV on days 2, 9, and 16</li>
<li>Repeat cycle every 28 days for a total of 2 cycles. Adjuvant therapy of stage II testicular cancer treated with orchiectomy and retroperitoneal lymph node dissection.</li>
</ul>
<blockquote>
<p>Einhorn LH, et al. J Clin Oncol 1989;7:387–391.</p>
</blockquote>
</div>
<div id="carboplatin-1" class="section level4" number="2.34.1.2">
<h4><span class="header-section-number">2.34.1.2</span> Carboplatin</h4>
<ul>
<li>Carboplatin: AUC of 7, IV on day 1</li>
<li>Administer one dose for adjuvant therapy of stage I seminoma.</li>
</ul>
<blockquote>
<p>Oliver RT, et al. Lancet 2005;366:293–300.</p>
</blockquote>
</div>
</div>
<div id="metastatic-disease---combination-regimens-7" class="section level3" number="2.34.2">
<h3><span class="header-section-number">2.34.2</span> Metastatic Disease - Combination Regimens</h3>
<div id="bep-1" class="section level4" number="2.34.2.1">
<h4><span class="header-section-number">2.34.2.1</span> BEP</h4>
<ul>
<li>Bleomycin: 30 U IV on days 1, 8, and 15</li>
<li>Etoposide: 100 mg/m2/day IV on days 1–5</li>
<li>Cisplatin: 20 mg/m2/day IV on days 1–5</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Nichols CR, et al. J Clin Oncol 1998;16:1287–1295.</p>
</blockquote>
</div>
<div id="ep-4" class="section level4" number="2.34.2.2">
<h4><span class="header-section-number">2.34.2.2</span> EP</h4>
<ul>
<li>Etoposide: 100 mg/m2/day IV on days 1–5</li>
<li>Cisplatin: 20 mg/m2/day IV on days 1–5</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Bosl G, et al. J Clin Oncol 1988;6:1231–1238.</p>
</blockquote>
</div>
<div id="pvb" class="section level4" number="2.34.2.3">
<h4><span class="header-section-number">2.34.2.3</span> PVB</h4>
<ul>
<li>Cisplatin: 20 mg/m2/day IV on days 1–5</li>
<li>Vinblastine: 0.15 mg/kg IV on days 1 and 2</li>
<li>Bleomycin: 30 U IV on days 2, 9, and 16</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Einhorn LH, et al. Ann Intern Med 1977;87:293–298.</p>
</blockquote>
</div>
<div id="vab-6" class="section level4" number="2.34.2.4">
<h4><span class="header-section-number">2.34.2.4</span> VAB-6</h4>
<ul>
<li>Vinblastine: 4 mg/m2 IV on day 1</li>
<li>Dactinomycin: 1 mg/m2 IV on day 1</li>
<li>Bleomycin: 30 U IV on day 1, then 20 U/m2</li>
<li>continuous infusion on days 1–3</li>
<li>Cisplatin: 20 mg/m2 IV on day 4</li>
<li>Cyclophosphamide: 600 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Vugrin D, et al. Ann Intern Med 1981;95:59–61.</p>
</blockquote>
</div>
<div id="veip-salvage-regimen" class="section level4" number="2.34.2.5">
<h4><span class="header-section-number">2.34.2.5</span> VeIP (salvage regimen)</h4>
<ul>
<li>Vinblastine: 0.11 mg/kg IV on days 1 and 2</li>
<li>Ifosfamide: 1,200 mg/m2/day IV on days 1–5</li>
<li>Cisplatin: 20 mg/m2/day IV on days 1–5</li>
<li>Mesna: 400 mg/m2 IV, given 15 minutes before first ifosfamide dose, then 1,200 mg/m2/day IV continuous infusion for 5 days</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Loehrer PJ, et al. Ann Intern Med 1988;109:540–546.</p>
</blockquote>
</div>
<div id="vip-salvage-regimen" class="section level4" number="2.34.2.6">
<h4><span class="header-section-number">2.34.2.6</span> VIP (salvage regimen)</h4>
<ul>
<li>Etoposide (VP-16): 75 mg/m2/day IV on days 1–5</li>
<li>Ifosfamide: 1,200 mg/m2/day IV on days 1–5</li>
<li>Cisplatin: 20 mg/m2/day IV on days 1–5</li>
<li>Mesna: 400 mg/m2 IV, given 15 minutes before first ifosfamide dose, then 1,200 mg/m2/day IV continuous infusion for 5 days</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Loehrer PJ, et al. Ann Intern Med 1988;109:540–546.</p>
</blockquote>
</div>
<div id="tip-salvage-regimen" class="section level4" number="2.34.2.7">
<h4><span class="header-section-number">2.34.2.7</span> TIP (salvage regimen)</h4>
<ul>
<li>Paclitaxel: 250 mg/m2 IV over 24 hours on day 1</li>
<li>Ifosfamide: 1,500 mg/m2/day IV on days 2–5</li>
<li>Cisplatin: 25 mg/m2/day IV on days 1–5</li>
<li>Mesna: 500 mg/m2 IV, given before ifosfamide dose, and at 4 and 8 hours after ifosfamide on days 2–5</li>
<li>Repeat cycle every 21 days for a total of 4 cycles. G-CSF support at 5 µg/kg/day SC should be given on days 7–18.</li>
</ul>
<blockquote>
<p>Kondagunat GV, et al. J Clin Oncol 2005;23:6549–6555.</p>
</blockquote>
</div>
<div id="paclitaxel-gemcitabine" class="section level4" number="2.34.2.8">
<h4><span class="header-section-number">2.34.2.8</span> Paclitaxel + Gemcitabine</h4>
<ul>
<li>Paclitaxel: 100 mg/m2 IV on days 1, 8, and 15</li>
<li>Gemcitabine: 1,000 mg/m2 IV on days 1, 8, and 15</li>
<li>Repeat cycle every 28 days for a total of 6 cycles.</li>
</ul>
<blockquote>
<p>Einhorn LH, et al. J Clin Oncol 2007;25:513–516.</p>
</blockquote>
</div>
<div id="paclitaxel-gemcitabine-oxaliplatin" class="section level4" number="2.34.2.9">
<h4><span class="header-section-number">2.34.2.9</span> Paclitaxel + Gemcitabine + Oxaliplatin</h4>
<ul>
<li>Paclitaxel: 80 mg/m2 IV on days 1 and 8</li>
<li>Gemcitabine: 800 mg/m2 IV on days 1 and 8</li>
<li>Oxaliplatin: 130 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Bokemeyer C, et al. Ann Oncol 2008;19:448–453.</p>
</blockquote>
</div>
</div>
<div id="metastatic-disease---single-agent-regimens-9" class="section level3" number="2.34.3">
<h3><span class="header-section-number">2.34.3</span> Metastatic Disease - Single-Agent Regimens</h3>
<div id="etoposide-3" class="section level4" number="2.34.3.1">
<h4><span class="header-section-number">2.34.3.1</span> Etoposide</h4>
<ul>
<li>Etoposide: 50 mg/m2 q day PO</li>
<li>Repeat cycle every 14–21 days.</li>
</ul>
<blockquote>
<p>Miller JC, et al. Semin Oncol 1990;17(1 Suppl 2):36–39.</p>
</blockquote>
</div>
</div>
</div>
<div id="thymoma" class="section level2" number="2.35">
<h2><span class="header-section-number">2.35</span> THYMOMA</h2>
<div id="combination-regimens-18" class="section level3" number="2.35.1">
<h3><span class="header-section-number">2.35.1</span> Combination Regimens</h3>
<div id="cap-3" class="section level4" number="2.35.1.1">
<h4><span class="header-section-number">2.35.1.1</span> CAP</h4>
<ul>
<li>Cyclophosphamide: 500 mg/m2 IV on day 1</li>
<li>Doxorubicin: 50 mg/m2 IV on day 1</li>
<li>Cisplatin: 50 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Loehrer PJ, et al. J Clin Oncol 1994;12:1164–1168.</p>
</blockquote>
</div>
<div id="cisplatin-etoposide-1" class="section level4" number="2.35.1.2">
<h4><span class="header-section-number">2.35.1.2</span> Cisplatin + Etoposide</h4>
<ul>
<li>Cisplatin: 60 mg/m2 IV on day 1</li>
<li>Etoposide: 120 mg/m2 IV on days 1–3</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Giaccone G, et al. J Clin Oncol 1996;14:814–820.</p>
</blockquote>
</div>
<div id="adoc" class="section level4" number="2.35.1.3">
<h4><span class="header-section-number">2.35.1.3</span> ADOC</h4>
<ul>
<li>Cisplatin: 50 mg/m2 IV on day 1</li>
<li>Doxorubicin: 40 mg/m2 IV on day 1</li>
<li>Vincristine: 0.6 mg/m2 IV on day 3</li>
<li>Cyclophosphamide: 700 mg/m2 IV on day 4</li>
<li>Repeat cycle every 28 days.</li>
</ul>
<blockquote>
<p>Fornasiero A, et al. Cancer 1991;68:30–33.</p>
</blockquote>
</div>
<div id="vip" class="section level4" number="2.35.1.4">
<h4><span class="header-section-number">2.35.1.4</span> VIP</h4>
<ul>
<li>Etoposide: 75 mg/m2 IV on days 1–4</li>
<li>Ifosfamide: 1,200 mg/m2 IV on days 1–4</li>
<li>Cisplatin: 20 mg/m2 IV on days 1–4</li>
<li>Mesna: 240 mg/m2 IV before first ifosfamide dose, then 4 and 8 hours later on days 1–4</li>
<li>Repeat cycle every 21 days for a total of 4 cycles. G-CSF support at 5 µg/kg/day should be given on days 5–15.</li>
</ul>
<blockquote>
<p>Loehrer PJ, et al. Cancer 2001;91:2010–2015.</p>
</blockquote>
</div>
<div id="gemcitabine-topotecan" class="section level4" number="2.35.1.5">
<h4><span class="header-section-number">2.35.1.5</span> Gemcitabine + Topotecan</h4>
<ul>
<li>Gemcitabine: 1,000 mg/m2 IV on days 1, 8, and 15</li>
<li>Topotecan: 0.75–1.5 mg/m2 IV on days 1, 8, and 15</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>William WN, et al. Am J Clin Oncol 2009;32:15–19.</p>
</blockquote>
</div>
<div id="carboplatin-paclitaxel-3" class="section level4" number="2.35.1.6">
<h4><span class="header-section-number">2.35.1.6</span> Carboplatin + Paclitaxel</h4>
<ul>
<li>Carboplatin: AUC of 6, IV on day 1</li>
<li>Paclitaxel: 225 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Lemma GL, et al. J Clin Oncol 2011;29:2060–2065.</p>
</blockquote>
</div>
</div>
</div>
<div id="thyroid-cancer" class="section level2" number="2.36">
<h2><span class="header-section-number">2.36</span> THYROID CANCER</h2>
<div id="combination-regimens-19" class="section level3" number="2.36.1">
<h3><span class="header-section-number">2.36.1</span> Combination Regimens</h3>
<div id="doxorubicin-cisplatin-1" class="section level4" number="2.36.1.1">
<h4><span class="header-section-number">2.36.1.1</span> Doxorubicin + Cisplatin</h4>
<ul>
<li>Doxorubicin: 60 mg/m2 IV on day 1</li>
<li>Cisplatin: 40 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Shimaoka K, et al. Cancer 1985;56:2155–2160.</p>
</blockquote>
</div>
</div>
<div id="single-agent-regimens-16" class="section level3" number="2.36.2">
<h3><span class="header-section-number">2.36.2</span> Single-Agent Regimens</h3>
<div id="doxorubicin-4" class="section level4" number="2.36.2.1">
<h4><span class="header-section-number">2.36.2.1</span> Doxorubicin</h4>
<ul>
<li>Doxorubicin: 60 mg/m2 IV on day 1</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Shimaoka K, et al. Cancer 1985;56:2155–2160.</p>
</blockquote>
</div>
<div id="sorafenib-4" class="section level4" number="2.36.2.2">
<h4><span class="header-section-number">2.36.2.2</span> Sorafenib</h4>
<ul>
<li>Sorafenib: 400 mg PO bid</li>
<li>Continue treatment until disease progression.</li>
</ul>
<blockquote>
<p>Gupta-Abramson V, et al. J Clin Oncol 2008;26:2010–2015.</p>
</blockquote>
</div>
<div id="sunitinib-5" class="section level4" number="2.36.2.3">
<h4><span class="header-section-number">2.36.2.3</span> Sunitinib</h4>
<ul>
<li>Sunitinib: 37.5 mg PO daily</li>
<li>Continue treatment until disease progression.</li>
</ul>
<blockquote>
<p>Carr LL, et al. Clin Cancer Res 2010:16:5260–5268.</p>
</blockquote>
<p>or</p>
<ul>
<li>Sunitinib: 50 mg PO daily for 4 weeks</li>
<li>Repeat cycle every 6 weeks.</li>
</ul>
<blockquote>
<p>Ravaud A, et al. Eur J Cancer 2017;76:110–117.</p>
</blockquote>
</div>
<div id="pazopanib-2" class="section level4" number="2.36.2.4">
<h4><span class="header-section-number">2.36.2.4</span> Pazopanib</h4>
<ul>
<li>Pazopanib: 800 mg PO daily</li>
<li>Continue treatment until disease progression.</li>
</ul>
<blockquote>
<p>Bible KC, et al. Lancet Oncol 2010;11:962–972.</p>
</blockquote>
</div>
<div id="vandetanib-medullary-carcinoma-of-the-thyroid" class="section level4" number="2.36.2.5">
<h4><span class="header-section-number">2.36.2.5</span> Vandetanib (medullary carcinoma of the thyroid)</h4>
<ul>
<li>Vandetanib: 300 mg PO daily</li>
<li>Continue treatment until disease progression.</li>
</ul>
<blockquote>
<p>Wells SA, et al. J Clin Oncol 2010;28:767–772.</p>
</blockquote>
</div>
<div id="cabozantinib-medullary-carcinoma-of-the-thyroid" class="section level4" number="2.36.2.6">
<h4><span class="header-section-number">2.36.2.6</span> Cabozantinib (medullary carcinoma of the thyroid)</h4>
<ul>
<li>Cabozantinib: 140 mg PO daily</li>
<li>Continue treatment until disease progression.</li>
</ul>
<blockquote>
<p>Kurzrock R, et al. J Clin Oncol 2011;29:2660–2666.</p>
</blockquote>
</div>
<div id="lenvatinib" class="section level4" number="2.36.2.7">
<h4><span class="header-section-number">2.36.2.7</span> Lenvatinib</h4>
<ul>
<li>Lenvatinib: 24 mg PO daily</li>
<li>Continue treatment until disease progression.</li>
</ul>
<blockquote>
<p>Schlumberger M, et al. N Engl J Med 2015;372:621–630.</p>
</blockquote>
</div>
</div>
</div>
<div id="waldenströms-macroglobulinemia" class="section level2" number="2.37">
<h2><span class="header-section-number">2.37</span> WALDENSTRÖM’S MACROGLOBULINEMIA</h2>
<div id="combination-regimens-20" class="section level3" number="2.37.1">
<h3><span class="header-section-number">2.37.1</span> Combination Regimens</h3>
<div id="bortezomib-dexamethasone-rituximab-bdr" class="section level4" number="2.37.1.1">
<h4><span class="header-section-number">2.37.1.1</span> Bortezomib + Dexamethasone + Rituximab (BDR)</h4>
<ul>
<li>Bortezomib: 1.3 mg/m2 IV on days 1, 4, 8, and 11</li>
<li>Dexamethasone: 40 mg IV on days 1, 4, 8, and 11</li>
<li>Rituxumab: 375 mg/m2 IV on day 11</li>
<li>Repeat for 4 cycles as induction therapy followed by a 12-week break and then 4 additional cycles, each given 12 weeks apart.</li>
</ul>
<blockquote>
<p>Treon SP, et al. J Clin Oncol 2009;27:3830–3835.</p>
</blockquote>
</div>
<div id="rituximab-dexamethasone-cyclophosphamide" class="section level4" number="2.37.1.2">
<h4><span class="header-section-number">2.37.1.2</span> Rituximab + Dexamethasone + Cyclophosphamide</h4>
<ul>
<li>Rituxumab: 375 mg/m2 IV on day 1</li>
<li>Dexamethasone: 20 mg IV on day 1</li>
<li>Cyclophosphamide: 100 mg/m2 PO bid</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Dimopoulos MA, et al. J Clin Oncol 2007;25:3344–3349.</p>
</blockquote>
</div>
<div id="carfilzomib-dexamethasone-rituximab-crd" class="section level4" number="2.37.1.3">
<h4><span class="header-section-number">2.37.1.3</span> Carfilzomib + Dexamethasone + Rituximab (CRD)</h4>
<ul>
<li>Carfilzomib: 20 mg/m2 IV on days 1, 2, 8, and 9 in cycle 1 and then 36 mg/m2 IV on days 1, 2, 8, and 9 in cycles 2–6</li>
<li>Dexamethasone: 20 mg IV on days 1, 2, 8, and 9</li>
<li>Rituxumab: 375 mg/m2 IV on days 2 and 9</li>
<li>Repeat cycle every 21 days for up to 6 induction cycles, followed by an 8-week break, and then 8 additional cycles of maintenance therapy as follows:</li>
<li>Carfilzomib: 36 mg/m2 IV on days 1 and 2 in cycle 1 and then 36 mg/m2 IV on days 1, 2, 8, and 9 in cycles 2–6</li>
<li>Dexamethasone: 20 mg IV on days and 1 and 2</li>
<li>Rituxumab: 375 mg/m2 IV on day 2</li>
<li>Repeat cycle every 8 weeks for up to 8 cycles.</li>
</ul>
<blockquote>
<p>Treon SP, et al. Blood 2014;124:503–510.</p>
</blockquote>
</div>
<div id="ixazomib-dexamethasone-rituximab-idr" class="section level4" number="2.37.1.4">
<h4><span class="header-section-number">2.37.1.4</span> Ixazomib + Dexamethasone + Rituximab (IDR)</h4>
<ul>
<li>Ixazomib: 4 mg/day PO on days 1, 8, and 15</li>
<li>Dexamethasone: 20 mg/day PO on days 1, 8, 15, and 22</li>
<li>Rituximab: 375 mg/m2 IV on day 1</li>
<li>Repeat cycle every 28 days for up to 6 cycles of induction.</li>
</ul>
<blockquote>
<p>Schlumberger M, et al. N Engl J Med 2015;372:621–630.</p>
</blockquote>
</div>
<div id="bendamustine-rituximab-2" class="section level4" number="2.37.1.5">
<h4><span class="header-section-number">2.37.1.5</span> Bendamustine + Rituximab</h4>
<ul>
<li>Bendamustine: 90 mg/m2 IV on days 1 and 2</li>
<li>Rituxumab: 375 mg/m2 IV on day 1</li>
<li>Repeat cycle every 28 days for 4 cycles.</li>
</ul>
<blockquote>
<p>Castillo JJ, et al. Clin Cancer Res 2018. doi: 10.1158/1078-0432.</p>
</blockquote>
</div>
</div>
<div id="single-agent-regimens-17" class="section level3" number="2.37.2">
<h3><span class="header-section-number">2.37.2</span> Single-Agent Regimens</h3>
<div id="dexamethasone-1" class="section level4" number="2.37.2.1">
<h4><span class="header-section-number">2.37.2.1</span> Dexamethasone</h4>
<ul>
<li>Dexamethasone: 40 mg IV or PO on days 1–4, 9–12, and 17–20</li>
<li>Repeat cycle every 21 days.</li>
</ul>
<blockquote>
<p>Alexanian R, et al. Ann Intern Med 1986;105:8–11.</p>
</blockquote>

</div>
</div>
</div>
</div>
            </section>

          </div>
        </div>
      </div>
<a href="chemotherapeutic-and-biologic-drugs.html" class="navigation navigation-prev " aria-label="Previous page"><i class="fa fa-angle-left"></i></a>
<a href="chemotherapy-dosage-based-on-hepatic-function.html" class="navigation navigation-next " aria-label="Next page"><i class="fa fa-angle-right"></i></a>
    </div>
  </div>
<script src="libs/gitbook-2.6.7/js/app.min.js"></script>
<script src="libs/gitbook-2.6.7/js/lunr.js"></script>
<script src="libs/gitbook-2.6.7/js/clipboard.min.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-search.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-sharing.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-fontsettings.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-bookdown.js"></script>
<script src="libs/gitbook-2.6.7/js/jquery.highlight.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-clipboard.js"></script>
<script>
gitbook.require(["gitbook"], function(gitbook) {
gitbook.start({
"sharing": {
"github": false,
"facebook": true,
"twitter": true,
"linkedin": false,
"weibo": false,
"instapaper": false,
"vk": false,
"whatsapp": false,
"all": ["facebook", "twitter", "linkedin", "weibo", "instapaper"]
},
"fontsettings": {
"theme": "white",
"family": "sans",
"size": 2
},
"edit": {
"link": null,
"text": null
},
"history": {
"link": null,
"text": null
},
"view": {
"link": null,
"text": null
},
"download": null,
"toc": {
"collapse": "subsection"
}
});
});
</script>

</body>

</html>
